<SEC-DOCUMENT>0001628280-22-008431.txt : 20220405
<SEC-HEADER>0001628280-22-008431.hdr.sgml : 20220405
<ACCEPTANCE-DATETIME>20220405171935
ACCESSION NUMBER:		0001628280-22-008431
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		11
FILED AS OF DATE:		20220405
DATE AS OF CHANGE:		20220405

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cardiff Oncology, Inc.
		CENTRAL INDEX KEY:			0001213037
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				272004382
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-264148
		FILM NUMBER:		22808175

	BUSINESS ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-952-7570

	MAIL ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trovagene, Inc.
		DATE OF NAME CHANGE:	20130304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrovaGene Inc.
		DATE OF NAME CHANGE:	20110830

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XENOMICS INC
		DATE OF NAME CHANGE:	20040719
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>crdfs-3040522.htm
<DESCRIPTION>S-3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if89c1f54c40443f2aa0a6238615b3fe9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As filed with the U.S. Securities and Exchange Commission on April 5, 2022</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Registration No. 333-</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, DC 20549</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.684%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM&#160;S-3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REGISTRATION STATEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNDER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THE SECURITIES ACT OF 1933</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.684%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">&#160;Cardiff Oncology, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27-2004382</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IRS Employer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">of incorporation or organization)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identification No.)</font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">11055 Flintkote Avenue</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">San Diego, CA 92121</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(858) 952-7570</font></div><div style="margin-bottom:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Mark Erlander, Ph.D.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cardiff Oncology, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">11055 Flintkote Avenue</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">San Diego, CA 92121</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(858) 952-7570</font></div><div style="margin-bottom:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Name, address including zip code, and telephone number, including area code, of agent for service)</font></div><div style="margin-bottom:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">With copies to&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Jeffrey J. Fessler, Esq.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sheppard, Mullin, Richter &#38; Hampton LLP</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">30 Rockefeller Plaza</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">New York, NY 10112</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Tel&#58; (212) 653-8700</font></div><div style="margin-bottom:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fax&#58; (212) 653-8701</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.684%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Approximate date of commencement of proposed sale to the public&#58; From time to time, after the effective date of this registration statement.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box&#58; </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box&#58; </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#9746;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities Act registration statement number of the earlier effective registration statement for the same offering. </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#34;emerging growth company&#34; in Rule 12b-2 of the Exchange Act. </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.515%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large accelerated filer </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">o</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">o</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer  </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">o</font></div></td></tr></table></div><div style="margin-bottom:4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</font></div><div style="margin-bottom:4pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment that specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act or until this Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.</font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_7"></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROSPECTUS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXPLANATORY NOTE</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This registration statement contains two prospectuses&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a base prospectus which covers the offering, issuance and sale by us of up to $250 million in the aggregate of the securities identified above from time to time in one or more offerings&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $100 million of our common stock that may be offered and sold under an Open Market Sale Agreement with Jefferies LLC.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The base prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the base prospectus will be specified in a prospectus supplement to the base prospectus. The specific terms of the securities to be issued and sold under the Sales Agreement are specified in the sales agreement prospectus that immediately follows the base prospectus.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#ff4040;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The information in this prospectus is not complete and may be changed. We may not sell these securities or accept an offer to buy these securities until the registration statement filed with the U.S. Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and we are not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#ff4040;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">PRELIMINARY PROSPECTUS</font></div><div style="text-align:center"><font style="color:#ff4040;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Subject to completion, dated April 5, 2022</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><img alt="cardiff_logoxrgbxtma.jpg" src="cardiff_logoxrgbxtma.jpg" style="height:36px;margin-bottom:5pt;vertical-align:text-bottom;width:180px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Securities</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Units</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We may offer and sell, from time to time in one or more offerings, any combination of common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock or debt securities, or any combination of the foregoing, either individually or as units comprised of one or more of the other securities, having an aggregate initial offering price not exceeding $250 million.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This prospectus provides a general description of the securities we may offer.&#160; Each time we sell a particular class or series of securities, we will provide specific terms of the securities offered in a supplement to this prospectus. &#160;The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. You should read carefully this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference herein or therein before you invest in any of our securities.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The specific terms of any securities to be offered, and the specific manner in which they may be offered, will be described in one or more supplements to this prospectus. This prospectus may not be used to consummate sales of any of these securities unless it is accompanied by a prospectus supplement. Before investing, you should carefully read this prospectus and any related prospectus supplement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our common stock is presently listed on The Nasdaq Capital Market under the symbol &#8220;CRDF.&#8221; On April 4, 2022 the last reported sale price of our common stock was $2.61 per share.  The applicable prospectus supplement will contain information, where applicable, as to any other listing on The Nasdaq Capital Market or any securities market or other exchange of the securities, if any, covered by the prospectus supplement.  Prospective purchasers of our securities are urged to obtain current information as to the market prices of our securities, where applicable.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These securities may be sold directly by us, through dealers or agents designated from time to time, to or through underwriters, dealers, or through a combination of these methods on a continuous or delayed basis. &#160;See &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Plan of Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221; in this prospectus. We may also describe the plan of distribution for any particular offering of our securities in a prospectus supplement. If any agents, underwriters or dealers are involved in the sale of any securities in respect of which this prospectus is being delivered, we will disclose their names and the nature of our arrangements with them in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from any such sale will also be included in a prospectus supplement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Investing in our securities involves various risks. &#160;See &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Risk Factors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8221; contained herein for more information on these risks. Additional risks will be described in the related prospectus supplements under the heading &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Risk Factors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">.&#8221; You should review that section of the related prospectus supplements for a discussion of matters that investors in our securities should consider.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the adequacy or accuracy of this prospectus or any accompanying prospectus supplement. &#160;Any representation to the contrary is a criminal offense.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The date of this prospectus is April     , 2022.</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_10"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:85.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_13" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">ABOUT THIS PROSPECTUS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_13" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_525" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">SUMMARY</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_525" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">RISK FACTORS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_16" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">11</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_19" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_19" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">11</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_22" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">USE OF PROCEEDS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_22" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">12</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DESCRIPTION OF CAPITAL STOCK</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_25" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">12</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_28" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DESCRIPTION OF DEBT SECURITIES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_28" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">14</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DESCRIPTION OF WARRANTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_31" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">20</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DESCRIPTION OF UNITS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_34" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">22</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_37" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">LEGAL OWNERSHIP OF SECURITIES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_37" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">23</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_40" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">PLAN OF DISTRIBUTION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_40" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">26</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_43" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">LEGAL MATTERS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_43" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">28</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_46" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EXPERTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_46" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">28</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_49" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">WHERE YOU CAN FIND MORE INFORMATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_49" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">28</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_52" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">INCORPORATION OF DOCUMENTS BY REFERENCE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_52" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">29</a></font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_13"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ABOUT THIS PROSPECTUS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission, or SEC, using a &#8220;shelf&#8221; registration process. Under this shelf registration statement, we may sell from time to time in one or more offerings of common stock and preferred stock, various series of debt securities and&#47;or warrants to purchase any of such securities, either individually or as units comprised of a combination of one or more of the other securities in one or more offerings up to a total dollar amount of $250 million. This prospectus provides you with a general description of the securities we may offer. Each time we sell any type or series of securities under this prospectus, we will provide a prospectus supplement that will contain more specific information about the terms of that offering.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This prospectus does not contain all of the information included in the registration statement. For a more complete understanding of the offering of the securities, you should refer to the registration statement, including its exhibits.  We may add, update or change, in a prospectus supplement or free writing prospectus, any of the information contained in this prospectus or in the documents we have incorporated by reference into this prospectus. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. This prospectus, together with the applicable prospectus supplement, any related free writing prospectus and the documents incorporated by reference into this prospectus and the applicable prospectus supplement, will include all material information relating to the applicable offering. You should carefully read both this prospectus and the applicable prospectus supplement and any related free writing prospectus, together with the additional information described under &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Where You Can Find More Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">,&#8221; before buying any of the securities being offered.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not authorized any dealer, agent or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus, any accompanying prospectus supplement or any related free writing prospectus that we may authorize to be provided to you. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus or an accompanying prospectus supplement, or any related free writing prospectus that we may authorize to be provided to you. This prospectus, the accompanying prospectus supplement and any related free writing prospectus, if any, do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, the accompanying prospectus supplement or any related free writing prospectus, if any, constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference (as our business, financial condition, results of operations and prospects may have changed since that date), even though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered or securities are sold on a later date.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in this prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus may not be used to consummate sales of our securities, unless it is accompanied by a prospectus supplement. To the extent there are inconsistencies between any prospectus supplement, this prospectus and any documents incorporated by reference, the document with the most recent date will control.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted by the rules&#160;and regulations of the SEC, the registration statement, of which this prospectus forms&#160;a part, includes additional information not contained in this prospectus. You may read the registration statement and the other reports we file with the SEC at the SEC&#8217;s web site or at the SEC&#8217;s offices described below under the heading &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Where You Can Find More Information.&#8221;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company References</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this prospectus &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Cardiff Oncology,&#160;Inc., a Delaware corporation, and its subsidiaries, unless the context otherwise requires.</font></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_525"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations that overcome disease resistance and improve disease response to standard treatment regimens and to increase overall survival. We are developing onvansertib, an oral and highly-selective Polo-like Kinase 1 (&#34;PLK1&#34;) inhibitor, in combination with standard-of-care anti-cancer therapeutics. Our clinical development programs incorporate tumor genomics and biomarker assays to refine assessment of patient response to treatment.</font></div><div style="text-indent:33.75pt"><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Drug Candidate, Onvansertib</font></div><div><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onvansertib, our lead compound, is a novel, highly potent, highly selective PLK1 inhibitor.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PLK1, a serine&#47;threonine kinase, has a well-understood mechanism of action within tumor cell proliferation and is overexpressed in a number of tumors (including colorectal, pancreatic, prostate, ovarian, breast and lung cancer). In particular, PLK1&#8217;s activity in various phases of the cell cycle provide multiple targets for a PLK1 inhibitor to inhibit DNA repair and interrupt cell division, thereby killing tumor cells.</font></div><div><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PLK1 inhibition has been considered an attractive target of anti-tumor therapeutics for the last two decades, however past PLK1 drug candidates have failed to show acceptable tolerability and efficacy. We believe the attributes of onvansertib described below, as well as clinical evidence of favorable safety and efficacy, with expected on-target, easy to manage and reversible side effects, may prove beneficial in addressing clinical therapeutic needs across a variety of cancers&#58;</font></div><div style="text-indent:33.75pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Onvansertib is highly potent and highly selective against the PLK1 enzyme (IC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:1.4pt;vertical-align:baseline">50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#61; 2nM&#59; IC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:1.4pt;vertical-align:baseline">50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> is the concentration for 50% inhibition), compared to prior PLK1 inhibitors that were pan-inhibitors of several PLK targets.  Low or no activity of onvansertib was observed on a panel of 63 kinases (IC50&#62;500 nM), including the PLK members PLK2 and PLK3 (IC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:1.4pt;vertical-align:baseline">50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#62;10,000 nM).</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Onvansertib has a relatively short drug half-life of 24 hours, compared to a half-life of approximately 5 days for prior PLK1 inhibitors.  A short half-life allows for flexible dosing and improved managing of drug concentrations to reduce dose-related toxicities.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Onvansertib is orally bioavailable, compared to prior PLK1 inhibitors that were delivered intravenously, allowing for relative ease of dosing.</font></div><div style="text-indent:33.75pt"><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In vitro studies have shown synergistic effects when onvansertib was administered in combination with different cytotoxic agents including antimicrotubule agents, topoisomerase 1 inhibitors, antimetabolites, alkylating agents, proteasome inhibitors, kinase inhibitors, BCL-2 inhibitors, and androgen biosynthesis inhibitors.</font></div><div style="text-indent:33.75pt"><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in vivo combination studies have confirmed the positive results obtained in vitro and synergistic effects have been observed in xenograft models of onvansertib in combination with irinotecan (including NKTR-102), 5-fluorouracil (&#34;5-FU&#34;), abiraterone, quizartinib, venetoclax, and paclitaxel, while additive effects in combination with cytarabine or bevacizumab have been demonstrated.</font></div><div style="text-indent:33.75pt"><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are three ongoing clinical trials in onvansertib in combination treatment&#58; second line treatment in patients with KRAS-mutated Metastatic Colorectal Cancer (&#34;mCRC&#34;), second line treatment in patients with Metastatic Pancreatic Ductal Adenocarcinoma (&#34;mPDAC&#34;), and in patients with Metastatic Castration-Resistant Prostate Cancer (&#34;mCRPC&#34;) showing resistance to abiraterone.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:102%">Phase 1b&#47;2 Clinical Trial in KRAS-mutated mCRC</font></div><div><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TROV-054 is a Phase 1b&#47;2 open-label multi-center clinical trial of onvansertib in combination with standard of care FOLFIRI and bevacizumab (Avastin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the second line treatment of patients with KRAS-mutated mCRC, which is being conducted at seven clinical trial sites across the U.S. - USC Norris Comprehensive Cancer Center, The Mayo Clinic Cancer Centers (Arizona, Minnesota and Florida), Kansas University Medical Center, Inova Schar Cancer Institute and CARTI Cancer Center.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The primary objective of this trial is to evaluate the Dose-Limiting Toxicities (&#34;DLTs&#34;) and maximum tolerated dose (&#34;MTD&#34;) or recommended Phase 2 dose (&#34;RP2D&#34;) of onvansertib in combination with FOLFIRI and bevacizumab (Phase 1b) and to continue to assess the safety and preliminary efficacy of onvansertib in combination with FOLFIRI and bevacizumab (Phase 2).</font></div><div style="text-indent:33.75pt"><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scientific rationale for this clinical trial is based on the two key principles of synthetic lethality and synergy, with the objective of demonstrating a proof-of-concept of clinical benefit within this phase1b&#47;2 trial. Synthetic lethality refers to a critical vulnerability to tumor cell death by way of PLK1 inhibition within CRC tumor cells harboring KRAS mutations versus KRAS wild-type isogenic cells. Synergy occurs when the combination of two drugs results in an unexpected greater activity than an expected additive effect of the two drugs. Onvansertib in combination with two DNA-damaging agents, irinotecan and 5-FU (two components of FOLFIRI), demonstrated synergy in colorectal cancer cell lines and both combinations have demonstrated significantly greater tumor growth inhibition than either drug alone in CRC in vivo models. We believe this synergy occurs because PLK1 can promote the repair of DNA damage caused by chemotherapeutic agents and by inhibiting PLK1, onvansertib leaves damaged tumor cells unable to replicate.</font></div><div><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data we presented on January 18, 2022 provided an update of the ongoing phase 1b&#47;2 clinical trial in KRAS-mutated metastatic colorectal cancer. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">12 of 35 (34%) patients treated per protocol at the RP2D in combination with FOLFIRI and bevacizumab achieved a Complete Response (&#34;CR&#34;) or Partial Response (&#34;PR&#34;) (CR&#58; 1 patient&#59; PR&#58; 11 patients)&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">17 of 48 (35%) patients across all dose levels achieved a CR or PR. Historically, Objective Response Rates (&#34;ORR&#34;) of 5-13% have been reported in similar second line patient populations treated with various different drug combinations, including the standard of care chemotherapy of FOLFIRI with bevacizumab&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">5 of 48 (10%) patients discontinued the trial to pursue potentially curative metastasis-directed therapy (surgical resection or microwave ablation)&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Median Progression-Free Survival (&#34;mPFS&#34;) across all response-evaluable patients (n&#61;48) is 9.4 months and has not yet been reached in those treated per protocol at the RP2D. Historically, mPFS of &#126;4.5-5.7 months has been reported in a similar patient population treated with standard of care chemotherapy of FOLFIRI with bevacizumab&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The combination regimen of onvansertib plus FOLFIRI&#47;bevacizumab is well tolerated with no major or unexpected toxicities attributed to onvansertib.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:102%">Phase 2 Clinical Trial in mPDAC</font></div><div><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CRDF-001 is a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan (Onivyde</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), leucovorin, and fluorouracil for second line treatment of patients with mPDAC, which is being conducted at six clinical trial sites across the U.S. &#8211; The Mayo Clinic Cancer Centers (Arizona, Minnesota and Florida), Kansas University Medical Center, Inova Schar Cancer Institute, and the University of Nebraska Medical Center.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first patient was dosed in June 2021. </font></div><div style="text-indent:33.75pt"><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of this trial is to assess the safety and preliminary efficacy of onvansertib in combination with nanoliposomal irinotecan (Onyvide</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), 5-FU and leucovorin as a second-line treatment in patients with mPDAC who have failed first-line gemcitabine-based therapy. The trial is expected to enroll approximately 45 patients across six sites in the U.S. including three of The Mayo Clinic Cancer Centers (Arizona, Minnesota and Florida), Kansas University Medical Center, Inova Schar Cancer Institute, and the University of Nebraska Medical Center.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 2 Clinical Trial in mCRPC</font></div><div><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TROV-053 is a Phase 2 open-label multi-center clinical trial of onvansertib in combination with abiraterone acetate (Zytiga</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and prednisone in patients with mCRPC, which is being conducted at three clinical trial sites - Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute and Massachusetts General Hospital.</font></div><div style="text-indent:33.75pt"><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of this trial is to observe the effects of onvansertib in combination with abiraterone and prednisone on disease control as assessed by Prostate Specific Antigen (&#34;PSA&#34;) decline or stabilization after 12 weeks of treatment in patients with mCRPC showing early signs of resistance to abiraterone.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-indent:33.75pt"><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rationale for this trial is based on the Mechanism of Action (&#34;MOA&#34;) of onvansertib and Zytiga</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the synergy of these two drugs when used in combination in pre-clinical experiments. Onvansertib inhibits tumor cell proliferation by inducing G2&#47;M (mitosis) arrest and consequently cell death. The combination of onvansertib and Zytiga</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> synergistically increases mitotic arrest and cell death in prostate cancer cells and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has demonstrated significantly greater tumor growth inhibition than either drug alone in vivo. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-indent:33.75pt"><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data as of July 2, 2021, as follow-up to the data presented on February 11, 2021, at the American Society of Clinical Oncology Genitourinary Cancers Symposium (&#8220;ASCO-GU&#8221;) provided evidence of the safety and efficacy of onvansertib in combination with abiraterone. Arms A (n&#61;17) and B (n&#61;20) and C (n&#61;13) showed 29%, 40% and 54% of patients, respectively, achieving the primary endpoint of disease control at 12 weeks. The more continuous dosing schedule of Arm C has shown an increase in the rate of patients achieving disease stabilization, to-date. Evidence of efficacy was observed in patients harboring Androgen Receptor (&#34;AR&#34;) alterations across all 3 arms. Circulating Tumor DNA (&#34;ctDNA&#34;) analysis revealed differences in baseline genomic profiles of patients achieving SD at 12 weeks vs. patients progressing before or at 12 weeks. Mutations exclusively present in patients with Stable Disease (&#34;SD&#34;) were associated with cell cycle and DNA repair pathways that may result in increased sensitivity to onvansertib and efficacy of the combination. Onvansertib plus abiraterone has demonstrated safety across all 3 dosing schedules.</font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborative Relationship</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Breakthrough Growth Initiative</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we entered into a Securities Purchase Agreement (the &#8220;SPA&#8221;) with Pfizer Inc., as part of the Pfizer Breakthrough Growth Initiative, pursuant to which Pfizer purchased 2.4 million shares of our common stock at a purchase price per share of $6.22 for gross proceeds of approximately $15.0 million. In connection with the purchase, Pfizer has agreed not to sell or transfer any of the shares, subject to certain customary exceptions, for a period of 180 days from the closing date of the SPA. In connection with the stock purchase, we and Pfizer entered into an Information Rights Agreement pursuant to which Adam Schayowitz, Ph.D., MBA, Vice President &#38; Medicine Team Group Lead for Breast Cancer, Colorectal Cancer and Melanoma at Pfizer will join our Scientific Advisory Board, and until May 17, 2023 we agreed to provide Pfizer with rights of first access to any pre-clinical or final clinical data and results generated as part of the onvansertib development program at least two business days prior to us providing such data to a third party.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Associated with Our Business</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We are a clinical stage company and may never earn a profit</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We will need to raise substantial additional capital to develop and commercialize onvansertib and our failure to obtain funding when needed may force us to delay, reduce or eliminate our product development programs or collaboration efforts.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Our product candidate, onvansertib, is in the early stages of clinical development and its commercial viability remains subject to current and future preclinical studies, clinical trials, regulatory approvals and the risks generally inherent in the development of a pharmaceutical product candidate. If we are unable to successfully advance or develop our product candidate, our business will be materially harmed.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">If the results of preclinical studies or clinical trials for our product candidate, including those that are subject to existing or future license or collaboration agreements, are unfavorable or delayed, we could be delayed or precluded from the further development or commercialization of our product candidate, which could materially harm our business.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">If third party vendors upon whom we intend to rely on to conduct our preclinical studies or clinical trials do not perform or fail to comply with strict regulations, these studies or trials of our product candidate may be delayed, terminated, or fail, or we could incur significant additional expenses, which could materially harm our business</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We, and our collaborators, must comply with extensive government regulations in order to advance our product candidate through the development process and ultimately obtain and maintain marketing approval for our products in the U.S. and abroad.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We have limited experience in the development of therapeutic product candidates and therefore may encounter difficulties developing our product candidate or managing our operations in the future.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Delays in clinical testing could result in increased costs to us and delay our ability to generate revenue.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidate, our business will be substantially harmed.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">If our product candidate is unable to compete effectively with marketed drugs targeting similar indications as our product candidate, our commercial opportunity will be reduced or eliminated.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">If the manufacturers upon whom we rely fail to produce our product candidate, in the volumes that we require on a timely basis, or fail to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may face delays in the development and commercialization of our product candidate.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">If we materially breach or default under terms of our license agreement with Nerviano Medical Sciences S.r.l. Nerviano Medical Sciences S.r.l. will have the right to terminate the agreement and we could lose critical license rights, which would materially harm our business.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">The outbreak of the novel coronavirus disease, COVID-19, could materially adversely impact our business, results of operations and financial condition, including our clinical trials.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">If we are unable to protect our intellectual property effectively, we may be unable to prevent third parties from using our technologies, which would impair our competitive advantage.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Our common stock price may be volatile and could fluctuate widely in price, which could result in substantial losses for investors.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Delaware law and our corporate charter and bylaws contain anti-takeover provisions that could delay or discourage takeover attempts that stockholders may consider favorable.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Company Information</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in the State of Florida on April&#160;26, 2002. On July&#160;2, 2004, we acquired Xenomics, a California corporation, which was in business to develop and commercialize urine-based molecular diagnostics technology. In 2007, we changed our fiscal year end from January&#160;31 to December&#160;31 and in January&#160;2010, we re-domesticated our state of incorporation from Florida to Delaware and our name was changed to Trovagene,&#160;Inc. On May&#160;6, 2020, we announced a change in our company name from Trovagene,&#160;Inc. to Cardiff Oncology,&#160;Inc.&#160;We have trademarks for the name TROVAGENE, TROVAGENE ONCOLOGY, and CARDIFF ONCOLOGY. Our principal executive offices are located at 11055 Flintkote Avenue, San Diego, CA 92121, and our telephone number is 858-952-7570. Our website address is</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;www.cardiffoncology.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The information on our website is not part of this prospectus. We have included our website address as a factual reference and do not intend it to be an active link to our website.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Securities We May&#160;Offer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may offer shares of our common stock and preferred stock, various series of debt securities and warrants to purchase any of such securities, either individually or in units, from time to time under this prospectus, together with any applicable prospectus supplement and related free writing prospectus, at prices and on terms to be determined by market conditions at the time of offering. If we issue any debt securities at a discount from their original stated principal amount, then, for purposes of calculating the total dollar amount of all securities issued under this prospectus, we will treat the initial offering price of the debt securities as the total original principal amount of the debt securities. Each time we offer securities under this prospectus, we will provide offerees with a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities being offered, including, to the extent applicable&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">designation or classification&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">aggregate principal amount or aggregate offering price&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maturity, if applicable&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">original issue discount, if any&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">rates and times of payment of interest or dividends, if any&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">redemption, conversion, exchange or sinking fund terms, if any&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ranking&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictive covenants, if any&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">voting or other rights, if any&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">important United States federal income tax considerations.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update, or change information contained in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may sell the securities to or through underwriters, dealers or agents or directly to purchasers. We, as well as any agents acting on our behalf, reserve the sole right to accept and to reject in whole or in part any proposed purchase of securities. Each prospectus supplement will set forth the names of any underwriters, dealers or agents involved in the sale of securities described in that prospectus supplement and any applicable fee, commission or discount arrangements with them, details regarding any over-allotment option granted to them, and net proceeds to us. The following is a summary of the securities we may offer with this prospectus.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have authorized 150,000,000 shares of common stock, par value $0.0001 per share. As of April 4, 2022, 43,306,061 shares of common stock were issued and outstanding.&#160; We may offer shares of our common stock either alone or underlying other registered securities convertible into or exercisable for our common stock. Holders of our common stock are entitled to such dividends as our board of directors (the &#8220;Board of Directors&#8221; or &#8220;Board&#8221;) may declare from time to time out of legally available funds, subject to the preferential rights of the holders of any shares of our preferred stock that are outstanding or that we may issue in the future. Currently, we do not pay any dividends on our common stock. Each holder of our common stock is entitled to one vote per share. In this prospectus, we provide a general description of, among other things, the rights and restrictions that apply to holders of our common stock.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have authorized 20,000,000 shares of preferred stock, par value $0.001, of which 277,100 shares are designated as Series A Convertible Preferred Stock, of which 60,600 shares are issued and outstanding as of April 4, 2022&#59; 8,860 shares are designated as Series B Convertible Preferred Stock, of which no shares are issued and outstanding as of April 4, 2022&#59; 200,000 shares are designated as Series C Convertible Preferred Stock, of which no shares are issued and outstanding as of April 4, 2022&#59; 154,670 shares are designated as Series D Convertible Preferred Stock, of which no shares are issued and outstanding as of April 4, 2022&#59; and 865,824  shares are designated Series E Convertible Preferred Stock, of which 327,509 shares are issued and outstanding as of April 4, 2022.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any authorized and undesignated shares of preferred stock may be issued from time to time in one or more additional series pursuant to a resolution or resolutions providing for such issue duly adopted by our Board of Directors (authority to do so being hereby expressly vested in the Board of Directors). The Board of Directors is further authorized, subject to limitations prescribed by law, to fix by resolution or resolutions the designations, powers, preferences and rights, and the qualifications, limitations or restrictions thereof, of any wholly unissued series of preferred stock, including without limitation authority to fix by resolution or resolutions the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions), redemption price or prices, and liquidation preferences of any such series, and the number of shares constituting any such series and the designation thereof, or any of the foregoing.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rights, preferences, privileges, and restrictions granted to or imposed upon any series of preferred stock that we offer and sell under this prospectus and applicable prospectus supplements will be set forth in a certificate of designation relating to the series. We will incorporate by reference into the registration statement of which this prospectus is a part the form of any certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of shares of that series of preferred stock. You should read any prospectus supplement and any free writing prospectus that we may authorize to be provided to you related to the series of preferred stock being offered, as well as the complete certificate of designation that contains the terms of the applicable series of preferred stock.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Securities</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may offer general debt obligations, which may be secured or unsecured, senior or subordinated, and convertible into shares of our common stock or preferred stock. In this prospectus, we refer to the senior debt securities and the subordinated debt securities together as the &#8220;debt securities.&#8221; We may issue debt securities under a note purchase agreement or under an indenture to be entered between us and a trustee. The indentures do not limit the amount of securities that may be issued under it and provide that debt securities may be issued in one or more series. The senior debt securities will have the same rank as all of our other indebtedness that is not subordinated. The subordinated debt securities will be subordinated to our senior debt on terms set forth in the applicable prospectus supplement. In addition, the subordinated debt securities will be effectively subordinated to creditors and preferred stockholders of our subsidiaries. Our Board of Directors will determine the terms of each series of debt securities being offered. This prospectus contains only general terms and provisions of the debt securities. The applicable prospectus supplement will describe the particular terms of the debt securities offered thereby. You should read any prospectus supplement and any free writing prospectus that we may authorize to be provided to you related to the series of debt securities being offered, as well as the complete note agreements and&#47;or indentures that contain the terms of the debt securities. The forms of senior and subordinated indentures have been filed as exhibits to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of debt securities being offered will be incorporated by reference into the registration statement of which this prospectus is a part from reports we file with the SEC.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may offer warrants for the purchase of shares of our common stock or preferred stock or of debt securities. We may issue the warrants by themselves or together with common stock, preferred stock or debt securities, and the warrants may be attached to or separate from any offered securities. Any warrants issued under this prospectus may be evidenced by warrant certificates.&#160; Warrants may be issued under a separate warrant agreement to be entered into between us and the investors or a warrant agent. Our Board of Directors will determine the terms of the warrants. This prospectus contains only general terms and provisions of the warrants. The applicable prospectus supplement will describe the particular terms of the warrants being offered thereby. You should read any prospectus supplement and any free writing prospectus that we may authorize to be provided to you related to the series of warrants being offered, as well as the complete warrant agreements that contain the terms of the warrants. Specific warrant agreements will contain additional important terms and provisions and will be incorporated by reference into the registration statement of which this prospectus is a part from reports we file with the SEC.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Units</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may offer units consisting of our common stock or preferred stock, debt securities and&#47;or warrants to purchase any of these securities in one or more series. We may evidence each series of units by unit certificates that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or trust company that we select. We will indicate the name and address of the unit agent in the applicable prospectus supplement relating to a particular series of units. This prospectus contains only a summary of certain general features of the units. The applicable prospectus supplement will describe the particular features of the units being offered thereby. You should read any prospectus supplement and any free writing prospectus that we may authorize to be provided to you related to the series of units being offered, as well as the complete unit agreements that contain the terms of the units. Specific unit agreements will contain additional important terms and provisions and will be incorporated by reference into the registration statement of which this prospectus is a part from reports we file with the SEC.</font></div><div><font><br></font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_16"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:42.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An investment in our securities involves a high degree of risk. This prospectus contains, and the prospectus supplement applicable to each offering of our securities will contain, a discussion of the risks applicable to an investment in our securities. Prior to making a decision about investing in our securities, you should carefully consider the specific factors discussed under the heading &#8220;Risk Factors&#8221; in this prospectus and the applicable prospectus supplement, together with all of the other information contained or incorporated by reference in the prospectus supplement or appearing or incorporated by reference in this prospectus. You should also consider the risks, uncertainties and assumptions discussed under Item 1A, &#8220;Risk Factors,&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on February 24, 2022, and any updates described in our Quarterly Reports on Form 10-Q, all of which are incorporated herein by reference, and may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future and any prospectus supplement related to a particular offering. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. The occurrence of any of these known or unknown risks might cause you to lose all or part of your investment in the offered securities.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_19"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:42.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus, any accompanying prospectus supplement, any related free writing prospectus and the documents incorporated by reference herein or therein contain, in addition to historical information, certain forward-looking statements within the meaning of Section 27A of the Securities Act or 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), that include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation and availability of resources. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets or future development and&#47;or otherwise are not statements of historical fact. These forward-looking statements are based on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown that could cause actual results and developments to differ materially from those expressed or implied in such statements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:42.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by terminology, such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;may,&#8221; &#8220;should&#8221;, &#8220;could&#8221; or the negative of such terms or other similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout this prospectus supplement or incorporated herein by reference.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:42.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks, uncertainties and other factors that may cause our actual results, performance or achievements to be different from those expressed or implied in our written or oral forward-looking statements may be found in this prospectus supplement under the heading &#8220;Risk Factors&#8221; and in our Annual Report on Form 10-K for the year ended December 31, 2021 under the headings &#8220;Risk Factors&#8221; and &#8220;Business,&#8221; as updated in our Quarterly Report(s) on Form 10-Q.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:42.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements speak only as of the date they are made. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:42.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of the information </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">presented in this prospectus supplement and incorporated herein by reference, and particularly our forward-looking statements, by these cautionary statements.</font></div><div style="text-indent:36pt"><font><br></font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_22"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">USE OF PROCEEDS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as described in any prospectus supplement and any free writing prospectus in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered under this prospectus for general corporate purposes, including the development and commercialization of our products, research and development, general and administrative expenses, license or technology acquisitions, and working capital and capital expenditures. We may also use the net proceeds to repay any debts and&#47;or invest in or acquire complementary businesses, products, or technologies, although we have no current commitments or agreements with respect to any such investments or acquisitions as of the date of this prospectus. We have not determined the amount of net proceeds to be used specifically for the foregoing purposes. As a result, our management will have broad discretion in the allocation of the net proceeds and investors will be relying on the judgment of our management regarding the application of the proceeds of any sale of the securities. Pending use of the net proceeds, we intend to invest the proceeds in short-term, investment-grade, interest-bearing instruments.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each time we offer securities under this prospectus, we will describe the intended use of the net proceeds from that offering in the applicable prospectus supplement. The actual amount of net proceeds we spend on a particular use will depend on many factors, including, our future capital expenditures, the amount of cash required by our operations, and our future revenue growth, if any. Therefore, we will retain broad discretion in the use of the net proceeds.</font></div><div style="text-indent:36pt"><font><br></font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_25"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF CAPITAL STOCK</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following description of our capital stock, together with any additional information we include in any applicable prospectus supplement or any related free writing prospectus, summarizes the material terms and provisions of our common stock and the preferred stock that we may offer under this prospectus. While the terms we have summarized below will apply generally to any future common stock or preferred stock that we may offer, we will describe the particular terms of any class or series of these securities in more detail in the applicable prospectus supplement. For the complete terms of our common stock and preferred stock, please refer to our amended and restated certificate of incorporation, as amended (&#8220;Certificate of Incorporation&#8221;), and our bylaws that are incorporated by reference into the registration statement of which this prospectus is a part or may be incorporated by reference in this prospectus or any applicable prospectus supplement. The terms of these securities may also be affected by Delaware General Corporation Law (the &#8220;DGCL&#8221;). The summary below and that contained in any applicable prospectus supplement or any related free writing prospectus are qualified in their entirety by reference to our Certificate of Incorporation and our bylaws.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this prospectus, our authorized capital stock consisted of 150,000,000 shares of common stock, $0.0001 par value per share, and 20,000,000 shares of preferred stock, $0.001 par value per share. Our Board may establish the rights and preferences of the preferred stock from time to time. As of April 4, 2022, there were 43,306,061 shares of our common stock issued and outstanding, 60,600 shares of our Series A Convertible Preferred Stock issued and outstanding and 327,509 shares of our Series E Convertible Preferred Stock issued and outstanding.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are authorized to issue up to a total of 150,000,000 shares of common stock, par value $0.0001 per share. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of our stockholders. Holders of our common stock have no cumulative voting rights. All shares of common stock offered hereby will, when issued, be fully paid and nonassessable, including shares of common stock issued upon the exercise of common stock warrants or subscription rights, if any.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, holders of our common stock have no preemptive or conversion rights or other subscription rights. Upon our liquidation, dissolution or winding- up, holders of our common stock are entitled to share in all assets remaining after payment of all liabilities and the liquidation preferences of any of our outstanding shares of preferred stock. Subject to preferences that may be applicable to any outstanding shares of preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our Board of Directors out of our assets which are legally available. Such dividends, if any, are payable in cash, in property or in shares of capital stock.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of a majority of the shares of our capital stock, represented in person or by proxy, are necessary to constitute a quorum for the transaction of business at any meeting. If a quorum is present, an action by stockholders entitled to vote on a matter is approved if the number of votes cast in favor of the action exceeds the number of votes cast in opposition to the action, with the exception of the election of directors, which requires a plurality of the votes cast.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors has the authority, without further action by the stockholders, to issue up to 20,000,000 shares of preferred stock in one or more series and to fix the designations, powers, preferences, privileges, and relative participating, optional, or special rights as well as the qualifications, limitations, or restrictions of the preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, and liquidation preferences, any or all of which may be greater than the rights of the common stock. Our Board of Directors, without stockholder approval, can issue preferred stock with voting, conversion, or other rights that could adversely affect the voting power and other rights of the holders of common stock. Preferred stock could be issued quickly with terms calculated to delay or prevent a change of control or make removal of management more difficult. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of our common stock, and may adversely affect the voting and other rights of the holders of common stock. At present, we have no plans to issue any shares of preferred stock following this offering.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Anti-Takeover Effects of Certain Provisions of our Certificate of Incorporation, Bylaws and the DGCL</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are governed by the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a publicly traded Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A business combination includes mergers, asset sales or other transactions resulting in a financial benefit to the stockholder. An interested stockholder is a person who, together with affiliates and associates, owns (or within three years, did own) 15% or more of the corporation&#8217;s voting stock, subject to certain exceptions. The statute could have the effect of delaying, deferring or preventing a change in control of our Company.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Certificate of Incorporation and bylaws contain provisions that could have the effect of discouraging potential acquisition proposals or making a tender offer or delaying or preventing a change in control, including changes a stockholder might consider favorable. In particular, our Certificate of Incorporation and bylaws, as applicable, among other things&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide our Board of Directors with the ability to alter our bylaws without stockholder approval&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that vacancies on our Board of Directors may be filled by a majority of directors in office, although less than a quorum.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such provisions may have the effect of discouraging a third-party from acquiring us, even if doing so would be beneficial to our stockholders. These provisions are intended to enhance the likelihood of continuity and stability in the composition of our Board of Directors and in the policies formulated by them, and to discourage some types of transactions that may involve an actual or threatened change in control of our Company. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage some tactics that may be used in proxy fights. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our Company outweigh the disadvantages of discouraging such proposals because, among other things, negotiation of such proposals could result in an improvement of their terms.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, these provisions could have the effect of discouraging others from making tender offers for our shares that could result from actual or rumored takeover attempts. These provisions also may have the effect of preventing changes in our management.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Listing</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on The Nasdaq Capital Market under the trading symbol &#8220;CRDF.&#8221;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transfer Agent and Registrar</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Transfer Agent and Registrar for our common stock is Philadelphia Stock Transfer,&#160;Inc.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_28"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF DEBT SECURITIES</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following description, together with the additional information we include in any applicable prospectus supplements or free writing prospectuses, summarizes the material terms and provisions of the debt securities that we may offer under this prospectus. We may issue debt securities, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any future debt securities we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement or free writing prospectus. The terms of any debt securities we offer under a prospectus supplement may differ from the terms we describe below. However, no prospectus supplement shall fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness. As of the date of this prospectus, we have no outstanding registered debt securities. Unless the context requires otherwise, whenever we refer to the &#8220;indentures,&#8221; we also are referring to any supplemental indentures that specify the terms of a particular series of debt securities.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will issue any senior debt securities under the senior indenture that we will enter into with the trustee named in the senior indenture. We will issue any subordinated debt securities under the subordinated indenture and any supplemental indentures that we will enter into with the trustee named in the subordinated indenture. We have filed forms of these documents as exhibits to the registration statement, of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indentures will be qualified under the Trust Indenture Act of 1939, as amended (the &#8220;Trust Indenture Act&#8221;). We use the term &#8220;trustee&#8221; to refer to either the trustee under the senior indenture or the trustee under the subordinated indenture, as applicable.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summaries of material provisions of the senior debt securities, the subordinated debt securities and the indentures are subject to, and qualified in their entirety by reference to, all of the provisions of the indenture and any supplemental indentures applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indentures that contains the terms of the debt securities. Except as we may otherwise indicate, the terms of the senior indenture and the subordinated indenture are identical.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of each series of debt securities will be established by or pursuant to a resolution of our Board of Directors and set forth or determined in the manner provided in an officers&#8217; certificate or by a supplemental indenture. Debt securities may be issued in separate series without limitation as to aggregate principal amount. We may specify a maximum aggregate principal amount for the debt securities of any series. We will describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the title&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the principal amount being offered, and if a series, the total amount authorized and the total amount outstanding&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any limit on the amount that may be issued&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether or not we will issue the series of debt securities in global form, and, if so, the terms and who the depositary will be&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the maturity date&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether and under what circumstances, if any, we will pay additional amounts on any debt securities held by a person who is not a United States person for tax purposes, and whether we can redeem the debt securities if we have to pay such additional amounts&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the annual interest rate, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the terms of the subordination of any series of subordinated debt&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the place where payments will be made&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on transfer, sale or other assignment, if any&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our right, if any, to defer payment of interest and the maximum length of any such deferral period&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the date, if any, after which, and the price at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provisions for a sinking fund purchase or other analogous fund, if any, including the date, if any, on which, and the price at which we are obligated, pursuant thereto or otherwise, to redeem, or at the holder&#8217;s option, to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether the indenture will restrict our ability or the ability of our subsidiaries, if any, to&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur additional indebtedness&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue additional securities&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">create liens&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pay dividends or make distributions in respect of our capital stock or the capital stock of our subsidiaries&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">redeem capital stock&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">place restrictions on our subsidiaries&#8217; ability to pay dividends, make distributions or transfer assets&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make investments or other restricted payments&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sell or otherwise dispose of assets&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into sale-leaseback transactions&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engage in transactions with stockholders or affiliates&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue or sell stock of our subsidiaries&#59; or</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effect a consolidation or merger&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether the indenture will require us to maintain any interest coverage, fixed charge, cash flow-based, asset-based or other financial ratios&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a discussion of certain material or special United States federal income tax considerations applicable to the debt securities&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">information describing any book-entry features&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the applicability of the provisions in the indenture on discharge&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether the debt securities are to be offered at a price such that they will be deemed to be offered at an &#8220;original issue discount&#8221; as defined in paragraph (a)&#160;of Section&#160;1273 of the Internal Revenue Code of 1986, as amended&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, including any additional events of default or covenants provided with respect to the debt securities, and any terms that may be required by us or advisable under applicable laws or regulations.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conversion or Exchange Rights</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will set forth in the applicable prospectus supplement the terms under which a series of debt securities may be convertible into or exchangeable for our common stock, our preferred stock or other securities (including securities of a third party). We will include provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock, our preferred stock or other securities (including securities of a third party) that the holders of the series of debt securities receive would be subject to adjustment.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidation, Merger or Sale</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indentures will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dispose of all or substantially all of our assets. However, any successor to or acquirer of such assets must assume all of our obligations under the indentures or the debt securities, as appropriate. If the debt securities are convertible into or exchangeable for our other securities or securities of other entities, the person with whom we consolidate or merge or to whom we sell all of our property must make provisions for the conversion of the debt securities into securities that the holders of the debt securities would have received if they had converted the debt securities before the consolidation, merger or sale.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Events of Default under the Indenture</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indentures with respect to any series of debt securities that we may issue&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if we fail to pay interest when due and payable and our failure continues for 90 days and the time for payment has not been extended&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if we fail to pay the principal, premium or sinking fund payment, if any, when due and payable at maturity, upon redemption or repurchase or otherwise, and the time for payment has not been extended&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if we fail to observe or perform any other covenant contained in the debt securities or the indentures, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive notice from the trustee or we and the trustee receive notice from the holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if specified events of bankruptcy, insolvency or reorganization occur.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will describe in each applicable prospectus supplement any additional events of default relating to the relevant series of debt securities.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default arises due to the occurrence of certain specified bankruptcy, insolvency or reorganization events, the unpaid principal, premium, if any, and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of the indentures, if an event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity or security satisfactory to it against any loss, liability or expense. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the direction so given by the holder is not in conflict with any law or the applicable indenture&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indentures will provide that if an event of default has occurred and is continuing, the trustee will be required in the exercise of its powers to use the degree of care that a prudent person would use in the conduct of its own affairs. The trustee, however, may refuse to follow any direction that conflicts with law or the indenture, or that the trustee determines is unduly prejudicial to the rights of any other holder of the relevant series of debt securities, or that would involve the trustee in personal</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liability. Prior to taking any action under the indentures, the trustee will be entitled to indemnification against all costs, expenses and liabilities that would be incurred by taking or not taking such action.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A holder of the debt securities of any series will have the right to institute a proceeding under the indentures or to appoint a receiver or trustee, or to seek other remedies only if&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the holder has given written notice to the trustee of a continuing event of default with respect to that series&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made a written request and such holders have offered reasonable indemnity to the trustee or security satisfactory to it against any loss, liability or expense or to be incurred in compliance with instituting the proceeding as trustee&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within 90 days after the notice, request and offer.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities, or other defaults that may be specified in the applicable prospectus supplement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will periodically file statements with the trustee regarding our compliance with specified covenants in the indentures.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indentures will provide that if a default occurs and is continuing and is actually known to a responsible officer of the trustee, the trustee must mail to each holder notice of the default within the earlier of 90 days after it occurs and 30 days after it is known by a responsible officer of the trustee or written notice of it is received by the trustee, unless such default has been cured or waived. Except in the case of a default in the payment of principal or premium of, or interest on, any debt security or certain other defaults specified in an indenture, the trustee shall be protected in withholding such notice if and so long as the Board of Directors, the executive committee or a trust committee of directors, or responsible officers of the trustee, in good faith determine that withholding notice is in the best interests of holders of the relevant series of debt securities.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Modification of Indenture&#59; Waiver</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of the indenture for any series of debt securities that we may issue, we and the trustee may change an indenture without the consent of any holders with respect to the following specific matters&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">to fix any ambiguity, defect or inconsistency in the indenture&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">to comply with the provisions described above under &#8220;Description of Debt Securities &#8212; Consolidation, Merger or Sale&#59;&#8221;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">to add to, delete from or revise the conditions, limitations and restrictions on the authorized amount, terms or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">to provide for the issuance of, and establish the form and terms and conditions of, the debt securities of any series as provided under &#8220;Description of Debt Securities &#8212; General,&#8221; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">to evidence and provide for the acceptance of appointment hereunder by a successor trustee&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">to provide for uncertificated debt securities and to make all appropriate changes for such purpose&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">to add such new covenants, restrictions, conditions or provisions for the benefit of the holders, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred to us in the indenture&#59; or</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">to change anything that does not adversely affect the interests of any holder of debt securities of any series in any material respect.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the indentures, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, subject to the terms of the indenture for any series of debt securities that we may issue or otherwise provided in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may only make the following changes with the consent of each holder of any outstanding debt securities affected&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">extending the stated maturity of the series of debt securities&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption or repurchase of any debt securities&#59; or</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discharge</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each indenture provides that, subject to the terms of the indenture and any limitation otherwise provided in the prospectus supplement applicable to a particular series of debt securities, we may elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations to&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">register the transfer or exchange of debt securities of the series&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">replace stolen, lost or mutilated debt securities of the series&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">maintain paying agencies&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">hold monies for payment in trust&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">recover excess money held by the trustee&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">compensate and indemnify the trustee&#59; and</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">appoint any successor trustee.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to exercise our rights to be discharged, we will deposit with the trustee money or government obligations sufficient to pay all the principal of, and any premium and interest on, the debt securities of the series on the dates payments are due.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form, Exchange and Transfer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will issue the debt securities of each series only in fully registered form without coupons and, unless we otherwise specify in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indentures will provide that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company or another depositary named by us and identified in a prospectus supplement with respect to that series. See &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Ownership of Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; below for a further description of the terms relating to any book-entry securities.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the option of the holder, subject to the terms of the indentures and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of the indentures and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will make no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we elect to redeem the debt securities of any series, we will not be required to&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing&#59; or</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information Concerning the Trustee</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture and is under no obligation to exercise any of the powers given it by the indentures at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur. However, upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Payment and Paying Agents</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest payment.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governing Law</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indentures and the debt securities will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act is applicable.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ranking Debt Securities</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The subordinated debt securities will be unsecured and will be subordinate and junior in priority of payment to certain other indebtedness to the extent described in a prospectus supplement. The subordinated indenture does not limit the amount of subordinated debt securities that we may issue. It also does not limit us from issuing any other secured or unsecured debt.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The senior debt securities will be unsecured and will rank equally in right of payment to all our other senior unsecured debt. The senior indenture does not limit the amount of senior debt securities that we may issue. It also does not limit us from issuing any other secured or unsecured debt.</font></div><div><font><br></font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_31"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF WARRANTS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following description, together with the additional information we may include in any applicable prospectus supplements and free writing prospectuses, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock or debt securities and may be issued in one or more series. Warrants may be offered independently or together with common stock, preferred stock or debt securities offered by any prospectus supplement, and may be attached to or separate from those securities. While the terms we have summarized below will apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants that we may offer in more detail in the applicable prospectus supplement and any applicable free writing prospectus. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may issue the warrants under a warrant agreement that we will enter into with a warrant agent to be selected by us. If selected, the warrant agent will act solely as an agent of ours in connection with the warrants and will not act as an agent for the holders or beneficial owners of the warrants. If applicable, we will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from a Current Report on Form&#160;8-K that we file with the SEC, the form of warrant agreement, including a form of warrant certificate, that describes the terms of the particular series of warrants we are offering before the issuance of the related series of warrants. The following summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to a particular series of warrants. We urge you to read the applicable prospectus supplement and any applicable free writing prospectus related to the particular series of warrants that we sell under this prospectus, as well as the complete warrant agreements and warrant certificates that contain the terms of the warrants.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will describe in the applicable prospectus supplement the terms relating to a series of warrants, including&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the offering price and aggregate number of warrants offered&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the currency for which the warrants may be purchased&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if applicable, the date on and after which the warrants and the related securities will be separately transferable&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the terms of any rights to redeem or call the warrants&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the dates on which the right to exercise the warrants will commence and expire&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the manner in which the warrant agreements and warrants may be modified&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">United States federal income tax consequences of holding or exercising the warrants&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the terms of the securities issuable upon exercise of the warrants&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture&#59; or</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise of Warrants</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the warrants may exercise the warrants by delivering the warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to us or the warrant agent as applicable.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon receipt of the required payment and the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised, then we will issue a new warrant certificate for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Enforceability of Rights by Holders of Warrants</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If selected, each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants.</font></div><div><font><br></font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_34"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF UNITS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following description, together with the additional information we may include in any applicable prospectus supplements and free writing prospectuses, summarizes the material terms and provisions of the units that we may offer under this prospectus.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the terms we have summarized below will apply generally to any units that we may offer under this prospectus, we will describe the particular terms of any series of units in more detail in the applicable prospectus supplement. The terms of any units offered under a prospectus supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from a Current Report on Form&#160;8-K that we file with the SEC, the form of unit agreement that describes the terms of the series of units we are offering, and any supplemental agreements, before the issuance of the related series of units. The following summaries of material terms and provisions of the units are subject to, and qualified in their entirety by reference to, all the provisions of the unit agreement and any supplemental agreements applicable to a particular series of units. We urge you to read the applicable prospectus supplements related to the particular series of units that we sell under this prospectus, as well as the complete unit agreement and any supplemental agreements that contain the terms of the units.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may issue units comprised of one or more debt securities, shares of common stock, shares of preferred stock and warrants in any combination. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will describe in the applicable prospectus supplement the terms of the series of units, including&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any provisions of the governing unit agreement that differ from those described below&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provisions described in this section, as well as those described under &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of Capital Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of Debt Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; will apply to each unit and to any common stock, preferred stock, debt security or warrant included in each unit, respectively.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unit Agent</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The name and address of the unit agent, if any, for any units we offer will be set forth in the applicable prospectus supplement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuance in Series</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may issue units in such amounts and in numerous distinct series as we determine.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Enforceability of Rights by Holders of Units</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each unit agent will act solely as our agent under the applicable unit agreement and will not assume any obligation or relationship of agency or trust with any holder of any unit. A single bank or trust company may act as unit agent for more than one series of units. A unit agent will have no duty or responsibility in case of any default by us under the applicable unit agreement or unit, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a unit may, without the consent of the related unit agent or the holder of any other unit, enforce by appropriate legal action its rights as holder under any security included in the unit.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, the unit agents and any of their agents may treat the registered holder of any unit certificate as an absolute owner of the units evidenced by that certificate for any purpose and as the person entitled to exercise the rights attaching to the units so requested, despite any notice to the contrary. See &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Ownership of Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</font></div><div><font><br></font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_37"></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL OWNERSHIP OF SECURITIES</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee or depositary or warrant agent maintain for this purpose as the &#8220;holders&#8221; of those securities. These persons are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#8220;indirect holders&#8221; of those securities. As we discuss below, indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Book-Entry Holders</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary&#8217;s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Only the person in whose name a security is registered is recognized as the holder of that security. Global securities will be registered in the name of the depositary or its participants. Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with their customers&#59; they are not obligated to do so under the terms of the securities.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, investors in a global security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary&#8217;s book-entry system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Street Name Holders</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate a global security or issue securities that are not issued in global form. In these cases, investors may choose to hold their securities in their own names or in &#8220;street name.&#8221; Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as the holders of those securities, and we or any such trustee or depositary will make all payments on those securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not legal holders, of those securities.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Holders</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations, as well as the obligations of any applicable trustee or third party employed by us or a trustee, run only to the legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, once we make a payment or give a notice to the holder, we have no further responsibility for the payment or notice even if that holder is required, under agreements with its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of an indenture, or for other purposes. In such an event, we would seek approval only from the legal holders, and not the indirect holders, of the securities. Whether and how the legal holders contact the indirect holders is up to the legal holders.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Special Considerations for Indirect Holders</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you hold securities through a bank, broker or other financial institution, either in book-entry form because the securities are represented by one or more global securities or in street name, you should check with your own institution to find out&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">how it handles securities payments and notices&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether it imposes fees or charges&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">how it would handle a request for the holders&#8217; consent, if ever required&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether and how you can instruct it to send you securities registered in your own name so you can be a legal holder, if that is permitted in the future&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if the securities are in book-entry form, how the depositary&#8217;s rules&#160;and procedures will affect these matters.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Global Securities</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each security issued in book-entry form will be represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, The Depository Trust Company, New York, NY, known as DTC, will be the depositary for all securities issued in book-entry form.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We describe those situations below under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;&#8212; Special Situations When A Global Security Will Be Terminated</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the security, but only an indirect holder of a beneficial interest in the global security.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the prospectus supplement for a particular security indicates that the security will be issued as a global security, then the security will be represented by a global security at all times unless and until the global security is terminated. If termination </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Special Considerations For Global Securities</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an indirect holder, an investor&#8217;s rights relating to a global security will be governed by the account rules&#160;of the investor&#8217;s financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are issued only as global securities, an investor should be aware of the following&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">an investor cannot cause the securities to be registered in his or her name, and cannot obtain non-global certificates for his or her interest in the securities, except in the special situations we describe below&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in non-book-entry form&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">an investor may not be able to pledge his or her interest in the global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the depositary&#8217;s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor&#8217;s interest in the global security. We and any applicable trustee have no responsibility for any aspect of the depositary&#8217;s actions or for its records of ownership interests in the global security. We and the trustee also do not supervise the depositary in any way&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in the global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">financial institutions that participate in the depositary&#8217;s book-entry system, and through which an investor holds its interest in the global security, may also have their own policies affecting payments, notices and other matters relating to the securities. There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Special Situations When A Global Security Will Be Terminated</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a few special situations described below, a global security will terminate and interests in it will be exchanged for physical certificates representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in securities transferred to their own names, so that they will be direct holders. We have described the rights of holders and street name investors above.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A global security will terminate when the following special situations occur&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90 days&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if we notify any applicable trustee that we wish to terminate that global security&#59; or</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular series of securities covered by the prospectus supplement. When a global security terminates, the </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">depositary, and neither we, nor any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders.</font></div><div><font><br></font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_40"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PLAN OF DISTRIBUTION</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may sell the securities being offered hereby in one or more of the following ways from time to time&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">through agents to the public or to investors&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">to underwriters for resale to the public or to investors&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">negotiated transactions&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">block trades&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">directly to investors&#59; or</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">through a combination of any of these methods of sale.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As set forth in more detail below, the securities may be distributed from time to time in one or more transactions&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">at a fixed price or prices, which may be changed&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">at market prices prevailing at the time of sale&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">at prices related to such prevailing market prices&#59; or</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">at negotiated prices.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will set forth in a prospectus supplement the terms of that particular offering of securities, including&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the name or names of any agents or underwriters&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the purchase price of the securities being offered and the proceeds we will receive from the sale&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any over-allotment options under which underwriters may purchase additional securities from us&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any agency fees or underwriting discounts and other items constituting agents&#8217; or underwriters&#8217; compensation&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any initial public offering price&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any discounts or concessions allowed or re-allowed or paid to dealers&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any securities exchanges or markets on which such securities may be listed.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Only underwriters named in an applicable prospectus supplement are underwriters of the securities offered by that prospectus supplement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If underwriters are used in an offering, we will execute an underwriting agreement with such underwriters and will specify the name of each underwriter and the terms of the transaction (including any underwriting discounts and other terms constituting compensation of the underwriters and any dealers) in a prospectus supplement. The securities may be offered to the public either through underwriting syndicates represented by managing underwriters or directly by one or more investment banking firms or others, as designated. If an underwriting syndicate is used, the managing underwriter(s)&#160;will be specified on the cover of the prospectus supplement. If underwriters are used in the sale, the offered securities will be acquired by the underwriters for their own accounts and may be resold from time to time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. Any public offering price and any discounts or concessions allowed or re-allowed or paid to dealers may be changed from time to time. Unless otherwise</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">set&#160;forth in the prospectus supplement, the obligations of the underwriters to purchase the offered securities will be subject to conditions precedent and the underwriters will be obligated to purchase all of the offered securities if any are purchased.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may grant to the underwriters options to purchase additional securities to cover over-allotments, if any, at the public offering price, with additional underwriting commissions or discounts, as may be set forth in a related prospectus supplement. The terms of any over-allotment option will be set forth in the prospectus supplement for those securities.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we use a dealer in the sale of the securities being offered pursuant to this prospectus or any prospectus supplement, we will sell the securities to the dealer, as principal.&#160; The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale.&#160; The names of the dealers and the terms of the transaction will be specified in a prospectus supplement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may sell the securities directly or through agents we designate from time to time.&#160; We will name any agent involved in the offering and sale of securities and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, any agent will act on a best-efforts basis for the period of its appointment.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may authorize agents or underwriters to solicit offers by institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the sale of the securities, underwriters, dealers or agents may receive compensation from us or from purchasers of the common stock for whom they act as agents in the form of discounts, concessions or commissions. Underwriters may sell the securities to or through dealers, and those dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters or commissions from the purchasers for whom they may act as agents. Underwriters, dealers and agents that participate in the distribution of the securities, and any institutional investors or others that purchase common stock directly and then resell the securities, may be deemed to be underwriters, and any discounts or commissions received by them from us and any profit on the resale of the common stock by them may be deemed to be underwriting discounts and commissions under the Securities Act.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may provide agents and underwriters with indemnification against particular civil liabilities, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to such liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may engage in at the market offerings into an existing trading market in accordance with Rule&#160;415(a)(4)&#160;under the Securities Act.&#160; In addition, we may enter into derivative transactions with third parties (including the writing of options), or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with such a transaction, the third parties may, pursuant to this prospectus and the applicable prospectus supplement, sell securities covered by this prospectus and the applicable prospectus supplement. If so, the third party may use securities borrowed from us or others to settle such sales and may use securities received from us to close out any related short positions. We may also loan or pledge securities covered by this prospectus and the applicable prospectus supplement to third parties, who may sell the loaned securities or, in an event of default in the case of a pledge, sell the pledged securities pursuant to this prospectus and the applicable prospectus supplement. The third party in such sale transactions will be an underwriter and will be identified in the applicable prospectus supplement or in a post-effective amendment.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To facilitate an offering of a series of securities, persons participating in the offering may engage in transactions that stabilize, maintain, or otherwise affect the market price of the securities. This may include over-allotments or short sales of the securities, which involves the sale by persons participating in the offering of more securities than have been sold to them by us. In those circumstances, such persons would cover such over-allotments or short positions by purchasing in the open market or by exercising the over-allotment option granted to those persons. In addition, those persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in the open market or by imposing penalty bids, whereby selling concessions allowed to underwriters or dealers participating in any such offering may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of the securities at a level above that which might otherwise prevail in the open market. Such transactions, if commenced, may be discontinued at any time. We make no representation or prediction as to the direction or magnitude of any effect that the transactions described above, if implemented, may have on the price of our securities.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</font></div></div></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_43"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise specified in the applicable prospectus supplement, each class or series of securities will be a new issue with no established trading market, other than our common stock, which is listed on The Nasdaq Capital Market. We may elect to list any other class or series of securities on any exchange or market, but we are not obligated to do so. It is possible that one or more underwriters may make a market in a class or series of securities, but the underwriters will not be obligated to do so and may discontinue any market making at any time without notice. We cannot give any assurance as to the liquidity of the trading market for any of the securities.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to comply with the securities laws of some U.S. states or territories, if applicable, the securities offered pursuant to this prospectus will be sold in those states only through registered or licensed brokers or dealers. In addition, in some states securities may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and complied with.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of these activities at any time.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any underwriters who are qualified market makers on The Nasdaq Capital Market may engage in passive market making transactions in the securities on The Nasdaq Capital Market in accordance with Rule&#160;103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security. If all independent bids are lowered below the passive market maker&#8217;s bid, however, the passive market maker&#8217;s bid must then be lowered when certain purchase limits are exceeded.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL MATTERS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The validity of the issuance of the securities offered hereby will be passed upon for us by Sheppard, Mullin, Richter&#160;&#38; Hampton LLP, New York, NY.&#160; Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_46"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXPERTS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements as of December 31, 2021 and 2020 and for the years then ended incorporated by reference in this prospectus and in the registration statement have been so incorporated in reliance on the report of BDO USA, LLP, an independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting.</font></div><div style="text-indent:36pt"><font><br></font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_49"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHERE YOU CAN FIND MORE INFORMATION</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus constitutes a part of the registration statement on&#160;Form&#160;S-3&#160;that&#160;we have filed with the SEC under the Securities Act. As permitted by the SEC&#8217;s rules, this prospectus supplement and any accompanying prospectus, which forms a part of the registration statement, do not contain all of the information that is included in the registration statement. You will find additional information about us in the registration statement. Any statement made in this prospectus supplement or any accompanying prospectus concerning legal documents are not necessarily complete and you should read the documents that are filed as exhibits to the registration statement or otherwise filed with the SEC for a more complete understanding of the document or matter.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Exchange Act and file annual, quarterly and current reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, over the Internet at the SEC&#8217;s website at</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> http&#58;&#47;&#47;www.sec.gov</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We also maintain a website at</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> www.cardiffoncology.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You may also read and copy any document we file with the SEC at its public reference facilities at 100 F Street, N.E., Room 1580, Washington, DC 20549. You may also obtain copies of these documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference facilities. You may also request a copy of these filings, at no cost, by writing or telephoning us at&#58; 11055 Flintkote Avenue, San Diego, California, 92121, (858) 952-7570.</font></div><div style="text-indent:36pt"><font><br></font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_52"></div><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCORPORATION OF DOCUMENTS BY REFERENCE</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus supplement is part of the registration statement, but the registration statement includes and incorporates by reference additional information and exhibits. The SEC permits us to &#8220;incorporate by reference&#8221; the information contained in documents we file with the SEC, which means that we can disclose important information to you by referring you to those documents rather than by including them in this prospectus supplement. Information that is incorporated by reference is considered to be part of this prospectus supplement and you should read it with the same care that you read this prospectus supplement and the accompanying prospectus. Information that we file later with the SEC will automatically update and supersede the information that is either contained, or incorporated by reference, in this prospectus supplement, and will be considered to be a part of this prospectus supplement from the date those documents are filed.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate by reference the documents listed below, all filings filed by us pursuant to the Exchange Act after the date of the registration statement of which this prospectus supplement and the accompanying prospectus forms a part, and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d)&#160;of the Exchange Act prior to the time that all securities covered by this prospectus supplement have been sold&#59; provided, however, that we are not incorporating any information furnished under either Item 2.02 or Item 7.01 of any current report on&#160;Form&#160;8-K&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1213037/000162828022003808/crdf-20211231.htm" style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on February 24, 2022</a></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our Current Reports on Form 8-K filed on </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1213037/000162828022000669/crdf-20220111.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">January 11</a><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1213037/000162828022000669/crdf-20220111.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">, 2022</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1213037/000162828022001039/crdf-20220118.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">January 18,2022</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1213037/000162828022001522/crdf-20220131.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">January 31, 2022</a></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828021007919/a2021proxy.htm" style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">our definitive Proxy Statement on Schedule 14a for our 2021 Annual Meeting of Stockholders, filed with the SEC on April 28, 2021</a></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000110465912039425/a12-9768_98a12b.htm" style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">the description of our common stock contained in our Registration Statement on Form 8-A filed with the Commission on May 23, 2012, including any amendments or reports filed with the SEC for the purposes of updating such description</a></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any statements made in a document incorporated by reference in this prospectus supplement are deemed to be modified or superseded for purposes of this prospectus supplement to the extent that a statement in this prospectus supplement or in any other subsequently filed document, which is also incorporated by reference, modifies or supersedes the statement. Any statement made in this prospectus supplement is deemed to be modified or superseded to the extent a statement in any subsequently filed document, which is incorporated by reference in this prospectus supplement, modifies or supersedes such statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information relating to us contained in this prospectus supplement should be read together with the information in the documents incorporated by reference. In addition, certain information, including financial information, contained in this prospectus or incorporated by reference in this prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">should be read in conjunction with documents we have filed with the SEC.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will provide to each person, including any beneficial holder, to whom a prospectus is delivered, at no cost, upon written or oral request, a copy of any or all of the information that has been incorporated by reference in the prospectus but not delivered with the prospectus. Requests for documents should be by writing to or telephoning us at the following address&#58; Cardiff Oncology, Inc., 11055 Flintkote Avenue, San Diego, CA 92121&#59; (858) 952-7570. Exhibits to these filings will not be sent unless those exhibits have been specifically incorporated by reference in such filings.</font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_58"></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#ff4040;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The information in this prospectus is not complete and may be changed. We may not sell these securities or accept an offer to buy these securities until the registration statement filed with the U.S. Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and we are not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#ff4040;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">PRELIMINARY PROSPECTUS</font></div><div style="text-align:center"><font style="color:#ff4040;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Subject to completion, dated April 5, 2022</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                                                       </font></div><div><font><br></font></div><div style="text-align:center"><img alt="cardiff_logoxrgbxtma.jpg" src="cardiff_logoxrgbxtma.jpg" style="height:38px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:103%">Up to $100,000,000 </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:103%">Common Stock</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into an Open Market Sale Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">SM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or the Sales Agreement, with Jefferies LLC, or Jefferies, dated March 12, 2021, relating to shares of our common stock, par value $0.0001 per share, offered by this prospectus. In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $100 million from time to time through Jefferies, acting as sales agent. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades on The Nasdaq Capital Market under the symbol &#8220;CRDF.&#8221; On April 4, 2022, the last reported sale price of our common stock on the Nasdaq Capital Market was $2.61 per share.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our common stock, if any, under this prospectus may be made in sales deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Jefferies is not required to sell any specific number or dollar amount of securities, but will act as sales agent on a best efforts basis and use commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by us, consistent with its normal trading and sales practices, on mutually agreed terms between us and Jefferies. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jefferies will be entitled to compensation at a fixed commission rate of 3.0% of the gross sales price per common share sold under the Sales Agreement. In connection with the sale of our common stock on our behalf, Jefferies will be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act and the compensation of Jefferies will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Jefferies with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended or the Exchange Act.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:99%">Investing in our common stock involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page 9 of this prospectus and in the documents incorporated by reference into this prospectus.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:88%">Neither the Securities and Exchange Commission (the &#8220;SEC&#8221;) nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus or the accompanying prospectus. Any representation to the contrary is a criminal offense.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:88%">Jefferies</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:88%">The date of this prospectus is April    , 2022. </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_61"></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PROSPECTUS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">About This Prospectus</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_64" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Disclosure Regarding Forward-Looking Statements</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_67" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Prospectus Summary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_70" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Offering</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Risk Factors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_76" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Use of Proceeds</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_79" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dilution</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_82" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Plan of Distribution</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_85" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Legal Matters</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_88" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">16</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Experts</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_91" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">16</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Where You Can Find More Information</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_94" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">16</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Incorporation of Documents by Reference</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_97" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">16</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are responsible for the information contained and incorporated by reference in this prospectus, in any accompanying prospectus supplement, and in any related free writing prospectus we prepare or authorize. We have not and Jefferies has not authorized anyone to give you any other information, and neither we nor Jefferies take any responsibility for any other information that others may give you. If you are in a jurisdiction where offers to sell, or solicitations of offers to purchase, the securities offered by this documentation are unlawful, or if you are a person to whom it is unlawful to direct these types of activities, then the offer presented in this document does not extend to you. The information contained in this document speaks only as of the date of this document, unless the information specifically indicates that another date applies. Our business, financial condition, results of operations and prospects may have changed since those dates.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_64"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ABOUT THIS PROSPECTUS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus relates to the offering of our common stock. Before buying any of the common stock that we are offering, we urge you to carefully read this prospectus, together with the accompanying prospectus and the information incorporated by reference as described under the heading &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Documents by Reference.&#8221; This prospectus is deemed a prospectus to the accompanying prospectus contained in the registration statement of which this prospectus forms a part. These documents contain important information that you should consider when making your investment decision.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus describes the specific terms of the common stock we are offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus. To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the accompanying prospectus and the information contained in any document incorporated by reference in this prospectus, on the other hand, you should rely on the information in this prospectus. If any statement in one of these documents is inconsistent with a statement in another document having a later date&#8212;for example, a document incorporated by reference into this prospectus&#8212;the statement in the document having the later date modifies or supersedes the earlier statement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should rely only on the information contained or incorporated by reference in this prospectus and the accompanying prospectus or contained in any free writing prospectus prepared by or on our behalf. We have not, and the underwriters have not, authorized anyone to provide you with different information. The distribution of this prospectus and sale of these securities in certain jurisdictions may be restricted by law. We are not, and the underwriters are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus, the accompanying prospectus and the documents incorporated by reference in this prospectus, and in any free writing prospectus that we have authorized for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks, service marks or trade names of any other companies appearing in this prospectus  are the property of their respective owners. Use or display by us of trademarks, service marks or trade names owned by others is not intended to and does not imply a relationship between us and, or endorsement or sponsorship by, the owners of the trademarks, service marks or trade names.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_67"></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus, the accompanying prospectus and the documents incorporated by reference herein and therein contain, in addition to historical information, certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act that include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation and availability of resources. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets or future development and&#47;or otherwise are not statements of historical fact. These forward-looking statements are based on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown that could cause actual results and developments to differ materially from those expressed or implied in such statements.</font></div><div><font><br></font></div><div style="text-indent:42.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by terminology, such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;may,&#8221; &#8220;should&#8221;, &#8220;could&#8221; or the negative of such terms or other similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout this prospectus or incorporated herein by reference.</font></div><div><font><br></font></div><div style="text-indent:42.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks, uncertainties and other factors that may cause our actual results, performance or achievements to be different from those expressed or implied in our written or oral forward-looking statements may be found in this prospectus under the heading &#8220;Risk Factors&#8221; and in our Annual Report on Form 10-K for the year ended December 31, 2021 under the headings &#8220;Risk Factors&#8221; and &#8220;Business,&#8221; as updated in our Quarterly Report(s) on Form 10-Q.</font></div><div><font><br></font></div><div style="text-indent:42.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements speak only as of the date they are made. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.</font></div><div><font><br></font></div><div style="text-indent:42.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of the information presented in this prospectus and incorporated herein by reference, and particularly our forward-looking statements, by these cautionary statements.</font></div><div style="text-align:justify;text-indent:42.85pt"><font><br></font></div><div><font><br></font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_70"></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:6.75pt 13.50pt 6.75pt 13.50pt"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROSPECTUS SUMMARY</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following summary highlights certain of the information contained elsewhere in or incorporated by reference into this prospectus. Because this is only a summary, however, it does not contain all the information you should consider before investing in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information included elsewhere in or incorporated by reference into this prospectus. Before you make an investment decision, you should read this entire prospectus and the accompanying prospectus carefully, including the risks of investing in our securities discussed under the section of this prospectus entitled &#8220;Risk Factors&#8221; and similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless the context otherwise requires, references to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;Cardiff&#8221; or the &#8220;Company&#8221; in this prospectus mean Cardiff Oncology,&#160;Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations that overcome disease resistance and improve disease response to standard treatment regimens and to increase overall survival. We are developing onvansertib, an oral and highly-selective Polo-like Kinase 1 (&#34;PLK1&#34;) inhibitor, in combination with standard-of-care anti-cancer therapeutics. Our clinical development programs incorporate tumor genomics and biomarker assays to refine assessment of patient response to treatment.</font></div><div style="text-indent:33.75pt"><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Drug Candidate, Onvansertib</font></div><div><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onvansertib, our lead compound, is a novel, highly potent, highly selective PLK1 inhibitor.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PLK1, a serine&#47;threonine kinase, has a well-understood mechanism of action within tumor cell proliferation and is overexpressed in a number of tumors (including colorectal, pancreatic, prostate, ovarian, breast and lung cancer). In particular, PLK1&#8217;s activity in various phases of the cell cycle provide multiple targets for a PLK1 inhibitor to inhibit DNA repair and interrupt cell division, thereby killing tumor cells.</font></div><div><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PLK1 inhibition has been considered an attractive target of anti-tumor therapeutics for the last two decades, however past PLK1 drug candidates have failed to show acceptable tolerability and efficacy. We believe the attributes of onvansertib described below, as well as clinical evidence of favorable safety and efficacy, with expected on-target, easy to manage and reversible side effects, may prove beneficial in addressing clinical therapeutic needs across a variety of cancers&#58;</font></div><div style="text-indent:33.75pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Onvansertib is highly potent and highly selective against the PLK1 enzyme (IC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:1.4pt;vertical-align:baseline">50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#61; 2nM&#59; IC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:1.4pt;vertical-align:baseline">50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> is the concentration for 50% inhibition), compared to prior PLK1 inhibitors that were pan-inhibitors of several PLK targets.  Low or no activity of onvansertib was observed on a panel of 63 kinases (IC50&#62;500 nM), including the PLK members PLK2 and PLK3 (IC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:1.4pt;vertical-align:baseline">50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#62;10,000 nM).</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Onvansertib has a relatively short drug half-life of 24 hours, compared to a half-life of approximately 5 days for prior PLK1 inhibitors.  A short half-life allows for flexible dosing and improved managing of drug concentrations to reduce dose-related toxicities.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Onvansertib is orally bioavailable, compared to prior PLK1 inhibitors that were delivered intravenously, allowing for relative ease of dosing.</font></div><div style="text-indent:33.75pt"><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In vitro studies have shown synergistic effects when onvansertib was administered in combination with different cytotoxic agents including antimicrotubule agents, topoisomerase 1 inhibitors, antimetabolites, alkylating agents, proteasome inhibitors, kinase inhibitors, BCL-2 inhibitors, and androgen biosynthesis inhibitors.</font></div><div style="text-indent:33.75pt"><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in vivo combination studies have confirmed the positive results obtained in vitro and synergistic effects have been observed in xenograft models of onvansertib in combination with irinotecan (including NKTR-102), 5-fluorouracil (&#34;5-FU&#34;), abiraterone, quizartinib, venetoclax, and paclitaxel, while additive effects in combination with cytarabine or bevacizumab have been demonstrated.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:6.75pt 13.50pt 6.75pt 13.50pt"><div style="text-indent:33.75pt"><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are three ongoing clinical trials in onvansertib in combination treatment&#58; second line treatment in patients with KRAS-mutated Metastatic Colorectal Cancer (&#34;mCRC&#34;), second line treatment in patients with Metastatic Pancreatic Ductal Adenocarcinoma (&#34;mPDAC&#34;), and in patients with Metastatic Castration-Resistant Prostate Cancer (&#34;mCRPC&#34;) showing resistance to abiraterone.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:102%">Phase 1b&#47;2 Clinical Trial in KRAS-mutated mCRC</font></div><div><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TROV-054 is a Phase 1b&#47;2 open-label multi-center clinical trial of onvansertib in combination with standard of care FOLFIRI and bevacizumab (Avastin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the second line treatment of patients with KRAS-mutated mCRC, which is being conducted at seven clinical trial sites across the U.S. - USC Norris Comprehensive Cancer Center, The Mayo Clinic Cancer Centers (Arizona, Minnesota and Florida), Kansas University Medical Center, Inova Schar Cancer Institute and CARTI Cancer Center.</font></div><div style="text-indent:33.75pt"><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of this trial is to evaluate the Dose-Limiting Toxicities (&#34;DLTs&#34;) and maximum tolerated dose (&#34;MTD&#34;) or recommended Phase 2 dose (&#34;RP2D&#34;) of onvansertib in combination with FOLFIRI and bevacizumab (Phase 1b) and to continue to assess the safety and preliminary efficacy of onvansertib in combination with FOLFIRI and bevacizumab (Phase 2).</font></div><div style="text-indent:33.75pt"><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scientific rationale for this clinical trial is based on the two key principles of synthetic lethality and synergy, with the objective of demonstrating a proof-of-concept of clinical benefit within this phase1b&#47;2 trial. Synthetic lethality refers to a critical vulnerability to tumor cell death by way of PLK1 inhibition within CRC tumor cells harboring KRAS mutations versus KRAS wild-type isogenic cells. Synergy occurs when the combination of two drugs results in an unexpected greater activity than an expected additive effect of the two drugs. Onvansertib in combination with two DNA-damaging agents, irinotecan and 5-FU (two components of FOLFIRI), demonstrated synergy in colorectal cancer cell lines and both combinations have demonstrated significantly greater tumor growth inhibition than either drug alone in CRC in vivo models. We believe this synergy occurs because PLK1 can promote the repair of DNA damage caused by chemotherapeutic agents and by inhibiting PLK1, onvansertib leaves damaged tumor cells unable to replicate.</font></div><div><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data we presented on January 18, 2022 provided an update of the ongoing phase 1b&#47;2 clinical trial in KRAS-mutated metastatic colorectal cancer. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">12 of 35 (34%) patients treated per protocol at the RP2D in combination with FOLFIRI and bevacizumab achieved a Complete Response (&#34;CR&#34;) or Partial Response (&#34;PR&#34;) (CR&#58; 1 patient&#59; PR&#58; 11 patients)&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">17 of 48 (35%) patients across all dose levels achieved a CR or PR. Historically, Objective Response Rates (&#34;ORR&#34;) of 5-13% have been reported in similar second line patient populations treated with various different drug combinations, including the standard of care chemotherapy of FOLFIRI with bevacizumab&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">5 of 48 (10%) patients discontinued the trial to pursue potentially curative metastasis-directed therapy (surgical resection or microwave ablation)&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Median Progression-Free Survival (&#34;mPFS&#34;) across all response-evaluable patients (n&#61;48) is 9.4 months and has not yet been reached in those treated per protocol at the RP2D. Historically, mPFS of &#126;4.5-5.7 months has been reported in a similar patient population treated with standard of care chemotherapy of FOLFIRI with bevacizumab&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The combination regimen of onvansertib plus FOLFIRI&#47;bevacizumab is well tolerated with no major or unexpected toxicities attributed to onvansertib.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:102%">Phase 2 Clinical Trial in mPDAC</font></div><div><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CRDF-001 is a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan (Onivyde</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), leucovorin, and fluorouracil for second line treatment of patients with mPDAC, which is being conducted at six clinical trial sites across the U.S. &#8211; The Mayo Clinic Cancer Centers (Arizona, Minnesota and Florida), Kansas University Medical Center, Inova Schar Cancer Institute, and the University of Nebraska Medical Center.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first patient was dosed in June 2021. </font></div><div style="text-indent:33.75pt"><font><br></font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:6.75pt 13.50pt 6.75pt 13.50pt"><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of this trial is to assess the safety and preliminary efficacy of onvansertib in combination with nanoliposomal irinotecan (Onyvide</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), 5-FU and leucovorin as a second-line treatment in patients with mPDAC who have failed first-line gemcitabine-based therapy. The trial is expected to enroll approximately 45 patients across six sites in the U.S. including three of The Mayo Clinic Cancer Centers (Arizona, Minnesota and Florida), Kansas University Medical Center, Inova Schar Cancer Institute, and the University of Nebraska Medical Center.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 2 Clinical Trial in mCRPC</font></div><div><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TROV-053 is a Phase 2 open-label multi-center clinical trial of onvansertib in combination with abiraterone acetate (Zytiga</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and prednisone in patients with mCRPC, which is being conducted at three clinical trial sites - Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute and Massachusetts General Hospital.</font></div><div style="text-indent:33.75pt"><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of this trial is to observe the effects of onvansertib in combination with abiraterone and prednisone on disease control as assessed by Prostate Specific Antigen (&#34;PSA&#34;) decline or stabilization after 12 weeks of treatment in patients with mCRPC showing early signs of resistance to abiraterone.</font></div><div style="text-indent:33.75pt"><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rationale for this trial is based on the Mechanism of Action (&#34;MOA&#34;) of onvansertib and Zytiga</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the synergy of these two drugs when used in combination in pre-clinical experiments. Onvansertib inhibits tumor cell proliferation by inducing G2&#47;M (mitosis) arrest and consequently cell death. The combination of onvansertib and Zytiga</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> synergistically increases mitotic arrest and cell death in prostate cancer cells and has demonstrated significantly greater tumor growth inhibition than either drug alone in vivo. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-indent:33.75pt"><font><br></font></div><div style="text-indent:33.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data as of July 2, 2021, as follow-up to the data presented on February 11, 2021, at the American Society of Clinical Oncology Genitourinary Cancers Symposium (&#8220;ASCO-GU&#8221;) provided evidence of the safety and efficacy of onvansertib in combination with abiraterone. Arms A (n&#61;17) and B (n&#61;20) and C (n&#61;13) showed 29%, 40% and 54% of patients, respectively, achieving the primary endpoint of disease control at 12 weeks. The more continuous dosing schedule of Arm C has shown an increase in the rate of patients achieving disease stabilization, to-date. Evidence of efficacy was observed in patients harboring Androgen Receptor (&#34;AR&#34;) alterations across all 3 arms. Circulating Tumor DNA (&#34;ctDNA&#34;) analysis revealed differences in baseline genomic profiles of patients achieving SD at 12 weeks vs. patients progressing before or at 12 weeks. Mutations exclusively present in patients with Stable Disease (&#34;SD&#34;) were associated with cell cycle and DNA repair pathways that may result in increased sensitivity to onvansertib and efficacy of the combination. Onvansertib plus abiraterone has demonstrated safety across all 3 dosing schedules.</font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborative Relationship</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Breakthrough Growth Initiative</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we entered into a Securities Purchase Agreement (the &#8220;SPA&#8221;) with Pfizer Inc., as part of the Pfizer Breakthrough Growth Initiative, pursuant to which Pfizer purchased 2.4 million shares of our common stock at a purchase price per share of $6.22 for gross proceeds of approximately $15.0 million. In connection with the purchase, Pfizer has agreed not to sell or transfer any of the shares, subject to certain customary exceptions, for a period of 180 days from the closing date of the SPA. In connection with the stock purchase, we and Pfizer entered into an Information Rights Agreement pursuant to which Adam Schayowitz, Ph.D., MBA, Vice President &#38; Medicine Team Group Lead for Breast Cancer, Colorectal Cancer and Melanoma at Pfizer will join our Scientific Advisory Board, and until May 17, 2023 we agreed to provide Pfizer with rights of first access to any pre-clinical or final clinical data and results generated as part of the onvansertib development program at least two business days prior to us providing such data to a third party.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Associated with Our Business</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We are a clinical stage company and may never earn a profit</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We will need to raise substantial additional capital to develop and commercialize onvansertib and our failure to obtain funding when needed may force us to delay, reduce or eliminate our product development programs or collaboration efforts.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Our product candidate, onvansertib, is in the early stages of clinical development and its commercial viability remains subject to current and future preclinical studies, clinical trials, regulatory approvals and the risks generally inherent in </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:6.75pt 13.50pt 6.75pt 13.50pt"><div style="padding-left:36pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the development of a pharmaceutical product candidate. If we are unable to successfully advance or develop our product candidate, our business will be materially harmed.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">If the results of preclinical studies or clinical trials for our product candidate, including those that are subject to existing or future license or collaboration agreements, are unfavorable or delayed, we could be delayed or precluded from the further development or commercialization of our product candidate, which could materially harm our business.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">If third party vendors upon whom we intend to rely on to conduct our preclinical studies or clinical trials do not perform or fail to comply with strict regulations, these studies or trials of our product candidate may be delayed, terminated, or fail, or we could incur significant additional expenses, which could materially harm our business</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We, and our collaborators, must comply with extensive government regulations in order to advance our product candidate through the development process and ultimately obtain and maintain marketing approval for our products in the U.S. and abroad.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">We have limited experience in the development of therapeutic product candidates and therefore may encounter difficulties developing our product candidate or managing our operations in the future.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Delays in clinical testing could result in increased costs to us and delay our ability to generate revenue.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidate, our business will be substantially harmed.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">If our product candidate is unable to compete effectively with marketed drugs targeting similar indications as our product candidate, our commercial opportunity will be reduced or eliminated.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">If the manufacturers upon whom we rely fail to produce our product candidate, in the volumes that we require on a timely basis, or fail to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may face delays in the development and commercialization of our product candidate.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">If we materially breach or default under terms of our license agreement with Nerviano Medical Sciences S.r.l. Nerviano Medical Sciences S.r.l. will have the right to terminate the agreement and we could lose critical license rights, which would materially harm our business.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">The outbreak of the novel coronavirus disease, COVID-19, could materially adversely impact our business, results of operations and financial condition, including our clinical trials.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">If we are unable to protect our intellectual property effectively, we may be unable to prevent third parties from using our technologies, which would impair our competitive advantage.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Our common stock price may be volatile and could fluctuate widely in price, which could result in substantial losses for investors.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Delaware law and our corporate charter and bylaws contain anti-takeover provisions that could delay or discourage takeover attempts that stockholders may consider favorable.</font></div><div style="text-align:justify"><font><br></font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:6.75pt 13.50pt 6.75pt 13.50pt"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Company Information</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in the State of Florida on April&#160;26, 2002. On July&#160;2, 2004, we acquired Xenomics, a California corporation, which was in business to develop and commercialize urine-based molecular diagnostics technology. In 2007, we changed our fiscal year end from January&#160;31 to December&#160;31 and in January&#160;2010, we re-domesticated our state of incorporation from Florida to Delaware and our name was changed to Trovagene,&#160;Inc. On May&#160;6, 2020, we announced a change in our company name from Trovagene,&#160;Inc. to Cardiff Oncology,&#160;Inc.&#160;We have trademarks for the name TROVAGENE, TROVAGENE ONCOLOGY, and CARDIFF ONCOLOGY. Our principal executive offices are located at 11055 Flintkote Avenue, San Diego, CA 92121, and our telephone number is 858-952-7570. Our website address is</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;www.cardiffoncology.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The information on our website is not part of this prospectus. We have included our website address as a factual reference and do not intend it to be an active link to our website.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_73"></div><div style="text-align:center"><font><br></font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE OFFERING</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:36.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.552%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common stock offered by us&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of our common stock having an aggregate offering price of up to $100,000,000.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common stock to be outstanding immediately after this offering&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Up to 81,620,237 shares, assuming the sale of up to 38,314,176 shares hereunder at a price of $2.61 per share, the closing price per share on The Nasdaq Capital Market on April 4, 2022, for aggregate gross proceeds of $100,000,000. Actual shares issued will vary depending on the sales prices under this offering.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Manner of offering&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;At the market offering&#8221; that may be made from time to time on The Nasdaq Capital Market or other existing trading market for our common stock through our sales agent, Jefferies LLC. See &#8220;Plan of Distribution&#8221; on page 16 of this prospectus.</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Use of Proceeds&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our management will retain broad discretion regarding the allocation and use of the net proceeds. We currently intend to use the net proceeds from this offering for general corporate purposes, including the development and commercialization of our products, research and development, general and administrative expenses, license or technology acquisitions, and working capital and capital expenditures. We may also use a portion of the remaining net proceeds, if any, to acquire or invest in complementary businesses, products and technologies, although we have no current commitments or agreements with respect to any acquisitions as of the date hereof. See &#8220;Use of Proceeds&#8221; on page 14. </font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk factors&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing in our common stock involves risks. See &#8220;Risk Factors&#8221; beginning on page 9 of this prospectus and in the documents incorporated by reference into this prospectus for a discussion of factors you should carefully consider before deciding to invest in our common stock.</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nasdaq Capital Market symbol&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CRDF</font></td></tr></table></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless we indicate otherwise, all information in this prospectus&#160;is based on 43,306,061 shares of common stock outstanding as of April 4, 2022 and&#160;excludes as of that date&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#183; 877 shares of common stock issuable upon conversion of outstanding Series&#160;A Convertible Preferred Stock&#59;</font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#183; 1,342,250 shares of common stock issuable upon conversion of outstanding Series&#160;E Convertible Preferred Stock&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#183; 5,467,611 shares of our common stock issuable upon exercise of outstanding stock options under our stock incentive plans at a weighted average exercise price of $5.88 per share&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#183; 4,490,159 shares of our common stock issuable upon exercise of outstanding warrants at a weighted average exercise price of $5.80 per share&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#183; 918,865 shares of common stock reserved for future grants and awards under our stock incentive plans.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_76"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">An investment in our common stock involves a high degree of risk. Before deciding whether to invest in our common stock, you should consider carefully the risks described below and discussed under the section captioned &#8220;Risk Factors&#8221; in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, which are each incorporated by reference in this prospectus and the accompanying prospectus in their entirety, as well as any amendment or update to our risk factors reflected in subsequent filings with the SEC, together with other information in this prospectus, the accompanying prospectus, and the information and documents incorporated by reference that we have authorized for use in connection with this offering. If any of these risks actually occur, our business, financial condition, results of operations or cash flows could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The risks and uncertainties summarized and described below are not intended to be exhaustive and are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business, prospects, financial condition and results of operations. Certain statements in this prospectus are forward-looking statements. Please also see the section entitled &#8220;Disclosure Regarding Forward-Looking Statements.&#8221;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to this Offering and Our Common Stock</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our common stock price may be volatile and could fluctuate widely in price, which could result in substantial losses for investors.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock historically has been, and we expect will continue to be, subject to significant fluctuations over short periods of time. For example, during the year ended December 31, 2021, the closing price of our common stock ranged from a low of $5.01 to a high of $19.57. These fluctuations may be due to various factors, many of which are beyond our control, including&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">technological innovations or new products and services introduced by us or our competitors&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">clinical trial results relating to our tests or those of our competitors&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">announcements or press releases relating to the industry or to our own business or prospects&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">coverage and reimbursement decisions by third party payors, such as Medicare and other managed care organizations&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">regulation and oversight of our product candidates and services, including by the FDA, Centers for Medicare &#38; Medicaid Services and comparable foreign agencies&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the establishment of partnerships with clinical reference laboratories&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">healthcare legislation&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">intellectual property disputes&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">additions or departures of key personnel&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">sales of our common stock&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">our ability to integrate operations, technology, products and services&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">our ability to execute our business plan&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">operating results below expectations&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">loss of any strategic relationship&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">industry developments&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">economic and other external factors&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">catastrophic weather and&#47;or global disease outbreaks, such as the recent COVID-19 pandemic&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">period-to-period fluctuations in our financial results.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, market fluctuations, as well as general political and economic conditions, could materially adversely affect the market price of our securities. Because we are a development stage company with no revenue from operations to date, other than licensing, milestone and royalty income, you should consider any one of these factors to be material. Our stock price may fluctuate widely as a result of any of the foregoing.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If you purchase our common stock in this offering, you may incur immediate and substantial dilution in the net tangible book value of your shares.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The offering price per share in this offering may exceed the net tangible book value per share of our common stock outstanding prior to this offering. Assuming that an aggregate of 38,314,176 shares of our common stock are sold at a price of $2.61 per share, the last reported sale price of our common stock on The Nasdaq Capital Market on April 4, 2022, for aggregate gross proceeds of approximately $100,000,000, and after deducting commissions and estimated offering expenses payable by us, you would experience immediate dilution of $(0.30) per share, representing the difference between our as adjusted net tangible book value per share as of December 31, 2021 after giving effect to this offering and the assumed public offering price. The exercise of outstanding stock options and warrants and conversion of preferred stock will result in further dilution of your investment.</font></div><div style="text-align:justify;text-indent:20.25pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This dilution would be due to the substantially lower price paid by some of our investors who purchased shares prior to this offering as compared to the assumed price offered to the public in this offering and the exercise of stock options granted to our employees, directors and consultants as well as the exercise of outstanding warrants and conversion of outstanding preferred stock. As a result of the dilution to investors purchasing shares in this offering, investors may receive significantly less than the purchase price paid in this offering, if anything, in the event of our liquidation. Further, because we expect we will need to raise additional capital to fund our future activities, we may in the future sell substantial amounts of common stock or securities exercisable or convertible into or exchangeable for common stock.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we will have broad discretion and flexibility in how the net proceeds from this offering are used, we may use the net proceeds in ways in which you disagree.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to use the net proceeds from this offering for general corporate purposes, including the development and commercialization of our products, research and development, general and administrative expenses, license or technology acquisitions, and working capital and capital expenditures.  See &#8220;Use of Proceeds&#8221; on page 13. We have not allocated specific amounts of the net proceeds from this offering for any of the foregoing purposes. Accordingly, our management will have significant discretion and flexibility in applying the net proceeds of this offering. You will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the net proceeds are being used appropriately. It is possible that the net proceeds will be invested in a way that does not yield a favorable, or any, return for us. The failure of our management to use such funds effectively could have a material adverse effect on our business, financial condition, operating results and cash flow.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">You may experience future dilution as a result of future equity offerings and other issuances of our securities. In addition, this offering and future equity offerings and other issuances of our common stock or other securities may adversely affect our common stock price.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities exercisable or convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in this offering. We may not be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock or securities exercisable or convertible into common stock in future transactions may be higher or lower than the price per </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">share in this offering. You will incur dilution upon exercise of any outstanding stock options or warrants, the conversion of any outstanding preferred stock or upon the issuance of shares of common stock under our stock incentive programs. In addition, the sale of shares in this offering and any future sales of a substantial number of shares of our common stock in the public market, or the perception that such sales may occur, could adversely affect the price of our common stock. We cannot predict the effect, if any, that market sales of those shares of common stock or the availability of those shares of common stock for sale will have on the market price of our common stock.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The outbreak of the novel coronavirus disease, COVID-19, could materially adversely impact our business, results of operations and financial condition, including our clinical trials.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and government measures taken in response have had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred&#59; supply chains have been disrupted&#59; facilities and production have been suspended&#59; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. While the extent of the impact of the COVID-19 pandemic on our business and financial results is uncertain, a continued and prolonged public health crisis such as the COVID-19 pandemic could have a material adverse effect on our business, financial condition and results of operations. As a result of the COVID-19 pandemic, we may experience disruptions that could severely impact our business and clinical trials, including&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.644%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">delays or difficulties in enrolling and retaining patients in our clinical trials&#59;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff&#59;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials&#59;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures (such as endoscopies that are deemed non-essential), which may impact the integrity of subject data and clinical study endpoints&#59;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines&#59;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">interruption of, or delays in receiving, supplies of our product candidate from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems&#59;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">limitations on employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people&#59;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">interruption or delays to our sourced clinical activities&#59; and</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">changes in clinical site procedures and requirements as well as regulatory requirements for conducting clinical trials during the pandemic.</font></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:30.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to evolve rapidly, with the status of operations and government restrictions evolving weekly. The extent to which the outbreak impacts our business and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</font></div><div style="text-align:justify;text-indent:30.6pt"><font><br></font></div><div style="text-indent:30.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our business could be materially adversely affected by other business disruptions to us or our third-party providers that could materially adversely affect our potential future revenue and financial condition and increase our costs and expenses. Our operations, and those of our contract research organizations, contract manufacturing organizations and other contractors, consultants and third parties could be subject to other global pandemics, earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could materially adversely affect our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce and process our product candidate. Our ability to obtain clinical supplies of our product candidate could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not paid dividends on our common stock in the past and do not expect to pay dividends on our common stock for the foreseeable future. Any return on investment may be limited to the value of our common stock.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid any cash dividends on our common stock. We expect that any income received from operations will be devoted to our future operations and growth. We do not expect to pay cash dividends on our common stock in the near future. Payment of dividends would depend upon our profitability at the time, cash available for those dividends, and other factors that our board of directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on an investor&#8217;s investment will only occur if our stock price appreciates. In addition, the terms of the Series A Convertible Preferred Stock prohibit us from paying dividends to the holders of our common stock so long as any dividends due on the Series A Convertible Preferred Stock remain unpaid. Furthermore, the terms of any debt agreements may also preclude us from paying dividends. Investors in our common stock should not rely on an investment in our company if they require dividend income. We expect that only appreciation of the price of our common stock, if any, will provide a return to investors in this offering for the foreseeable future.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The common stock offered hereby will be sold in &#8220;at the market&#8221; offerings, and investors who buy shares at different times will likely pay different prices.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors who purchase shares in this offering at different times will likely pay different prices, and so may experience different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold, and there is no minimum or maximum sales price. Investors may experience a decline in the value of their shares as a result of share sales made at prices lower than the prices they paid.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The actual number of shares we will issue under the Sales Agreement, at any one time or in total, is uncertain.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain limitations in the Sales Agreement and compliance with applicable law, we have the discretion to deliver placement notices to Jefferies at any time throughout the term of the Sales Agreement. The number of shares that are sold by Jefferies after delivering a placement notice will fluctuate based on the market price of the common stock during the sales period and limits we set with Jefferies. Because the price per share of each share sold will fluctuate based on the market price of our common stock during the sales period, it is not possible at this stage to predict the number of shares that will be ultimately issued.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a smaller reporting company, and we cannot be certain if the reduced disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently a &#8220;smaller reporting company,&#8221; as defined in Rule 405 under the Securities Act.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a smaller reporting company, we take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#8220;smaller reporting companies,&#8221; including, but not limited to, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the provisions of Section 404(b) of the Sarbanes-Oxley Act of 2002, as amended, requiring that independent registered public accounting firms provide an attestation report on the effectiveness of internal control over financial reporting. Decreased disclosures in our SEC filings due to our status as a &#8220;smaller reporting company&#8221; may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_79"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">USE OF PROCEEDS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may issue and sell shares of our common stock having aggregate sales proceeds of up to $100 million from time to time. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. There can be no assurance that we will sell any shares under or fully utilize our Sales Agreement with Jefferies as a source of financing.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to use the net proceeds from the sale of the shares for general corporate purposes, including the development and commercialization of our products, research and development, general and administrative expenses, license or technology acquisitions, and working capital and capital expenditures. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. The amounts and timing of our actual expenditures will depend on numerous factors, including the factors described under &#8220;Risk Factors&#8221; in this prospectus and in the documents incorporated by reference herein, as well as the amount of cash used in our operations. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the application of the net proceeds. We may also use a portion of the remaining net proceeds, if any, to acquire or invest in complementary businesses, products and technologies, although we have no current commitments or agreements with respect to any acquisitions as of the date hereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pending the uses described above, we plan to invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_82"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DILUTION</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the public offering price per share and the as adjusted net tangible book value per share after this offe</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ring. As of December 31, 2021, our net tangible book value was $140.4 million, or $3.35 per share. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net tangible book value per share represents our total tangible assets (excluding deferred issuance costs) less our total liabilities, divided by the number of shares outstanding. Dilution with respect to net tangible book value per share represents the difference between the amount per share paid by purchasers of shares of common stock in this offering and the net tangible book value per share of our common stock immediately after this offering. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pro forma net tangible book value as of December 31, 2021 is approximately $140.4 million, or $3.24 per share, after giving effect to 327,535 shares of Series E Convertible Preferred Stock converted to 1,342,357 shares of common stock on January 5, 2022. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After giving effect to the sale of 38,314,176 shares of common stock in this offering at an assumed public offering price of $2.61 per share, the last reported sale price of our common stock on The Nasdaq Capital Market on April 4, 2022, and after deducting commissions and estimated aggregate offering expenses payable by us, our as pro forma adjusted net tangible book value as of December 31, 2021 would have been approximately $237.4 million, or approximately $2.91 per share of common stock. This represents an immediate decrease in pro forma as adjusted net tangible book value of $0.33 per share to our existing stockholders and an immediate dilution in net tangible book value of $(0.30) per share to investors participating in this offering at the assumed public offering price.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:71.640%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed public offering price per share</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.61&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net tangible book value per share as of December 31, 2021</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.24&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in pro forma tangible per share attributable to this offering</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.33)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pro forma as adjusted net tangible book value per share as of December 31, 2021,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">after giving effect to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">this offering</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilution in net tangible book value per share to investors participating in this offering</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information discussed above is illustrative only and will adjust based on the actual public offering price and other terms of this offering determined at pricing.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above discussion and table is based on 41,963,704 shares of common stock outstanding as of December 31, 2021 and excludes as of that date&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#183; 877 shares of common stock issuable upon conversion of outstanding Series&#160;A Convertible Preferred Stock&#59;</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#183; 1,342,250 shares of common stock issuable upon conversion of outstanding Series E Convertible Preferred Stock, after giving effect to 327,535 shares of Series E Convertible Preferred Stock converted to 1,342,357 shares of common stock on January 5, 2022&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#183; 3,771,984 shares of our common stock issuable upon exercise of outstanding stock options under our stock incentive plans at a weighted average exercise price of $7.13 per share&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#183; 4,490,159 shares of our common stock issuable upon exercise of outstanding warrants at a weighted average exercise price of $5.80 per share&#59; and</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#183; 2,284,862 shares of common stock reserved for future grants and awards under our stock incentive plans.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_85"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PLAN OF DISTRIBUTION </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into a sales agreement with Jefferies, under which we may offer and sell up to $100 million of our shares of common stock from time to time through Jefferies acting as agent. Sales of our shares of common stock, if any, under this prospectus will be made by any method that is deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4)  under the Securities Act.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each time we wish to issue and sell shares of common stock under the sales agreement, we will notify Jefferies of the number of shares to be issued, the dates on which such sales are anticipated to be made, any limitation on the number of shares to be sold in any one day and any minimum price below which sales may not be made. Once we have so instructed Jefferies, unless Jefferies declines to accept the terms of such notice, Jefferies has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such shares up to the amount specified on such terms. The obligations of Jefferies under the sales agreement to sell our shares of common stock are subject to a number of conditions that we must meet.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The settlement of sales of shares between us and Jefferies is generally anticipated to occur on the second trading day following the date on which the sale was made. Sales of our shares of common stock as contemplated in this prospectus will be settled through the facilities of The Depository Trust Company or by such other means as we and Jefferies may agree upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will pay Jefferies a commission equal to 3.0% of the aggregate gross proceeds we receive from each sale of our shares of common stock. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. In addition, we have agreed to reimburse Jefferies for the fees and disbursements of its counsel, payable upon execution of the sales agreement, in an amount not to exceed $50,000, in addition to certain ongoing disbursements of its legal counsel, unless we and Jefferies otherwise agree. We estimate that the total expenses for the offering, excluding any commissions or expense reimbursement payable to Jefferies under the terms of the sales agreement, will be approximately $35,000. The remaining sale proceeds, after deducting any other transaction fees, will equal our net proceeds from the sale of such shares.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jefferies will provide written confirmation to us before the open on The Nasdaq Capital Market on the day following each day on which our shares of common stock are sold under the sales agreement. Each confirmation will include the number of shares sold on that day, the aggregate gross proceeds of such sales and the proceeds to us. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the sale of our shares of common stock on our behalf, Jefferies will be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act, and the compensation of Jefferies will be deemed to be underwriting commissions or discounts. We have agreed to indemnify Jefferies against certain civil liabilities, including liabilities under the Securities Act. We have also agreed to contribute to payments Jefferies may be required to make in respect of such liabilities. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The offering of our shares of common stock pursuant to the sales agreement will terminate upon the earlier of (i) the sale of all shares of common stock subject to the sales agreement and (ii) the termination of the sales agreement as permitted therein.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary of the material provisions of the sales agreement does not purport to be a complete statement of its terms and conditions. A copy of the sales agreement is filed as an exhibit to the registration statement of which this prospectus forms a part.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jefferies and its affiliates may in the future provide various investment banking, commercial banking, financial advisory and other financial services for us and our affiliates, for which services they may in the future receive customary fees. In the course of its business, Jefferies may actively trade our securities for its own account or for the accounts of customers, and, accordingly, Jefferies may at any time hold long or short positions in such securities.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A prospectus supplement and the accompanying prospectus in electronic format may be made available on a website maintained by Jefferies, and Jefferies may distribute the prospectus supplement and the accompanying prospectus electronically.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_88"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL MATTERS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The validity of the securities offered hereby will be passed upon for us by Sheppard, Mullin, Richter &#38; Hampton, New York, New York. Jefferies LLC is being represented in connection with this offering by Latham &#38; Watkins LLP, New York, New York.</font></div><div style="text-indent:36pt"><font><br></font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_91"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXPERTS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements as of December 31, 2021 and 2020 and for the years then ended incorporated by reference in this prospectus and in the registration statement have been so incorporated in reliance on the report of BDO USA, LLP, an independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting.</font></div><div style="text-indent:36pt"><font><br></font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_94"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHERE YOU CAN FIND MORE INFORMATION</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus constitutes a part of the registration statement on&#160;Form&#160;S-3&#160;that&#160;we have filed with the SEC under the Securities Act. As permitted by the SEC&#8217;s rules, this prospectus and any accompanying prospectus, which forms a part of the registration statement, do not contain all of the information that is included in the registration statement. You will find additional information about us in the registration statement. Any statement made in this prospectus or any accompanying prospectus concerning legal documents are not necessarily complete and you should read the documents that are filed as exhibits to the registration statement or otherwise filed with the SEC for a more complete understanding of the document or matter.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Exchange Act and file annual, quarterly and current reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, over the Internet at the SEC&#8217;s website at</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> http&#58;&#47;&#47;www.sec.gov</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We also maintain a website at</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> www.cardiffoncology.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You may also read and copy any document we file with the SEC at its public reference facilities at 100 F Street, N.E., Room 1580, Washington, DC 20549. You may also obtain copies of these documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference facilities. You may also request a copy of these filings, at no cost, by writing or telephoning us at&#58; 11055 Flintkote Avenue, San Diego, California, 92121, (858) 952-7570.</font></div><div style="text-indent:36pt"><font><br></font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_97"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCORPORATION OF DOCUMENTS BY REFERENCE</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC permits us to &#8220;incorporate by reference&#8221; the information contained in documents we file with the SEC, which means that we can disclose important information to you by referring you to those documents rather than by including them in this prospectus. Information that is incorporated by reference is considered to be part of this prospectus and you should read it with the same care that you read this prospectus and the accompanying prospectus. Information that we file later with the SEC will automatically update and supersede the information that is either contained, or incorporated by reference, in this prospectus, and will be considered to be a part of this prospectus from the date those documents are filed.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate by reference the documents listed below, all filings filed by us pursuant to the Exchange Act after the date of the registration statement of which this prospectus and the accompanying prospectus forms a part, and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d)&#160;of the Exchange Act prior to the time that all securities covered by this prospectus have been sold&#59; provided, however, that we are not incorporating any information furnished under either Item 2.02 or Item 7.01 of any current report on&#160;Form&#160;8-K&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1213037/000162828022003808/crdf-20211231.htm" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on February 24, 2022</a></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our Current Reports on Form 8-K filed on </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1213037/000162828022000669/crdf-20220111.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">January 11, 2022</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1213037/000162828022001039/crdf-20220118.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">January 18,2022</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1213037/000162828022001522/crdf-20220131.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">January 31, 2022</a></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828021007919/a2021proxy.htm" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">our definitive Proxy Statement on Schedule 14a for our 2021 Annual Meeting of Stockholders, filed with the SEC on April 28, 2021</a></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000110465912039425/a12-9768_98a12b.htm" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">the description of our common stock contained in our Registration Statement on Form 8-A filed with the Commission on May 23, 2012, including any amendments or reports filed with the SEC for the purposes of updating such description</a></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any statements made in a document incorporated by reference in this prospectus are deemed to be modified or superseded for purposes of this prospectus to the extent that a statement in this prospectus or in any other subsequently filed document, which is also incorporated by reference, modifies or supersedes the statement. Any statement made in this prospectus is deemed to be modified or superseded to the extent a statement in any subsequently filed document, which is incorporated by reference in this prospectus, modifies or supersedes such statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information relating to us contained in this prospectus should be read together with the information in the documents incorporated by reference. In addition, certain information, including financial information, contained in this prospectus, the accompanying prospectus or incorporated by reference in this prospectus and the accompanying prospectus should be read in conjunction with documents we have filed with the SEC.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will provide to each person, including any beneficial holder, to whom a prospectus is delivered, at no cost, upon written or oral request, a copy of any or all of the information that has been incorporated by reference in the prospectus but not delivered with the prospectus. Requests for documents should be by writing to or telephoning us at the following address&#58; Cardiff Oncology,&#160;Inc., 11055 Flintkote Avenue, San Diego, CA 92121&#59; (858)&#160;952-7570. Exhibits to these filings will not be sent unless those exhibits have been specifically incorporated by reference in such filings.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-indent:49.5pt"><font><br></font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_100"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><img alt="cardiff_logoxrgbxtma.jpg" src="cardiff_logoxrgbxtma.jpg" style="height:38px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Up to $100,000,000</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Shares of Common Stock</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">________________</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:103%">PROSPECTUS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">________________</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:88%">Jefferies</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">April    , 2022</font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_103"></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INFORMATION NOT REQUIRED IN PROSPECTUS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.  Other Expenses of Issuance and Distribution.</font></div><div style="text-indent:42.75pt"><font><br></font></div><div style="text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth an estimate of the fees and expenses relating to the issuance and distribution of the securities being registered hereby, other than underwriting discounts and commissions, all of which shall be borne by the registrant. </font></div><div style="text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of such fees and expenses are estimated&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SEC registration fee</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,175&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting fees and expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal fees and expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous fees and expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**&#160;&#160;&#160;&#160;These fees and expenses depend on the securities offered and the number of issuances and accordingly cannot be estimated at this time.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15.&#160;&#160;Indemnification of Directors and Officers.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 102 of the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;) permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our amended and restated certificate of incorporation, as amended, provides that no director of the Company shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation, as amended, and bylaws will provide indemnification for our directors and officers to the fullest extent permitted by the DGCL. We will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending  action by or in the right of us by reason of the fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an &#8220;Indemnitee&#8221;), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our amended and restated certificate of incorporation, as amended, and bylaws provide that we will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">II-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#8217; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys&#8217; fees) actually and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee under certain circumstances.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have entered into separate indemnification agreements with each of our directors and executive officers. Each indemnification agreement provides, among other things, for indemnification to the fullest extent permitted by law and our amended and restated certificate of incorporation, as amended, and bylaws against any and all expenses, judgments, fines, penalties and amounts paid in settlement of any claim. The indemnification agreements will provide for the advancement or payment of all expenses to the indemnitee and for the reimbursement to us if it is found that such indemnitee is not entitled to such indemnification under applicable law and our amended and restated certificate of incorporation and amended and restated bylaws.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out of claims based on acts or omissions in their capacities as directors or officers.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;16.&#160;&#160;Exhibits.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:14.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br>Number</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1*</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form of Underwriting Agreement.</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828021004640/a12ex031221.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Open Market Sale Agreement&#8480;, dated as of March 12, 2021, between the Company and Jefferies LLC (incorporated by reference to Exhibit 1.2 to the Company&#8217;s Form S-3ASR filed on March 12, 2021)</a></font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000110465911066179/a11-28276_1ex3d1.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Amended and Restated Certificate of Incorporation. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 10-12G filed on November 25, 2011).</a></font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000110465912019409/a12-6668_1def14a.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to Appendix B to the Company&#8217;s Proxy Statement on Schedule 14A filed on March 20, 2012).</a></font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000110465911066179/a11-28276_1ex3d2.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">By-Laws  (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Form 10-12G filed on November 25, 2011).</a></font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000119312518190679/d601889dex31.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock. (incorporated by reference to Exhibit 3.1 to Form 8-K filed on June 12, 2018).</a></font></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000119312519021144/d692543dex31.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Form 8-K filed on January 29, 2019).</a></font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000119312519024055/d647432dex31.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment to Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Form 8-K filed on January 31, 2019).</a></font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">II-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:14.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000119312519044909/d711195dex31.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed on February 20, 2019).</a></font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020006555/trov050620ex31.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Trovagene, Inc. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed on May 6, 2020).</a></font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.10</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020009534/a31crdf061620.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Form 8-K filed on Jun 16, 2020).</a></font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1213037/000110465911066179/a11-28276_1ex4d1.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Form 10-12G filed on November 25, 2011).</a></font></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2*</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form of Certificate of Designation with respect to Preferred Stock</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3**</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="a43ex040522.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Form of Senior Indenture</a></font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4**</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="a44ex040522.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Form of Subordinated Indenture</a></font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5*</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form of Senior Note</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6*</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form of Subordinated Note</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7*</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form of Warrant</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8*</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form of Warrant Agreement</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9*</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form of Unit Agreement</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1**</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="a51ex040522.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Opinion of Sheppard Mullin Richter &#38; Hampton LLP</a></font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1**</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="a231ex040522.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Consent of BDO USA, LLP</a></font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2**</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="a51ex040522.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Consent of Sheppard Mullin Richter &#38; Hampton LLP (included in Exhibit 5.1)</a></font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1**</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if89c1f54c40443f2aa0a6238615b3fe9_106" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Power of Attorney (included on signature page hereto)</a></font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1*</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Statement of Eligibility of Trustee on Form T-1 under the Trust Indenture Act of 1939, as amended</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="ex-filingfees.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Filing Fee Table</a></font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent applicable, to be filed by an amendment or as an exhibit to a document filed under the Securities Exchange Act of 1934, as amended, and incorporated by reference herein.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">** Filed herewith.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 17.&#160;&#160;Undertakings.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;The undersigned Registrant hereby undertakes&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;to file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;to include any prospectus required by Section&#160;10(a)(3)&#160;of the Securities Act&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;to reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">II-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&#160;424(b)&#160;if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective Registration Statement&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided, however, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement&#59;.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(l)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof&#59; provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(5) That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(6) That, for purposes of determining any liability under the Securities Act, each filing of the registrant&#8217;s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">employee benefit plan&#8217;s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">II-4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)&#160;&#160;Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8) To file an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of Section 310 of the Trust Indenture Act of 1939 in accordance with the rules and regulations prescribed by the Securities and Exchange Commission under Section 305(b)(2) of the Trust Indenture Act of 1939.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">II-5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="if89c1f54c40443f2aa0a6238615b3fe9_106"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on April 5, 2022.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARDIFF ONCOLOGY,&#160;INC.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Mark Erlander, his true and lawful attorney-in-fact and agent with full power of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities to sign any or all amendments (including, without limitation, post-effective amendments) to this Registration Statement, any related Registration Statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and any or all pre- or post-effective amendments thereto, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that said attorney-in-fact and agent, or any substitute or substitutes for him, may lawfully do or cause to be done by virtue hereof. </font></div><div style="text-indent:24.75pt"><font><br></font></div><div style="text-align:justify;text-indent:18.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">II-6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:24.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark Erlander</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 5, 2022</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; James Levine</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 5, 2022</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Levine</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Rodney S. Markin</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board and Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 5, 2022</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rodney S. Markin</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; James O. Armitage</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 5, 2022</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James O. Armitage</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Brancaccio</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 5, 2022</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Brancaccio</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mani Mohindru</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 5, 2022</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mani Mohindru</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Gary W. Pace</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 5, 2022</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gary W. Pace</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Renee Tannenbaum</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 5, 2022</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renee Tannenbaum</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; L&#226;le White</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 5, 2022</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">L&#226;le White</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">II-7</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>a43ex040522.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0574e594312d490b886a348c8421f9a5_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY, INC.,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ISSUER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;TRUSTEE&#93;,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRUSTEE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDENTURE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DATED AS OF , 20__</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SENIOR DEBT SECURITIES</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:89.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.214%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Page</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE I DEFINITIONS</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1.1 Definitions of Terms</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.1 Designation and Terms of Securities</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.2 Form of Securities and Trustee's Certificate</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.3 Denominations&#58; Provisions for Payment</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.4 Execution and Authentications</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.5 Registration of Transfer and Exchange</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.6 Temporary Securities</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.7 Mutilated, Destroyed, Lost or Stolen Securities</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.8 Cancellation</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.9 Benefits of Indenture</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.10 Authenticating Agent</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.11 Global Securities</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE III REDEMPTION OF SECURITIES AND SINKING FUND PROVISIONS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.1 Redemption</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.2 Notice of Redemption</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.3 Payment Upon Redemption</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.4 Sinking Fund</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.5 Satisfaction of Sinking Fund Payments with Securities</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.6 Redemption of Securities for Sinking Fund</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE IV COVENANTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.1 Payment of Principal, Premium and Interest</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.2 Maintenance of Office or Agency</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.3 Paying Agents</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.4 Appointment to Fill Vacancy in Office of Trustee</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.5 Compliance with Consolidation Provisions</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE V SECURITYHOLDERS' LISTS AND REPORTS BY THE COMPANY AND THE TRUSTEE</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.1 Company to Furnish Trustee Names and Addresses of Securityholders</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.2 Preservation Of Information&#59; Communications With Securityholders</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.3 Reports by the Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.4 Reports by the Trustee</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE VI REMEDIES OF THE TRUSTEE AND SECURITYHOLDERS ON EVENT OF DEFAULT</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.1 Events of Default</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.2 Collection of Indebtedness and Suits for Enforcement by Trustee</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-1-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:89.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.214%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.3 Application of Moneys Collected</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.4 Limitation on Suits</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.5 Rights and Remedies Cumulative&#59; Delay or Omission Not Waiver</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.6 Control by Securityholders</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.7 Undertaking to Pay Costs</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE VII CONCERNING THE TRUSTEE</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.1 Certain Duties and Responsibilities of Trustee</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.2 Certain Rights of Trustee</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.3 Trustee Not Responsible for Recitals or Issuance or Securities</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.4 May Hold Securities</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.5 Moneys Held in Trust</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.6 Compensation and Reimbursement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.7 Reliance on Officer's Certificate</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.8 Disqualification&#59; Conflicting Interests</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.9 Corporate Trustee Required&#59; Eligibility</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.10 Resignation and Removal&#59; Appointment of Successor</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.11 Acceptance of Appointment By Successor</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-2-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:89.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.214%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:30pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.12 Merger, Conversion, Consolidation or Succession to Business</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.13 Preferential Collection of Claims Against the Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.14 Notice of Default</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE VIII CONCERNING THE SECURITYHOLDERS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.1 Evidence of Action by Securityholders</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.2 Proof of Execution by Securityholders</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.3 Who May be Deemed Owners</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.4 Certain Securities Owned by Company Disregarded</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.5 Actions Binding on Future Securityholders</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE IX SUPPLEMENTAL INDENTURES</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.1 Supplemental Indentures Without the Consent of Securityholders</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.2 Supplemental Indentures With Consent of Securityholders</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.3 Effect of Supplemental Indentures</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.4 Securities Affected by Supplemental Indentures</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.5 Execution of Supplemental Indentures</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE X SUCCESSOR ENTITY</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10.1 Company May Consolidate, Etc</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10.2 Successor Entity Substituted</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10.3 Evidence of Consolidation, Etc</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE XI SATISFACTION AND DISCHARGE</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.1 Satisfaction and Discharge of Indenture</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.2 Discharge of Obligations</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.3 Deposited Moneys to be Held in Trust</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.4 Payment of Moneys Held by Paying Agents</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.5 Repayment to Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE XII IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.1 No Recourse</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE XIII MISCELLANEOUS PROVISIONS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.1 Effect on Successors and Assigns</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.2 Actions by Successor</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.3 Surrender of Company Powers</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.4 Notices</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.5 Governing Law</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.6 Treatment of Securities as Debt</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.7 Certificates and Opinions as to Conditions Precedent</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.8 Payments on Business Days</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.9 Conflict with Trust Indenture Act</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.10 Counterparts</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.11 Separability</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.12 Compliance Certificates</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-3-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDENTURE</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-4-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INDENTURE, dated as of &#91;  &#93;, among Cardiff Oncology, Inc., a Delaware corporation (the &#34;Company&#34;), and &#91;TRUSTEE&#93;, as trustee (the &#34;Trustee&#34;)&#58;</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of debt securities (hereinafter referred to as the &#34;Securities&#34;), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as registered Securities without coupons, to be authenticated by the certificate of the Trustee&#59;</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, to provide the terms and conditions upon which the Securities are to be authenticated, issued and delivered, the Company has duly authorized the execution of this Indenture&#59; and</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, all things necessary to make this Indenture a valid agreement of the Company, in accordance with its terms, have been done.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the premises and the purchase of the Securities by the holders thereof, it is mutually covenanted and agreed as follows for the equal and ratable benefit of the holders of Securities&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE I</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DEFINITIONS</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 1.1 Definitions of Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms defined in this Section (except as in this Indenture or any indenture supplemental hereto otherwise expressly provided or unless the context otherwise requires) for all purposes of this Indenture and of any indenture supplemental hereto shall have the respective meanings specified in this Section and shall include the plural as well as the singular. All other terms used in this Indenture that are defined in the Trust Indenture Act of 1939, as amended, or that are by reference in such Act defined in the Securities Act of 1933, as amended (except as herein or any indenture supplemental hereto otherwise expressly provided or unless the context otherwise requires), shall have the meanings assigned to such terms in said Trust Indenture Act and in said Securities Act as in force at the date of the execution of this instrument.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Authenticating Agent&#34; means an authenticating agent with respect to all or any of the series of Securities appointed by the Trustee pursuant to Section 2.10.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Bankruptcy Law&#34; means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Board of Directors&#34; means the Board of Directors of the Company or any duly authorized committee of such Board.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Board Resolution&#34; means a copy of a resolution certified by the Secretary or an Assistant Secretary of the Company to have been duly adopted by the Board of Directors and to be in full force and effect on the date of such certification.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Business Day&#34; means, with respect to any series of Securities, any day other than a day on which federal or state banking institutions in the Borough of Manhattan, the City of New York, or in the city of the Corporate Trust Office of the Trustee, are authorized or obligated by law, executive order or regulation to close.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Certificate&#34; means a certificate signed by any Officer. The Certificate need not comply with the provisions of Section 13.07.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Company&#34; means Cardiff Oncology, Inc., a corporation duly organized and existing under the laws of the State of Delaware, and, subject to the provisions of Article Ten, shall also include its successors and assigns.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Corporate Trust Office&#34; means the office of the Trustee at which, at any particular time, its corporate trust business shall be principally administered, which office at the date hereof is located at .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Custodian&#34; means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Default&#34; means any event, act or condition that with notice or lapse of time, or both, would constitute an Event of Default.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-5-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Defaulted Interest&#34; has the meaning set forth in Section 2.03.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Depositary&#34; means, with respect to Securities of any series for which the Company shall determine that such Securities will be issued as a Global Security, The Depository Trust Company, another clearing agency, or any successor registered as a clearing agency under the Exchange Act, or other applicable statute or regulation, which, in each case, shall be designated by the Company pursuant to either Section 2.01 or 2.11.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Event of Default&#34; means, with respect to Securities of a particular series, any event specified in Section 6.01, continued for the period of time, if any, therein designated.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Exchange Act&#34; means the Securities and Exchange Act of 1934, as amended.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Global Security&#34; means, with respect to any series of Securities, a Security executed by the Company and delivered by the Trustee to the Depositary or pursuant to the Depositary's instruction, all in accordance with the Indenture, which shall be registered in the name of the Depositary or its nominee.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Governmental Obligations&#34; means securities that are (a) direct obligations of the United States of America for the payment of which its full faith and credit is pledged or (b) obligations of a Person controlled or supervised by and acting as an agency or instrumentality of the United States of America, the payment of which is unconditionally guaranteed as a full faith and credit obligation by the United States of America that, in either case, are not callable or redeemable at the option of the issuer thereof at any time prior to the stated maturity of the Securities, and shall also include a depositary receipt issued by a bank or trust company as custodian with respect to any such Governmental Obligation or a specific payment of principal of or interest on any such Governmental Obligation held by such custodian for the account of the holder of such depositary receipt&#59; provided, however, that (except as required by law) such custodian is not authorized to make any deduction from the amount payable to the holder of such depositary receipt from any amount received by the custodian in respect of the Governmental Obligation or the specific payment of principal of or interest on the Governmental Obligation evidenced by such depositary receipt.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;herein&#34;, &#34;hereof&#34; and &#34;hereunder&#34;, and other words of similar import, refer to this Indenture as a whole and not to any particular Article, Section or other subdivision.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Indenture&#34; means this instrument as originally executed or as it may from time to time be supplemented or amended by one or more indentures supplemental hereto entered into in accordance with the terms hereof.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Interest Payment Date&#34;, when used with respect to any installment of interest on a Security of a particular series, means the date specified in such Security or in a Board Resolution or in an indenture supplemental hereto with respect to such series as the fixed date on which an installment of interest with respect to Securities of that series is due and payable.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Officer&#34; means, with respect to the Company, the chairman of the Board of Directors, a chief executive officer, a president, a chief financial officer, a chief operating officer, any executive vice president, any senior vice president, any vice president, the treasurer or any assistant treasurer, the controller or any assistant controller or the secretary or any assistant secretary.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Officer's Certificate&#34; means a certificate signed by any Officer. Each such certificate shall include the statements provided for in Section 13.07, if and to the extent required by the provisions thereof.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Opinion of Counsel&#34; means an opinion in writing subject to customary exceptions of legal counsel, who may be an employee of or counsel for the Company, that is delivered to the Trustee in accordance with the terms hereof. Each such opinion shall include the statements provided for in Section 13.07, if and to the extent required by the provisions thereof.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Outstanding&#34;, when used with reference to Securities of any series, means, subject to the provisions of Section 8.04, as of any particular time, all Securities of that series theretofore authenticated and delivered by the Trustee under this Indenture, except (a) Securities theretofore canceled by the Trustee or any paying agent, or delivered to the Trustee or any paying agent for cancellation or that have previously been canceled&#59; (b) Securities or portions thereof for the payment or redemption of which moneys or Governmental Obligations in the necessary amount shall have been deposited in trust with the Trustee or with any</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">paying agent (other than the Company) or shall have been set aside and segregated in trust by the Company (if the Company shall act as its own paying agent)&#59; provided, however, that if such Securities or portions of such Securities are to be redeemed prior to the maturity thereof, notice of such redemption shall have been given as provided in Article Three, or provision satisfactory to the Trustee shall have been made for giving such notice&#59; and (c) Securities in lieu of or in substitution for which other Securities shall have been authenticated and delivered pursuant to the terms of Section 2.07.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-6-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Person&#34; means any individual, corporation, partnership, joint venture, joint-stock company, limited liability company, association, trust, unincorporated organization, any other entity or organization, including a government or political subdivision or an agency or instrumentality thereof.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Predecessor Security&#34; of any particular Security means every previous Security evidencing all or a portion of the same debt as that evidenced by such particular Security&#59; and, for the purposes of this definition, any Security authenticated and delivered under Section 2.07 in lieu of a lost, destroyed or stolen Security shall be deemed to evidence the same debt as the lost, destroyed or stolen Security.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Responsible Officer&#34; when used with respect to the Trustee means the chairman of its board of directors, the chief executive officer, the president, any vice president, the secretary, the treasurer, any trust officer, any corporate trust officer or any other officer or assistant officer of the Trustee customarily performing functions similar to those performed by the Persons who at the time shall be such officers, respectively, or to whom any corporate trust matter is referred because of his or her knowledge of and familiarity with the particular subject.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Securities&#34; means the debt Securities authenticated and delivered under this Indenture.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Securityholder&#34;, &#34;holder of Securities&#34;, &#34;registered holder&#34;, or other similar term, means the Person or Persons in whose name or names a particular Security shall be registered on the books of the Company kept for that purpose in accordance with the terms of this Indenture.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Security Register&#34; and &#34;Security Registrar&#34; shall have the meanings as set forth in Section 2.05.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Subsidiary&#34; means, with respect to any Person, (i) any corporation at least a majority of whose outstanding Voting Stock shall at the time be owned, directly or indirectly, by such Person or by one or more of its Subsidiaries or by such Person and one or more of its Subsidiaries, (ii) any general partnership, joint venture or similar entity, at least a majority of whose outstanding partnership or similar interests shall at the time be owned by such Person, or by one or more of its Subsidiaries, or by such Person and one or more of its Subsidiaries and (iii) any limited partnership of which such Person or any of its Subsidiaries is a general partner.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Trustee&#34; means , and, subject to the provisions of Article Seven, shall also include its successors and assigns, and, if at any time there is more than one Person acting in such capacity hereunder, &#34;Trustee&#34; shall mean each such Person. The term &#34;Trustee&#34; as used with respect to a particular series of the Securities shall mean the trustee with respect to that series.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Trust Indenture Act&#34; means the Trust Indenture Act of 1939, as amended.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Voting Stock&#34;, as applied to stock of any Person, means shares, interests, participations or other equivalents in the equity interest (however designated) in such Person having ordinary voting power for the election of a majority of the directors (or the equivalent) of such Person, other than shares, interests, participations or other equivalents having such power only by reason of the occurrence of a contingency.</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE II</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-7-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND EXCHANGE OF SECURITIES</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.1 Designation and Terms of Securities.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The aggregate principal amount of Securities that may be authenticated and delivered under this Indenture is unlimited. The Securities may be issued in one or more series up to the aggregate principal amount of Securities of that series from time to time authorized by or pursuant to a Board Resolution or pursuant to one or more indentures supplemental hereto. Prior to the initial issuance of Securities of any series, there shall be established in or pursuant to a Board Resolution, and set forth in an Officer's Certificate, or established in one or more indentures supplemental hereto&#58;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) the title of the Securities of the series (which shall distinguish the Securities of that series from all other Securities)&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) any limit upon the aggregate principal amount of the Securities of that series that may be authenticated and delivered under this Indenture (except for Securities authenticated and delivered upon registration of transfer of, or in exchange for, or in lieu of, other Securities of that series)&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) the date or dates on which the principal of the Securities of the series is payable, any original issue discount that may apply to the Securities of that series upon their issuance, the principal amount due at maturity, and the place(s) of payment&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv) the rate or rates at which the Securities of the series shall bear interest or the manner of calculation of such rate or rates, if any&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v) the date or dates from which such interest shall accrue, the Interest Payment Dates on which such interest will be payable or the manner of determination of such Interest Payment Dates, the place(s) of payment, and the record date for the determination of holders to whom interest is payable on any such Interest Payment Dates or the manner of determination of such record dates&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi) the right, if any, to extend the interest payment periods and the duration of such extension&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vii) the period or periods within which, the price or prices at which and the terms and conditions upon which Securities of the series may be redeemed, in whole or in part, at the option of the Company&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(viii) the obligation, if any, of the Company to redeem or purchase Securities of the series pursuant to any sinking fund, mandatory redemption, or analogous provisions (including payments made in cash in satisfaction of future sinking fund obligations) or at the option of a holder thereof and the period or periods within which, the price or prices at which, and the terms and conditions upon which, Securities of the series shall be redeemed or purchased, in whole or in part, pursuant to such obligation&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ix) the form of the Securities of the series including the form of the Certificate of Authentication for such series&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(x) if other than denominations of one thousand U.S. dollars ($1,000) or any integral multiple thereof, the denominations in which the Securities of the series shall be issuable&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xi) any and all other terms (including terms, to the extent applicable, relating to any auction or remarketing of the Securities of that series and any security for the obligations of the Company with respect to such Securities) with respect to such series (which terms shall not be inconsistent with the terms of this Indenture, as amended by any supplemental indenture) including any terms which may be required by or advisable under United States laws or regulations or advisable in connection with the marketing of Securities of that series&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xii) whether the Securities are issuable as a Global Security and, in such case, the terms and the identity of the Depositary for such series&#59;</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xiii) whether the Securities will be convertible into or exchangeable for shares of common stock, preferred stock or other securities of the Company or any other Person and, if so, the terms and conditions upon which such Securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at the Company's option or the holders' option) conversion or exchange features, and the applicable conversion or exchange period&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-8-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xiv) if other than the principal amount thereof, the portion of the principal amount of Securities of the series which shall be payable upon declaration of acceleration of the maturity thereof pursuant to Section 6.01&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xv) any additional or different Events of Default or restrictive covenants (which may include, among other restrictions, restrictions on the Company's ability or the ability of the Company's Subsidiaries to&#58; incur additional indebtedness&#59; issue additional securities&#59; create liens&#59; pay dividends or make distributions in respect of the capital stock of the Company or the Company's Subsidiaries&#59; redeem capital stock&#59; place restrictions on the Company's Subsidiaries' ability to pay dividends, make distributions or transfer assets&#59; make investments or other restricted payments&#59; sell or otherwise dispose of assets&#59; enter into sale- leaseback transactions&#59; engage in transactions with stockholders or affiliates&#59; issue or sell stock of the Company's Subsidiaries&#59; or effect a consolidation or merger) or financial covenants (which may include, among other financial covenants, financial covenants that require the Company and its Subsidiaries to maintain specified interest coverage, fixed charge, cash flow-based, asset-based or other financial ratios) provided for with respect to the Securities of the series&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xvi) if other than dollars, the coin or currency in which the Securities of the series are denominated (including, but not limited to, foreign currency)&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xvii) the terms and conditions, if any, upon which the Company shall pay amounts in addition to the stated interest, premium, if any and principal amounts of the Securities of the series to any Securityholder that is not a &#34;United States person&#34; for federal tax purposes&#59; and</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xviii) any restrictions on transfer, sale or assignment of the Securities of the series.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Securities of any one series shall be substantially identical except as may otherwise be provided in or pursuant to any such Board Resolution or in any indentures supplemental hereto.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of the terms of the series are established by action taken pursuant to a Board Resolution of the Company, a copy of an appropriate record of such action shall be certified by the secretary or an assistant secretary of the Company and delivered to the Trustee at or prior to the delivery of the Officer's Certificate of the Company setting forth the terms of the series.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities of any particular series may be issued at various times, with different dates on which the principal or any installment of principal is payable, with different rates of interest, if any, or different methods by which rates of interest may be determined, with different dates on which such interest may be payable and with different redemption dates.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.2 Form of Securities and Trustee's Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Securities of any series and the Trustee's certificate of authentication to be borne by such Securities shall be substantially of the tenor and purport as set forth in one or more indentures supplemental hereto or as provided in a Board Resolution, and set forth in an Officer's Certificate, and they may have such letters, numbers or other marks of identification or designation and such legends or endorsements printed, lithographed or engraved thereon as the Company may deem appropriate and as are not inconsistent with the provisions of this Indenture, or as may be required to comply with any law or with any rule or regulation made pursuant thereto or with any rule or regulation of any securities exchange on which Securities of that series may be listed, or to conform to usage.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.3 Denominations&#58; Provisions for Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Securities shall be issuable as registered Securities and in the denominations of one thousand U.S. dollars ($1,000) or any integral multiple thereof, subject to Section 2.01(a)(10).</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Securities of a particular series shall bear interest payable on the dates and at the rate specified with respect to that series. Subject to Section 2.01(a)(16), the principal of and the interest on the Securities of any series, as well as any premium thereon in case of redemption thereof prior to maturity, shall be payable in the coin or currency of the United States of America that at the time is legal tender for public and private debt, at the office or agency of the Company maintained for that purpose.</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Security shall be dated the date of its authentication. Interest on the Securities shall be computed on the basis of a 360-day year composed of twelve 30-day months.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-9-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest installment on any Security that is payable, and is punctually paid or duly provided for, on any Interest Payment Date for Securities of that series shall be paid to the Person in whose name said Security (or one or more Predecessor Securities) is registered at the close of business on the regular record date for such interest installment. In the event that any Security of a particular series or portion thereof is called for redemption and the redemption date is subsequent to a regular record date with respect to any Interest Payment Date and prior to such Interest Payment Date, interest on such Security will be paid upon presentation and surrender of such Security as provided in Section 3.03.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any interest on any Security that is payable, but is not punctually paid or duly provided for, on any Interest Payment Date for Securities of the same series (herein called &#34;Defaulted Interest&#34;) shall forthwith cease to be payable to the registered holder on the relevant regular record date by virtue of having been such holder&#59; and such Defaulted Interest shall be paid by the Company, at its election, as provided in clause (1) or clause (2) below&#58;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) The Company may make payment of any Defaulted Interest on Securities to the Persons in whose names such Securities (or their respective Predecessor Securities) are registered at the close of business on a special record date for the payment of such Defaulted Interest, which shall be fixed in the following manner&#58; the Company shall notify the Trustee in writing of the amount of Defaulted Interest proposed to be paid on each such Security and the date of the proposed payment, and at the same time the Company shall deposit with the Trustee an amount of money equal to the aggregate amount proposed to be paid in respect of such Defaulted Interest or shall make arrangements satisfactory to the Trustee for such deposit prior to the date of the proposed payment, such money when deposited to be held in trust for the benefit of the Persons entitled to such Defaulted Interest as in this clause provided. Thereupon the Trustee shall fix a special record date for the payment of such Defaulted Interest which shall not be more than 15 nor less than 10 days prior to the date of the proposed payment and not less than 10 days after the receipt by the Trustee of the notice of the proposed payment. The Trustee shall promptly notify the Company of such special record date and, in the name and at the expense of the Company, shall cause notice of the proposed payment of such Defaulted Interest and the special record date therefor to be mailed, first class postage prepaid, to each Securityholder at his or her address as it appears in the Security Register (as hereinafter defined), not less than 10 days prior to such special record date. Notice of the proposed payment of such Defaulted Interest and the special record date therefor having been mailed as aforesaid, such Defaulted Interest shall be paid to the Persons in whose names such Securities (or their respective Predecessor Securities) are registered on such special record date.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) The Company may make payment of any Defaulted Interest on any Securities in any other lawful manner not inconsistent with the requirements of any securities exchange on which such Securities may be listed, and upon such notice as may be required by such exchange, if, after notice given by the Company to the Trustee of the proposed payment pursuant to this clause, such manner of payment shall be deemed practicable by the Trustee.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise set forth in a Board Resolution or one or more indentures supplemental hereto establishing the terms of any series of Securities pursuant to Section 2.01 hereof, the term &#34;regular record date&#34; as used in this Section with respect to a series of Securities and any Interest Payment Date for such series shall mean either the fifteenth day of the month immediately preceding the month in which an Interest Payment Date established for such series pursuant to Section 2.01 hereof shall occur, if such Interest Payment Date is the first day of a month, or the first day of the month in which an Interest Payment Date established for such series pursuant to Section 2.01 hereof shall occur, if such Interest Payment Date is the fifteenth day of a month, whether or not such date is a Business Day.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the foregoing provisions of this Section, each Security of a series delivered under this Indenture upon transfer of or in exchange for or in lieu of any other Security of such series shall carry the rights to interest accrued and unpaid, and to accrue, that were carried by such other Security.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.4 Execution and Authentications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Securities shall be signed on behalf of the Company by one of its Officers. Signatures may be in the form of a manual or facsimile signature.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use the facsimile signature of any Person who shall have been an Officer, notwithstanding the fact that at the time the Securities shall be authenticated and delivered or disposed of such Person shall have ceased to be such an officer of the Company. The Securities may contain such notations, legends or endorsements required by law, stock exchange rule or usage. Each Security shall be dated the date of its authentication by the Trustee.</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-10-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Security shall not be valid until authenticated manually by an authorized signatory of the Trustee, or by an Authenticating Agent. Such signature shall be conclusive evidence that the Security so authenticated has been duly authenticated and delivered hereunder and that the holder is entitled to the benefits of this Indenture. At any time and from time to time after the execution and delivery of this Indenture, the Company may deliver Securities of any series executed by the Company to the Trustee for authentication, together with a written order of the Company for the authentication and delivery of such Securities, signed by an Officer, and the Trustee in accordance with such written order shall authenticate and deliver such Securities.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-11-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In authenticating such Securities and accepting the additional responsibilities under this Indenture in relation to such Securities, the Trustee shall be entitled to receive, if requested, and (subject to Section 7.01) shall be fully protected in relying upon, an Opinion of Counsel stating that the form and terms thereof have been established in conformity with the provisions of this Indenture.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trustee shall not be required to authenticate such Securities if the issue of such Securities pursuant to this Indenture will affect the Trustee's own rights, duties or immunities under the Securities and this Indenture or otherwise in a manner that is not reasonably acceptable to the Trustee.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.5 Registration of Transfer and Exchange.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Securities of any series may be exchanged upon presentation thereof at the office or agency of the Company designated for such purpose, for other Securities of such series of authorized denominations, and for a like aggregate principal amount, upon payment of a sum sufficient to cover any tax or other governmental charge in relation thereto, all as provided in this Section. In respect of any Securities so surrendered for exchange, the Company shall execute, the Trustee shall authenticate and such office or agency shall deliver in exchange therefor the Security or Securities of the same series that the Securityholder making the exchange shall be entitled to receive, bearing numbers not contemporaneously outstanding.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The Company shall keep, or cause to be kept, at its office or agency designated for such purpose a register or registers (herein referred to as the &#34;Security Register&#34;) in which, subject to such reasonable regulations as it may prescribe, the Company shall register the Securities and the transfers of Securities as in this Article provided and which at all reasonable times shall be open for inspection by the Trustee. The registrar for the purpose of registering Securities and transfer of Securities as herein provided shall be appointed as authorized by Board Resolution (the &#34;Security Registrar&#34;).</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon surrender for transfer of any Security at the office or agency of the Company designated for such purpose, the Company shall execute, the Trustee shall authenticate and such office or agency shall deliver in the name of the transferee or transferees a new Security or Securities of the same series as the Security presented for a like aggregate principal amount.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Securities presented or surrendered for exchange or registration of transfer, as provided in this Section, shall be accompanied (if so required by the Company or the Security Registrar) by a written instrument or instruments of transfer, in form satisfactory to the Company or the Security Registrar, duly executed by the registered holder or by such holder's duly authorized attorney in writing.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Except as provided pursuant to Section 2.01 pursuant to a Board Resolution, and set forth in an Officer's Certificate, or established in one or more indentures supplemental to this Indenture, no service charge shall be made for any exchange or registration of transfer of Securities, or issue of new Securities in case of partial redemption of any series, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge in relation thereto, other than exchanges pursuant to Section 2.06, Section 3.03(b) and Section 9.04 not involving any transfer.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) The Company shall not be required (i) to issue, exchange or register the transfer of any Securities during a period beginning at the opening of business 15 days before the day of the mailing of a notice of redemption of less than all the Outstanding Securities of the same series and ending at the close of business on the day of such mailing, nor (ii) to register the transfer of or exchange any Securities of any series or portions thereof called for redemption, other than the unredeemed portion of any such Securities being redeemed in part. The provisions of this Section 2.05 are, with respect to any Global Security, subject to Section 2.11 hereof.</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.6 Temporary Securities.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-12-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pending the preparation of definitive Securities of any series, the Company may execute, and the Trustee shall authenticate and deliver, temporary Securities (printed, lithographed or typewritten) of any authorized denomination. Such temporary Securities shall be substantially in the form of the definitive Securities in lieu of which they are issued, but with such omissions, insertions and variations as may be appropriate for temporary Securities, all as may be determined by the Company. Every temporary Security of any series shall be executed by the Company and be authenticated by the Trustee upon the same conditions and in substantially the same manner, and with like effect, as the definitive Securities of such series. Without unnecessary delay the Company will execute and will furnish definitive Securities of such series and thereupon any or all temporary Securities of such series may be surrendered in exchange therefor (without charge to the holders), at the office or agency of the Company designated for the purpose, and the Trustee shall authenticate and such office or agency shall deliver in exchange for such temporary Securities an equal aggregate principal amount of definitive Securities of such series, unless the Company advises the Trustee to the effect that definitive Securities need not be executed and furnished until further notice from the Company. Until so exchanged, the temporary Securities of such series shall be entitled to the same benefits under this Indenture as definitive Securities of such series authenticated and delivered hereunder.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.7 Mutilated, Destroyed, Lost or Stolen Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In case any temporary or definitive Security shall become mutilated or be destroyed, lost or stolen, the Company (subject to the next succeeding sentence) shall execute, and upon the Company's request the Trustee (subject as aforesaid) shall authenticate and deliver, a new Security of the same series, bearing a number not contemporaneously outstanding, in exchange and substitution for the mutilated Security, or in lieu of and in substitution for the Security so destroyed, lost or stolen. In every case the applicant for a substituted Security shall furnish to the Company and the Trustee such security or indemnity as may be required by them to save each of them harmless, and, in every case of destruction, loss or theft, the applicant shall also furnish to the Company and the Trustee evidence to their satisfaction of the destruction, loss or theft of the applicant's Security and of the ownership thereof. The Trustee may authenticate any such substituted Security and deliver the same upon the written request or authorization of any officer of the Company. Upon the issuance of any substituted Security, the Company may require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto and any other expenses (including the fees and expenses of the Trustee) connected therewith.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In case any Security that has matured or is about to mature shall become mutilated or be destroyed, lost or stolen, the Company may, instead of issuing a substitute Security, pay or authorize the payment of the same (without surrender thereof except in the case of a mutilated Security) if the applicant for such payment shall furnish to the Company and the Trustee such security or indemnity as they may require to save them harmless, and, in case of destruction, loss or theft, evidence to the satisfaction of the Company and the Trustee of the destruction, loss or theft of such Security and of the ownership thereof.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Every replacement Security issued pursuant to the provisions of this Section shall constitute an additional contractual obligation of the Company whether or not the mutilated, destroyed, lost or stolen Security shall be found at any time, or be enforceable by anyone, and shall be entitled to all the benefits of this Indenture equally and proportionately with any and all other Securities of the same series duly issued hereunder. All Securities shall be held and owned upon the express condition that the foregoing provisions are exclusive with respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities, and shall preclude (to the extent lawful) any and all other rights or remedies, notwithstanding any law or statute existing or hereafter enacted to the contrary with respect to the replacement or payment of negotiable instruments or other securities without their surrender.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.8 Cancellation.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Securities surrendered for the purpose of payment, redemption, exchange or registration of transfer shall, if surrendered to the Company or any paying agent, be delivered to the Trustee for cancellation, or, if surrendered to the Trustee, shall be cancelled by it, and no Securities shall be issued in lieu thereof except as expressly required or permitted by any of the provisions of this Indenture. On request of the Company at the time of such surrender, the Trustee shall deliver to the Company canceled Securities held by the Trustee. In the absence of such request the Trustee may dispose of canceled Securities in accordance with its standard procedures and deliver a certificate of disposition to the Company. If the Company shall otherwise acquire any of the Securities, however, such acquisition shall not operate as a redemption or satisfaction of the indebtedness represented by such Securities unless and until the same are delivered to the Trustee for cancellation.</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.9 Benefits of Indenture.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-13-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nothing in this Indenture or in the Securities, express or implied, shall give or be construed to give to any Person, other than the parties hereto and the holders of the Securities any legal or equitable right, remedy or claim under or in respect of this Indenture, or under any covenant, condition or provision herein contained&#59; all such covenants, conditions and provisions being for the sole benefit of the parties hereto and of the holders of the Securities.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.10 Authenticating Agent.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">So long as any of the Securities of any series remain Outstanding there may be an Authenticating Agent for any or all such series of Securities which the Trustee shall have the right to appoint. Said Authenticating Agent shall be authorized to act on behalf of the Trustee to authenticate Securities of such series issued upon exchange, transfer or partial redemption thereof, and Securities so authenticated shall be entitled to the benefits of this Indenture and shall be valid and obligatory for all purposes as if authenticated by the Trustee hereunder. All references in this Indenture to the authentication of Securities by the Trustee shall be deemed to include authentication by an Authenticating Agent for such series. Each Authenticating Agent shall be acceptable to the Company and shall be a corporation that has a combined capital and surplus, as most recently reported or determined by it, sufficient under the laws of any jurisdiction under which it is organized or in which it is doing business to conduct a trust business, and that is otherwise authorized under such laws to conduct such business and is subject to supervision or examination by federal or state authorities. If at any time any Authenticating Agent shall cease to be eligible in accordance with these provisions, it shall resign immediately.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any Authenticating Agent may at any time resign by giving written notice of resignation to the Trustee and to the Company. The Trustee may at any time (and upon request by the Company shall) terminate the agency of any Authenticating Agent by giving written notice of termination to such Authenticating Agent and to the Company. Upon resignation, termination or cessation of eligibility of any Authenticating Agent, the Trustee may appoint an eligible successor Authenticating Agent acceptable to the Company. Any successor Authenticating Agent, upon acceptance of its appointment hereunder, shall become vested with all the rights, powers and duties of its predecessor hereunder as if originally named as an Authenticating Agent pursuant hereto.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.11 Global Securities.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) If the Company shall establish pursuant to Section 2.01 that the Securities of a particular series are to be issued as a Global Security, then the Company shall execute and the Trustee shall, in accordance with Section 2.04, authenticate and deliver, a Global Security that (i) shall represent, and shall be denominated in an amount equal to the aggregate principal amount of, all of the Outstanding Securities of such series, (ii) shall be registered in the name of the Depositary or its nominee, (iii) shall be delivered by the Trustee to the Depositary or pursuant to the Depositary's instruction and (iv) shall bear a legend substantially to the following effect&#58; &#34;Except as otherwise provided in Section 2.11 of the Indenture, this Security may be transferred, in whole but not in part, only to another nominee of the Depositary or to a successor Depositary or to a nominee of such successor Depositary.&#34;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Notwithstanding the provisions of Section 2.05, the Global Security of a series may be transferred, in whole but not in part and in the manner provided in Section 2.05, only to another nominee of the Depositary for such series, or to a successor Depositary for such series selected or approved by the Company or to a nominee of such successor Depositary.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) If at any time the Depositary for a series of the Securities notifies the Company that it is unwilling or unable to continue as Depositary for such series or if at any time the Depositary for such series shall no longer be registered or in good standing under the Exchange Act, or other applicable statute or regulation, and a successor Depositary for such series is not appointed by the Company within 90 days after the Company receives such notice or becomes aware of such condition, as the case may be, or if an Event of Default has occurred and is continuing and the Company has received a request from the Depositary or from the Trustee, this Section 2.11 shall no longer be applicable to the Securities of such series and the Company will execute, and subject to Section 2.04, the Trustee will authenticate and deliver the Securities of such series in definitive registered form without coupons, in authorized denominations, and in an aggregate principal amount equal to the principal amount of the Global Security of such series in exchange for such Global Security. In addition, the Company may at any time determine that the Securities of any series shall no longer be represented by a Global Security and that the provisions of this Section 2.11 shall no longer apply to the Securities of such series. In such event the Company will execute and, subject to Section 2.04, the Trustee, upon receipt of an Officer's Certificate evidencing such determination by the Company, will authenticate and deliver the Securities of such series in definitive registered form without coupons, in authorized denominations, and in an aggregate principal amount equal to the principal amount of the Global Security of such series in</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-14-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exchange for such Global Security. Upon the exchange of the Global Security for such Securities in definitive registered form without coupons, in authorized denominations, the Global Security shall be canceled by the Trustee. Such Securities in definitive registered form issued in exchange for the Global Security pursuant to this Section 2.11(c) shall be registered in such names and in such authorized denominations as the Depositary, pursuant to instructions from its direct or indirect participants or otherwise, shall instruct the Trustee. The Trustee shall deliver such Securities to the Depositary for delivery to the Persons in whose names such Securities are so registered.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-15-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE III</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REDEMPTION OF SECURITIES AND SINKING FUND PROVISIONS</font></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.1 Redemption.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem the Securities of any series issued hereunder on and after the dates and in accordance with the terms established for such series pursuant to Section 2.01 hereof.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.2 Notice of Redemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) In case the Company shall desire to exercise such right to redeem all or, as the case may be, a portion of the Securities of any series in accordance with any right the Company reserved for itself to do so pursuant to Section 2.01 hereof, the Company shall, or shall cause the Trustee to, give notice of such redemption to holders of the Securities of such series to be redeemed by mailing, first class postage prepaid, a notice of such redemption not less than 30 days and not more than 90 days before the date fixed for redemption of that series to such holders at their last addresses as they shall appear upon the Security Register, unless a shorter period is specified in the Securities to be redeemed. Any notice that is mailed in the manner herein provided shall be conclusively presumed to have been duly given, whether or not the registered holder receives the notice. In any case, failure duly to give such notice to the holder of any Security of any series designated for redemption in whole or in part, or any defect in the notice, shall not affect the validity of the proceedings for the redemption of any other Securities of such series or any other series. In the case of any redemption of Securities prior to the expiration of any restriction on such redemption provided in the terms of such Securities or elsewhere in this Indenture, the Company shall furnish the Trustee with an Officer's Certificate evidencing compliance with any such restriction.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each such notice of redemption shall specify the date fixed for redemption and the redemption price at which Securities of that series are to be redeemed, and shall state that payment of the redemption price of such Securities to be redeemed will be made at the office or agency of the Company, upon presentation and surrender of such Securities, that interest accrued to the date fixed for redemption will be paid as specified in said notice, that from and after said date interest will cease to accrue and that the redemption is from a sinking fund, if such is the case. If less than all the Securities of a series are to be redeemed, the notice to the holders of Securities of that series to be redeemed in part shall specify the particular Securities to be so redeemed.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In case any Security is to be redeemed in part only, the notice that relates to such Security shall state the portion of the principal amount thereof to be redeemed, and shall state that on and after the redemption date, upon surrender of such Security, a new Security or Securities of such series in principal amount equal to the unredeemed portion thereof will be issued.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) If less than all the Securities of a series are to be redeemed, the Company shall give the Trustee at least 45 days' notice (unless a shorter notice shall be satisfactory to the Trustee) in advance of the date fixed for redemption as to the aggregate principal amount of Securities of the series to be redeemed, and thereupon the Trustee shall select, by lot or in such other manner as it shall deem appropriate and fair in its discretion and that may provide for the selection of a portion or portions (equal to one thousand U.S. dollars ($1,000) or any integral multiple thereof) of the principal amount of such Securities of a denomination larger than $1,000, the Securities to be redeemed and shall thereafter promptly notify the Company in writing of the numbers of the Securities to be redeemed, in whole or in part. The Company may, if and whenever it shall so elect, by delivery of instructions signed on its behalf by an Officer, instruct the Trustee or any paying agent to call all or any part of the Securities of a particular series for redemption and to give notice of redemption in the manner set forth in this Section, such notice to be in the name of the Company or its own name as the Trustee or such paying agent may deem advisable. In any case in which notice of redemption is to be given by the Trustee or any such paying agent, the Company shall deliver or cause to be delivered to, or permit to remain with, the Trustee or such paying agent, as the case may be, such Security Register, transfer books or other records, or suitable copies or extracts therefrom, sufficient to enable the Trustee or such paying agent to give any notice by mail that may be required under the provisions of this Section.</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="padding-left:4.4pt;text-indent:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.3 Payment Upon Redemption.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-16-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) If the giving of notice of redemption shall have been completed as above provided, the Securities or portions of Securities of the series to be redeemed specified in such notice shall become due and payable on the date and at the place stated in such notice at the applicable redemption price, together with interest accrued to the date fixed for redemption and interest on such Securities or portions of Securities shall cease to accrue on and after the date fixed for redemption, unless the Company shall default in the payment of such redemption price and accrued interest with respect to any such Security or portion thereof. On presentation and surrender of such Securities on or after the date fixed for redemption at the place of payment specified in the notice, said Securities shall be paid and redeemed at the applicable redemption price for such series, together with interest accrued thereon to the date fixed for redemption (but if the date fixed for redemption is an interest payment date, the interest installment payable on such date shall be payable to the registered holder at the close of business on the applicable record date pursuant to Section 2.03).</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Upon presentation of any Security of such series that is to be redeemed in part only, the Company shall execute and the Trustee shall authenticate and the office or agency where the Security is presented shall deliver to the holder thereof, at the expense of the Company, a new Security of the same series of authorized denominations in principal amount equal to the unredeemed portion of the Security so presented.</font></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.4 Sinking Fund.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provisions of Sections 3.04, 3.05 and 3.06 shall be applicable to any sinking fund for the retirement of Securities of a series, except as otherwise specified as contemplated by Section 2.01 for Securities of such series.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The minimum amount of any sinking fund payment provided for by the terms of Securities of any series is herein referred to as a &#34;mandatory sinking fund payment,&#34; and any payment in excess of such minimum amount provided for by the terms of Securities of any series is herein referred to as an &#34;optional sinking fund payment&#34;. If provided for by the terms of Securities of any series, the cash amount of any sinking fund payment may be subject to reduction as provided in Section 3.05. Each sinking fund payment shall be applied to the redemption of Securities of any series as provided for by the terms of Securities of such series.</font></div><div style="padding-left:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.5 Satisfaction of Sinking Fund Payments with Securities.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company (i) may deliver Outstanding Securities of a series and (ii) may apply as a credit Securities of a series that have been redeemed either at the election of the Company pursuant to the terms of such Securities or through the application of permitted optional sinking fund payments pursuant to the terms of such Securities, in each case in satisfaction of all or any part of any sinking fund payment with respect to the Securities of such series required to be made pursuant to the terms of such Securities as provided for by the terms of such series, provided that such Securities have not been previously so credited. Such Securities shall be received and credited for such purpose by the Trustee at the redemption price specified in such Securities for redemption through operation of the sinking fund and the amount of such sinking fund payment shall be reduced accordingly.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.6 Redemption of Securities for Sinking Fund.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not less than 45 days prior to each sinking fund payment date for any series of Securities (unless a shorter period shall be satisfactory to the Trustee), the Company will deliver to the Trustee an Officer's Certificate specifying the amount of the next ensuing sinking fund payment for that series pursuant to the terms of the series, the portion thereof, if any, that is to be satisfied by delivering and crediting Securities of that series pursuant to Section 3.05 and the basis for such credit and will, together with such Officer's Certificate, deliver to the Trustee any Securities to be so delivered. Not less than 30 days before each such sinking fund payment date the Trustee shall select the Securities to be redeemed upon such sinking fund payment date in the manner specified in Section 3.02 and cause notice of the redemption thereof to be given in the name of and at the expense of the Company in the manner provided in Section 3.02. Such notice having been duly given, the redemption of such Securities shall be made upon the terms and in the manner stated in Section 3.03.</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE IV</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-17-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVENANTS</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 4.1 Payment of Principal, Premium and Interest.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will duly and punctually pay or cause to be paid the principal of (and premium, if any) and interest on the Securities of that series at the time and place and in the manner provided herein and established with respect to such Securities. Payments of principal on the Securities may be made at the time provided herein and established with respect to such Securities by U.S. dollar check drawn on and mailed to the address of the Securityholder entitled thereto as such address shall appear in the Security Register, or U.S. dollar wire transfer to, a U.S. dollar account (such wire transfer to be made only to a Securityholder of an aggregate principal amount of Securities of the applicable series in excess of U.S. $2,000,000 and only if such Securityholder shall have furnished wire instructions to the Trustee no later than 15 days prior to the relevant payment date). Payments of interest on the Securities may be made at the time provided herein and established with respect to such Securities by U.S. dollar check mailed to the address of the Securityholder entitled thereto as such address shall appear in the Security Register, or U.S. dollar wire transfer to, a U.S. dollar account (such a wire transfer to be made only to a Securityholder of an aggregate principal amount of Securities of the applicable series in excess of U.S. $2,000,000 and only if such Securityholder shall have furnished wire instructions in writing to the Security Registrar and the Trustee no later than 15 days prior to the relevant payment date.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 4.2 Maintenance of Office or Agency.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">So long as any series of the Securities remain Outstanding, the Company agrees to maintain an office or agency with respect to each such series and at such other location or locations as may be designated as provided in this Section 4.02, where (i) Securities of that series may be presented for payment, (ii) Securities of that series may be presented as herein above authorized for registration of transfer and exchange, and (iii) notices and demands to or upon the Company in respect of the Securities of that series and this Indenture may be given or served, such designation to continue with respect to such office or agency until the Company shall, by written notice signed by any officer authorized to sign an Officer's Certificate and delivered to the Trustee, designate some other office or agency for such purposes or any of them. If at any time the Company shall fail to maintain any such required office or agency or shall fail to furnish the Trustee with the address thereof, such presentations, notices and demands may be made or served at the Corporate Trust Office of the Trustee, and the Company hereby appoints the Trustee as its agent to receive all such presentations, notices and demands. The Company initially appoints the Corporate Trust Office of the Trustee as its paying agent with respect to the Securities.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 4.3 Paying Agents.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) If the Company shall appoint one or more paying agents for all or any series of the Securities, other than the Trustee, the Company will cause each such paying agent to execute and deliver to the Trustee an instrument in which such agent shall agree with the Trustee, subject to the provisions of this Section&#58;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) that it will hold all sums held by it as such agent for the payment of the principal of (and premium, if any) or interest on the Securities of that series (whether such sums have been paid to it by the Company or by any other obligor of such Securities) in trust for the benefit of the Persons entitled thereto&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) that it will give the Trustee notice of any failure by the Company (or by any other obligor of such Securities) to make any payment of the principal of (and premium, if any) or interest on the Securities of that series when the same shall be due and payable&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) that it will, at any time during the continuance of any failure referred to in the preceding paragraph (a)(2) above, upon the written request of the Trustee, forthwith pay to the Trustee all sums so held in trust by such paying agent&#59; and</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv) that it will perform all other duties of paying agent as set forth in this Indenture.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) If the Company shall act as its own paying agent with respect to any series of the Securities, it will on or before each due date of the principal of (and premium, if any) or interest on Securities of that series, set aside, segregate and hold in trust for the benefit of the Persons entitled thereto a sum sufficient to pay such principal (and premium, if any) or interest so becoming due on Securities of that series until such sums shall be paid to such Persons or otherwise disposed of as herein provided and will promptly notify the Trustee of such action, or any failure (by it or any other obligor on such Securities) to take such action. Whenever the Company shall have one or more paying agents for any series of Securities, it will, prior to each due date of the principal of (and premium, if any) or interest on any Securities of that series, deposit with the paying agent a sum sufficient to pay the principal (and premium, if any) or interest so becoming due, such sum to be held in trust for the benefit of</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-18-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Persons entitled to such principal, premium or interest, and (unless such paying agent is the Trustee) the Company will promptly notify the Trustee of this action or failure so to act.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-19-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Notwithstanding anything in this Section to the contrary, (i) the agreement to hold sums in trust as provided in this Section is subject to the provisions of Section 11.05, and (ii) the Company may at any time, for the purpose of obtaining the satisfaction and discharge of this Indenture or for any other purpose, pay, or direct any paying agent to pay, to the Trustee all sums held in trust by the Company or such paying agent, such sums to be held by the Trustee upon the same terms and conditions as those upon which such sums were held by the Company or such paying agent&#59; and, upon such payment by the Company or any paying agent to the Trustee, the Company or such paying agent shall be released from all further liability with respect to such money.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 4.4 Appointment to Fill Vacancy in Office of Trustee.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, whenever necessary to avoid or fill a vacancy in the office of Trustee, will appoint, in the manner provided in Section 7.10, a Trustee, so that there shall at all times be a Trustee hereunder.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 4.5 Compliance with Consolidation Provisions.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will not, while any of the Securities remain Outstanding, consolidate with or merge into any other Person, in either case where the Company is not the survivor of such transaction, or sell or convey all or substantially all of its property to any other Person unless the provisions of Article Ten hereof are complied with.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE V</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITYHOLDERS' LISTS AND REPORTS BY THE COMPANY AND THE TRUSTEE</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.1 Company to Furnish Trustee Names and Addresses of Securityholders.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will furnish or cause to be furnished to the Trustee (a) within 15 days after each regular record date (as defined in Section 2.03) a list, in such form as the Trustee may reasonably require, of the names and addresses of the holders of each series of Securities as of such regular record date, provided that the Company shall not be obligated to furnish or cause to furnish such list at any time that the list shall not differ in any respect from the most recent list furnished to the Trustee by the Company and (b) at such other times as the Trustee may request in writing within 30 days after the receipt by the Company of any such request, a list of similar form and content as of a date not more than 15 days prior to the time such list is furnished&#59; provided, however, that, in either case, no such list need be furnished for any series for which the Trustee shall be the Security Registrar.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.2 Preservation Of Information&#59; Communications With Securityholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The Trustee shall preserve, in as current a form as is reasonably practicable, all information as to the names and addresses of the holders of Securities contained in the most recent list furnished to it as provided in Section 5.01 and as to the names and addresses of holders of Securities received by the Trustee in its capacity as Security Registrar (if acting in such capacity).</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The Trustee may destroy any list furnished to it as provided in Section 5.01 upon receipt of a new list so furnished.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Securityholders may communicate as provided in Section 312(b) of the Trust Indenture Act with other Securityholders with respect to their rights under this Indenture or under the Securities, and, in connection with any such communications, the Trustee shall satisfy its obligations under Section 312(b) of the Trust Indenture Act in accordance with the provisions of Section 312(b) of the Trust Indenture Act.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.3 Reports by the Company.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company covenants and agrees to provide (which delivery may be via electronic mail) to the Trustee, after the Company files the same with the Securities and Exchange Commission, copies of the annual reports and of the information,</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">documents and other reports (or copies of such portions of any of the foregoing as the Securities and Exchange Commission may from time to time by rules and regulations prescribe) that the Company files with the Securities and Exchange Commission pursuant to Section 13 or Section 15(d) of the Exchange Act&#59; provided, however, the Company shall not be required to deliver to the Trustee any materials for which the Company has sought and received confidential treatment by the Securities and Exchange Commission&#59; and provided further, so long as such filings by the Company are available on the Securities and Exchange Commission's Electronic Data Gathering, Analysis and Retrieval System (EDGAR), such filings shall be deemed to have been filed with the Trustee for purposes of this Section 5.03 without any further action required by the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-20-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.4 Reports by the Trustee.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) If required by Section 313(a) of the Trust Indenture Act, the Trustee, within sixty (60) days after each May 1, shall transmit by mail, first class postage prepaid, to the Securityholders, as their names and addresses appear upon the Security Register, a brief report dated as of such May 1, which complies with Section 313(a) of the Trust Indenture Act.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The Trustee shall comply with Section 313(b) and 313(c) of the Trust Indenture Act.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) A copy of each such report shall, at the time of such transmission to Securityholders, be filed by the Trustee with the Company, with each securities exchange upon which any Securities are listed (if so listed) and also with the Securities and Exchange Commission. The Company agrees to notify the Trustee when any Securities become listed on any securities exchange.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE VI</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REMEDIES OF THE TRUSTEE AND SECURITYHOLDERS ON EVENT OF DEFAULT</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 6.1 Events of Default.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Whenever used herein with respect to Securities of a particular series, &#34;Event of Default&#34; means any one or more of the following events that has occurred and is continuing&#58;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) the Company defaults in the payment of any installment of interest upon any of the Securities of that series, as and when the same shall become due and payable, and such default continues for a period of 90 days&#59; provided, however, that a valid extension of an interest payment period by the Company in accordance with the terms of any indenture supplemental hereto shall not constitute a default in the payment of interest for this purpose&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) the Company defaults in the payment of the principal of (or premium, if any, on) any of the Securities of that series as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to that series&#59; provided, however, that a valid extension of the maturity of such Securities in accordance with the terms of any indenture supplemental hereto shall not constitute a default in the payment of principal or premium, if any&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) the Company fails to observe or perform any other of its covenants or agreements with respect to that series contained in this Indenture or otherwise established with respect to that series of Securities pursuant to Section 2.01 hereof (other than a covenant or agreement that has been expressly included in this Indenture solely for the benefit of one or more series of Securities other than such series) for a period of 90 days after the date on which written notice of such failure, requiring the same to be remedied and stating that such notice is a &#34;Notice of Default&#34; hereunder, shall have been given to the Company by the Trustee, by registered or certified mail, or to the Company and the Trustee by the holders of at least 25% in principal amount of the Securities of that series at the time Outstanding&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv) the Company pursuant to or within the meaning of any Bankruptcy Law (i) commences a voluntary case, (ii) consents to the entry of an order for relief against it in an involuntary case, (iii) consents to the appointment of a Custodian of it or for all or substantially all of its property or (iv) makes a general assignment for the benefit of its creditors&#59; or</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v) a court of competent jurisdiction enters an order under any Bankruptcy Law that (i) is for relief against the Company in an involuntary case, (ii) appoints a Custodian of the Company for all or substantially all of its property or (iii) orders the liquidation of the Company, and the order or decree remains unstayed and in effect for 90 days.</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) In each and every such case (other than an Event of Default specified in clause (4) or clause (5) above), unless the principal of all the Securities of that series shall have already become due and payable, either the Trustee or the holders of not less than 25% in aggregate principal amount of the Securities of that series then Outstanding hereunder, by notice in writing to the Company (and to the Trustee if given by such Securityholders), may declare the principal of (and premium, if any, on) and accrued and unpaid interest on all the Securities of that series to be due and payable immediately, and upon any such declaration the same shall become and shall be immediately due and payable. If an Event of Default specified in clause (4) or clause (5) above occurs, the principal of and accrued and unpaid interest on all the Securities of that series shall automatically be immediately due and payable without any declaration or other act on the part of the Trustee or the holders of the Securities.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-21-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) At any time after the principal of (and premium, if any, on) and accrued and unpaid interest on the Securities of that series shall have been so declared due and payable, and before any judgment or decree for the payment of the moneys due shall have been obtained or entered as hereinafter provided, the holders of a majority in aggregate principal amount of the Securities of that series then Outstanding hereunder, by written notice to the Company and the Trustee, may rescind and annul such declaration and its consequences if&#58; (i) the Company has paid or deposited with the Trustee a sum sufficient to pay all matured installments of interest upon all the Securities of that series and the principal of (and premium, if any, on) any and all Securities of that series that shall have become due otherwise than by acceleration (with interest upon such principal and premium, if any, and, to the extent that such payment is enforceable under applicable law, upon overdue installments of interest, at the rate per annum expressed in the Securities of that series to the date of such payment or deposit) and the amount payable to the Trustee under Section 7.06, and (ii) any and all Events of Default under the Indenture with respect to such series, other than the nonpayment of principal on (and premium, if any, on) and accrued and unpaid interest on Securities of that series that shall not have become due by their terms, shall have been remedied or waived as provided in Section 6.06.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No such rescission and annulment shall extend to or shall affect any subsequent default or impair any right consequent thereon.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) In case the Trustee shall have proceeded to enforce any right with respect to Securities of that series under this Indenture and such proceedings shall have been discontinued or abandoned because of such rescission or annulment or for any other reason or shall have been determined adversely to the Trustee, then and in every such case, subject to any determination in such proceedings, the Company and the Trustee shall be restored respectively to their former positions and rights hereunder, and all rights, remedies and powers of the Company and the Trustee shall continue as though no such proceedings had been taken.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 6.2 Collection of Indebtedness and Suits for Enforcement by Trustee.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The Company covenants that (i) in case it shall default in the payment of any installment of interest on any of the Securities of a series, or in any payment required by any sinking or analogous fund established with respect to that series as and when the same shall have become due and payable, and such default shall have continued for a period of 90 days, or (ii) in case it shall default in the payment of the principal of (or premium, if any, on) any of the Securities of a series when the same shall have become due and payable, whether upon maturity of the Securities of a series or upon redemption or upon declaration or otherwise then, upon demand of the Trustee, the Company will pay to the Trustee, for the benefit of the holders of the Securities of that series, the whole amount that then shall have been become due and payable on all such Securities for principal (and premium, if any) or interest, or both, as the case may be, with interest upon the overdue principal (and premium, if any) and (to the extent that payment of such interest is enforceable under applicable law) upon overdue installments of interest at the rate per annum expressed in the Securities of that series&#59; and, in addition thereto, such further amount as shall be sufficient to cover the costs and expenses of collection, and the amount payable to the Trustee under Section 7.06.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) If the Company shall fail to pay such amounts forthwith upon such demand, the Trustee, in its own name and as trustee of an express trust, shall be entitled and empowered to institute any action or proceedings at law or in equity for the collection of the sums so due and unpaid, and may prosecute any such action or proceeding to judgment or final decree, and may enforce any such judgment or final decree against the Company or other obligor upon the Securities of that series and collect the moneys adjudged or decreed to be payable in the manner provided by law or equity out of the property of the Company or other obligor upon the Securities of that series, wherever situated.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) In case of any receivership, insolvency, liquidation, bankruptcy, reorganization, readjustment, arrangement, composition or judicial proceedings affecting the Company, or its creditors or property, the Trustee shall have power to intervene in such proceedings and take any action therein that may be permitted by the court and shall (except as may be otherwise provided by law) be entitled to file such proofs of claim and other papers and documents as may be necessary or advisable in order to have the claims of the Trustee and of the holders of Securities of such series allowed for the entire amount</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due and payable by the Company under the Indenture at the date of institution of such proceedings and for any additional amount that may become due and payable by the Company after such date, and to collect and receive any moneys or other property payable or deliverable on any such claim, and to distribute the same after the deduction of the amount payable to the Trustee under Section 7.06&#59; and any receiver, assignee or trustee in bankruptcy or reorganization is hereby authorized by each of the holders of Securities of such series to make such payments to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-22-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trustee, and, in the event that the Trustee shall consent to the making of such payments directly to such Securityholders, to pay to the Trustee any amount due it under Section 7.06.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-23-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) All rights of action and of asserting claims under this Indenture, or under any of the terms established with respect to Securities of that series, may be enforced by the Trustee without the possession of any of such Securities, or the production thereof at any trial or other proceeding relative thereto, and any such suit or proceeding instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery of judgment shall, after provision for payment to the Trustee of any amounts due under Section 7.06, be for the ratable benefit of the holders of the Securities of such series.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In case of an Event of Default hereunder, the Trustee may in its discretion proceed to protect and enforce the rights vested in it by this Indenture by such appropriate judicial proceedings as the Trustee shall deem most effectual to protect and enforce any of such rights, either at law or in equity or in bankruptcy or otherwise, whether for the specific enforcement of any covenant or agreement contained in the Indenture or in aid of the exercise of any power granted in this Indenture, or to enforce any other legal or equitable right vested in the Trustee by this Indenture or by law.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nothing contained herein shall be deemed to authorize the Trustee to authorize or consent to or accept or adopt on behalf of any Securityholder any plan of reorganization, arrangement, adjustment or composition affecting the Securities of that series or the rights of any holder thereof or to authorize the Trustee to vote in respect of the claim of any Securityholder in any such proceeding.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 6.3 Application of Moneys Collected.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any moneys collected by the Trustee pursuant to this Article with respect to a particular series of Securities shall be applied in the following order, at the date or dates fixed by the Trustee and, in case of the distribution of such moneys on account of principal (or premium, if any) or interest, upon presentation of the Securities of that series, and notation thereon of the payment, if only partially paid, and upon surrender thereof if fully paid&#58;</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FIRST&#58; To the payment of reasonable costs and expenses of collection and of all amounts payable to the Trustee under Section 7.06&#59;</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECOND&#58; To the payment of the amounts then due and unpaid upon Securities of such series for principal (and premium, if any) and interest, in respect of which or for the benefit of which such money has been collected, ratably, without preference or priority of any kind, according to the amounts due and payable on such Securities for principal (and premium, if any) and interest, respectively&#59; and</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIRD&#58; To the payment of the remainder, if any, to the Company or any other Person lawfully entitled thereto.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 6.4 Limitation on Suits.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No holder of any Security of any series shall have any right by virtue or by availing of any provision of this Indenture to institute any suit, action or proceeding in equity or at law upon or under or with respect to this Indenture or for the appointment of a receiver or trustee, or for any other remedy hereunder, unless (i) such holder previously shall have given to the Trustee written notice of an Event of Default and of the continuance thereof with respect to the Securities of such series specifying such Event of Default, as hereinbefore provided&#59; (ii) the holders of not less than 25% in aggregate principal amount of the Securities of such series then Outstanding shall have made written request upon the Trustee to institute such action, suit or proceeding in its own name as Trustee hereunder&#59; (iii) such holder or holders shall have offered to the Trustee such reasonable indemnity as it may require against the costs, expenses and liabilities to be incurred therein or thereby&#59; (iv) the Trustee for 90 days after its receipt of such notice, request and offer of indemnity, shall have failed to institute any such action, suit or proceeding and (v) during such 90 day period, the holders of a majority in principal amount of the Securities of that series do not give the Trustee a direction inconsistent with the request.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding anything contained herein to the contrary or any other provisions of this Indenture, the right of any holder of any Security to receive payment of the principal of (and premium, if any) and interest on such Security, as therein provided, on or after the respective due dates expressed in such Security (or in the case of redemption, on the redemption date),</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or to institute suit for the enforcement of any such payment on or after such respective dates or redemption date, shall not be impaired or affected without the consent of such holder and by accepting a Security hereunder it is expressly understood, intended and covenanted by the taker and holder of every Security of such series with every other such taker and holder and the Trustee, that no one or more holders of Securities of such series shall have any right in any manner whatsoever by virtue or by availing of any provision of this Indenture to affect, disturb or prejudice the rights of the holders of any other of such Securities, or to obtain or seek to obtain priority over or preference to any other such holder, or to enforce any right under this Indenture, except in the manner herein </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-24-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided and for the equal, ratable and common benefit of all holders of Securities of such series. For the protection and enforcement of the provisions of this Section, each and every Securityholder and the Trustee shall be entitled to such relief as can be given either at law or in equity.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-25-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 6.5 Rights and Remedies Cumulative&#59; Delay or Omission Not Waiver.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Except as otherwise provided in Section 2.07, all powers and remedies given by this Article to the Trustee or to the Securityholders shall, to the extent permitted by law, be deemed cumulative and not exclusive of any other powers and remedies available to the Trustee or the holders of the Securities, by judicial proceedings or otherwise, to enforce the performance or observance of the covenants and agreements contained in this Indenture or otherwise established with respect to such Securities.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) No delay or omission of the Trustee or of any holder of any of the Securities to exercise any right or power accruing upon any Event of Default occurring and continuing as aforesaid shall impair any such right or power, or shall be construed to be a waiver of any such default or an acquiescence therein&#59; and, subject to the provisions of Section 6.04, every power and remedy given by this Article or by law to the Trustee or the Securityholders may be exercised from time to time, and as often as shall be deemed expedient, by the Trustee or by the Securityholders.</font></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 6.6 Control by Securityholders.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of a majority in aggregate principal amount of the Securities of any series at the time Outstanding, determined in accordance with Section 8.04, shall have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred on the Trustee with respect to such series&#59; provided, however, that such direction shall not be in conflict with any rule of law or with this Indenture. Subject to the provisions of Section 7.01, the Trustee shall have the right to decline to follow any such direction if the Trustee in good faith shall, by a Responsible Officer or officers of the Trustee, determine that the proceeding so directed, subject to the Trustee's duties under the Trust Indenture Act, would involve the Trustee in personal liability or might be unduly prejudicial to the Securityholders not involved in the proceeding. The holders of a majority in aggregate principal amount of the Securities of any series at the time Outstanding affected thereby, determined in accordance with Section 8.04, may on behalf of the holders of all of the Securities of such series waive any past default in the performance of any of the covenants contained herein or established pursuant to Section 2.01 with respect to such series and its consequences, except a default in the payment of the principal of, or premium, if any, or interest on, any of the Securities of that series as and when the same shall become due by the terms of such Securities otherwise than by acceleration (unless such default has been cured and a sum sufficient to pay all matured installments of interest and principal and any premium has been deposited with the Trustee (in accordance with Section 6.01(c)). Upon any such waiver, the default covered thereby shall be deemed to be cured for all purposes of this Indenture and the Company, the Trustee and the holders of the Securities of such series shall be restored to their former positions and rights hereunder, respectively&#59; but no such waiver shall extend to any subsequent or other default or impair any right consequent thereon.</font></div><div style="padding-left:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 6.7 Undertaking to Pay Costs.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All parties to this Indenture agree, and each holder of any Securities by such holder's acceptance thereof shall be deemed to have agreed, that any court may in its discretion require, in any suit for the enforcement of any right or remedy under this Indenture, or in any suit against the Trustee for any action taken or omitted by it as Trustee, the filing by any party litigant in such suit of an undertaking to pay the costs of such suit, and that such court may in its discretion assess reasonable costs, including reasonable attorneys' fees, against any party litigant in such suit, having due regard to the merits and good faith of the claims or defenses made by such party litigant&#59; but the provisions of this Section shall not apply to any suit instituted by the Trustee, to any suit instituted by any Securityholder, or group of Securityholders, holding more than 10% in aggregate principal amount of the Outstanding Securities of any series, or to any suit instituted by any Securityholder for the enforcement of the payment of the principal of (or premium, if any) or interest on any Security of such series, on or after the respective due dates expressed in such Security or established pursuant to this Indenture.</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE VII</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-26-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONCERNING THE TRUSTEE</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.1 Certain Duties and Responsibilities of Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The Trustee, prior to the occurrence of an Event of Default with respect to the Securities of a series and after the curing of all Events of Default with respect to the Securities of that series that may have occurred, shall undertake to perform with respect to the Securities of such series such duties and only such duties as are specifically set forth in this Indenture, and no implied covenants shall be read into this Indenture against the Trustee. In case an Event of Default with respect to the Securities of a series has occurred (that has not been cured or waived), the Trustee shall exercise with respect to Securities of that series such of the rights and powers vested in it by this Indenture, and use the same degree of care and skill in their exercise, as a prudent man would exercise or use under the circumstances in the conduct of his own affairs.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) No provision of this Indenture shall be construed to relieve the Trustee from liability for its own negligent action, its own negligent failure to act, or its own willful misconduct, except that&#58;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) prior to the occurrence of an Event of Default with respect to the Securities of a series and after the curing or waiving of all such Events of Default with respect to that series that may have occurred&#58; (A) the duties and obligations of the Trustee shall with respect to the Securities of such series be determined solely by the express provisions of this Indenture, and the Trustee shall not be liable with respect to the Securities of such series except for the performance of such duties and obligations as are specifically set forth in this Indenture, and no implied covenants or obligations shall be read into this Indenture against the Trustee&#59; and (B) in the absence of bad faith on the part of the Trustee, the Trustee may with respect to the Securities of such series conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon any certificates or opinions furnished to the Trustee and conforming to the requirements of this Indenture&#59; but in the case of any such certificates or opinions that by any provision hereof are specifically required to be furnished to the Trustee, the Trustee shall be under a duty to examine the same to determine whether or not they conform to the requirements of this Indenture&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) the Trustee shall not be liable for any error of judgment made in good faith by a Responsible Officer or Responsible Officers of the Trustee, unless it shall be proved that the Trustee was negligent in ascertaining the pertinent facts&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) the Trustee shall not be liable with respect to any action taken or omitted to be taken by it in good faith in accordance with the direction of the holders of not less than a majority in principal amount of the Securities of any series at the time Outstanding relating to the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred upon the Trustee under this Indenture with respect to the Securities of that series&#59; and</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) none of the provisions contained in this Indenture shall require the Trustee to expend or risk its own funds or otherwise incur personal financial liability in the performance of any of its duties or in the exercise of any of its rights or powers if there is reasonable ground for believing that the repayment of such funds or liability is not reasonably assured to it under the terms of this Indenture or adequate indemnity against such risk is not reasonably assured to it.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.2 Certain Rights of Trustee.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise provided in Section 7.01&#58;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The Trustee may rely and shall be protected in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, consent, order, approval, bond, security or other paper or document believed by it to be genuine and to have been signed or presented by the proper party or parties&#59;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any request, direction, order or demand of the Company mentioned herein shall be sufficiently evidenced by a Board Resolution or an instrument signed in the name of the Company by any authorized officer of the Company (unless other evidence in respect thereof is specifically prescribed herein)&#59;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) The Trustee may consult with counsel and the written advice of such counsel or, if requested, any Opinion of Counsel shall be full and complete authorization and protection in respect of any action taken or suffered or omitted hereunder in good faith and in reliance thereon&#59;</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) The Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the request, order or direction of any of the Securityholders pursuant to the provisions of this Indenture, unless such Securityholders shall have offered to the Trustee reasonable security or indemnity against the costs, expenses and liabilities that may be incurred therein or thereby&#59; nothing contained herein shall, however, relieve the Trustee of the obligation, upon the occurrence of an Event of Default with respect to a series of the Securities (that has not been cured or waived), to exercise with respect to Securities of that series such of the rights and powers </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-27-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vested in it by this Indenture, and to use the same degree of care and skill in their exercise, as a prudent man would exercise or use under the circumstances in the conduct of his own affairs&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-28-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e) The Trustee shall not be liable for any action taken or omitted to be taken by it in good faith and believed by it to be authorized or within the discretion or rights or powers conferred upon it by this Indenture&#59;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f) The Trustee shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request, consent, order, approval, bond, security, or other papers or documents, unless requested in writing so to do by the holders of not less than a majority in principal amount of the Outstanding Securities of the particular series affected thereby (determined as provided in Section 8.04)&#59; provided, however, that if the payment within a reasonable time to the Trustee of the costs, expenses or liabilities likely to be incurred by it in the making of such investigation is, in the opinion of the Trustee, not reasonably assured to the Trustee by the security afforded to it by the terms of this Indenture, the Trustee may require reasonable indemnity against such costs, expenses or liabilities as a condition to so proceeding. The reasonable expense of every such examination shall be paid by the Company or, if paid by the Trustee, shall be repaid by the Company upon demand&#59; and</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g) The Trustee may execute any of the trusts or powers hereunder or perform any duties hereunder either directly or by or through agents or attorneys and the Trustee shall not be responsible for any misconduct or negligence on the part of any agent or attorney appointed with due care by it hereunder.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Trustee shall not be deemed to have knowledge of any Default or Event of Default except (1) any Event of Default occurring pursuant to Sections 6.01(a)(1) and 6.01(a)(2) or (2) any Default or Event of Default of which the Trustee shall have received written notification in the manner set forth in this Indenture or a Responsible Officer of the Trustee shall have obtained actual knowledge. Delivery of reports, information and documents to the Trustee under Section 5.03 is for informational purposes only and the information and the Trustee's receipt of the foregoing shall not constitute constructive notice of any information contained therein, or determinable from information contained therein including the Company's compliance with any of their covenants thereunder (as to which the Trustee is entitled to rely exclusively on an Officer's Certificate).</font></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.3 Trustee Not Responsible for Recitals or Issuance or Securities.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The recitals contained herein and in the Securities shall be taken as the statements of the Company, and the Trustee assumes no responsibility for the correctness of the same.</font></div><div style="text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The Trustee makes no representations as to the validity or sufficiency of this Indenture or of the Securities.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) The Trustee shall not be accountable for the use or application by the Company of any of the Securities or of the proceeds of such Securities, or for the use or application of any moneys paid over by the Trustee in accordance with any provision of this Indenture or established pursuant to Section 2.01, or for the use or application of any moneys received by any paying agent other than the Trustee.</font></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.4 May Hold Securities.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trustee or any paying agent or Security Registrar, in its individual or any other capacity, may become the owner or pledgee of Securities with the same rights it would have if it were not Trustee, paying agent or Security Registrar.</font></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.5 Moneys Held in Trust.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the provisions of Section 11.05, all moneys received by the Trustee shall, until used or applied as herein provided, be held in trust for the purposes for which they were received, but need not be segregated from other funds except to the extent required by law. The Trustee shall be under no liability for interest on any moneys received by it hereunder except such as it may agree with the Company to pay thereon.</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.6 Compensation and Reimbursement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-29-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The Company covenants and agrees to pay to the Trustee, and the Trustee shall be entitled to, such reasonable compensation (which shall not be limited by any provision of law in regard to the compensation of a trustee of an express trust) as the Company and the Trustee may from time to time agree in writing, for all services rendered by it in the execution of the trusts hereby created and in the exercise and performance of any of the powers and duties hereunder of the Trustee, and, except as otherwise expressly provided herein, the Company will pay or reimburse the Trustee upon its request for all reasonable expenses, disbursements and advances incurred or made by the Trustee in accordance with any of the provisions of this Indenture (including the reasonable compensation and the expenses and disbursements of its counsel and of all Persons not regularly in its employ), except any such expense, disbursement or advance as may arise from its negligence or bad faith and except as the Company and Trustee may from time to time agree in writing. The Company also covenants to indemnify the Trustee (and its officers, agents, directors and employees) for, and to hold it harmless against, any loss, liability or expense incurred without negligence or bad faith on the part of the Trustee and arising out of or in connection with the acceptance or administration of this trust, including the reasonable costs and expenses of defending itself against any claim of liability in the premises.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The obligations of the Company under this Section to compensate and indemnify the Trustee and to pay or reimburse the Trustee for reasonable expenses, disbursements and advances shall constitute additional indebtedness hereunder. Such additional indebtedness shall be secured by a lien prior to that of the Securities upon all property and funds held or collected by the Trustee as such, except funds held in trust for the benefit of the holders of particular Securities.</font></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.7 Reliance on Officer's Certificate.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise provided in Section 7.01, whenever in the administration of the provisions of this Indenture the Trustee shall deem it reasonably necessary or desirable that a matter be proved or established prior to taking or suffering or omitting to take any action hereunder, such matter (unless other evidence in respect thereof be herein specifically prescribed) may, in the absence of negligence or bad faith on the part of the Trustee, be deemed to be conclusively proved and established by an Officer's Certificate delivered to the Trustee and such certificate, in the absence of negligence or bad faith on the part of the Trustee, shall be full warrant to the Trustee for any action taken, suffered or omitted to be taken by it under the provisions of this Indenture upon the faith thereof.</font></div><div style="padding-left:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.8 Disqualification&#59; Conflicting Interests.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Trustee has or shall acquire any &#34;conflicting interest&#34; within the meaning of Section 310(b) of the Trust Indenture Act, the Trustee and the Company shall in all respects comply with the provisions of Section 310(b) of the Trust Indenture Act.</font></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.9 Corporate Trustee Required&#59; Eligibility.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There shall at all times be a Trustee with respect to the Securities issued hereunder which shall at all times be a corporation organized and doing business under the laws of the United States of America or any state or territory thereof or of the District of Columbia, or a corporation or other Person permitted to act as trustee by the Securities and Exchange Commission, authorized under such laws to exercise corporate trust powers, having a combined capital and surplus of at least fifty million U.S. dollars ($50,000,000), and subject to supervision or examination by federal, state, territorial, or District of Columbia authority.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If such corporation or other Person publishes reports of condition at least annually, pursuant to law or to the requirements of the aforesaid supervising or examining authority, then for the purposes of this Section, the combined capital and surplus of such corporation or other Person shall be deemed to be its combined capital and surplus as set forth in its most recent report of condition so published. The Company may not, nor may any Person directly or indirectly controlling, controlled by, or under common control with the Company, serve as Trustee. In case at any time the Trustee shall cease to be eligible in accordance with the provisions of this Section, the Trustee shall resign immediately in the manner and with the effect specified in Section 7.10.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.10 Resignation and Removal&#59; Appointment of Successor.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The Trustee or any successor hereafter appointed may at any time resign with respect to the Securities of one or more series by giving written notice thereof to the Company and by transmitting notice of resignation by mail, first class postage prepaid, to the Securityholders of such series, as their names and addresses appear upon the Security Register. Upon</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receiving such notice of resignation, the Company shall promptly appoint a successor trustee with respect to Securities of such series by written instrument, in duplicate, executed by order of the Board of Directors, one copy of which instrument shall be delivered to the resigning Trustee and one copy to the successor trustee. If no successor </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-30-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trustee shall have been so appointed and have accepted appointment within 30 days after the mailing of such notice of resignation, the resigning Trustee may petition any court of competent jurisdiction for the appointment of a successor trustee with respect to Securities of such series, or any Securityholder of that series who has been a bona fide holder of a Security or Securities for at least six months may on behalf of himself and all others similarly situated, petition any such court for the appointment of a successor trustee. Such court may thereupon after such notice, if any, as it may deem proper and prescribe, appoint a successor trustee.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-31-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) In case at any time any one of the following shall occur&#58;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the Trustee shall fail to comply with the provisions of Section 7.08 after written request therefor by the Company or by any Securityholder who has been a bona fide holder of a Security or Securities for at least six months&#59; or</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) the Trustee shall cease to be eligible in accordance with the provisions of Section 7.09 and shall fail to resign after written request therefor by the Company or by any such Securityholder&#59; or</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) the Trustee shall become incapable of acting, or shall be adjudged a bankrupt or insolvent, or commence a voluntary bankruptcy proceeding, or a receiver of the Trustee or of its property shall be appointed or consented to, or any public officer shall take charge or control of the Trustee or of its property or affairs for the purpose of rehabilitation, conservation or liquidation&#59; then, in any such case, the Company may remove the Trustee with respect to all Securities and appoint a successor trustee by written instrument, in duplicate, executed by order of the Board of Directors, one copy of which instrument shall be delivered to the Trustee so removed and one copy to the successor trustee, or any Securityholder who has been a bona fide holder of a Security or Securities for at least six months may, on behalf of that holder and all others similarly situated, petition any court of competent jurisdiction for the removal of the Trustee and the appointment of a successor trustee. Such court may thereupon after such notice, if any, as it may deem proper and prescribe, remove the Trustee and appoint a successor trustee.</font></div><div style="text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) The holders of a majority in aggregate principal amount of the Securities of any series at the time Outstanding may at any time remove the Trustee with respect to such series by so notifying the Trustee and the Company and may appoint a successor Trustee for such series with the consent of the Company.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Any resignation or removal of the Trustee and appointment of a successor trustee with respect to the Securities of a series pursuant to any of the provisions of this Section shall become effective upon acceptance of appointment by the successor trustee as provided in Section 7.11.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e) Any successor trustee appointed pursuant to this Section may be appointed with respect to the Securities of one or more series or all of such series, and at any time there shall be only one Trustee with respect to the Securities of any particular series.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.11 Acceptance of Appointment By Successor.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) In case of the appointment hereunder of a successor trustee with respect to all Securities, every such successor trustee so appointed shall execute, acknowledge and deliver to the Company and to the retiring Trustee an instrument accepting such appointment, and thereupon the resignation or removal of the retiring Trustee shall become effective and such successor trustee, without any further act, deed or conveyance, shall become vested with all the rights, powers, trusts and duties of the retiring Trustee&#59; but, on the request of the Company or the successor trustee, such retiring Trustee shall, upon payment of its charges, execute and deliver an instrument transferring to such successor trustee all the rights, powers, and trusts of the retiring Trustee and shall duly assign, transfer and deliver to such successor trustee all property and money held by such retiring Trustee hereunder.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) In case of the appointment hereunder of a successor trustee with respect to the Securities of one or more (but not all) series, the Company, the retiring Trustee and each successor trustee with respect to the Securities of one or more series shall execute and deliver an indenture supplemental hereto wherein each successor trustee shall accept such appointment and which (i) shall contain such provisions as shall be necessary or desirable to transfer and confirm to, and to vest in, each successor trustee all the rights, powers, trusts and duties of the retiring Trustee with respect to the Securities of that or those series to which the appointment of such successor trustee relates, (ii) shall contain such provisions as shall be deemed necessary or desirable to confirm that all the rights, powers, trusts and duties of the retiring Trustee with respect to the Securities of that or</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">those series as to which the retiring Trustee is not retiring shall continue to be vested in the retiring Trustee, and (iii) shall add to or change any of the provisions of this Indenture as shall be necessary to provide for or facilitate the administration of the trusts hereunder by more than one Trustee, it being understood that nothing herein or in such supplemental indenture shall constitute such Trustees co-trustees of the same trust, that each such Trustee shall be trustee of a trust or trusts hereunder separate and apart from any trust or trusts hereunder administered by any other such Trustee and that no Trustee shall be responsible for any act or failure to act on the part of any other Trustee hereunder&#59; and upon the execution and delivery of such supplemental indenture the resignation or removal of the retiring Trustee shall become effective to the extent provided therein, such retiring Trustee shall with respect to the Securities of that or those series to which the appointment of such successor trustee relates have no further responsibility for the exercise of rights and powers or for the performance of the duties and obligations vested in the Trustee under this Indenture, and each such successor trustee, without any further act, deed or conveyance, shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-32-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">become vested with all the rights, powers, trusts and duties of the retiring Trustee with respect to the Securities of that or those series to which the appointment of such successor trustee relates&#59; but, on request of the Company or any successor trustee, such retiring Trustee shall duly assign, transfer and deliver to such successor trustee, to the extent contemplated by such supplemental indenture, the property and money held by such retiring Trustee hereunder with respect to the Securities of that or those series to which the appointment of such successor trustee relates.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-33-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Upon request of any such successor trustee, the Company shall execute any and all instruments for more fully and certainly vesting in and confirming to such successor trustee all such rights, powers and trusts referred to in paragraph (a) or (b) of this Section, as the case may be.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) No successor trustee shall accept its appointment unless at the time of such acceptance such successor trustee shall be qualified and eligible under this Article.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e) Upon acceptance of appointment by a successor trustee as provided in this Section, the Company shall transmit notice of the succession of such trustee hereunder by mail, first class postage prepaid, to the Securityholders, as their names and addresses appear upon the Security Register. If the Company fails to transmit such notice within ten days after acceptance of appointment by the successor trustee, the successor trustee shall cause such notice to be transmitted at the expense of the Company.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.12 Merger, Conversion, Consolidation or Succession to Business.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any corporation into which the Trustee may be merged or converted or with which it may be consolidated, or any corporation resulting from any merger, conversion or consolidation to which the Trustee shall be a party, or any corporation succeeding to the corporate trust business of the Trustee, including the administration of the trust created by this Indenture, shall be the successor of the Trustee hereunder, provided that such corporation shall be qualified under the provisions of Section 7.08 and eligible under the provisions of Section 7.09, without the execution or filing of any paper or any further act on the part of any of the parties hereto, anything herein to the contrary notwithstanding. In case any Securities shall have been authenticated, but not delivered, by the Trustee then in office, any successor by merger, conversion or consolidation to such authenticating Trustee may adopt such authentication and deliver the Securities so authenticated with the same effect as if such successor Trustee had itself authenticated such Securities.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.13 Preferential Collection of Claims Against the Company.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trustee shall comply with Section 311(a) of the Trust Indenture Act, excluding any creditor relationship described in Section 311(b) of the Trust Indenture Act. A Trustee who has resigned or been removed shall be subject to Section 311(a) of the Trust Indenture Act to the extent included therein.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.14 Notice of Default</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any Default or any Event of Default occurs and is continuing and if such Default or Event of Default is known to a Responsible Officer of the Trustee, the Trustee shall mail to each Securityholder in the manner and to the extent provided in Section 313(c) of the Trust Indenture Act notice of the Default or Event of Default within the earlier of 90 days after it occurs and 30 days after it is known to a Responsible Officer of the Trustee or written notice of it is received by the Trustee, unless such Default or Event of Default has been cured&#59; provided, however, that, except in the case of a default in the payment of the principal of (or premium, if any) or interest on any Security, the Trustee shall be protected in withholding such notice if and so long as the board of directors, the executive committee or a trust committee of directors and&#47;or Responsible Officers of the Trustee in good faith determine that the withholding of such notice is in the interest of the Securityholders.</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE VIII</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-34-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONCERNING THE SECURITYHOLDERS</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.1 Evidence of Action by Securityholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whenever in this Indenture it is provided that the holders of a majority or specified percentage in aggregate principal amount of the Securities of a particular series may take any action (including the making of any demand or request, the giving of any notice, consent or waiver or the taking of any other action), the fact that at the time of taking any such action the holders of such majority or specified percentage of that series have joined therein may be evidenced by any instrument or any number of instruments of similar tenor executed by such holders of Securities of that series in person or by agent or proxy appointed in writing.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company shall solicit from the Securityholders of any series any request, demand, authorization, direction, notice, consent, waiver or other action, the Company may, at its option, as evidenced by an Officer's Certificate, fix in advance a record date for such series for the determination of Securityholders entitled to give such request, demand, authorization, direction, notice, consent, waiver or other action, but the Company shall have no obligation to do so. If such a record date is fixed, such request, demand, authorization, direction, notice, consent, waiver or other action may be given before or after the record date, but only the Securityholders of record at the close of business on the record date shall be deemed to be Securityholders for the purposes of determining whether Securityholders of the requisite proportion of Outstanding Securities of that series have authorized or agreed or consented to such request, demand, authorization, direction, notice, consent, waiver or other action, and for that purpose the Outstanding Securities of that series shall be computed as of the record date&#59; provided, however, that no such authorization, agreement or consent by such Securityholders on the record date shall be deemed effective unless it shall become effective pursuant to the provisions of this Indenture not later than six months after the record date.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.2 Proof of Execution by Securityholders.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the provisions of Section 7.01, proof of the execution of any instrument by a Securityholder (such proof will not require notarization) or his agent or proxy and proof of the holding by any Person of any of the Securities shall be sufficient if made in the following manner&#58;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The fact and date of the execution by any such Person of any instrument may be proved in any reasonable manner acceptable to the Trustee.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The ownership of Securities shall be proved by the Security Register of such Securities or by a certificate of the Security Registrar thereof.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trustee may require such additional proof of any matter referred to in this Section as it shall deem necessary.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.3 Who May be Deemed Owners.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the due presentment for registration of transfer of any Security, the Company, the Trustee, any paying agent and any Security Registrar may deem and treat the Person in whose name such Security shall be registered upon the books of the Company as the absolute owner of such Security (whether or not such Security shall be overdue and notwithstanding any notice of ownership or writing thereon made by anyone other than the Security Registrar) for the purpose of receiving payment of or on account of the principal of, premium, if any, and (subject to Section 2.03) interest on such Security and for all other purposes&#59; and neither the Company nor the Trustee nor any paying agent nor any Security Registrar shall be affected by any notice to the contrary.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.4 Certain Securities Owned by Company Disregarded.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether the holders of the requisite aggregate principal amount of Securities of a particular series have concurred in any direction, consent or waiver under this Indenture, the Securities of that series that are owned by the Company or any other obligor on the Securities of that series or by any Person directly or indirectly controlling or controlled by or under common control with the Company or any other obligor on the Securities of that series shall be disregarded and deemed not to be Outstanding for the purpose of any such determination, except that for the purpose of determining whether the Trustee shall be protected in relying on any such direction, consent or waiver, only Securities of such series that the Trustee actually knows are so owned shall be so disregarded. The Securities so owned that have been pledged in good faith may be regarded as</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding for the purposes of this Section, if the pledgee shall establish to the satisfaction of the Trustee the pledgee's right so to act with respect to such Securities and that the pledgee is not a Person directly or indirectly controlling or controlled by or under direct or indirect common control with the Company or any such other obligor. In case of a dispute as to such right, any decision by the Trustee taken upon the advice of counsel shall be full protection to the Trustee.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-35-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.5 Actions Binding on Future Securityholders.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time prior to (but not after) the evidencing to the Trustee, as provided in Section 8.01, of the taking of any action by the holders of the majority or percentage in aggregate principal amount of the Securities of a particular series specified in this Indenture in connection with such action, any holder of a Security of that series that is shown by the evidence to be included in the Securities the holders of which have consented to such action may, by filing written notice with the Trustee, and upon proof of holding as provided in Section 8.02, revoke such action so far as concerns such Security. Except as aforesaid any such action taken by the holder of any Security shall be conclusive and binding upon such holder and upon all future holders and owners of such Security, and of any Security issued in exchange therefor, on registration of transfer thereof or in place thereof, irrespective of whether or not any notation in regard thereto is made upon such Security. Any action taken by the holders of the majority or percentage in aggregate principal amount of the Securities of a particular series specified in this Indenture in connection with such action shall be conclusively binding upon the Company, the Trustee and the holders of all the Securities of that series.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE IX</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUPPLEMENTAL INDENTURES</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 9.1 Supplemental Indentures Without the Consent of Securityholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to any supplemental indenture otherwise authorized by this Indenture, the Company and the Trustee may from time to time and at any time enter into an indenture or indentures supplemental hereto (which shall conform to the provisions of the Trust Indenture Act as then in effect), without the consent of the Securityholders, for one or more of the following purposes&#58;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) to cure any ambiguity, defect, or inconsistency herein or in the Securities of any series&#59;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) to comply with Article Ten&#59;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) to provide for uncertificated Securities in addition to or in place of certificated Securities&#59;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) to add to the covenants, restrictions, conditions or provisions relating to the Company for the benefit of the holders of all or any series of Securities (and if such covenants, restrictions, conditions or provisions are to be for the benefit of less than all series of Securities, stating that such covenants, restrictions, conditions or provisions are expressly being included solely for the benefit of such series), to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an Event of Default, or to surrender any right or power herein conferred upon the Company&#59;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e) to add to, delete from, or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication, and delivery of Securities, as herein set forth&#59;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f) to make any change that does not adversely affect the rights of any Securityholder in any material respect&#59;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g) to provide for the issuance of and establish the form and terms and conditions of the Securities of any series as provided in Section 2.01, to establish the form of any certifications required to be furnished pursuant to the terms of this Indenture or any series of Securities, or to add to the rights of the holders of any series of Securities&#59;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h) to evidence and provide for the acceptance of appointment hereunder by a successor trustee&#59; or</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) to comply with any requirements of the Securities and Exchange Commission or any successor in connection with the qualification of this Indenture under the Trust Indenture Act.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trustee is hereby authorized to join with the Company in the execution of any such supplemental indenture, and to make any further appropriate agreements and stipulations that may be therein contained, but the Trustee shall not be obligated</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to enter into any such supplemental indenture that affects the Trustee's own rights, duties or immunities under this Indenture or otherwise.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-36-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any supplemental indenture authorized by the provisions of this Section may be executed by the Company and the Trustee without the consent of the holders of any of the Securities at the time Outstanding, notwithstanding any of the provisions of Section 9.02.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 9.2 Supplemental Indentures With Consent of Securityholders.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the consent (evidenced as provided in Section 8.01) of the holders of not less than a majority in aggregate principal amount of the Securities of each series affected by such supplemental indenture or indentures at the time Outstanding, the Company, when authorized by a Board Resolution, and the Trustee may from time to time and at any time enter into an indenture or indentures supplemental hereto (which shall conform to the provisions of the Trust Indenture Act as then in effect) for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this Indenture or of any supplemental indenture or of modifying in any manner not covered by Section 9.01 the rights of the holders of the Securities of such series under this Indenture&#59; provided, however, that no such supplemental indenture shall, without the consent of the holders of each Security then Outstanding and affected thereby, (a) extend the fixed maturity of any Securities of any series, or reduce the principal amount thereof, or reduce the rate or extend the time of payment of interest thereon, or reduce any premium payable upon the redemption thereof or (b) reduce the aforesaid percentage of Securities, the holders of which are required to consent to any such supplemental indenture.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It shall not be necessary for the consent of the Securityholders of any series affected thereby under this Section to approve the particular form of any proposed supplemental indenture, but it shall be sufficient if such consent shall approve the substance thereof.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 9.3 Effect of Supplemental Indentures.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the execution of any supplemental indenture pursuant to the provisions of this Article or of Section 10.01, this Indenture shall, with respect to such series, be and be deemed to be modified and amended in accordance therewith and the respective rights, limitations of rights, obligations, duties and immunities under this Indenture of the Trustee, the Company and the holders of Securities of the series affected thereby shall thereafter be determined, exercised and enforced hereunder subject in all respects to such modifications and amendments, and all the terms and conditions of any such supplemental indenture shall be and be deemed to be part of the terms and conditions of this Indenture for any and all purposes.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 9.4 Securities Affected by Supplemental Indentures.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities of any series affected by a supplemental indenture, authenticated and delivered after the execution of such supplemental indenture pursuant to the provisions of this Article or of Section 10.01, may bear a notation in form approved by the Company, provided such form meets the requirements of any securities exchange upon which such series may be listed, as to any matter provided for in such supplemental indenture. If the Company shall so determine, new Securities of that series so modified as to conform, in the opinion of the Board of Directors, to any modification of this Indenture contained in any such supplemental indenture may be prepared by the Company, authenticated by the Trustee and delivered in exchange for the Securities of that series then Outstanding.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 9.5 Execution of Supplemental Indentures.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the request of the Company, accompanied by its Board Resolutions authorizing the execution of any such supplemental indenture, and upon the filing with the Trustee of evidence of the consent of Securityholders required to consent thereto as aforesaid, the Trustee shall join with the Company in the execution of such supplemental indenture unless such supplemental indenture affects the Trustee's own rights, duties or immunities under this Indenture or otherwise, in which case the Trustee may in its discretion but shall not be obligated to enter into such supplemental indenture. The Trustee, subject to the provisions of Section 7.01, may receive an Officer's Certificate or, if requested, an Opinion of Counsel as conclusive evidence that any supplemental indenture executed pursuant to this Article is authorized or permitted by, and conforms to, the terms of this Article and that it is proper for the Trustee under the provisions of this Article to join in the execution thereof&#59; provided, however, that such Officer's Certificate or Opinion of Counsel need not be provided in connection with the execution of a supplemental indenture that establishes the terms of a series of Securities pursuant to Section 2.01 hereof.</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Promptly after the execution by the Company and the Trustee of any supplemental indenture pursuant to the provisions of this Section, the Trustee shall transmit by mail, first class postage prepaid, a notice, setting forth in general terms the substance of such supplemental indenture, to the Securityholders of all series affected thereby as their names and addresses appear upon the Security Register. Any failure of the Trustee to mail such notice, or any defect therein, shall not, however, in any way impair or affect the validity of any such supplemental indenture.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-37-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE X</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUCCESSOR ENTITY</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 10.1 Company May Consolidate, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as provided pursuant to Section 2.01 pursuant to a Board Resolution, and set forth in an Officer's Certificate, or established in one or more indentures supplemental to this Indenture, nothing contained in this Indenture shall prevent any consolidation or merger of the Company with or into any other Person (whether or not affiliated with the Company) or successive consolidations or mergers in which the Company or its successor or successors shall be a party or parties, or shall prevent any sale, conveyance, transfer or other disposition of the property of the Company or its successor or successors as an entirety, or substantially as an entirety, to any other corporation (whether or not affiliated with the Company or its successor or successors) authorized to acquire and operate the same&#59; provided, however, (a) the Company hereby covenants and agrees that, upon any such consolidation or merger (in each case, if the Company is not the survivor of such transaction), sale, conveyance, transfer or other disposition, the due and punctual payment of the principal of (premium, if any) and interest on all of the Securities of all series in accordance with the terms of each series, according to their tenor, and the due and punctual performance and observance of all the covenants and conditions of this Indenture with respect to each series or established with respect to such series pursuant to Section 2.01 to be kept or performed by the Company shall be expressly assumed, by supplemental indenture (which shall conform to the provisions of the Trust Indenture Act, as then in effect) reasonably satisfactory in form to the Trustee executed and delivered to the Trustee by the entity formed by such consolidation, or into which the Company shall have been merged, or by the entity which shall have acquired such property and (b) in the event that the Securities of any series then Outstanding are convertible into or exchangeable for shares of common stock or other securities of the Company, such entity shall, by such supplemental indenture, make provision so that the Securityholders of Securities of that series shall thereafter be entitled to receive upon conversion or exchange of such Securities the number of securities or property to which a holder of the number of shares of common stock or other securities of the Company deliverable upon conversion or exchange of those Securities would have been entitled had such conversion or exchange occurred immediately prior to such consolidation, merger, sale, conveyance, transfer or other disposition.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 10.2 Successor Entity Substituted.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) In case of any such consolidation, merger, sale, conveyance, transfer or other disposition and upon the assumption by the successor entity by supplemental indenture, executed and delivered to the Trustee and satisfactory in form to the Trustee, of the obligations set forth under Section 10.01 on all of the Securities of all series Outstanding, such successor entity shall succeed to and be substituted for the Company with the same effect as if it had been named as the Company herein, and thereupon the predecessor corporation shall be relieved of all obligations and covenants under this Indenture and the Securities.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) In case of any such consolidation, merger, sale, conveyance, transfer or other disposition, such changes in phraseology and form (but not in substance) may be made in the Securities thereafter to be issued as may be appropriate.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Nothing contained in this Article shall require any action by the Company in the case of a consolidation or merger of any Person into the Company where the Company is the survivor of such transaction, or the acquisition by the Company, by purchase or otherwise, of all or any part of the property of any other Person (whether or not affiliated with the Company).</font></div><div style="padding-left:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 10.3 Evidence of Consolidation, Etc. to Trustee.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trustee, subject to the provisions of Section 7.01, may receive an Officer's Certificate and, if requested, an Opinion of Counsel as conclusive evidence that any such consolidation, merger, sale, conveyance, transfer or other disposition, and any such assumption, comply with the provisions of this Article.</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE XI</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-38-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SATISFACTION AND DISCHARGE</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 11.1 Satisfaction and Discharge of Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If at any time&#58; (a) the Company shall have delivered to the Trustee for cancellation all Securities of a series theretofore authenticated and not delivered to the Trustee for cancellation (other than any Securities that shall have been destroyed, lost or stolen and that shall have been replaced or paid as provided in Section 2.07 and Securities for whose payment money or Governmental Obligations have theretofore been deposited in trust or segregated and held in trust by the Company and thereupon repaid to the Company or discharged from such trust, as provided in Section 11.05)&#59; or (b) all such Securities of a particular series not theretofore delivered to the Trustee for cancellation shall have become due and payable, or are by their terms to become due and payable within one year or are to be called for redemption within one year under arrangements satisfactory to the Trustee for the giving of notice of redemption, and the Company shall deposit or cause to be deposited with the Trustee as trust funds the entire amount in moneys or Governmental Obligations or a combination thereof, sufficient in the opinion of a nationally recognized firm of independent public accountants expressed in a written certification thereof delivered to the Trustee, to pay at maturity or upon redemption all Securities of that series not theretofore delivered to the Trustee for cancellation, including principal (and premium, if any) and interest due or to become due to such date of maturity or date fixed for redemption, as the case may be, and if the Company shall also pay or cause to be paid all other sums payable hereunder with respect to such series by the Company then this Indenture shall thereupon cease to be of further effect with respect to such series except for the provisions of Sections 2.03, 2.05, 2.07, 4.01, 4.02, 4.03 and 7.10, that shall survive until the date of maturity or redemption date, as the case may be, and Sections 7.06 and 11.05, that shall survive to such date and thereafter, and the Trustee, on demand of the Company and at the cost and expense of the Company shall execute proper instruments acknowledging satisfaction of and discharging this Indenture with respect to such series.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 11.2 Discharge of Obligations.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If at any time all such Securities of a particular series not heretofore delivered to the Trustee for cancellation or that have not become due and payable as described in Section 11.01 shall have been paid by the Company by depositing irrevocably with the Trustee as trust funds moneys or an amount of Governmental Obligations sufficient to pay at maturity or upon redemption all such Securities of that series not theretofore delivered to the Trustee for cancellation, including principal (and premium, if any) and interest due or to become due to such date of maturity or date fixed for redemption, as the case may be, and if the Company shall also pay or cause to be paid all other sums payable hereunder by the Company with respect to such series, then after the date such moneys or Governmental Obligations, as the case may be, are deposited with the Trustee the obligations of the Company under this Indenture with respect to such series shall cease to be of further effect except for the provisions of Sections 2.03, 2.05, 2.07, 4,01, 4.02, 4,03, 7.06, 7.10 and 11.05 hereof that shall survive until such Securities shall mature and be paid.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter, Sections 7.06 and 11.05 shall survive.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 11.3 Deposited Moneys to be Held in Trust.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All moneys or Governmental Obligations deposited with the Trustee pursuant to Sections 11.01 or 11.02 shall be held in trust and shall be available for payment as due, either directly or through any paying agent (including the Company acting as its own paying agent), to the holders of the particular series of Securities for the payment or redemption of which such moneys or Governmental Obligations have been deposited with the Trustee.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 11.4 Payment of Moneys Held by Paying Agents.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the satisfaction and discharge of this Indenture all moneys or Governmental Obligations then held by any paying agent under the provisions of this Indenture shall, upon demand of the Company, be paid to the Trustee and thereupon such paying agent shall be released from all further liability with respect to such moneys or Governmental Obligations.</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 11.5 Repayment to Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-39-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any moneys or Governmental Obligations deposited with any paying agent or the Trustee, or then held by the Company, in trust for payment of principal of or premium, if any, or interest on the Securities of a particular series that are not applied but remain unclaimed by the holders of such Securities for at least two years after the date upon which the principal of (and premium, if any) or interest on such Securities shall have respectively become due and payable, or such other shorter period set forth in applicable escheat or abandoned or unclaimed property law, shall be repaid to the Company on May 31 of each year or upon the Company's request or (if then held by the Company) shall be discharged from such trust&#59; and thereupon the paying agent and the Trustee shall be released from all further liability with respect to such moneys or Governmental Obligations, and the holder of any of the Securities entitled to receive such payment shall thereafter, as a general creditor, look only to the Company for the payment thereof.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE XII</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 12.1 No Recourse</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No recourse under or upon any obligation, covenant or agreement of this Indenture, or of any Security, or for any claim based thereon or otherwise in respect thereof, shall be had against any incorporator, stockholder, officer or director, past, present or future as such, of the Company or of any predecessor or successor corporation, either directly or through the Company or any such predecessor or successor corporation, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise&#59; it being expressly understood that this Indenture and the obligations issued hereunder are solely corporate obligations, and that no such personal liability whatever shall attach to, or is or shall be incurred by, the incorporators, stockholders, officers or directors as such, of the Company or of any predecessor or successor corporation, or any of them, because of the creation of the indebtedness hereby authorized, or under or by reason of the obligations, covenants or agreements contained in this Indenture or in any of the Securities or implied therefrom&#59; and that any and all such personal liability of every name and nature, either at common law or in equity or by constitution or statute, of, and any and all such rights and claims against, every such incorporator, stockholder, officer or director as such, because of the creation of the indebtedness hereby authorized, or under or by reason of the obligations, covenants or agreements contained in this Indenture or in any of the Securities or implied therefrom, are hereby expressly waived and released as a condition of, and as a consideration for, the execution of this Indenture and the issuance of such Securities.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE XIII</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MISCELLANEOUS PROVISIONS</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.1 Effect on Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All the covenants, stipulations, promises and agreements in this Indenture made by or on behalf of the Company shall bind its successors and assigns, whether so expressed or not.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.2 Actions by Successor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any act or proceeding by any provision of this Indenture authorized or required to be done or performed by any board, committee or officer of the Company shall and may be done and performed with like force and effect by the corresponding board, committee or officer of any corporation that shall at the time be the lawful successor of the Company.</font></div><div style="padding-left:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.3 Surrender of Company Powers.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company by instrument in writing executed by authority of its Board of Directors and delivered to the Trustee may surrender any of the powers reserved to the Company, and thereupon such power so surrendered shall terminate both as to the Company and as to any successor corporation.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.4 Notices.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise expressly provided herein, any notice, request or demand that by any provision of this Indenture is required or permitted to be given, made or served by the Trustee or by the holders of Securities or by any other Person pursuant</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to this Indenture to or on the Company may be given or served by being deposited in first class mail, postage prepaid, addressed (until another address is filed in writing by the Company with the Trustee), as follows&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-40-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any notice, election, request or demand by the Company or any Securityholder or by any other Person pursuant to this Indenture to or upon the Trustee shall be deemed to have been sufficiently given or made, for all purposes, if given or made in writing at the Corporate Trust Office of the Trustee.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.5 Governing Law.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Indenture and each Security shall be deemed to be a contract made under the internal laws of the State of New York, and for all purposes shall be construed in accordance with the laws of said State, except to the extent that the Trust Indenture Act is applicable.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.6 Treatment of Securities as Debt.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is intended that the Securities will be treated as indebtedness and not as equity for federal income tax purposes. The provisions of this Indenture shall be interpreted to further this intention.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.7 Certificates and Opinions as to Conditions Precedent.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Upon any application or demand by the Company to the Trustee to take any action under any of the provisions of this Indenture, the Company shall furnish to the Trustee an Officer's Certificate stating that all conditions precedent provided for in this Indenture (other than the certificate to be delivered pursuant to Section 13.12) relating to the proposed action have been complied with and, if requested, an Opinion of Counsel stating that in the opinion of such counsel all such conditions precedent have been complied with, except that in the case of any such application or demand as to which the furnishing of such documents is specifically required by any provision of this Indenture relating to such particular application or demand, no additional certificate or opinion need be furnished.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Each certificate or opinion provided for in this Indenture and delivered to the Trustee with respect to compliance with a condition or covenant in this Indenture shall include (i) a statement that the Person making such certificate or opinion has read such covenant or condition&#59; (ii) a brief statement as to the nature and scope of the examination or investigation upon which the statements or opinions contained in such certificate or opinion are based&#59; (iii) a statement that, in the opinion of such Person, he has made such examination or investigation as is reasonably necessary to enable him to express an informed opinion as to whether or not such covenant or condition has been complied with&#59; and (iv) a statement as to whether or not, in the opinion of such Person, such condition or covenant has been complied with.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.8 Payments on Business Days.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as provided pursuant to Section 2.01 pursuant to a Board Resolution, and set forth in an Officer's Certificate, or established in one or more indentures supplemental to this Indenture, in any case where the date of maturity of interest or principal of any Security or the date of redemption of any Security shall not be a Business Day, then payment of interest or principal (and premium, if any) may be made on the next succeeding Business Day with the same force and effect as if made on the nominal date of maturity or redemption, and no interest shall accrue for the period after such nominal date.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.9 Conflict with Trust Indenture Act.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If and to the extent that any provision of this Indenture limits, qualifies or conflicts with the duties imposed by Sections 310 to 317, inclusive, of the Trust Indenture Act, such imposed duties shall control.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.10 Counterparts.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Indenture may be executed in any number of counterparts, each of which shall be an original, but such counterparts shall together constitute but one and the same instrument.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.11 Separability.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In case any one or more of the provisions contained in this Indenture or in the Securities of any series shall for any reason be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any</font></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other provisions of this Indenture or of such Securities, but this Indenture and such Securities shall be construed as if such invalid or illegal or unenforceable provision had never been contained herein or therein.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-41-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.12 Compliance Certificates.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company shall deliver to the Trustee, within 120 days after the end of each fiscal year during which any Securities of any series were outstanding, an officer's certificate stating whether or not the signers know of any Default or Event of Default that occurred during such fiscal year. Such certificate shall contain a certification from the principal executive officer, principal financial officer or principal accounting officer of the Company that a review has been conducted of the activities of the Company and the Company's performance under this Indenture and that the Company has complied with all conditions and covenants under this Indenture. For purposes of this Section 13.12, such compliance shall be determined without regard to any period of grace or requirement of notice provided under this Indenture. If the officer of the Company signing such certificate has knowledge of such a Default or Event of Default, the certificate shall describe any such Default or Event of Default and its status.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed all as of the day and year first above written.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:47.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.851%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY, INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;TRUSTEE&#93;, as Trustee</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><img alt="image_210.jpg" src="image_210.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-42-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>3
<FILENAME>a44ex040522.htm
<DESCRIPTION>EX-4.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ifae7850d3eea4d39832422703a8e949c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.4</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY, INC.,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ISSUER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;TRUSTEE&#93;,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRUSTEE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDENTURE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DATED AS OF , 20__</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBORDINATED DEBT SECURITIES</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:89.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.214%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Page</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE 1 DEFINITIONS</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1.01 Definitions of Terms</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.01 Designation and Terms of Securities</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.02 Form of Securities and Trustee's Certificate</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.03 Denominations&#58; Provisions for Payment</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.04 Execution and Authentications</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.05 Registration of Transfer and Exchange</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.06 Temporary Securities</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.07 Mutilated, Destroyed, Lost or Stolen Securities</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.08 Cancellation</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.09 Benefits of Indenture</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.10 Authenticating Agent</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.11 Global Securities</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE 3 REDEMPTION OF SECURITIES AND SINKING FUND PROVISIONS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.01 Redemption</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.02 Notice of Redemption</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.03 Payment Upon Redemption</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.04 Sinking Fund</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.05 Satisfaction of Sinking Fund Payments with Securities</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.06 Redemption of Securities for Sinking Fund</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE 4 COVENANTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.01 Payment of Principal, Premium and Interest</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.02 Maintenance of Office or Agency</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.03 Paying Agents</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.04 Appointment to Fill Vacancy in Office of Trustee</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.05 Compliance with Consolidation Provisions</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE 5 SECURITYHOLDERS' LISTS AND REPORTS BY THE COMPANY AND THE TRUSTEE</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.01 Company to Furnish Trustee Names and Addresses of Securityholders</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.02 Preservation Of Information&#59; Communications With Securityholders</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.03 Reports by the Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.04 Reports by the Trustee</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE 6 REMEDIES OF THE TRUSTEE AND SECURITYHOLDERS ON EVENT OF DEFAULT</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.01 Events of Default</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.02 Collection of Indebtedness and Suits for Enforcement by Trustee</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:89.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.214%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.03 Application of Moneys Collected</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.04 Limitation on Suits</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.05 Rights and Remedies Cumulative&#59; Delay or Omission Not Waiver</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.06 Control by Securityholders</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.07 Undertaking to Pay Costs</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE 7 CONCERNING THE TRUSTEE</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.01 Certain Duties and Responsibilities of Trustee</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.02 Certain Rights of Trustee</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.03 Trustee Not Responsible for Recitals or Issuance or Securities</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.04 May Hold Securities</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.05 Moneys Held in Trust</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.06 Compensation and Reimbursement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.07 Reliance on Officer's Certificate</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.08 Disqualification&#59; Conflicting Interests</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.09 Corporate Trustee Required&#59; Eligibility</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.10 Resignation and Removal&#59; Appointment of Successor</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.11 Acceptance of Appointment By Successor</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:89.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.214%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.12 Merger, Conversion, Consolidation or Succession to Business</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.13 Preferential Collection of Claims Against the Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.14 Notice of Default</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE 8 CONCERNING THE SECURITYHOLDERS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.01 Evidence of Action by Securityholders</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.02 Proof of Execution by Securityholders</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.03 Who May be Deemed Owners</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.04 Certain Securities Owned by Company Disregarded</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.05 Actions Binding on Future Securityholders</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE 9 SUPPLEMENTAL INDENTURES</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.01 Supplemental Indentures Without the Consent of Securityholders</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.02 Supplemental Indentures With Consent of Securityholders</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.03 Effect of Supplemental Indentures</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.04 Securities Affected by Supplemental Indentures</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.05 Execution of Supplemental Indentures</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE 10 SUCCESSOR ENTITY</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10.01 Company May Consolidate, Etc</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10.02 Successor Entity Substituted</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10.03 Evidence of Consolidation, Etc</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE 11 SATISFACTION AND DISCHARGE</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.01 Satisfaction and Discharge of Indenture</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.02 Discharge of Obligations</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.03 Deposited Moneys to be Held in Trust</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.04 Payment of Moneys Held by Paying Agents</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.05 Repayment to Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE 12 IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.01 No Recourse</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE 13 MISCELLANEOUS PROVISIONS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.01 Effect on Successors and Assigns</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.02 Actions by Successor</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.03 Surrender of Company Powers</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.04 Notices</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.05 Governing Law</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.06 Treatment of Securities as Debt</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.07 Certificates and Opinions as to Conditions Precedent</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.08 Payments on Business Days</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.09 Conflict with Trust Indenture Act</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.10 Counterparts</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.11 Separability</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.12 Compliance Certificates</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARTICLE 14 SUBORDINATION OF SECURITIES</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 14.01 Subordination Terms</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><img alt="image_2.jpg" src="image_2.jpg" style="height:0px;margin-bottom:5pt;vertical-align:text-bottom;width:39px"></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) This Table of Contents does not constitute part of the Indenture and shall not have any bearing on the interpretation of any of its terms or provisions.</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDENTURE</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INDENTURE , dated as of &#91; </font><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#93;, among </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cardiff Oncology, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> , a Delaware corporation (the &#34;Company&#34;), and &#91; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRUSTEE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#93;, as trustee (the &#34;Trustee&#34;)&#58;</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of subordinated debt securities (hereinafter referred to as the &#34;Securities&#34;), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as registered Securities without coupons, to be authenticated by the certificate of the Trustee&#59;</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, to provide the terms and conditions upon which the Securities are to be authenticated, issued and delivered, the Company has duly authorized the execution of this Indenture&#59; and</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, all things necessary to make this Indenture a valid agreement of the Company, in accordance with its terms, have been done.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the premises and the purchase of the Securities by the holders thereof, it is mutually covenanted and agreed as follows for the equal and ratable benefit of the holders of Securities&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE 1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DEFINITIONS</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 1.01 Definitions of Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms defined in this Section (except as in this Indenture or any indenture supplemental hereto otherwise expressly provided or unless the context otherwise requires) for all purposes of this Indenture and of any indenture supplemental hereto shall have the respective meanings specified in this Section and shall include the plural as well as the singular. All other terms used in this Indenture that are defined in the Trust Indenture Act of 1939, as amended, or that are by reference in such Act defined in the Securities Act of 1933, as amended (except as herein or any indenture supplemental hereto otherwise expressly provided or unless the context otherwise requires), shall have the meanings assigned to such terms in said Trust Indenture Act and in said Securities Act as in force at the date of the execution of this instrument.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Authenticating Agent&#34; means an authenticating agent with respect to all or any of the series of Securities appointed by the Trustee pursuant to Section 2.10.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Bankruptcy Law&#34; means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Board of Directors&#34; means the Board of Directors of the Company or any duly authorized committee of such Board.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Board Resolution&#34; means a copy of a resolution certified by the Secretary or an Assistant Secretary of the Company to have been duly adopted by the Board of Directors and to be in full force and effect on the date of such certification.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Business Day&#34; means, with respect to any series of Securities, any day other than a day on which federal or state banking institutions in the Borough of Manhattan, the City of New York, or in the city of the Corporate Trust Office of the Trustee, are authorized or obligated by law, executive order or regulation to close.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Certificate&#34; means a certificate signed by any Officer. The Certificate need not comply with the provisions of Section 13.07.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Company&#34; means Cardiff Oncology, Inc., a corporation duly organized and existing under the laws of the State of Delaware, and, subject to the provisions of Article Ten, shall also include its successors and assigns.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Corporate Trust Office&#34; means the office of the Trustee at which, at any particular time, its corporate trust business shall be principally administered, which office at the date hereof is located at .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Custodian&#34; means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Default&#34; means any event, act or condition that with notice or lapse of time, or both, would constitute an Event of Default.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Defaulted Interest&#34; has the meaning set forth in Section 2.03.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Depositary&#34; means, with respect to Securities of any series for which the Company shall determine that such Securities will be issued as a Global Security, The Depository Trust Company, another clearing agency, or any successor registered as a clearing agency under the Exchange Act, or other applicable statute or regulation, which, in each case, shall be designated by the Company pursuant to either Section 2.01 or 2.11.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Event of Default&#34; means, with respect to Securities of a particular series, any event specified in Section 6.01, continued for the period of time, if any, therein designated.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Exchange Act&#34; means the Securities and Exchange Act of 1934, as amended.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Global Security&#34; means, with respect to any series of Securities, a Security executed by the Company and delivered by the Trustee to the Depositary or pursuant to the Depositary's instruction, all in accordance with the Indenture, which shall be registered in the name of the Depositary or its nominee.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Governmental Obligations&#34; means securities that are (a) direct obligations of the United States of America for the payment of which its full faith and credit is pledged or (b) obligations of a Person controlled or supervised by and acting as an agency or instrumentality of the United States of America, the payment of which is unconditionally guaranteed as a full faith and credit obligation by the United States of America that, in either case, are not callable or redeemable at the option of the issuer thereof at any time prior to the stated maturity of the Securities, and shall also include a depositary receipt issued by a bank or trust company as custodian with respect to any such Governmental Obligation or a specific payment of principal of or interest on any such Governmental Obligation held by such custodian for the account of the holder of such depositary receipt&#59; provided, however, that (except as required by law) such custodian is not authorized to make any deduction from the amount payable to the holder of such depositary receipt from any amount received by the custodian in respect of the Governmental Obligation or the specific payment of principal of or interest on the Governmental Obligation evidenced by such depositary receipt.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;herein&#34;, &#34;hereof&#34; and &#34;hereunder&#34;, and other words of similar import, refer to this Indenture as a whole and not to any particular Article, Section or other subdivision.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Indenture&#34; means this instrument as originally executed or as it may from time to time be supplemented or amended by one or more indentures supplemental hereto entered into in accordance with the terms hereof.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Interest Payment Date&#34;, when used with respect to any installment of interest on a Security of a particular series, means the date specified in such Security or in a Board Resolution or in an indenture supplemental hereto with respect to such series as the fixed date on which an installment of interest with respect to Securities of that series is due and payable.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Officer&#34; means, with respect to the Company, the chairman of the Board of Directors, a chief executive officer, a president, a chief financial officer, a chief operating officer, any executive vice president, any senior vice president, any vice president, the treasurer or any assistant treasurer, the controller or any assistant controller or the secretary or any assistant secretary.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Officer's Certificate&#34; means a certificate signed by any Officer. Each such certificate shall include the statements provided for in Section 13.07, if and to the extent required by the provisions thereof.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Opinion of Counsel&#34; means an opinion in writing subject to customary exceptions of legal counsel, who may be an employee of or counsel for the Company, that is delivered to the Trustee in accordance with the terms hereof. Each such opinion shall include the statements provided for in Section 13.07, if and to the extent required by the provisions thereof.</font></div><div style="text-indent:25.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Outstanding&#34;, when used with reference to Securities of any series, means, subject to the provisions of Section 8.04, as of any particular time, all Securities of that series theretofore authenticated and delivered by the Trustee under this Indenture, except (a) Securities theretofore canceled by the Trustee or any paying agent, or delivered to the Trustee or any paying agent for cancellation or that have previously been canceled&#59; (b) Securities or portions thereof for the payment or redemption of which moneys or Governmental Obligations in the necessary amount shall have been deposited in trust with the Trustee or with any</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">paying agent (other than the Company) or shall have been set aside and segregated in trust by the Company (if the Company shall act as its own paying agent)&#59; provided, however, that if such Securities or portions of such Securities are to be redeemed prior to the maturity thereof, notice of such redemption shall have been given as provided in Article Three, or provision satisfactory to the Trustee shall have been made for giving such notice&#59; and (c) Securities in lieu of or in substitution for which other Securities shall have been authenticated and delivered pursuant to the terms of Section 2.07.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Person&#34; means any individual, corporation, partnership, joint venture, joint-stock company, limited liability company, association, trust, unincorporated organization, any other entity or organization, including a government or political subdivision or an agency or instrumentality thereof.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Predecessor Security&#34; of any particular Security means every previous Security evidencing all or a portion of the same debt as that evidenced by such particular Security&#59; and, for the purposes of this definition, any Security authenticated and delivered under Section 2.07 in lieu of a lost, destroyed or stolen Security shall be deemed to evidence the same debt as the lost, destroyed or stolen Security.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Responsible Officer&#34; when used with respect to the Trustee means the chairman of its board of directors, the chief executive officer, the president, any vice president, the secretary, the treasurer, any trust officer, any corporate trust officer or any other officer or assistant officer of the Trustee customarily performing functions similar to those performed by the Persons who at the time shall be such officers, respectively, or to whom any corporate trust matter is referred because of his or her knowledge of and familiarity with the particular subject.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Securities&#34; means the debt Securities authenticated and delivered under this Indenture.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Securityholder&#34;, &#34;holder of Securities&#34;, &#34;registered holder&#34;, or other similar term, means the Person or Persons in whose name or names a particular Security shall be registered on the books of the Company kept for that purpose in accordance with the terms of this Indenture.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Security Register&#34; and &#34;Security Registrar&#34; shall have the meanings as set forth in Section 2.05.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Subsidiary&#34; means, with respect to any Person, (i) any corporation at least a majority of whose outstanding Voting Stock shall at the time be owned, directly or indirectly, by such Person or by one or more of its Subsidiaries or by such Person and one or more of its Subsidiaries, (ii) any general partnership, joint venture or similar entity, at least a majority of whose outstanding partnership or similar interests shall at the time be owned by such Person, or by one or more of its Subsidiaries, or by such Person and one or more of its Subsidiaries and (iii) any limited partnership of which such Person or any of its Subsidiaries is a general partner.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Trustee&#34; means , and, subject to the provisions of Article Seven, shall also include its successors and assigns, and, if at any time there is more than one Person acting in such capacity hereunder, &#34;Trustee&#34; shall mean each such Person. The term &#34;Trustee&#34; as used with respect to a particular series of the Securities shall mean the trustee with respect to that series.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Trust Indenture Act&#34; means the Trust Indenture Act of 1939, as amended.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Voting Stock&#34;, as applied to stock of any Person, means shares, interests, participations or other equivalents in the equity interest (however designated) in such Person having ordinary voting power for the election of a majority of the directors (or the equivalent) of such Person, other than shares, interests, participations or other equivalents having such power only by reason of the occurrence of a contingency.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE 2</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE OF SECURITIES</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.01 Designation and Terms of Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The aggregate principal amount of Securities that may be authenticated and delivered under this Indenture is unlimited. The Securities may be issued in one or more series up to the aggregate principal amount of Securities of that series from time to time authorized by or pursuant to a Board Resolution or pursuant to one or more indentures supplemental hereto. Prior to the initial issuance of Securities of any series, there shall be established in or pursuant to a Board Resolution, and set forth in an Officer's Certificate, or established in one or more indentures supplemental hereto&#58;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the title of the Securities of the series (which shall distinguish the Securities of that series from all other Securities)&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) any limit upon the aggregate principal amount of the Securities of that series that may be authenticated and delivered under this Indenture (except for Securities authenticated and delivered upon registration of transfer of, or in exchange for, or in lieu of, other Securities of that series)&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) the date or dates on which the principal of the Securities of the series is payable, any original issue discount that may apply to the Securities of that series upon their issuance, the principal amount due at maturity, and the place(s) of payment&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) the rate or rates at which the Securities of the series shall bear interest or the manner of calculation of such rate or rates, if any&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) the date or dates from which such interest shall accrue, the Interest Payment Dates on which such interest will be payable or the manner of determination of such Interest Payment Dates, the place(s) of payment, and the record date for the determination of holders to whom interest is payable on any such Interest Payment Dates or the manner of determination of such record dates&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) the right, if any, to extend the interest payment periods and the duration of such extension&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7) the period or periods within which, the price or prices at which and the terms and conditions upon which Securities of the series may be redeemed, in whole or in part, at the option of the Company&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8) the obligation, if any, of the Company to redeem or purchase Securities of the series pursuant to any sinking fund, mandatory redemption, or analogous provisions (including payments made in cash in satisfaction of future sinking fund obligations) or at the option of a holder thereof and the period or periods within which, the price or prices at which, and the terms and conditions upon which, Securities of the series shall be redeemed or purchased, in whole or in part, pursuant to such obligation&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9) the form of the Securities of the series including the form of the Certificate of Authentication for such series&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10) if other than denominations of one thousand U.S. dollars ($1,000) or any integral multiple thereof, the denominations in which the Securities of the series shall be issuable&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11) any and all other terms (including terms, to the extent applicable, relating to any auction or remarketing of the Securities of that series and any security for the obligations of the Company with respect to such Securities) with respect to such series (which terms shall not be inconsistent with the terms of this Indenture, as amended by any supplemental indenture) including any terms which may be required by or advisable under United States laws or regulations or advisable in connection with the marketing of Securities of that series&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12) whether the Securities are issuable as a Global Security and, in such case, the terms and the identity of the Depositary for such series&#59;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13) whether the Securities will be convertible into or exchangeable for shares of common stock, preferred stock or other securities of the Company or any other Person and, if so, the terms and conditions upon which such Securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at the Company's option or the holders' option) conversion or exchange features, and the applicable conversion or exchange period&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14) if other than the principal amount thereof, the portion of the principal amount of Securities of the series which shall be payable upon declaration of acceleration of the maturity thereof pursuant to Section 6.01&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15) any additional or different Events of Default or restrictive covenants (which may include, among other restrictions, restrictions on the Company's ability or the ability of the Company's Subsidiaries to&#58; incur additional indebtedness&#59; issue additional securities&#59; create liens&#59; pay dividends or make distributions in respect of the capital stock of the Company or the Company's Subsidiaries&#59; redeem capital stock&#59; place restrictions on the Company's Subsidiaries' ability to pay dividends, make distributions or transfer assets&#59; make investments or other restricted payments&#59; sell or otherwise dispose of assets&#59; enter into sale-leaseback transactions&#59; engage in transactions with stockholders or affiliates&#59; issue or sell stock of the Company's Subsidiaries&#59; or effect a consolidation or merger) or financial covenants (which may include, among other financial covenants, financial covenants that require the Company and its Subsidiaries to maintain specified interest coverage, fixed charge, cash flow-based, asset-based or other financial ratios) provided for with respect to the Securities of the series&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16) if other than dollars, the coin or currency in which the Securities of the series are denominated (including, but not limited to, foreign currency)&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17) the terms and conditions, if any, upon which the Company shall pay amounts in addition to the stated interest, premium, if any and principal amounts of the Securities of the series to any Securityholder that is not a &#34;United States person&#34; for federal tax purposes&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18) any restrictions on transfer, sale or assignment of the Securities of the series&#59; and</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19) the subordination terms of the Securities of the series.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Securities of any one series shall be substantially identical except as may otherwise be provided in or pursuant to any such Board Resolution or in any indentures supplemental hereto.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of the terms of the series are established by action taken pursuant to a Board Resolution of the Company, a copy of an appropriate record of such action shall be certified by the secretary or an assistant secretary of the Company and delivered to the Trustee at or prior to the delivery of the Officer's Certificate of the Company setting forth the terms of the series.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities of any particular series may be issued at various times, with different dates on which the principal or any installment of principal is payable, with different rates of interest, if any, or different methods by which rates of interest may be determined, with different dates on which such interest may be payable and with different redemption dates.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.02 Form of Securities and Trustee's Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Securities of any series and the Trustee's certificate of authentication to be borne by such Securities shall be substantially of the tenor and purport as set forth in one or more indentures supplemental hereto or as provided in a Board Resolution, and set forth in an Officer's Certificate, and they may have such letters, numbers or other marks of identification or designation and such legends or endorsements printed, lithographed or engraved thereon as the Company may deem appropriate and as are not inconsistent with the provisions of this Indenture, or as may be required to comply with any law or with any rule or regulation made pursuant thereto or with any rule or regulation of any securities exchange on which Securities of that series may be listed, or to conform to usage.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.03 Denominations&#58; Provisions for Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Securities shall be issuable as registered Securities and in the denominations of one thousand U.S. dollars ($1,000) or any integral multiple thereof, subject to Section 2.01(a)(10). The Securities of a particular series shall bear interest payable on the dates and at the rate specified with respect to that series. Subject to Section 2.01(a)(16), the principal of and the interest on the Securities of any series, as well as any premium thereon in case of redemption thereof prior to maturity, shall be payable in the coin or currency of the United States of America that at the time is legal tender for public and private debt, at the office or</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agency of the Company maintained for that purpose. Each Security shall be dated the date of its authentication. Interest on the Securities shall be computed on the basis of a 360-day year composed of twelve 30-day months.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest installment on any Security that is payable, and is punctually paid or duly provided for, on any Interest Payment Date for Securities of that series shall be paid to the Person in whose name said Security (or one or more Predecessor Securities) is registered at the close of business on the regular record date for such interest installment. In the event that any Security of a particular series or portion thereof is called for redemption and the redemption date is subsequent to a regular record date with respect to any Interest Payment Date and prior to such Interest Payment Date, interest on such Security will be paid upon presentation and surrender of such Security as provided in Section 3.03.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any interest on any Security that is payable, but is not punctually paid or duly provided for, on any Interest Payment Date for Securities of the same series (herein called &#34;Defaulted Interest&#34;) shall forthwith cease to be payable to the registered holder on the relevant regular record date by virtue of having been such holder&#59; and such Defaulted Interest shall be paid by the Company, at its election, as provided in clause (1) or clause (2) below&#58;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Company may make payment of any Defaulted Interest on Securities to the Persons in whose names such Securities (or their respective Predecessor Securities) are registered at the close of business on a special record date for the payment of such Defaulted Interest, which shall be fixed in the following manner&#58; the Company shall notify the Trustee in writing of the amount of Defaulted Interest proposed to be paid on each such Security and the date of the proposed payment, and at the same time the Company shall deposit with the Trustee an amount of money equal to the aggregate amount proposed to be paid in respect of such Defaulted Interest or shall make arrangements satisfactory to the Trustee for such deposit prior to the date of the proposed payment, such money when deposited to be held in trust for the benefit of the Persons entitled to such Defaulted Interest as in this clause provided. Thereupon the Trustee shall fix a special record date for the payment of such Defaulted Interest which shall not be more than 15 nor less than 10 days prior to the date of the proposed payment and not less than 10 days after the receipt by the Trustee of the notice of the proposed payment. The Trustee shall promptly notify the Company of such special record date and, in the name and at the expense of the Company, shall cause notice of the proposed payment of such Defaulted Interest and the special record date therefor to be mailed, first class postage prepaid, to each Securityholder at his or her address as it appears in the Security Register (as hereinafter defined), not less than 10 days prior to such special record date. Notice of the proposed payment of such Defaulted Interest and the special record date therefor having been mailed as aforesaid, such Defaulted Interest shall be paid to the Persons in whose names such Securities (or their respective Predecessor Securities) are registered on such special record date.</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The Company may make payment of any Defaulted Interest on any Securities in any other lawful manner not inconsistent with the requirements of any securities exchange on which such Securities may be listed, and upon such notice as may be required by such exchange, if, after notice given by the Company to the Trustee of the proposed payment pursuant to this clause, such manner of payment shall be deemed practicable by the Trustee.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise set forth in a Board Resolution or one or more indentures supplemental hereto establishing the terms of any series of Securities pursuant to Section 2.01 hereof, the term &#34;regular record date&#34; as used in this Section with respect to a series of Securities and any Interest Payment Date for such series shall mean either the fifteenth day of the month immediately preceding the month in which an Interest Payment Date established for such series pursuant to Section 2.01 hereof shall occur, if such Interest Payment Date is the first day of a month, or the first day of the month in which an Interest Payment Date established for such series pursuant to Section 2.01 hereof shall occur, if such Interest Payment Date is the fifteenth day of a month, whether or not such date is a Business Day.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the foregoing provisions of this Section, each Security of a series delivered under this Indenture upon transfer of or in exchange for or in lieu of any other Security of such series shall carry the rights to interest accrued and unpaid, and to accrue, that were carried by such other Security.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.04 Execution and Authentications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Securities shall be signed on behalf of the Company by one of its Officers. Signatures may be in the form of a manual or facsimile signature.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use the facsimile signature of any Person who shall have been an Officer, notwithstanding the fact that at the time the Securities shall be authenticated and delivered or disposed of such Person shall have ceased to be such an officer of the Company. The Securities may contain such notations, legends or endorsements required by law, stock exchange rule or usage. Each Security shall be dated the date of its authentication by the Trustee.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Security shall not be valid until authenticated manually by an authorized signatory of the Trustee, or by an Authenticating Agent. Such signature shall be conclusive evidence that the Security so authenticated has been duly authenticated and delivered hereunder and that the holder is entitled to the benefits of this Indenture. At any time and from time to time after the execution and delivery of this Indenture, the Company may deliver Securities of any series executed by the Company to the Trustee for authentication, together with a written order of the Company for the authentication and delivery of such Securities, signed by an Officer, and the Trustee in accordance with such written order shall authenticate and deliver such Securities.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In authenticating such Securities and accepting the additional responsibilities under this Indenture in relation to such Securities, the Trustee shall be entitled to receive, if requested, and (subject to Section 7.01) shall be fully protected in relying upon, an Opinion of Counsel stating that the form and terms thereof have been established in conformity with the provisions of this Indenture.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trustee shall not be required to authenticate such Securities if the issue of such Securities pursuant to this Indenture will affect the Trustee's own rights, duties or immunities under the Securities and this Indenture or otherwise in a manner that is not reasonably acceptable to the Trustee.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.05 Registration of Transfer and Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Securities of any series may be exchanged upon presentation thereof at the office or agency of the Company designated for such purpose, for other Securities of such series of authorized denominations, and for a like aggregate principal amount, upon payment of a sum sufficient to cover any tax or other governmental charge in relation thereto, all as provided in this Section. In respect of any Securities so surrendered for exchange, the Company shall execute, the Trustee shall authenticate and such office or agency shall deliver in exchange therefor the Security or Securities of the same series that the Securityholder making the exchange shall be entitled to receive, bearing numbers not contemporaneously outstanding.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The Company shall keep, or cause to be kept, at its office or agency designated for such purpose a register or registers (herein referred to as the &#34;Security Register&#34;) in which, subject to such reasonable regulations as it may prescribe, the Company shall register the Securities and the transfers of Securities as in this Article provided and which at all reasonable times shall be open for inspection by the Trustee. The registrar for the purpose of registering Securities and transfer of Securities as herein provided shall be appointed as authorized by Board Resolution (the &#34;Security Registrar&#34;).</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon surrender for transfer of any Security at the office or agency of the Company designated for such purpose, the Company shall execute, the Trustee shall authenticate and such office or agency shall deliver in the name of the transferee or transferees a new Security or Securities of the same series as the Security presented for a like aggregate principal amount.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Securities presented or surrendered for exchange or registration of transfer, as provided in this Section, shall be accompanied (if so required by the Company or the Security Registrar) by a written instrument or instruments of transfer, in form satisfactory to the Company or the Security Registrar, duly executed by the registered holder or by such holder's duly authorized attorney in writing.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Except as provided pursuant to Section 2.01 pursuant to a Board Resolution, and set forth in an Officer's Certificate, or established in one or more indentures supplemental to this Indenture, no service charge shall be made for any exchange or registration of transfer of Securities, or issue of new Securities in case of partial redemption of any series, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge in relation thereto, other than exchanges pursuant to Section 2.06, Section 3.03(b) and Section 9.04 not involving any transfer.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) The Company shall not be required (i) to issue, exchange or register the transfer of any Securities during a period beginning at the opening of business 15 days before the day of the mailing of a notice of redemption of less than all the Outstanding Securities of the same series and ending at the close of business on the day of such mailing, nor (ii) to register the transfer of or exchange any Securities of any series or portions thereof called for redemption, other than the unredeemed portion of any such Securities being redeemed in part. The provisions of this Section 2.05 are, with respect to any Global Security, subject to Section 2.11 hereof.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.06 Temporary Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pending the preparation of definitive Securities of any series, the Company may execute, and the Trustee shall authenticate and deliver, temporary Securities (printed, lithographed or typewritten) of any authorized denomination. Such temporary Securities shall be substantially in the form of the definitive Securities in lieu of which they are issued, but with such omissions, insertions and variations as may be appropriate for temporary Securities, all as may be determined by the Company. Every temporary Security of any series shall be executed by the Company and be authenticated by the Trustee upon the same conditions and in substantially the same manner, and with like effect, as the definitive Securities of such series. Without unnecessary delay the Company will execute and will furnish definitive Securities of such series and thereupon any or all temporary Securities of such series may be surrendered in exchange therefor (without charge to the holders), at the office or agency of the Company designated for the purpose, and the Trustee shall authenticate and such office or agency shall deliver in exchange for such temporary Securities an equal aggregate principal amount of definitive Securities of such series, unless the Company advises the Trustee to the effect that definitive Securities need not be executed and furnished until further notice from the Company. Until so exchanged, the temporary Securities of such series shall be entitled to the same benefits under this Indenture as definitive Securities of such series authenticated and delivered hereunder.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.07 Mutilated, Destroyed, Lost or Stolen Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In case any temporary or definitive Security shall become mutilated or be destroyed, lost or stolen, the Company (subject to the next succeeding sentence) shall execute, and upon the Company's request the Trustee (subject as aforesaid) shall authenticate and deliver, a new Security of the same series, bearing a number not contemporaneously outstanding, in exchange and substitution for the mutilated Security, or in lieu of and in substitution for the Security so destroyed, lost or stolen. In every case the applicant for a substituted Security shall furnish to the Company and the Trustee such security or indemnity as may be required by them to save each of them harmless, and, in every case of destruction, loss or theft, the applicant shall also furnish to the Company and the Trustee evidence to their satisfaction of the destruction, loss or theft of the applicant's Security and of the ownership thereof. The Trustee may authenticate any such substituted Security and deliver the same upon the written request or authorization of any officer of the Company. Upon the issuance of any substituted Security, the Company may require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto and any other expenses (including the fees and expenses of the Trustee) connected therewith.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In case any Security that has matured or is about to mature shall become mutilated or be destroyed, lost or stolen, the Company may, instead of issuing a substitute Security, pay or authorize the payment of the same (without surrender thereof except in the case of a mutilated Security) if the applicant for such payment shall furnish to the Company and the Trustee such security or indemnity as they may require to save them harmless, and, in case of destruction, loss or theft, evidence to the satisfaction of the Company and the Trustee of the destruction, loss or theft of such Security and of the ownership thereof.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Every replacement Security issued pursuant to the provisions of this Section shall constitute an additional contractual obligation of the Company whether or not the mutilated, destroyed, lost or stolen Security shall be found at any time, or be enforceable by anyone, and shall be entitled to all the benefits of this Indenture equally and proportionately with any and all other Securities of the same series duly issued hereunder. All Securities shall be held and owned upon the express condition that the foregoing provisions are exclusive with respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities, and shall preclude (to the extent lawful) any and all other rights or remedies, notwithstanding any law or statute existing or hereafter enacted to the contrary with respect to the replacement or payment of negotiable instruments or other securities without their surrender.</font></div><div style="padding-left:21.6pt;text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.08 Cancellation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Securities surrendered for the purpose of payment, redemption, exchange or registration of transfer shall, if surrendered to the Company or any paying agent, be delivered to the Trustee for cancellation, or, if surrendered to the Trustee, shall be cancelled by it, and no Securities shall be issued in lieu thereof except as expressly required or permitted by any of the provisions of this Indenture. On request of the Company at the time of such surrender, the Trustee shall deliver to the Company canceled Securities held by the Trustee. In the absence of such request the Trustee may dispose of canceled Securities in accordance with its standard procedures and deliver a certificate of disposition to the Company. If the Company shall otherwise acquire any of the Securities, however, such acquisition shall not operate as a redemption or satisfaction of the indebtedness represented by such Securities unless and until the same are delivered to the Trustee for cancellation.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.09 Benefits of Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nothing in this Indenture or in the Securities, express or implied, shall give or be construed to give to any Person, other than the parties hereto and the holders of the Securities (and, with respect to the provisions of Article Fourteen, the holders of</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any indebtedness of the Company to which the Securities of any series are subordinated) any legal or equitable right, remedy or claim under or in respect of this Indenture, or under any covenant, condition or provision herein contained&#59; all such covenants, conditions and provisions being for the sole benefit of the parties hereto and of the holders of the Securities (and, with respect to the provisions of Article Fourteen, the holders of any indebtedness of the Company to which the Securities of any series are subordinated).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.10 Authenticating Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">So long as any of the Securities of any series remain Outstanding there may be an Authenticating Agent for any or all such series of Securities which the Trustee shall have the right to appoint. Said Authenticating Agent shall be authorized to act on behalf of the Trustee to authenticate Securities of such series issued upon exchange, transfer or partial redemption thereof, and Securities so authenticated shall be entitled to the benefits of this Indenture and shall be valid and obligatory for all purposes as if authenticated by the Trustee hereunder. All references in this Indenture to the authentication of Securities by the Trustee shall be deemed to include authentication by an Authenticating Agent for such series. Each Authenticating Agent shall be acceptable to the Company and shall be a corporation that has a combined capital and surplus, as most recently reported or determined by it, sufficient under the laws of any jurisdiction under which it is organized or in which it is doing business to conduct a trust business, and that is otherwise authorized under such laws to conduct such business and is subject to supervision or examination by federal or state authorities. If at any time any Authenticating Agent shall cease to be eligible in accordance with these provisions, it shall resign immediately.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any Authenticating Agent may at any time resign by giving written notice of resignation to the Trustee and to the Company. The Trustee may at any time (and upon request by the Company shall) terminate the agency of any Authenticating Agent by giving written notice of termination to such Authenticating Agent and to the Company. Upon resignation, termination or cessation of eligibility of any Authenticating Agent, the Trustee may appoint an eligible successor Authenticating Agent acceptable to the Company. Any successor Authenticating Agent, upon acceptance of its appointment hereunder, shall become vested with all the rights, powers and duties of its predecessor hereunder as if originally named as an Authenticating Agent pursuant hereto.</font></div><div style="padding-left:21.6pt;text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.11 Global Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) If the Company shall establish pursuant to Section 2.01 that the Securities of a particular series are to be issued as a Global Security, then the Company shall execute and the Trustee shall, in accordance with Section 2.04, authenticate and deliver, a Global Security that (i) shall represent, and shall be denominated in an amount equal to the aggregate principal amount of, all of the Outstanding Securities of such series, (ii) shall be registered in the name of the Depositary or its nominee, (iii) shall be delivered by the Trustee to the Depositary or pursuant to the Depositary's instruction and (iv) shall bear a legend substantially to the following effect&#58; &#34;Except as otherwise provided in Section 2.11 of the Indenture, this Security may be transferred, in whole but not in part, only to another nominee of the Depositary or to a successor Depositary or to a nominee of such successor Depositary.&#34;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Notwithstanding the provisions of Section 2.05, the Global Security of a series may be transferred, in whole but not in part and in the manner provided in Section 2.05, only to another nominee of the Depositary for such series, or to a successor Depositary for such series selected or approved by the Company or to a nominee of such successor Depositary.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) If at any time the Depositary for a series of the Securities notifies the Company that it is unwilling or unable to continue as Depositary for such series or if at any time the Depositary for such series shall no longer be registered or in good standing under the Exchange Act, or other applicable statute or regulation, and a successor Depositary for such series is not appointed by the Company within 90 days after the Company receives such notice or becomes aware of such condition, as the case may be, or if an Event of Default has occurred and is continuing and the Company has received a request from the Depositary or from the Trustee, this Section 2.11 shall no longer be applicable to the Securities of such series and the Company will execute, and subject to Section 2.04, the Trustee will authenticate and deliver the Securities of such series in definitive registered form without coupons, in authorized denominations, and in an aggregate principal amount equal to the principal amount of the Global Security of such series in exchange for such Global Security. In addition, the Company may at any time determine that the Securities of any series shall no longer be represented by a Global Security and that the provisions of this Section 2.11 shall no longer apply to the Securities of such series. In such event the Company will execute and, subject to Section 2.04, the Trustee, upon receipt of an Officer's Certificate evidencing such determination by the Company, will authenticate and deliver the Securities of such series in definitive registered form without coupons, in authorized denominations, and in an aggregate principal amount equal to the principal amount of the Global Security of such series in exchange for such Global Security. Upon the exchange of the Global Security for such Securities in definitive registered form</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">without coupons, in authorized denominations, the Global Security shall be canceled by the Trustee. Such Securities in definitive registered form issued in exchange for the Global Security pursuant to this Section 2.11(c) shall be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">registered in such names and in such authorized denominations as the Depositary, pursuant to instructions from its direct or indirect participants or otherwise, shall instruct the Trustee. The Trustee shall deliver such Securities to the Depositary for delivery to the Persons in whose names such Securities are so registered.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE 3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REDEMPTION OF SECURITIES AND SINKING FUND PROVISIONS</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.01 Redemption.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem the Securities of any series issued hereunder on and after the dates and in accordance with the terms established for such series pursuant to Section 2.01 hereof.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.02 Notice of Redemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) In case the Company shall desire to exercise such right to redeem all or, as the case may be, a portion of the Securities of any series in accordance with any right the Company reserved for itself to do so pursuant to Section 2.01 hereof, the Company shall, or shall cause the Trustee to, give notice of such redemption to holders of the Securities of such series to be redeemed by mailing, first class postage prepaid, a notice of such redemption not less than 30 days and not more than 90 days before the date fixed for redemption of that series to such holders at their last addresses as they shall appear upon the Security Register, unless a shorter period is specified in the Securities to be redeemed. Any notice that is mailed in the manner herein provided shall be conclusively presumed to have been duly given, whether or not the registered holder receives the notice. In any case, failure duly to give such notice to the holder of any Security of any series designated for redemption in whole or in part, or any defect in the notice, shall not affect the validity of the proceedings for the redemption of any other Securities of such series or any other series. In the case of any redemption of Securities prior to the expiration of any restriction on such redemption provided in the terms of such Securities or elsewhere in this Indenture, the Company shall furnish the Trustee with an Officer's Certificate evidencing compliance with any such restriction.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each such notice of redemption shall specify the date fixed for redemption and the redemption price at which Securities of that series are to be redeemed, and shall state that payment of the redemption price of such Securities to be redeemed will be made at the office or agency of the Company, upon presentation and surrender of such Securities, that interest accrued to the date fixed for redemption will be paid as specified in said notice, that from and after said date interest will cease to accrue and that the redemption is from a sinking fund, if such is the case. If less than all the Securities of a series are to be redeemed, the notice to the holders of Securities of that series to be redeemed in part shall specify the particular Securities to be so redeemed.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In case any Security is to be redeemed in part only, the notice that relates to such Security shall state the portion of the principal amount thereof to be redeemed, and shall state that on and after the redemption date, upon surrender of such Security, a new Security or Securities of such series in principal amount equal to the unredeemed portion thereof will be issued.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) If less than all the Securities of a series are to be redeemed, the Company shall give the Trustee at least 45 days' notice (unless a shorter notice shall be satisfactory to the Trustee) in advance of the date fixed for redemption as to the aggregate principal amount of Securities of the series to be redeemed, and thereupon the Trustee shall select, by lot or in such other manner as it shall deem appropriate and fair in its discretion and that may provide for the selection of a portion or portions (equal to one thousand U.S. dollars ($1,000) or any integral multiple thereof) of the principal amount of such Securities of a denomination larger than $1,000, the Securities to be redeemed and shall thereafter promptly notify the Company in writing of the numbers of the Securities to be redeemed, in whole or in part. The Company may, if and whenever it shall so elect, by delivery of instructions signed on its behalf by an Officer, instruct the Trustee or any paying agent to call all or any part of the Securities of a particular series for redemption and to give notice of redemption in the manner set forth in this Section, such notice to be in the name of the Company or its own name as the Trustee or such paying agent may deem advisable. In any case in which notice of redemption is to be given by the Trustee or any such paying agent, the Company shall deliver or cause to be delivered to, or permit to remain with, the Trustee or such paying agent, as the case may be, such Security Register, transfer books or other records, or suitable copies or extracts therefrom, sufficient to enable the Trustee or such paying agent to give any notice by mail that may be required under the provisions of this Section.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.03 Payment Upon Redemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) If the giving of notice of redemption shall have been completed as above provided, the Securities or portions of Securities of the series to be redeemed specified in such notice shall become due and payable on the date and at the place stated in such notice at the applicable redemption price, together with interest accrued to the date fixed for redemption and interest on such Securities or portions of Securities shall cease to accrue on and after the date fixed for redemption, unless the Company shall default in the payment of such redemption price and accrued interest with respect to any such Security or portion thereof. On presentation and surrender of such Securities on or after the date fixed for redemption at the place of payment specified in the notice, said Securities shall be paid and redeemed at the applicable redemption price for such series, together with interest accrued thereon to the date fixed for redemption (but if the date fixed for redemption is an interest payment date, the interest installment payable on such date shall be payable to the registered holder at the close of business on the applicable record date pursuant to Section 2.03).</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Upon presentation of any Security of such series that is to be redeemed in part only, the Company shall execute and the Trustee shall authenticate and the office or agency where the Security is presented shall deliver to the holder thereof, at the expense of the Company, a new Security of the same series of authorized denominations in principal amount equal to the unredeemed portion of the Security so presented.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.04 Sinking Fund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provisions of Sections 3.04, 3.05 and 3.06 shall be applicable to any sinking fund for the retirement of Securities of a series, except as otherwise specified as contemplated by Section 2.01 for Securities of such series.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The minimum amount of any sinking fund payment provided for by the terms of Securities of any series is herein referred to as a &#34;mandatory sinking fund payment,&#34; and any payment in excess of such minimum amount provided for by the terms of Securities of any series is herein referred to as an &#34;optional sinking fund payment&#34;. If provided for by the terms of Securities of any series, the cash amount of any sinking fund payment may be subject to reduction as provided in Section 3.05. Each sinking fund payment shall be applied to the redemption of Securities of any series as provided for by the terms of Securities of such series.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.05 Satisfaction of Sinking Fund Payments with Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company (i) may deliver Outstanding Securities of a series and (ii) may apply as a credit Securities of a series that have been redeemed either at the election of the Company pursuant to the terms of such Securities or through the application of permitted optional sinking fund payments pursuant to the terms of such Securities, in each case in satisfaction of all or any part of any sinking fund payment with respect to the Securities of such series required to be made pursuant to the terms of such Securities as provided for by the terms of such series, provided that such Securities have not been previously so credited. Such Securities shall be received and credited for such purpose by the Trustee at the redemption price specified in such Securities for redemption through operation of the sinking fund and the amount of such sinking fund payment shall be reduced accordingly.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.06 Redemption of Securities for Sinking Fund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not less than 45 days prior to each sinking fund payment date for any series of Securities (unless a shorter period shall be satisfactory to the Trustee), the Company will deliver to the Trustee an Officer's Certificate specifying the amount of the next ensuing sinking fund payment for that series pursuant to the terms of the series, the portion thereof, if any, that is to be satisfied by delivering and crediting Securities of that series pursuant to Section 3.05 and the basis for such credit and will, together with such Officer's Certificate, deliver to the Trustee any Securities to be so delivered. Not less than 30 days before each such sinking fund payment date the Trustee shall select the Securities to be redeemed upon such sinking fund payment date in the manner specified in Section 3.02 and cause notice of the redemption thereof to be given in the name of and at the expense of the Company in the manner provided in Section 3.02. Such notice having been duly given, the redemption of such Securities shall be made upon the terms and in the manner stated in Section 3.03.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE 4</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVENANTS</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 4.01 Payment of Principal, Premium and Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will duly and punctually pay or cause to be paid the principal of (and premium, if any) and interest on the Securities of that series at the time and place and in the manner provided herein and established with respect to such Securities.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments of principal on the Securities may be made at the time provided herein and established with respect to such Securities by U.S. dollar check drawn on and mailed to the address of the Securityholder entitled thereto as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such address shall appear in the Security Register, or U.S. dollar wire transfer to, a U.S. dollar account (such wire transfer to be made only to a Securityholder of an aggregate principal amount of Securities of the applicable series in excess of U.S. $2,000,000 and only if such Securityholder shall have furnished wire instructions to the Trustee no later than 15 days prior to the relevant payment date). Payments of interest on the Securities may be made at the time provided herein and established with respect to such Securities by U.S. dollar check mailed to the address of the Securityholder entitled thereto as such address shall appear in the Security Register, or U.S. dollar wire transfer to, a U.S. dollar account (such a wire transfer to be made only to a Securityholder of an aggregate principal amount of Securities of the applicable series in excess of U.S. $2,000,000 and only if such Securityholder shall have furnished wire instructions in writing to the Security Registrar and the Trustee no later than 15 days prior to the relevant payment date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:21.6pt;text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 4.02 Maintenance of Office or Agency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">So long as any series of the Securities remain Outstanding, the Company agrees to maintain an office or agency with respect to each such series and at such other location or locations as may be designated as provided in this Section 4.02, where (i) Securities of that series may be presented for payment, (ii) Securities of that series may be presented as herein above authorized for registration of transfer and exchange, and (iii) notices and demands to or upon the Company in respect of the Securities of that series and this Indenture may be given or served, such designation to continue with respect to such office or agency until the Company shall, by written notice signed by any officer authorized to sign an Officer's Certificate and delivered to the Trustee, designate some other office or agency for such purposes or any of them. If at any time the Company shall fail to maintain any such required office or agency or shall fail to furnish the Trustee with the address thereof, such presentations, notices and demands may be made or served at the Corporate Trust Office of the Trustee, and the Company hereby appoints the Trustee as its agent to receive all such presentations, notices and demands. The Company initially appoints the Corporate Trust Office of the Trustee as its paying agent with respect to the Securities.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 4.03 Paying Agents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) If the Company shall appoint one or more paying agents for all or any series of the Securities, other than the Trustee, the Company will cause each such paying agent to execute and deliver to the Trustee an instrument in which such agent shall agree with the Trustee, subject to the provisions of this Section&#58;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) that it will hold all sums held by it as such agent for the payment of the principal of (and premium, if any) or interest on the Securities of that series (whether such sums have been paid to it by the Company or by any other obligor of such Securities) in trust for the benefit of the Persons entitled thereto&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) that it will give the Trustee notice of any failure by the Company (or by any other obligor of such Securities) to make any payment of the principal of (and premium, if any) or interest on the Securities of that series when the same shall be due and payable&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) that it will, at any time during the continuance of any failure referred to in the preceding paragraph (a)(2) above, upon the written request of the Trustee, forthwith pay to the Trustee all sums so held in trust by such paying agent&#59; and</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) that it will perform all other duties of paying agent as set forth in this Indenture.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) If the Company shall act as its own paying agent with respect to any series of the Securities, it will on or before each due date of the principal of (and premium, if any) or interest on Securities of that series, set aside, segregate and hold in trust for the benefit of the Persons entitled thereto a sum sufficient to pay such principal (and premium, if any) or interest so becoming due on Securities of that series until such sums shall be paid to such Persons or otherwise disposed of as herein provided and will promptly notify the Trustee of such action, or any failure (by it or any other obligor on such Securities) to take such action. Whenever the Company shall have one or more paying agents for any series of Securities, it will, prior to each due date of the principal of (and premium, if any) or interest on any Securities of that series, deposit with the paying agent a sum sufficient to pay the principal (and premium, if any) or interest so becoming due, such sum to be held in trust for the benefit of the Persons entitled to such principal, premium or interest, and (unless such paying agent is the Trustee) the Company will promptly notify the Trustee of this action or failure so to act.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Notwithstanding anything in this Section to the contrary, (i) the agreement to hold sums in trust as provided in this Section is subject to the provisions of Section 11.05, and (ii) the Company may at any time, for the purpose of obtaining the satisfaction and discharge of this Indenture or for any other purpose, pay, or direct any paying agent to pay, to the Trustee all sums held in trust by the Company or such paying agent, such sums to be held by the Trustee upon the same terms and conditions as those upon which such sums were held by the Company or such paying agent&#59; and, upon such payment by the Company or any paying agent to the Trustee, the Company or such paying agent shall be released from all further liability with respect to such money.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:21.6pt;text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 4.04 Appointment to Fill Vacancy in Office of Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, whenever necessary to avoid or fill a vacancy in the office of Trustee, will appoint, in the manner provided in Section 7.10, a Trustee, so that there shall at all times be a Trustee hereunder.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 4.05 Compliance with Consolidation Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will not, while any of the Securities remain Outstanding, consolidate with or merge into any other Person, in either case where the Company is not the survivor of such transaction, or sell or convey all or substantially all of its property to any other Person unless the provisions of Article Ten hereof are complied with.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE 5</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITYHOLDERS' LISTS AND REPORTS BY THE COMPANY AND THE TRUSTEE</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.01 Company to Furnish Trustee Names and Addresses of Securityholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will furnish or cause to be furnished to the Trustee (a) within 15 days after each regular record date (as defined in Section 2.03) a list, in such form as the Trustee may reasonably require, of the names and addresses of the holders of each series of Securities as of such regular record date, provided that the Company shall not be obligated to furnish or cause to furnish such list at any time that the list shall not differ in any respect from the most recent list furnished to the Trustee by the Company and (b) at such other times as the Trustee may request in writing within 30 days after the receipt by the Company of any such request, a list of similar form and content as of a date not more than 15 days prior to the time such list is furnished&#59; provided, however, that, in either case, no such list need be furnished for any series for which the Trustee shall be the Security Registrar.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.02 Preservation Of Information&#59; Communications With Securityholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The Trustee shall preserve, in as current a form as is reasonably practicable, all information as to the names and addresses of the holders of Securities contained in the most recent list furnished to it as provided in Section 5.01 and as to the names and addresses of holders of Securities received by the Trustee in its capacity as Security Registrar (if acting in such capacity).</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The Trustee may destroy any list furnished to it as provided in Section 5.01 upon receipt of a new list so furnished.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Securityholders may communicate as provided in Section 312(b) of the Trust Indenture Act with other Securityholders with respect to their rights under this Indenture or under the Securities, and, in connection with any such communications, the Trustee shall satisfy its obligations under Section 312(b) of the Trust Indenture Act in accordance with the provisions of Section 312(b) of the Trust Indenture Act.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.03 Reports by the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company covenants and agrees to provide (which delivery may be via electronic mail) to the Trustee, after the Company files the same with the Securities and Exchange Commission, copies of the annual reports and of the information, documents and other reports (or copies of such portions of any of the foregoing as the Securities and Exchange Commission may from time to time by rules and regulations prescribe) that the Company files with the Securities and Exchange Commission pursuant to Section 13 or Section 15(d) of the Exchange Act&#59; provided, however, the Company shall not be required to deliver to the Trustee any materials for which the Company has sought and received confidential treatment by the Securities and Exchange Commission&#59; and provided further, so long as such filings by the Company are available on the</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities and Exchange Commission's Electronic Data Gathering, Analysis and Retrieval System (EDGAR), such filings shall be deemed to have been filed with the Trustee for purposes of this Section 5.03 without any further action required by the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:21.6pt;text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.04 Reports by the Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) If required by Section 313(a) of the Trust Indenture Act, the Trustee, within sixty (60) days after each May 1, shall transmit by mail, first class postage prepaid, to the Securityholders, as their names and addresses appear upon the Security Register, a brief report dated as of such May 1, which complies with Section 313(a) of the Trust Indenture Act.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The Trustee shall comply with Section 313(b) and 313(c) of the Trust Indenture Act.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) A copy of each such report shall, at the time of such transmission to Securityholders, be filed by the Trustee with the Company, with each securities exchange upon which any Securities are listed (if so listed) and also with the Securities and Exchange Commission. The Company agrees to notify the Trustee when any Securities become listed on any securities exchange.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE 6</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REMEDIES OF THE TRUSTEE AND SECURITYHOLDERS ON EVENT OF DEFAULT</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 6.01 Events of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Whenever used herein with respect to Securities of a particular series, &#34;Event of Default&#34; means any one or more of the following events that has occurred and is continuing&#58;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the Company defaults in the payment of any installment of interest upon any of the Securities of that series, as and when the same shall become due and payable, and such default continues for a period of 90 days&#59; provided, however, that a valid extension of an interest payment period by the Company in accordance with the terms of any indenture supplemental hereto shall not constitute a default in the payment of interest for this purpose&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) the Company defaults in the payment of the principal of (or premium, if any, on) any of the Securities of that series as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to that series&#59; provided, however, that a valid extension of the maturity of such Securities in accordance with the terms of any indenture supplemental hereto shall not constitute a default in the payment of principal or premium, if any&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) the Company fails to observe or perform any other of its covenants or agreements with respect to that series contained in this Indenture or otherwise established with respect to that series of Securities pursuant to Section 2.01 hereof (other than a covenant or agreement that has been expressly included in this Indenture solely for the benefit of one or more series of Securities other than such series) for a period of 90 days after the date on which written notice of such failure, requiring the same to be remedied and stating that such notice is a &#34;Notice of Default&#34; hereunder, shall have been given to the Company by the Trustee, by registered or certified mail, or to the Company and the Trustee by the holders of at least 25% in principal amount of the Securities of that series at the time Outstanding&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) the Company pursuant to or within the meaning of any Bankruptcy Law (i) commences a voluntary case, (ii) consents to the entry of an order for relief against it in an involuntary case, (iii) consents to the appointment of a Custodian of it or for all or substantially all of its property or (iv) makes a general assignment for the benefit of its creditors&#59; or</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) a court of competent jurisdiction enters an order under any Bankruptcy Law that (i) is for relief against the Company in an involuntary case, (ii) appoints a Custodian of the Company for all or substantially all of its property or (iii) orders the liquidation of the Company, and the order or decree remains unstayed and in effect for 90 days.</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) In each and every such case (other than an Event of Default specified in clause (4) or clause (5) above), unless the principal of all the Securities of that series shall have already become due and payable, either the Trustee or the holders of not less than 25% in aggregate principal amount of the Securities of that series then Outstanding hereunder, by notice in writing to the Company (and to the Trustee if given by such Securityholders), may declare the principal of (and premium, if any, on) and accrued and unpaid interest on all the Securities of that series to be due and payable immediately, and upon any</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such declaration the same shall become and shall be immediately due and payable. If an Event of Default specified in clause (4) or clause (5) above occurs, the principal of and accrued and unpaid interest on all the Securities of that series shall automatically be immediately due and payable without any declaration or other act on the part of the Trustee or the holders of the Securities.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) At any time after the principal of (and premium, if any, on) and accrued and unpaid interest on the Securities of that series shall have been so declared due and payable, and before any judgment or decree for the payment of the moneys due shall have been obtained or entered as hereinafter provided, the holders of a majority in aggregate principal amount of the Securities of that series then Outstanding hereunder, by written notice to the Company and the Trustee, may rescind and annul such declaration and its consequences if&#58; (i) the Company has paid or deposited with the Trustee a sum sufficient to pay all matured installments of interest upon all the Securities of that series and the principal of (and premium, if any, on) any and all Securities of that series that shall have become due otherwise than by acceleration (with interest upon such principal and premium, if any, and, to the extent that such payment is enforceable under applicable law, upon overdue installments of interest, at the rate per annum expressed in the Securities of that series to the date of such payment or deposit) and the amount payable to the Trustee under Section 7.06, and (ii) any and all Events of Default under the Indenture with respect to such series, other than the nonpayment of principal on (and premium, if any, on) and accrued and unpaid interest on Securities of that series that shall not have become due by their terms, shall have been remedied or waived as provided in Section 6.06.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No such rescission and annulment shall extend to or shall affect any subsequent default or impair any right consequent thereon.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) In case the Trustee shall have proceeded to enforce any right with respect to Securities of that series under this Indenture and such proceedings shall have been discontinued or abandoned because of such rescission or annulment or for any other reason or shall have been determined adversely to the Trustee, then and in every such case, subject to any determination in such proceedings, the Company and the Trustee shall be restored respectively to their former positions and rights hereunder, and all rights, remedies and powers of the Company and the Trustee shall continue as though no such proceedings had been taken.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 6.02 Collection of Indebtedness and Suits for Enforcement by Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The Company covenants that (i) in case it shall default in the payment of any installment of interest on any of the Securities of a series, or in any payment required by any sinking or analogous fund established with respect to that series as and when the same shall have become due and payable, and such default shall have continued for a period of 90 days, or (ii) in case it shall default in the payment of the principal of (or premium, if any, on) any of the Securities of a series when the same shall have become due and payable, whether upon maturity of the Securities of a series or upon redemption or upon declaration or otherwise then, upon demand of the Trustee, the Company will pay to the Trustee, for the benefit of the holders of the Securities of that series, the whole amount that then shall have been become due and payable on all such Securities for principal (and premium, if any) or interest, or both, as the case may be, with interest upon the overdue principal (and premium, if any) and (to the extent that payment of such interest is enforceable under applicable law) upon overdue installments of interest at the rate per annum expressed in the Securities of that series&#59; and, in addition thereto, such further amount as shall be sufficient to cover the costs and expenses of collection, and the amount payable to the Trustee under Section 7.06.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) If the Company shall fail to pay such amounts forthwith upon such demand, the Trustee, in its own name and as trustee of an express trust, shall be entitled and empowered to institute any action or proceedings at law or in equity for the collection of the sums so due and unpaid, and may prosecute any such action or proceeding to judgment or final decree, and may enforce any such judgment or final decree against the Company or other obligor upon the Securities of that series and collect the moneys adjudged or decreed to be payable in the manner provided by law or equity out of the property of the Company or other obligor upon the Securities of that series, wherever situated.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) In case of any receivership, insolvency, liquidation, bankruptcy, reorganization, readjustment, arrangement, composition or judicial proceedings affecting the Company, or its creditors or property, the Trustee shall have power to intervene in such proceedings and take any action therein that may be permitted by the court and shall (except as may be otherwise provided by law) be entitled to file such proofs of claim and other papers and documents as may be necessary or advisable in order to have the claims of the Trustee and of the holders of Securities of such series allowed for the entire amount due and payable by the Company under the Indenture at the date of institution of such proceedings and for any additional amount that may become due and payable by the Company after such date, and to collect and receive any moneys or other property payable or deliverable on any such claim, and to distribute the same after the deduction of the amount payable to the Trustee under Section 7.06&#59; and any receiver, assignee or trustee in bankruptcy or reorganization is hereby authorized by each</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the holders of Securities of such series to make such payments to the Trustee, and, in the event that the Trustee shall consent to the making of such payments directly to such Securityholders, to pay to the Trustee any amount due it under Section 7.06.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) All rights of action and of asserting claims under this Indenture, or under any of the terms established with respect to Securities of that series, may be enforced by the Trustee without the possession of any of such Securities, or the production thereof at any trial or other proceeding relative thereto, and any such suit or proceeding instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery of judgment shall, after provision for payment to the Trustee of any amounts due under Section 7.06, be for the ratable benefit of the holders of the Securities of such series.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In case of an Event of Default hereunder, the Trustee may in its discretion proceed to protect and enforce the rights vested in it by this Indenture by such appropriate judicial proceedings as the Trustee shall deem most effectual to protect and enforce any of such rights, either at law or in equity or in bankruptcy or otherwise, whether for the specific enforcement of any covenant or agreement contained in the Indenture or in aid of the exercise of any power granted in this Indenture, or to enforce any other legal or equitable right vested in the Trustee by this Indenture or by law.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nothing contained herein shall be deemed to authorize the Trustee to authorize or consent to or accept or adopt on behalf of any Securityholder any plan of reorganization, arrangement, adjustment or composition affecting the Securities of that series or the rights of any holder thereof or to authorize the Trustee to vote in respect of the claim of any Securityholder in any such proceeding.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 6.03 Application of Moneys Collected</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any moneys collected by the Trustee pursuant to this Article with respect to a particular series of Securities shall be applied in the following order, at the date or dates fixed by the Trustee and, in case of the distribution of such moneys on account of principal (or premium, if any) or interest, upon presentation of the Securities of that series, and notation thereon of the payment, if only partially paid, and upon surrender thereof if fully paid&#58;</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FIRST&#58; To the payment of all indebtedness of the Company to which such series of Securities is subordinated to the extent required by Section 7.06 and Article Fourteen&#59;</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECOND&#58; To the payment of the amounts then due and unpaid upon Securities of such series for principal (and premium, if any) and interest, in respect of which or for the benefit of which such money has been collected, ratably, without preference or priority of any kind, according to the amounts due and payable on such Securities for principal (and premium, if any) and interest, respectively&#59; and</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIRD&#58; To the payment of the remainder, if any, to the Company or any other Person lawfully entitled thereto.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 6.04 Limitation on Suits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No holder of any Security of any series shall have any right by virtue or by availing of any provision of this Indenture to institute any suit, action or proceeding in equity or at law upon or under or with respect to this Indenture or for the appointment of a receiver or trustee, or for any other remedy hereunder, unless (i) such holder previously shall have given to the Trustee written notice of an Event of Default and of the continuance thereof with respect to the Securities of such series specifying such Event of Default, as hereinbefore provided&#59; (ii) the holders of not less than 25% in aggregate principal amount of the Securities of such series then Outstanding shall have made written request upon the Trustee to institute such action, suit or proceeding in its own name as Trustee hereunder&#59; (iii) such holder or holders shall have offered to the Trustee such reasonable indemnity as it may require against the costs, expenses and liabilities to be incurred therein or thereby&#59; (iv) the Trustee for 90 days after its receipt of such notice, request and offer of indemnity, shall have failed to institute any such action, suit or proceeding and (v) during such 90 day period, the holders of a majority in principal amount of the Securities of that series do not give the Trustee a direction inconsistent with the request.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding anything contained herein to the contrary or any other provisions of this Indenture, the right of any holder of any Security to receive payment of the principal of (and premium, if any) and interest on such Security, as therein provided, on or after the respective due dates expressed in such Security (or in the case of redemption, on the redemption date), or to institute suit for the enforcement of any such payment on or after such respective dates or redemption date, shall not be</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impaired or affected without the consent of such holder and by accepting a Security hereunder it is expressly understood, intended and covenanted by the taker and holder of every Security of such series with every other such taker and holder and the Trustee, that no one or more holders of Securities of such series shall have any right in any manner whatsoever by virtue or by availing of any provision of this Indenture to affect, disturb or prejudice the rights of the holders of any other of such Securities, or to obtain or seek to obtain priority over or preference to any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other such holder, or to enforce any right under this Indenture, except in the manner herein provided and for the equal, ratable and common benefit of all holders of Securities of such series. For the protection and enforcement of the provisions of this Section, each and every Securityholder and the Trustee shall be entitled to such relief as can be given either at law or in equity.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 6.05 Rights and Remedies Cumulative&#59; Delay or Omission Not Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Except as otherwise provided in Section 2.07, all powers and remedies given by this Article to the Trustee or to the Securityholders shall, to the extent permitted by law, be deemed cumulative and not exclusive of any other powers and remedies available to the Trustee or the holders of the Securities, by judicial proceedings or otherwise, to enforce the performance or observance of the covenants and agreements contained in this Indenture or otherwise established with respect to such Securities.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) No delay or omission of the Trustee or of any holder of any of the Securities to exercise any right or power accruing upon any Event of Default occurring and continuing as aforesaid shall impair any such right or power, or shall be construed to be a waiver of any such default or an acquiescence therein&#59; and, subject to the provisions of Section 6.04, every power and remedy given by this Article or by law to the Trustee or the Securityholders may be exercised from time to time, and as often as shall be deemed expedient, by the Trustee or by the Securityholders.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 6.06 Control by Securityholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of a majority in aggregate principal amount of the Securities of any series at the time Outstanding, determined in accordance with Section 8.04, shall have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred on the Trustee with respect to such series&#59; provided, however, that such direction shall not be in conflict with any rule of law or with this Indenture. Subject to the provisions of Section 7.01, the Trustee shall have the right to decline to follow any such direction if the Trustee in good faith shall, by a Responsible Officer or officers of the Trustee, determine that the proceeding so directed, subject to the Trustee's duties under the Trust Indenture Act, would involve the Trustee in personal liability or might be unduly prejudicial to the Securityholders not involved in the proceeding. The holders of a majority in aggregate principal amount of the Securities of any series at the time Outstanding affected thereby, determined in accordance with Section 8.04, may on behalf of the holders of all of the Securities of such series waive any past default in the performance of any of the covenants contained herein or established pursuant to Section 2.01 with respect to such series and its consequences, except a default in the payment of the principal of, or premium, if any, or interest on, any of the Securities of that series as and when the same shall become due by the terms of such Securities otherwise than by acceleration (unless such default has been cured and a sum sufficient to pay all matured installments of interest and principal and any premium has been deposited with the Trustee (in accordance with Section 6.01(c)). Upon any such waiver, the default covered thereby shall be deemed to be cured for all purposes of this Indenture and the Company, the Trustee and the holders of the Securities of such series shall be restored to their former positions and rights hereunder, respectively&#59; but no such waiver shall extend to any subsequent or other default or impair any right consequent thereon.</font></div><div style="padding-left:21.6pt;text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 6.07 Undertaking to Pay Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All parties to this Indenture agree, and each holder of any Securities by such holder's acceptance thereof shall be deemed to have agreed, that any court may in its discretion require, in any suit for the enforcement of any right or remedy under this Indenture, or in any suit against the Trustee for any action taken or omitted by it as Trustee, the filing by any party litigant in such suit of an undertaking to pay the costs of such suit, and that such court may in its discretion assess reasonable costs, including reasonable attorneys' fees, against any party litigant in such suit, having due regard to the merits and good faith of the claims or defenses made by such party litigant&#59; but the provisions of this Section shall not apply to any suit instituted by the Trustee, to any suit instituted by any Securityholder, or group of Securityholders, holding more than 10% in aggregate principal amount of the Outstanding Securities of any series, or to any suit instituted by any Securityholder for the enforcement of the payment of the principal of (or premium, if any) or interest on any Security of such series, on or after the respective due dates expressed in such Security or established pursuant to this Indenture.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE 7</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONCERNING THE TRUSTEE</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.01 Certain Duties and Responsibilities of Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The Trustee, prior to the occurrence of an Event of Default with respect to the Securities of a series and after the curing of all Events of Default with respect to the Securities of that series that may have occurred, shall undertake to perform with respect to the Securities of such series such duties and only such duties as are specifically set forth in this Indenture, and no implied covenants shall be read into this Indenture against the Trustee. In case an Event of Default with respect to the Securities of a series has occurred (that has not been cured or waived), the Trustee shall exercise with respect to Securities of that series such of the rights and powers vested in it by this Indenture, and use the same degree of care and skill in their exercise, as a prudent man would exercise or use under the circumstances in the conduct of his own affairs.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) No provision of this Indenture shall be construed to relieve the Trustee from liability for its own negligent action, its own negligent failure to act, or its own willful misconduct, except that&#58;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) prior to the occurrence of an Event of Default with respect to the Securities of a series and after the curing or waiving of all such Events of Default with respect to that series that may have occurred&#58;(A) the duties and obligations of the Trustee shall with respect to the Securities of such series be determined solely by the express provisions of this Indenture, and the Trustee shall not be liable with respect to the Securities of such series except for the performance of such duties and obligations as are specifically set forth in this Indenture, and no implied covenants or obligations shall be read into this Indenture against the Trustee&#59; and (B) in the absence of bad faith on the part of the Trustee, the Trustee may with respect to the Securities of such series conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon any certificates or opinions furnished to the Trustee and conforming to the requirements of this Indenture&#59; but in the case of any such certificates or opinions that by any provision hereof are specifically required to be furnished to the Trustee, the Trustee shall be under a duty to examine the same to determine whether or not they conform to the requirements of this Indenture&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) the Trustee shall not be liable for any error of judgment made in good faith by a Responsible Officer or Responsible Officers of the Trustee, unless it shall be proved that the Trustee was negligent in ascertaining the pertinent facts&#59;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) the Trustee shall not be liable with respect to any action taken or omitted to be taken by it in good faith in accordance with the direction of the holders of not less than a majority in principal amount of the Securities of any series at the time Outstanding relating to the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred upon the Trustee under this Indenture with respect to the Securities of that series&#59; and</font></div><div style="text-indent:70.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv) None of the provisions contained in this Indenture shall require the Trustee to expend or risk its own funds or otherwise incur personal financial liability in the performance of any of its duties or in the exercise of any of its rights or powers if there is reasonable ground for believing that the repayment of such funds or liability is not reasonably assured to it under the terms of this Indenture or adequate indemnity against such risk is not reasonably assured to it.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.02 Certain Rights of Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise provided in Section 7.01&#58;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The Trustee may rely and shall be protected in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, consent, order, approval, bond, security or other paper or document believed by it to be genuine and to have been signed or presented by the proper party or parties&#59;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any request, direction, order or demand of the Company mentioned herein shall be sufficiently evidenced by a Board Resolution or an instrument signed in the name of the Company by any authorized officer of the Company (unless other evidence in respect thereof is specifically prescribed herein)&#59;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) The Trustee may consult with counsel and the written advice of such counsel or, if requested, any Opinion of Counsel shall be full and complete authorization and protection in respect of any action taken or suffered or omitted hereunder in good faith and in reliance thereon&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) The Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the request, order or direction of any of the Securityholders pursuant to the provisions of this Indenture, unless such Securityholders shall have offered to the Trustee reasonable security or indemnity against the costs, expenses and liabilities that may be incurred therein or thereby&#59; nothing contained herein shall, however, relieve the Trustee of the obligation, upon the occurrence of an Event of Default with respect to a series of the Securities (that has not been cured or waived), to exercise with respect to Securities of that series such of the rights and powers vested in it by this Indenture, and to use the same degree of care and skill in their exercise, as a prudent man would exercise or use under the circumstances in the conduct of his own affairs&#59;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e) The Trustee shall not be liable for any action taken or omitted to be taken by it in good faith and believed by it to be authorized or within the discretion or rights or powers conferred upon it by this Indenture&#59;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f) The Trustee shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request, consent, order, approval, bond, security, or other papers or documents, unless requested in writing so to do by the holders of not less than a majority in principal amount of the Outstanding Securities of the particular series affected thereby (determined as provided in Section 8.04)&#59; provided, however, that if the payment within a reasonable time to the Trustee of the costs, expenses or liabilities likely to be incurred by it in the making of such investigation is, in the opinion of the Trustee, not reasonably assured to the Trustee by the security afforded to it by the terms of this Indenture, the Trustee may require reasonable indemnity against such costs, expenses or liabilities as a condition to so proceeding. The reasonable expense of every such examination shall be paid by the Company or, if paid by the Trustee, shall be repaid by the Company upon demand&#59; and</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g) The Trustee may execute any of the trusts or powers hereunder or perform any duties hereunder either directly or by or through agents or attorneys and the Trustee shall not be responsible for any misconduct or negligence on the part of any agent or attorney appointed with due care by it hereunder.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Trustee shall not be deemed to have knowledge of any Default or Event of Default except (1) any Event of Default occurring pursuant to Sections 6.01(a)(1) and 6.01(a)(2) or (2) any Default or Event of Default of which the Trustee shall have received written notification in the manner set forth in this Indenture or a Responsible Officer of the Trustee shall have obtained actual knowledge. Delivery of reports, information and documents to the Trustee under Section 5.03 is for informational purposes only and the information and the Trustee's receipt of the foregoing shall not constitute constructive notice of any information contained therein, or determinable from information contained therein including the Company's compliance with any of their covenants thereunder (as to which the Trustee is entitled to rely exclusively on an Officer's Certificate).</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.03 Trustee Not Responsible for Recitals or Issuance or Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The recitals contained herein and in the Securities shall be taken as the statements of the Company, and the Trustee assumes no responsibility for the correctness of the same.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The Trustee makes no representations as to the validity or sufficiency of this Indenture or of the Securities.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) The Trustee shall not be accountable for the use or application by the Company of any of the Securities or of the proceeds of such Securities, or for the use or application of any moneys paid over by the Trustee in accordance with any provision of this Indenture or established pursuant to Section 2.01, or for the use or application of any moneys received by any paying agent other than the Trustee.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.04 May Hold Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trustee or any paying agent or Security Registrar, in its individual or any other capacity, may become the owner or pledgee of Securities with the same rights it would have if it were not Trustee, paying agent or Security Registrar.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.05 Moneys Held in Trust</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the provisions of Section 11.05, all moneys received by the Trustee shall, until used or applied as herein provided, be held in trust for the purposes for which they were received, but need not be segregated from other funds except to the extent required by law. The Trustee shall be under no liability for interest on any moneys received by it hereunder except such as it may agree with the Company to pay thereon.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.06 Compensation and Reimbursement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The Company covenants and agrees to pay to the Trustee, and the Trustee shall be entitled to, such reasonable compensation (which shall not be limited by any provision of law in regard to the compensation of a trustee of an express trust) as the Company and the Trustee may from time to time agree in writing, for all services rendered by it in the execution of the trusts hereby created and in the exercise and performance of any of the powers and duties hereunder of the Trustee, and, except as otherwise expressly provided herein, the Company will pay or reimburse the Trustee upon its request for all reasonable expenses, disbursements and advances incurred or made by the Trustee in accordance with any of the provisions of this Indenture (including the reasonable compensation and the expenses and disbursements of its counsel and of all Persons not regularly in its employ), except any such expense, disbursement or advance as may arise from its negligence or bad faith and except as the Company and Trustee may from time to time agree in writing. The Company also covenants to indemnify the Trustee (and its officers, agents, directors and employees) for, and to hold it harmless against, any loss, liability or expense incurred without negligence or bad faith on the part of the Trustee and arising out of or in connection with the acceptance or administration of this trust, including the reasonable costs and expenses of defending itself against any claim of liability in the premises.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The obligations of the Company under this Section to compensate and indemnify the Trustee and to pay or reimburse the Trustee for reasonable expenses, disbursements and advances shall constitute indebtedness of the Company to which the Securities are subordinated. Such additional indebtedness shall be secured by a lien prior to that of the Securities upon all property and funds held or collected by the Trustee as such, except funds held in trust for the benefit of the holders of particular Securities.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.07 Reliance on Officer's Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise provided in Section 7.01, whenever in the administration of the provisions of this Indenture the Trustee shall deem it reasonably necessary or desirable that a matter be proved or established prior to taking or suffering or omitting to take any action hereunder, such matter (unless other evidence in respect thereof be herein specifically prescribed) may, in the absence of negligence or bad faith on the part of the Trustee, be deemed to be conclusively proved and established by an Officer's Certificate delivered to the Trustee and such certificate, in the absence of negligence or bad faith on the part of the Trustee, shall be full warrant to the Trustee for any action taken, suffered or omitted to be taken by it under the provisions of this Indenture upon the faith thereof.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.08 Disqualification&#59; Conflicting Interests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Trustee has or shall acquire any &#34;conflicting interest&#34; within the meaning of Section 310(b) of the Trust Indenture Act, the Trustee and the Company shall in all respects comply with the provisions of Section 310(b) of the Trust Indenture Act.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.09 Corporate Trustee Required&#59; Eligibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There shall at all times be a Trustee with respect to the Securities issued hereunder which shall at all times be a corporation organized and doing business under the laws of the United States of America or any state or territory thereof or of the District of Columbia, or a corporation or other Person permitted to act as trustee by the Securities and Exchange Commission, authorized under such laws to exercise corporate trust powers, having a combined capital and surplus of at least fifty million U.S. dollars ($50,000,000), and subject to supervision or examination by federal, state, territorial, or District of Columbia authority.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If such corporation or other Person publishes reports of condition at least annually, pursuant to law or to the requirements of the aforesaid supervising or examining authority, then for the purposes of this Section, the combined capital and surplus of such corporation or other Person shall be deemed to be its combined capital and surplus as set forth in its most recent report of condition so published. The Company may not, nor may any Person directly or indirectly controlling, controlled by, or under common control with the Company, serve as Trustee. In case at any time the Trustee shall cease to be eligible in accordance with the provisions of this Section, the Trustee shall resign immediately in the manner and with the effect specified in Section 7.10.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.10 Resignation and Removal&#59; Appointment of Successor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The Trustee or any successor hereafter appointed may at any time resign with respect to the Securities of one or more series by giving written notice thereof to the Company and by transmitting notice of resignation by mail, first class postage prepaid, to the Securityholders of such series, as their names and addresses appear upon the Security Register. Upon receiving such notice of resignation, the Company shall promptly appoint a successor trustee with respect to Securities of such series by written instrument, in duplicate, executed by order of the Board of Directors, one copy of which instrument shall be delivered to the resigning Trustee and one copy to the successor trustee. If no successor trustee shall have been so appointed and have accepted appointment within 30 days after the mailing of such notice of resignation, the resigning Trustee may petition any court of competent jurisdiction for the appointment of a successor trustee with respect to Securities of such series, or any Securityholder of that series who has been a bona fide holder of a Security or Securities for at least six months may on behalf of himself and all others similarly situated, petition any such court for the appointment of a successor trustee. Such court may thereupon after such notice, if any, as it may deem proper and prescribe, appoint a successor trustee.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) In case at any time any one of the following shall occur&#58;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) the Trustee shall fail to comply with the provisions of Section 7.08 after written request therefor by the Company or by any Securityholder who has been a bona fide holder of a Security or Securities for at least six months&#59; or</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) the Trustee shall cease to be eligible in accordance with the provisions of Section 7.09 and shall fail to resign after written request therefor by the Company or by any such Securityholder&#59; or</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) the Trustee shall become incapable of acting, or shall be adjudged a bankrupt or insolvent, or commence a voluntary bankruptcy proceeding, or a receiver of the Trustee or of its property shall be appointed or consented to, or any public officer shall take charge or control of the Trustee or of its property or affairs for the purpose of rehabilitation, conservation or liquidation&#59;</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">then, in any such case, the Company may remove the Trustee with respect to all Securities and appoint a successor trustee by written instrument, in duplicate, executed by order of the Board of Directors, one copy of which instrument shall be delivered to the Trustee so removed and one copy to the successor trustee, or any Securityholder who has been a bona fide holder of a Security or Securities for at least six months may, on behalf of that holder and all others similarly situated, petition any court of competent jurisdiction for the removal of the Trustee and the appointment of a successor trustee. Such court may thereupon after such notice, if any, as it may deem proper and prescribe, remove the Trustee and appoint a successor trustee.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) The holders of a majority in aggregate principal amount of the Securities of any series at the time Outstanding may at any time remove the Trustee with respect to such series by so notifying the Trustee and the Company and may appoint a successor Trustee for such series with the consent of the Company.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Any resignation or removal of the Trustee and appointment of a successor trustee with respect to the Securities of a series pursuant to any of the provisions of this Section shall become effective upon acceptance of appointment by the successor trustee as provided in Section 7.11.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e) Any successor trustee appointed pursuant to this Section may be appointed with respect to the Securities of one or more series or all of such series, and at any time there shall be only one Trustee with respect to the Securities of any particular series.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.11 Acceptance of Appointment By Successor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) In case of the appointment hereunder of a successor trustee with respect to all Securities, every such successor trustee so appointed shall execute, acknowledge and deliver to the Company and to the retiring Trustee an instrument accepting such appointment, and thereupon the resignation or removal of the retiring Trustee shall become effective and such successor trustee, without any further act, deed or conveyance, shall become vested with all the rights, powers, trusts and duties of the retiring Trustee&#59; but, on the request of the Company or the successor trustee, such retiring Trustee shall, upon payment of its charges, execute and deliver an instrument transferring to such successor trustee all the rights, powers, and trusts of the retiring Trustee and shall duly assign, transfer and deliver to such successor trustee all property and money held by such retiring Trustee hereunder.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) In case of the appointment hereunder of a successor trustee with respect to the Securities of one or more (but not all) series, the Company, the retiring Trustee and each successor trustee with respect to the Securities of one or more series shall execute and deliver an indenture supplemental hereto wherein each successor trustee shall accept such appointment and which (i) shall contain such provisions as shall be necessary or desirable to transfer and confirm to, and to vest in, each successor trustee all the rights, powers, trusts and duties of the retiring Trustee with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respect to the Securities of that or those series to which the appointment of such successor trustee relates, (ii) shall contain such provisions as shall be deemed necessary or desirable to confirm that all the rights, powers, trusts and duties of the retiring Trustee with respect to the Securities of that or those series as to which the retiring Trustee is not retiring shall continue to be vested in the retiring Trustee, and (iii) shall add to or change any of the provisions of this Indenture as shall be necessary to provide for or facilitate the administration of the trusts hereunder by more than one Trustee, it being understood that nothing herein or in such supplemental indenture shall constitute such Trustees co-trustees of the same trust, that each such Trustee shall be trustee of a trust or trusts hereunder separate and apart from any trust or trusts hereunder administered by any other such Trustee and that no Trustee shall be responsible for any act or failure to act on the part of any other Trustee hereunder&#59; and upon the execution and delivery of such supplemental indenture the resignation or removal of the retiring Trustee shall become effective to the extent provided therein, such retiring Trustee shall with respect to the Securities of that or those series to which the appointment of such successor trustee relates have no further responsibility for the exercise of rights and powers or for the performance of the duties and obligations vested in the Trustee under this Indenture, and each such successor trustee, without any further act, deed or conveyance, shall become vested with all the rights, powers, trusts and duties of the retiring Trustee with respect to the Securities of that or those series to which the appointment of such successor trustee relates&#59; but, on request of the Company or any successor trustee, such retiring Trustee shall duly assign, transfer and deliver to such successor trustee, to the extent contemplated by such supplemental indenture, the property and money held by such retiring Trustee hereunder with respect to the Securities of that or those series to which the appointment of such successor trustee relates.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:43.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Upon request of any such successor trustee, the Company shall execute any and all instruments for more fully and certainly vesting in and confirming to such successor trustee all such rights, powers and trusts referred to in paragraph (a) or (b) of this Section, as the case may be.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) No successor trustee shall accept its appointment unless at the time of such acceptance such successor trustee shall be qualified and eligible under this Article.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e) Upon acceptance of appointment by a successor trustee as provided in this Section, the Company shall transmit notice of the succession of such trustee hereunder by mail, first class postage prepaid, to the Securityholders, as their names and addresses appear upon the Security Register. If the Company fails to transmit such notice within ten days after acceptance of appointment by the successor trustee, the successor trustee shall cause such notice to be transmitted at the expense of the Company.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.12 Merger, Conversion, Consolidation or Succession to Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any corporation into which the Trustee may be merged or converted or with which it may be consolidated, or any corporation resulting from any merger, conversion or consolidation to which the Trustee shall be a party, or any corporation succeeding to the corporate trust business of the Trustee, including the administration of the trust created by this Indenture, shall be the successor of the Trustee hereunder, provided that such corporation shall be qualified under the provisions of Section 7.08 and eligible under the provisions of Section 7.09, without the execution or filing of any paper or any further act on the part of any of the parties hereto, anything herein to the contrary notwithstanding. In case any Securities shall have been authenticated, but not delivered, by the Trustee then in office, any successor by merger, conversion or consolidation to such authenticating Trustee may adopt such authentication and deliver the Securities so authenticated with the same effect as if such successor Trustee had itself authenticated such Securities.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.13 Preferential Collection of Claims Against the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trustee shall comply with Section 311(a) of the Trust Indenture Act, excluding any creditor relationship described in Section 311(b) of the Trust Indenture Act. A Trustee who has resigned or been removed shall be subject to Section 311(a) of the Trust Indenture Act to the extent included therein.</font></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.14 Notice of Default</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any Default or any Event of Default occurs and is continuing and if such Default or Event of Default is known to a Responsible Officer of the Trustee, the Trustee shall mail to each Securityholder in the manner and to the extent provided in</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 313(c) of the Trust Indenture Act notice of the Default or Event of Default within the earlier of 90 days after it occurs and 30 days after it is known to a Responsible Officer of the Trustee or written notice of it is received by the Trustee, unless such Default or Event of Default has been cured&#59; provided, however, that, except in the case of a default in the payment of the principal of (or premium, if any) or interest on any Security, the Trustee shall be protected in withholding such notice if and so long as the board of directors, the executive committee or a trust committee of directors and&#47;or Responsible Officers of the Trustee in good faith determine that the withholding of such notice is in the interest of the Securityholders.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE 8</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONCERNING THE SECURITYHOLDERS</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.01 Evidence of Action by Securityholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whenever in this Indenture it is provided that the holders of a majority or specified percentage in aggregate principal amount of the Securities of a particular series may take any action (including the making of any demand or request, the giving of any notice, consent or waiver or the taking of any other action), the fact that at the time of taking any such action the holders of such majority or specified percentage of that series have joined therein may be evidenced by any instrument or any number of instruments of similar tenor executed by such holders of Securities of that series in person or by agent or proxy appointed in writing.</font></div><div style="padding-left:21.6pt;text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company shall solicit from the Securityholders of any series any request, demand, authorization, direction, notice, consent, waiver or other action, the Company may, at its option, as evidenced by an Officer's Certificate, fix in advance a record date for such series for the determination of Securityholders entitled to give such request, demand, authorization, direction, notice, consent, waiver or other action, but the Company shall have no obligation to do so. If such a record date is fixed, such request, demand, authorization, direction, notice, consent, waiver or other action may be given before or after the record date, but only the Securityholders of record at the close of business on the record date shall be deemed to be Securityholders for the purposes of determining whether Securityholders of the requisite proportion of Outstanding Securities of that series have authorized or agreed or consented to such request, demand, authorization, direction, notice, consent, waiver or other action, and for that purpose the Outstanding Securities of that series shall be computed as of the record date&#59; provided, however, that no such authorization, agreement or consent by such Securityholders on the record date shall be deemed effective unless it shall become effective pursuant to the provisions of this Indenture not later than six months after the record date.</font></div><div style="padding-left:4.4pt;text-indent:17.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.02 Proof of Execution by Securityholders.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the provisions of Section 7.01, proof of the execution of any instrument by a Securityholder (such proof will not require notarization) or his agent or proxy and proof of the holding by any Person of any of the Securities shall be sufficient if made in the following manner&#58;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The fact and date of the execution by any such Person of any instrument may be proved in any reasonable manner acceptable to the Trustee.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The ownership of Securities shall be proved by the Security Register of such Securities or by a certificate of the Security Registrar thereof.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trustee may require such additional proof of any matter referred to in this Section as it shall deem necessary.</font></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.03 Who May be Deemed Owners.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the due presentment for registration of transfer of any Security, the Company, the Trustee, any paying agent and any Security Registrar may deem and treat the Person in whose name such Security shall be registered upon the books of the Company as the absolute owner of such Security (whether or not such Security shall be overdue and notwithstanding any notice of ownership or writing thereon made by anyone other than the Security Registrar) for the purpose of receiving payment of or on account of the principal of, premium, if any, and (subject to Section 2.03) interest on such Security and for all other purposes&#59; and neither the Company nor the Trustee nor any paying agent nor any Security Registrar shall be affected by any notice to the contrary.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.04 Certain Securities Owned by Company Disregarded.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether the holders of the requisite aggregate principal amount of Securities of a particular series have concurred in any direction, consent or waiver under this Indenture, the Securities of that series that are owned by the Company or any other obligor on the Securities of that series or by any Person directly or indirectly controlling or controlled by or under common control with the Company or any other obligor on the Securities of that series shall be disregarded and deemed not to be Outstanding for the purpose of any such determination, except that for the purpose of determining whether the Trustee shall be protected in relying on any such direction, consent or waiver, only Securities of such series that the Trustee actually knows are so owned shall be so disregarded. The Securities so owned that have been pledged in good faith may be regarded as Outstanding for the purposes of this Section, if the pledgee shall establish to the satisfaction of the Trustee the pledgee's right so to act with respect to such Securities and that the pledgee is not a Person directly or indirectly controlling or controlled by or under direct or indirect common control with the Company or any such other obligor. In case of a dispute as to such right, any decision by the Trustee taken upon the advice of counsel shall be full protection to the Trustee.</font></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.05 Actions Binding on Future Securityholders.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time prior to (but not after) the evidencing to the Trustee, as provided in Section 8.01, of the taking of any action by the holders of the majority or percentage in aggregate principal amount of the Securities of a particular series specified in this Indenture in connection with such action, any holder of a Security of that series that is shown by the evidence to be included in the Securities the holders of which have consented to such action may, by filing written notice with the Trustee, and upon proof of holding as provided in Section 8.02, revoke such action so far as concerns such Security. Except as aforesaid any such action taken by the holder of any Security shall be conclusive and binding upon such holder and upon all future holders and owners of such Security, and of any Security issued in exchange therefor, on registration of transfer thereof or in place thereof, irrespective of whether or not any notation in regard thereto is made upon such Security. Any action taken by the holders of the majority or percentage in aggregate principal amount of the Securities of a particular series specified in this Indenture in connection with such action shall be conclusively binding upon the Company, the Trustee and the holders of all the Securities of that series.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE 9</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUPPLEMENTAL INDENTURES</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 9.01 Supplemental Indentures Without the Consent of Securityholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to any supplemental indenture otherwise authorized by this Indenture, the Company and the Trustee may from time to time and at any time enter into an indenture or indentures supplemental hereto (which shall conform to the provisions of the Trust Indenture Act as then in effect), without the consent of the Securityholders, for one or more of the following purposes&#58;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) to cure any ambiguity, defect, or inconsistency herein or in the Securities of any series&#59;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) to comply with Article Ten&#59;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) to provide for uncertificated Securities in addition to or in place of certificated Securities&#59;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) to add to the covenants, restrictions, conditions or provisions relating to the Company for the benefit of the holders of all or any series of Securities (and if such covenants, restrictions, conditions or provisions are to be for the benefit of less than all series of Securities, stating that such covenants, restrictions, conditions or provisions are expressly being included solely for the benefit of such series), to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an Event of Default, or to surrender any right or power herein conferred upon the Company&#59;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e) to add to, delete from, or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication, and delivery of Securities, as herein set forth&#59;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f) to make any change that does not adversely affect the rights of any Securityholder in any material respect&#59;</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g) to provide for the issuance of and establish the form and terms and conditions of the Securities of any series as provided in Section 2.01, to establish the form of any certifications required to be furnished pursuant to the terms of this Indenture or any series of Securities, or to add to the rights of the holders of any series of Securities&#59;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h) to evidence and provide for the acceptance of appointment hereunder by a successor trustee&#59; or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) to comply with any requirements of the Securities and Exchange Commission or any successor in connection with the qualification of this Indenture under the Trust Indenture Act.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trustee is hereby authorized to join with the Company in the execution of any such supplemental indenture, and to make any further appropriate agreements and stipulations that may be therein contained, but the Trustee shall not be obligated to enter into any such supplemental indenture that affects the Trustee's own rights, duties or immunities under this Indenture or otherwise.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any supplemental indenture authorized by the provisions of this Section may be executed by the Company and the Trustee without the consent of the holders of any of the Securities at the time Outstanding, notwithstanding any of the provisions of Section 9.02.</font></div><div style="padding-left:21.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 9.02 Supplemental Indentures With Consent of Securityholders.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the consent (evidenced as provided in Section 8.01) of the holders of not less than a majority in aggregate principal amount of the Securities of each series affected by such supplemental indenture or indentures at the time Outstanding, the Company, when authorized by a Board Resolution, and the Trustee may from time to time and at any time enter into an indenture or indentures supplemental hereto (which shall conform to the provisions of the Trust Indenture Act as then in effect) for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this Indenture or of any supplemental indenture or of modifying in any manner not covered by Section 9.01 the rights of the holders of the Securities of such series under this Indenture&#59; provided, however, that no such supplemental indenture shall, without the consent of the holders of each Security then Outstanding and affected thereby, (a) extend the fixed maturity of any Securities of any series, or reduce the principal amount thereof, or reduce the rate or extend the time of payment of interest thereon, or reduce any premium payable upon the redemption thereof or (b) reduce the aforesaid percentage of Securities, the holders of which are required to consent to any such supplemental indenture.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It shall not be necessary for the consent of the Securityholders of any series affected thereby under this Section to approve the particular form of any proposed supplemental indenture, but it shall be sufficient if such consent shall approve the substance thereof.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 9.03 Effect of Supplemental Indentures.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the execution of any supplemental indenture pursuant to the provisions of this Article or of Section 10.01, this Indenture shall, with respect to such series, be and be deemed to be modified and amended in accordance therewith and the respective rights, limitations of rights, obligations, duties and immunities under this Indenture of the Trustee, the Company and the holders of Securities of the series affected thereby shall thereafter be determined, exercised and enforced hereunder subject in all respects to such modifications and amendments, and all the terms and conditions of any such supplemental indenture shall be and be deemed to be part of the terms and conditions of this Indenture for any and all purposes.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 9.04 Securities Affected by Supplemental Indentures.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities of any series affected by a supplemental indenture, authenticated and delivered after the execution of such supplemental indenture pursuant to the provisions of this Article or of Section 10.01, may bear a notation in form approved by the Company, provided such form meets the requirements of any securities exchange upon which such series may be listed, as to any matter provided for in such supplemental indenture. If the Company shall so determine, new Securities of that series so modified as to conform, in the opinion of the Board of Directors, to any modification of this Indenture contained in any such supplemental indenture may be prepared by the Company, authenticated by the Trustee and delivered in exchange for the Securities of that series then Outstanding.</font></div><div style="padding-left:4.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 9.05 Execution of Supplemental Indentures.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the request of the Company, accompanied by its Board Resolutions authorizing the execution of any such supplemental indenture, and upon the filing with the Trustee of evidence of the consent of Securityholders required to consent thereto as aforesaid, the Trustee shall join with the Company in the execution of such supplemental indenture unless such supplemental indenture affects the Trustee's own rights, duties or immunities under this Indenture or otherwise, in which case</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Trustee may in its discretion but shall not be obligated to enter into such supplemental indenture. The Trustee, subject to the provisions of Section 7.01, may receive an Officer's Certificate or, if requested, an Opinion of Counsel as conclusive evidence that any supplemental indenture executed pursuant to this Article is authorized or permitted by, and conforms to, the terms of this Article and that it is proper for the Trustee under the provisions of this Article to join in the execution thereof&#59; provided, however, that such Officer's Certificate or Opinion of Counsel need not be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided in connection with the execution of a supplemental indenture that establishes the terms of a series of Securities pursuant to Section 2.01 hereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Promptly after the execution by the Company and the Trustee of any supplemental indenture pursuant to the provisions of this Section, the Trustee shall transmit by mail, first class postage prepaid, a notice, setting forth in general terms the substance of such supplemental indenture, to the Securityholders of all series affected thereby as their names and addresses appear upon the Security Register. Any failure of the Trustee to mail such notice, or any defect therein, shall not, however, in any way impair or affect the validity of any such supplemental indenture.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE 10</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUCCESSOR ENTITY</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 10.01 Company May Consolidate, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as provided pursuant to Section 2.01 pursuant to a Board Resolution, and set forth in an Officer's Certificate, or established in one or more indentures supplemental to this Indenture, nothing contained in this Indenture shall prevent any consolidation or merger of the Company with or into any other Person (whether or not affiliated with the Company) or successive consolidations or mergers in which the Company or its successor or successors shall be a party or parties, or shall prevent any sale, conveyance, transfer or other disposition of the property of the Company or its successor or successors as an entirety, or substantially as an entirety, to any other corporation (whether or not affiliated with the Company or its successor or successors) authorized to acquire and operate the same&#59; provided, however, (a) the Company hereby covenants and agrees that, upon any such consolidation or merger (in each case, if the Company is not the survivor of such transaction), sale, conveyance, transfer or other disposition, the due and punctual payment of the principal of (premium, if any) and interest on all of the Securities of all series in accordance with the terms of each series, according to their tenor, and the due and punctual performance and observance of all the covenants and conditions of this Indenture with respect to each series or established with respect to such series pursuant to Section 2.01 to be kept or performed by the Company shall be expressly assumed, by supplemental indenture (which shall conform to the provisions of the Trust Indenture Act, as then in effect) reasonably satisfactory in form to the Trustee executed and delivered to the Trustee by the entity formed by such consolidation, or into which the Company shall have been merged, or by the entity which shall have acquired such property and (b) in the event that the Securities of any series then Outstanding are convertible into or exchangeable for shares of common stock or other securities of the Company, such entity shall, by such supplemental indenture, make provision so that the Securityholders of Securities of that series shall thereafter be entitled to receive upon conversion or exchange of such Securities the number of securities or property to which a holder of the number of shares of common stock or other securities of the Company deliverable upon conversion or exchange of those Securities would have been entitled had such conversion or exchange occurred immediately prior to such consolidation, merger, sale, conveyance, transfer or other disposition.</font></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 10.02 Successor Entity Substituted.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) In case of any such consolidation, merger, sale, conveyance, transfer or other disposition and upon the assumption by the successor entity by supplemental indenture, executed and delivered to the Trustee and satisfactory in form to the Trustee, of the obligations set forth under Section 10.01 on all of the Securities of all series Outstanding, such successor entity shall succeed to and be substituted for the Company with the same effect as if it had been named as the Company herein, and thereupon the predecessor corporation shall be relieved of all obligations and covenants under this Indenture and the Securities.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) In case of any such consolidation, merger, sale, conveyance, transfer or other disposition, such changes in phraseology and form (but not in substance) may be made in the Securities thereafter to be issued as may be appropriate.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Nothing contained in this Article shall require any action by the Company in the case of a consolidation or merger of any Person into the Company where the Company is the survivor of such transaction, or the acquisition by the Company, by purchase or otherwise, of all or any part of the property of any other Person (whether or not affiliated with the Company).</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 10.03 Evidence of Consolidation, Etc. to Trustee.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trustee, subject to the provisions of Section 7.01, may receive an Officer's Certificate and, if requested, an Opinion of Counsel as conclusive evidence that any such consolidation, merger, sale, conveyance, transfer or other disposition, and any such assumption, comply with the provisions of this Article.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE 11</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SATISFACTION AND DISCHARGE</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 11.01 Satisfaction and Discharge of Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If at any time&#58; (a) the Company shall have delivered to the Trustee for cancellation all Securities of a series theretofore authenticated and not delivered to the Trustee for cancellation (other than any Securities that shall have been destroyed, lost or stolen and that shall have been replaced or paid as provided in Section 2.07 and Securities for whose payment money or Governmental Obligations have theretofore been deposited in trust or segregated and held in trust by the Company and thereupon repaid to the Company or discharged from such trust, as provided in Section 11.05)&#59; or (b) all such Securities of a particular series not theretofore delivered to the Trustee for cancellation shall have become due and payable, or are by their terms to become due and payable within one year or are to be called for redemption within one year under arrangements satisfactory to the Trustee for the giving of notice of redemption, and the Company shall deposit or cause to be deposited with the Trustee as trust funds the entire amount in moneys or Governmental Obligations or a combination thereof, sufficient in the opinion of a nationally recognized firm of independent public accountants expressed in a written certification thereof delivered to the Trustee, to pay at maturity or upon redemption all Securities of that series not theretofore delivered to the Trustee for cancellation, including principal (and premium, if any) and interest due or to become due to such date of maturity or date fixed for redemption, as the case may be, and if the Company shall also pay or cause to be paid all other sums payable hereunder with respect to such series by the Company then this Indenture shall thereupon cease to be of further effect with respect to such series except for the provisions of Sections 2.03, 2.05, 2.07, 4.01, 4.02, 4.03 and 7.10, that shall survive until the date of maturity or redemption date, as the case may be, and Sections 7.06 and 11.05, that shall survive to such date and thereafter, and the Trustee, on demand of the Company and at the cost and expense of the Company shall execute proper instruments acknowledging satisfaction of and discharging this Indenture with respect to such series.</font></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 11.02 Discharge of Obligations.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If at any time all such Securities of a particular series not heretofore delivered to the Trustee for cancellation or that have not become due and payable as described in Section 11.01 shall have been paid by the Company by depositing irrevocably with the Trustee as trust funds moneys or an amount of Governmental Obligations sufficient to pay at maturity or upon redemption all such Securities of that series not theretofore delivered to the Trustee for cancellation, including principal (and premium, if any) and interest due or to become due to such date of maturity or date fixed for redemption, as the case may be, and if the Company shall also pay or cause to be paid all other sums payable hereunder by the Company with respect to such series, then after the date such moneys or Governmental Obligations, as the case may be, are deposited with the Trustee the obligations of the Company under this Indenture with respect to such series shall cease to be of further effect except for the provisions of Sections 2.03, 2.05, 2.07, 4,01, 4.02, 4,03, 7.06, 7.10 and 11.05 hereof that shall survive until such Securities shall mature and be paid.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter, Sections 7.06 and 11.05 shall survive.</font></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 11.03 Deposited Moneys to be Held in Trust.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All moneys or Governmental Obligations deposited with the Trustee pursuant to Sections 11.01 or 11.02 shall be held in trust and shall be available for payment as due, either directly or through any paying agent (including the Company acting as its own paying agent), to the holders of the particular series of Securities for the payment or redemption of which such moneys or Governmental Obligations have been deposited with the Trustee.</font></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 11.04 Payment of Moneys Held by Paying Agents.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the satisfaction and discharge of this Indenture all moneys or Governmental Obligations then held by any paying agent under the provisions of this Indenture shall, upon demand of the Company, be paid to the Trustee and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thereupon such paying agent shall be released from all further liability with respect to such moneys or Governmental Obligations.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 11.05 Repayment to Company.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any moneys or Governmental Obligations deposited with any paying agent or the Trustee, or then held by the Company, in trust for payment of principal of or premium, if any, or interest on the Securities of a particular series that are not applied but remain unclaimed by the holders of such Securities for at least two years after the date upon which the principal of (and premium, if any) or interest on such Securities shall have respectively become due and payable, or such other shorter period set forth in applicable escheat or abandoned or unclaimed property law, shall be repaid to the Company on May 31 of each year or upon the Company's request or (if then held by the Company) shall be discharged from such trust&#59; and thereupon the paying agent and the Trustee shall be released from all further liability with respect to such moneys or Governmental Obligations, and the holder of any of the Securities entitled to receive such payment shall thereafter, as a general creditor, look only to the Company for the payment thereof.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE 12</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 12.01 No Recourse</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No recourse under or upon any obligation, covenant or agreement of this Indenture, or of any Security, or for any claim based thereon or otherwise in respect thereof, shall be had against any incorporator, stockholder, officer or director, past, present or future as such, of the Company or of any predecessor or successor corporation, either directly or through the Company or any such predecessor or successor corporation, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise&#59; it being expressly understood that this Indenture and the obligations issued hereunder are solely corporate obligations, and that no such personal liability whatever shall attach to, or is or shall be incurred by, the incorporators, stockholders, officers or directors as such, of the Company or of any predecessor or successor corporation, or any of them, because of the creation of the indebtedness hereby authorized, or under or by reason of the obligations, covenants or agreements contained in this Indenture or in any of the Securities or implied therefrom&#59; and that any and all such personal liability of every name and nature, either at common law or in equity or by constitution or statute, of, and any and all such rights and claims against, every such incorporator, stockholder, officer or director as such, because of the creation of the indebtedness hereby authorized, or under or by reason of the obligations, covenants or agreements contained in this Indenture or in any of the Securities or implied therefrom, are hereby expressly waived and released as a condition of, and as a consideration for, the execution of this Indenture and the issuance of such Securities.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE 13</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MISCELLANEOUS PROVISIONS</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.01 Effect on Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All the covenants, stipulations, promises and agreements in this Indenture made by or on behalf of the Company shall bind its successors and assigns, whether so expressed or not.</font></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.02 Actions by Successor.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any act or proceeding by any provision of this Indenture authorized or required to be done or performed by any board, committee or officer of the Company shall and may be done and performed with like force and effect by the corresponding board, committee or officer of any corporation that shall at the time be the lawful successor of the Company.</font></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.03 Surrender of Company Powers.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company by instrument in writing executed by authority of its Board of Directors and delivered to the Trustee may surrender any of the powers reserved to the Company, and thereupon such power so surrendered shall terminate both as to the Company and as to any successor corporation.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.04 Notices.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise expressly provided herein, any notice, request or demand that by any provision of this Indenture is required or permitted to be given, made or served by the Trustee or by the holders of Securities or by any other Person pursuant to this Indenture to or on the Company may be given or served by being deposited in first class mail, postage prepaid, addressed (until another address is filed in writing by the Company with the Trustee), as follows&#58; . Any notice, election, request or demand by the Company or any Securityholder or by any other Person pursuant to this Indenture to or upon the Trustee shall be deemed to have been sufficiently given or made, for all purposes, if given or made in writing at the Corporate Trust Office of the Trustee.</font></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.05 Governing Law.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Indenture and each Security shall be deemed to be a contract made under the internal laws of the State of New York, and for all purposes shall be construed in accordance with the laws of said State, except to the extent that the Trust Indenture Act is applicable.</font></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.06 Treatment of Securities as Debt.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is intended that the Securities will be treated as indebtedness and not as equity for federal income tax purposes. The provisions of this Indenture shall be interpreted to further this intention.</font></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.07 Certificates and Opinions as to Conditions Precedent.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Upon any application or demand by the Company to the Trustee to take any action under any of the provisions of this Indenture, the Company shall furnish to the Trustee an Officer's Certificate stating that all conditions precedent provided for in this Indenture (other than the certificate to be delivered pursuant to Section 13.12) relating to the proposed action have been complied with and, if requested, an Opinion of Counsel stating that in the opinion of such counsel all such conditions precedent have been complied with, except that in the case of any such application or demand as to which the furnishing of such documents is specifically required by any provision of this Indenture relating to such particular application or demand, no additional certificate or opinion need be furnished.</font></div><div style="text-indent:47.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Each certificate or opinion provided for in this Indenture and delivered to the Trustee with respect to compliance with a condition or covenant in this Indenture shall include (i) a statement that the Person making such certificate or opinion has read such covenant or condition&#59; (ii) a brief statement as to the nature and scope of the examination or investigation upon which the statements or opinions contained in such certificate or opinion are based&#59; (iii) a statement that, in the opinion of such Person, he has made such examination or investigation as is reasonably necessary to enable him to express an informed opinion as to whether or not such covenant or condition has been complied with&#59; and (iv) a statement as to whether or not, in the opinion of such Person, such condition or covenant has been complied with.</font></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.08 Payments on Business Days.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as provided pursuant to Section 2.01 pursuant to a Board Resolution, and set forth in an Officer's Certificate, or established in one or more indentures supplemental to this Indenture, in any case where the date of maturity of interest or principal of any Security or the date of redemption of any Security shall not be a Business Day, then payment of interest or principal (and premium, if any) may be made on the next succeeding Business Day with the same force and effect as if made on the nominal date of maturity or redemption, and no interest shall accrue for the period after such nominal date.</font></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.09 Conflict with Trust Indenture Act.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If and to the extent that any provision of this Indenture limits, qualifies or conflicts with the duties imposed by Sections 310 to 317, inclusive, of the Trust Indenture Act, such imposed duties shall control.</font></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.10 Counterparts.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Indenture may be executed in any number of counterparts, each of which shall be an original, but such counterparts shall together constitute but one and the same instrument.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.11 Separability.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In case any one or more of the provisions contained in this Indenture or in the Securities of any series shall for any reason be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Indenture or of such Securities, but this Indenture and such Securities shall be construed as if such invalid or illegal or unenforceable provision had never been contained herein or therein.</font></div><div style="padding-left:4.4pt;text-indent:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.12 Compliance Certificates.</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company shall deliver to the Trustee, within 120 days after the end of each fiscal year during which any Securities of any series were outstanding, an officer's certificate stating whether or not the signers know of any Default or Event of Default that occurred during such fiscal year. Such certificate shall contain a certification from the principal executive officer, principal financial officer or principal accounting officer of the Company that a review has been conducted of the activities of the Company and the Company's performance under this Indenture and that the Company has complied with all conditions and covenants under this Indenture. For purposes of this Section 13.12, such compliance shall be determined without regard to any period of grace or requirement of notice provided under this Indenture. If the officer of the Company signing such certificate has knowledge of such a Default or Event of Default, the certificate shall describe any such Default or Event of Default and its status.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE 14</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBORDINATION OF SECURITIES</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 14.01 Subordination Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> .</font></div><div style="text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payment by the Company of the principal of, premium, if any, and interest on any series of Securities issued hereunder shall be subordinated to the extent set forth in an indenture supplemental hereto relating to such series.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="padding-left:21.6pt;text-indent:23.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">I N WITNESS W HEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> , the parties hereto have caused this Indenture to be duly executed all as of the day and year first above written.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY, INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRUSTEE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#93;, as Trustee</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</font></div><div><img alt="image_29.jpg" src="image_29.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:35.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.953%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>a51ex040522.htm
<DESCRIPTION>EX-5.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6f6ae13c27794569bb62272046dc8411_1"></div><div style="min-height:99pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit 5.1</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.881%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><img alt="image_02.jpg" src="image_02.jpg" style="height:31px;margin-bottom:5pt;vertical-align:text-bottom;width:230px"></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">Sheppard, Mullin, Richter &#38; Hampton LLP</font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">30 Rockefeller Plaza </font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">New York, New York 10112-0015</font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">212.653.8700 main</font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">212.653.8701 fax</font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">www.sheppardmullin.com</font></div></td></tr></table></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 5, 2022</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VIA ELECTRONIC MAIL</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11055 Flintkote Avenue</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, CA 92121</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Re&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registration Statement on Form&#160;S-3</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ladies and Gentlemen&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have acted as special counsel to  Cardiff Oncology, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), in connection with the automatic shelf Registration Statement on Form S-3 (as amended or supplemented, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), filed by the Company on April 5, 2022 with the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Commission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) under the Securities Act of 1933, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The Registration Statement relates to the proposed issuance and sale from time to time pursuant to Rule 415 under the Securities Act, as set forth in the Registration Statement, the prospectus contained therein (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Base Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and one or more supplements to the Base Prospectus (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Prospectus Supplement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and any free-writing prospectus(es) of up to $250,000,000 aggregate offering proceeds, of the following securities of the Company (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">shares of common stock, par value $0.0001 per share, of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">shares of preferred stock, par value $0.001 par value, of the Company, in one or more series or classes (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt securities, in one or more series (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Debt Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), which may be issued pursuant to an indenture to be dated on or about the date of the first issuance of Debt Securities thereunder, but which may not be guaranteed by any affiliates of the Company or any other person, by and between a trustee to be selected by the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and the Company, in the form filed as Exhibit 4.3 or Exhibit 4.4 to the Registration Statement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warrants to purchase Common Stock, Preferred Stock or Debt Securities (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), which may be issued under warrant agreements (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Warrant Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), to be dated on or about the date of the first issuance of the applicable Warrants thereunder, by and between the Company and a warrant agent to be selected by the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Warrant Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">units consisting of Common Stock, Preferred Stock, Debt Securities, or Warrants (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), which may be issued under unit agreements (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Unit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), to be dated on or about the date of the first issuance of the applicable Units thereunder, by and between the Company and the other parties thereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Unit Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also acting as counsel for the Company in connection with the sales agreement prospectus included in the Registration Statement (the &#8220;Sales Agreement Prospectus&#8221;) relating to the issuance and sale of shares of Common Stock having an aggregate offering price of up to $100,000,000 (the &#8220;Sales Agreement Shares&#8221;) under an Open Market Sale Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, dated March 12, 2021, between the Company and Jefferies LLC (the &#8220;Sales Agreement&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are delivering this opinion pursuant to the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-1-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:right"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.881%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><img alt="image_02.jpg" src="image_02.jpg" style="height:31px;margin-bottom:5pt;vertical-align:text-bottom;width:230px"></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">Sheppard, Mullin, Richter &#38; Hampton LLP</font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">30 Rockefeller Plaza </font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">New York, New York 10112-0015</font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">212.653.8700 main</font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">212.653.8701 fax</font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">www.sheppardmullin.com</font></div></td></tr></table></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this opinion, we have examined and relied upon originals, or copies certified to our satisfaction, of such records, documents, certificates, opinions, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. As to certain factual matters, we have relied upon certificates of officers of the Company and have not independently sought to verify such matters.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In rendering this opinion, we have assumed (i) the genuineness and authenticity of all signatures on original documents&#59; (ii) the authenticity of all documents submitted to us as originals&#59; (iii) the conformity to originals of all documents submitted to us as copies&#59; (iv) the accuracy, completeness and authenticity of certificates of public officials&#59; (v) the due authorization, execution and delivery of all documents where authorization, execution and delivery are prerequisites to the effectiveness of such documents&#59; (vi) that the Registration Statement and any required post-effective amendment thereto have all become effective under the Securities Act and the Base Prospectus, other than for the Sales Agreement Shares, any and all Prospectus Supplement(s) required by applicable laws and any and all free-writing prospectus(es) related to the offer and sale of the Securities have been delivered and filed as required by such laws&#59; (vii) that the issuance and sale of the Securities do not violate any applicable law, are in conformity with the Company&#8217;s then operative Certificate of Incorporation (as defined below) and bylaws, do not result in a default under or breach of any agreement or instrument binding upon the Company and comply with any applicable requirement or restriction imposed by any court or governmental body having jurisdiction over the Company or its properties or assets&#59; (viii) a prospectus supplement will have been prepared and filed with the Commission describing the Securities offered thereby&#59; (ix) other than for the Sales Agreement Shares, a definitive purchase, underwriting or similar agreement with respect to any Securities offered will have been duly authorized and validly executed and delivered by the Company and the other parties thereto, as applicable&#59; and (x) if the holders of the Debt Securities are granted rights to inspect corporate books and records and to vote in the election of directors or any matters on which stockholders of the Company may vote, such rights will be set forth in the Certificate of Incorporation or the Certificate of Incorporation grants to the Company&#8217;s Board of Directors the power to confer such voting or inspection rights and the Company&#8217;s Board of Directors will have conferred such rights.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our opinion as to the Common Stock or other Securities convertible into, exercisable for, or including Common Stock, we have been advised by the Company and for purposes of this opinion we have assumed that, at the time of issuance and sale, a sufficient number of shares of Common Stock are authorized and available for issuance and that the consideration for the issuance and sale of the Common Stock (or for Preferred Stock or Debt Securities convertible into Common Stock, or for Warrants exercisable for Common Stock, or Units consisting of or including Common Stock) is in an amount that is not less than the par value of the Common Stock. With respect to our opinion as to the Preferred Stock or other Securities convertible into, exercisable for, or including Preferred Stock, we have assumed that, (a) at the time of issuance and sale, a sufficient number of shares of Preferred Stock are authorized, designated and available for issuance and that the consideration for the issuance and sale of the Preferred Stock (or for Debt Securities convertible into Preferred Stock, or for Warrants exercisable for Preferred Stock or for Units consisting of or including Preferred Stock) is in an amount that is not less than the par value of the Preferred Stock, and (b) the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation privileges of each series of Preferred Stock will be set forth in a certificate of designation to be approved by the Company&#8217;s Board of Directors, or in an amendment to the Company&#8217;s then operative certificate of incorporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Certificate of Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), to be approved by the Company&#8217;s Board of Directors and stockholders, and that one or both of these documents will be filed either as an exhibit to an amendment to the Registration Statement to be filed after the date of this opinion or as an exhibit to a Current Report on Form 8-K to be filed after the Registration Statement has become effective. We have also assumed with respect to the Debt Securities offered under the Registration Statement and the related Indenture, that such securities will be executed in the form filed as an exhibit to the Registration Statement and that the Trustee under the Indenture shall have been qualified pursuant to the Trust Indenture Act of 1939 at the time the Debt Securities are offered or issued (or such later time as may be permitted pursuant to the rules, regulations, interpretations or positions of the Commission). We have also assumed that (i) with respect to Securities being issued upon conversion of any convertible Preferred Stock, the applicable convertible Preferred Stock will be duly authorized, validly issued, fully paid and nonassessable&#59; and (ii) with respect to any Securities being issued upon </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:right"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.881%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><img alt="image_02.jpg" src="image_02.jpg" style="height:31px;margin-bottom:5pt;vertical-align:text-bottom;width:230px"></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">Sheppard, Mullin, Richter &#38; Hampton LLP</font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">30 Rockefeller Plaza </font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">New York, New York 10112-0015</font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">212.653.8700 main</font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">212.653.8701 fax</font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">www.sheppardmullin.com</font></div></td></tr></table></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conversion of any convertible Debt Securities or upon exercise of any Warrants or relating to any Units, the applicable convertible Debt Securities or Warrants or Units will be valid and legally binding obligations of the Company, enforceable against the Company in accordance with their terms, except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting creditors&#8217; rights, and subject to general equity principles and to limitations on availability of equitable relief, including specific performance. We have also assumed with respect to the Warrants offered under the Registration Statement, that (a) such Warrants will be issued pursuant to a Warrant Agreement, (b) the Warrant Agreement will be filed either as an exhibit to an amendment to the Registration Statement to be filed after the date of this opinion or as an exhibit to a Current Report on Form 8-K to be filed after the Registration Statement has become effective, and (c) the particular terms of any series of Warrants will be set forth in a supplement to the prospectus forming a part of the Registration Statement. We have also assumed with respect to the Units offered under the Registration Statement, that (a) such Units will be issued pursuant to a Unit Agreement, (b) the Unit Agreement will be filed either as an exhibit to an amendment to the Registration Statement to be filed after the date of this opinion or as an exhibit to a Current Report on Form 8-K to be filed after the Registration Statement has become effective, and (c) the particular terms of any series of Units will be set forth in a supplement to the prospectus forming a part of the Registration Statement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary, our opinion herein is expressed solely with respect to the federal laws of the United States, the Delaware General Corporation Law and, as to the Debt Securities constituting valid and legally binding obligations of the Company, solely with respect to the laws of the State of New York. We express no opinion as to any provision of the Debt Securities that&#58; (a) relates to the subject matter jurisdiction of any federal court of the United States of America or any federal appellate court to adjudicate any controversy related to the Debt Securities or (b) contains a waiver of an inconvenient forum. We express no opinion as to whether the laws of any jurisdiction are applicable to the subject matter hereof. We are not rendering any opinion as to compliance with any federal or state law, rule or regulation relating to securities, or to the sale or issuance thereof. We express no opinions concerning (i) the validity or enforceability of any provisions contained in indentures that purport to waive or not give effect to rights to notices, defenses, subrogation or other rights or benefits that cannot be effectively waived under applicable law&#59; or (ii) the validity or enforceability of any provisions contained in Warrant Agreements or Unit Agreements that purport to waive or not give effect to rights to notices, defenses, subrogation or other rights or benefits that cannot be effectively waived under applicable law.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On the basis of the foregoing and in reliance thereon, and subject to the qualifications herein stated, we are of the opinion that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">With respect to the Common Stock offered under the Registration Statement, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(other than the Sales Agreement Shares) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided that (i) the issuance of the Common Stock has been duly authorized by all necessary corporate action on the part of the Company&#59; and (ii) the certificates for the Common Stock have been duly executed by the Company, countersigned by the transfer agent therefor and duly delivered to the purchasers thereof against the requisite payment therefor, which the Company has received, the Common Stock, when issued and sold as contemplated in the Registration Statement, the Base Prospectus and the related Prospectus Supplement(s) and any related free-writing prospectus(es) and in accordance with any applicable duly authorized, executed and delivered purchase, underwriting or similar agreement, or upon conversion of any convertible Preferred Stock or convertible Debt Securities in accordance with their terms, or upon exercise of any Warrants in accordance with their terms, will be duly authorized, validly issued, fully paid and nonassessable.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">With respect to the Preferred Stock offered under the Registration Statement, provided that (i) the terms and issuance of the Preferred Stock have been duly authorized by all necessary corporate action on the part of the Company&#59; (ii) appropriate certificates of amendment to the then operative Certificate of Incorporation relating to the terms and issuance of Preferred Stock have been duly approved by the Company&#8217;s Board of Directors and been filed with and accepted by the State of Delaware&#59; and (iii) the certificates for the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:right"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.881%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><img alt="image_02.jpg" src="image_02.jpg" style="height:31px;margin-bottom:5pt;vertical-align:text-bottom;width:230px"></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">Sheppard, Mullin, Richter &#38; Hampton LLP</font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">30 Rockefeller Plaza </font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">New York, New York 10112-0015</font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">212.653.8700 main</font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">212.653.8701 fax</font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">www.sheppardmullin.com</font></div></td></tr></table></div><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred Stock have been duly executed by the Company, countersigned by the transfer agent therefor and duly delivered to the purchasers thereof against the requisite payment therefor, which the Company has received, then the Preferred Stock, when issued and sold as contemplated in the Registration Statement, the Base Prospectus and the related Prospectus Supplement(s) and any related free-writing prospectus(es) and in accordance with any applicable duly authorized, executed and delivered purchase, underwriting or similar agreement, or upon conversion of any convertible Debt Securities in accordance with their terms, or upon exercise of any Warrants in accordance with their terms, will be duly authorized, validly issued, fully paid and nonassessable.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">With respect to any series of the Debt Securities issued under the Indenture and offered under the Registration Statement, provided that (i) the Indenture has been duly authorized by the Company and the Trustee by all necessary corporate action&#59; (ii) the Indenture in substantially the form filed as an exhibit to the Registration Statement, has been duly executed and delivered by the Company and the Trustee&#59; (iii) the terms of the Debt Securities and of their issuance and sale have been duly authorized by the Company by all necessary corporate action&#59; (iv) the terms of the Debt Securities and of their issuance and sale have been duly established in conformity with the Indenture&#59; and (v) the Debt Securities have been duly executed and delivered by the Company and authenticated by the Trustee pursuant to the Indenture and delivered against the requisite payment therefor, which the Company has received, then the Debt Securities, when issued and sold in accordance with the Indenture and as contemplated by the Registration Statement, the Prospectus and the related Prospectus Supplement(s), and a duly authorized, executed and delivered purchase, underwriting or similar agreement, will be valid and legally binding obligations of the Company, enforceable against the Company in accordance with their terms, or upon exercise of any Warrants in accordance with their terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting creditors&#8217; rights, and subject to general equity principles and to limitations on availability of equitable relief, including specific performance.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">With respect to the Warrants issued under a Warrant Agreement and offered under the Registration Statement, provided that (i) the Warrant Agreement has been duly authorized by the Company and the Warrant Agent by all necessary corporate action&#59; (ii) the Warrant Agreement has been duly executed and delivered by the Company and the Warrant Agent as described in the Registration Statement, the Prospectus and the related Prospectus Supplement(s)&#59; (iii) the issuance and terms of the Warrants have been duly authorized by the Company by all necessary corporate action&#59; and (iv) the Warrants have been duly executed and delivered by the Company and authenticated by the Warrant Agent pursuant to the Warrant Agreement and delivered against the requisite payment therefor, which the Company has received, and assuming that the Warrants are then issued and sold as contemplated in the Registration Statement, the Prospectus and the Prospectus Supplement(s), then the Warrants, when issued and sold in accordance with the Warrant Agreement and a duly authorized, executed and delivered purchase, underwriting or similar agreement, will be valid and legally binding obligations of the Company, enforceable against the Company in accordance with their terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting creditors&#8217; rights, and subject to general equity principles and to limitations on availability of equitable relief, including specific performance.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">With respect to the Units issued under a Unit Agreement and offered under the Registration Statement, provided that (i) the Unit Agreement has been duly authorized by the Company and the Unit Parties by all necessary corporate action&#59; (ii) the Unit Agreement has been duly executed and delivered by the Company and the Unit Parties as described in the Registration Statement, the Prospectus and the related Prospectus Supplement(s)&#59; (iii) the issuance and terms of the Units have been duly authorized by the Company by all necessary corporate action&#59; and (iv) the Units have been duly executed and delivered by the Company and authenticated by the Unit Parties pursuant to the Unit Agreement and delivered against the requisite </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-4-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="margin-bottom:6pt;text-align:right"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.881%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><img alt="image_02.jpg" src="image_02.jpg" style="height:31px;margin-bottom:5pt;vertical-align:text-bottom;width:230px"></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">Sheppard, Mullin, Richter &#38; Hampton LLP</font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">30 Rockefeller Plaza </font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">New York, New York 10112-0015</font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">212.653.8700 main</font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">212.653.8701 fax</font></div><div style="padding-left:144pt"><font style="color:#717073;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:113%">www.sheppardmullin.com</font></div></td></tr></table></div><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payment therefor, which the Company has received, and assuming that the Units are then issued and sold as contemplated in the Registration Statement, the Prospectus and the Prospectus Supplement(s), then the Units, when issued and sold in accordance with the Unit Agreement and a duly authorized, executed and delivered purchase, underwriting or similar agreement, will constitute valid and legally binding obligations of the Company, enforceable against the Company in accordance with their terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting creditors&#8217; rights, and subject to general equity principles and to limitations on availability of equitable relief, including specific performance.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">With respect to the Sales Agreement Shares, such Sales Agreement Shares have been duly authorized for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issuance and, when the Sales Agreement Shares have been issued and paid for in accordance with the terms </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and conditions of the Sales Agreement, the Sales Agreement Shares will be validly issued, fully paid and non-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assessable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing opinions are qualified to the extent that the enforceability of any document, instrument or the Securities may be limited by or subject to bankruptcy, insolvency, fraudulent transfer or conveyance, reorganization, moratorium or other similar laws relating to or affecting creditors&#8217; rights generally, and general equitable or public policy principles.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hereby consent to the filing of this opinion as an exhibit to the above-referenced Registration Statement and to the use of our name wherever it appears in the Registration Statement, the Base Prospectus, the Sales Agreement Prospectus and any Prospectus Supplement. In giving such consent, we do not believe that we are &#8220;experts&#8221; within the meaning of such term as used in the Securities Act or the rules and regulations of the Commission issued thereunder with respect to any part of the Registration Statement, including this opinion as an exhibit or otherwise.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This opinion is expressed as of the date hereof unless otherwise expressly stated, and we disclaim any undertaking to advise you of any subsequent changes in the facts stated or assumed herein or of any subsequent changes in applicable laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Very truly yours,</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; SHEPPARD, MULLIN, RICHTER&#160;&#38;&#160;HAMPTON&#160;LLP</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHEPPARD, MULLIN, RICHTER&#160;&#38;&#160;HAMPTON&#160;LLP</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-5-</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>a231ex040522.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6c8dfb7e9163495b936b5335f15856a8_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%;text-decoration:underline">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">Cardiff Oncology, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">San Diego, California</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement of our report dated February 24, 2022, relating to the financial statements of Cardiff Oncology, Inc. (the &#8220;Company&#8221;), appearing in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">We also consent to the reference to us under the caption &#8220;Experts&#8221; in the Prospectus.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">&#47;s&#47; BDO USA, LLP</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">San Diego, California</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">April 5, 2022</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>6
<FILENAME>ex-filingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ifbc7f74a644f4c2e84b95c2ffed418b1_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 107</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Calculation of Filing Fee Tables</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FORM S-3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Form Type)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CARDIFF ONCOLOGY, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Exact Name of Registrant as Specified in its Charter)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Table 1&#58; Newly Registered Securities</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Security <br>Type</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Security <br>Class <br>Title</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fee <br>Calculation <br>Rule</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount <br>Registered (1)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Proposed <br>Maximum <br>Offering <br>Price Per <br>Share(1)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maximum <br>Aggregate <br>Offering <br>Price(2)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fee <br>Rate</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of <br>Registration <br>Fee(3)</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fees to Be Paid</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:0.35pt;padding-right:0.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity</font></div><div style="padding-left:0.35pt;padding-right:0.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Debt</font></div><div style="padding-left:0.35pt;padding-right:0.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Unallocated</font></div><div style="padding-left:0.35pt;padding-right:0.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Universal Shelf)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:0.35pt;padding-right:0.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $0.0001 per share</font></div><div style="padding-left:0.35pt;padding-right:0.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred Stock, par value $0.001 per share</font></div><div style="padding-left:0.35pt;padding-right:0.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt Securities</font></div><div style="padding-left:0.35pt;padding-right:0.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</font></div><div style="padding-left:0.35pt;padding-right:0.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Units (4)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457(o)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$250,000,000</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0000927</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$23,175</font></td></tr><tr style="height:21pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Offering Amounts</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$23,175</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Fees Previously Paid</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Fee Offsets (3)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8,728 (5)</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Fee Due</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$14,447 (5)</font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.437%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">An indeterminate number of securities or aggregate principal amount, as the case may be, of common stock and preferred stock, such indeterminate principal amount of debt securities, such indeterminate number of warrants to purchase common stock, preferred stock or debt securities, and such indeterminate number of units (the &#8220;Universal Shelf Securities&#8221;), as shall have an aggregate initial offering price not to exceed $250,000,000. If any debt securities are issued at an original issue discount, then the offering price of such debt securities shall be in such greater principal amount as shall result in an aggregate offering price not to exceed $250,000,000, less the aggregate offering price of any securities previously issued hereunder. Any securities issued hereunder may be sold separately or as units with other securities issued hereunder. The proposed maximum initial offering price per unit will be determined, from time to time, by the registrant in connection with the issuance by the registrant of the securities registered hereunder. The securities registered also include such indeterminate amounts and numbers of debt securities, common stock and preferred stock as may be issuable upon conversion, redemption, exchange, exercise or settlement of any securities registered hereunder, including under any applicable antidilution provisions.&#160;&#160;Pursuant to Rule&#160;416(a)&#160;under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), this Registration Statement shall be deemed to cover any additional number of securities as may be offered or issued from time to time upon stock splits, stock dividends, recapitalizations or similar transactions.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The proposed maximum aggregate offering price per unit will be determined from time to time by the Registrant in connection with the sale and issuance by the Registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction&#160;II.D. of Form&#160;S-3 under the Securities Act.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated solely for the purpose of calculating the registration fee pursuant to Rule&#160;457(o)&#160;under the Securities Act.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Any securities registered under the registration statement may be sold separately or as units with other securities registered under the registration statement.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">On March&#160;12, 2021, the registrant filed a registration statement on Form&#160;S-3&#160;(File&#160;No.&#160;333-254217)(the&#160;&#8220;Prior Registration Statement&#8221;), registering, among other securities, the issuance of up to $100,000,000 of common stock (the &#8220;Prior Securities&#8221;). The registration fee associated with the Prior Securities was $10,910. Pursuant to the Prior Registration Statement, the registrant sold $20,000,000 of Prior Securities, which equates to an associated registration fee of $2,182 based on the total registration fee paid in connection with the filing of the Prior Registration Statement. Accordingly, the unused registration fee paid in connection with the Prior Registration is $8,728.<br></font><font style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pursuant to Rule 457(p) under the Securities Act, the registration fee applicable to the $250,000,000 of Universal Shelf Securities of the registrant being registered hereby in the amount of $23,175 is offset by $8,728 in registration fees previously paid by the registrant with respect to the Prior Securities that were registered but not issued pursuant to the Prior Registration Statement.</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Table 2&#58; Fee Offset Claims and Sources</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Registrant <br>or Filer <br>Name</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form <br>or <br>Filing <br>Type</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">File <br>Number</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Initial <br>Filing <br>Date</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fee Offset <br>Claimed</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Security <br>Type <br>Associated <br>with Fee <br>Offset <br>Claimed</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Security <br>Title <br>Associated <br>with Fee <br>Offset <br>Claimed</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unsold <br>Securities <br>Associated <br>with Fee <br>Offset <br>Claimed</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unsold <br>Aggregate <br>Offering <br>Amount <br>Associated <br>with Fee<br>Offset <br>Claimed</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee Offset <br>Claims</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiff Oncology, Inc.</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-3ASR</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-254217</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#47;12&#47;2021</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8,728</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$80,000,000</font></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>cardiff_logoxrgbxtma.jpg
<TEXT>
begin 644 cardiff_logoxrgbxtma.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M Q$!_\0 Y@ !  (" @,! 0            H+" D&!P,$!0$" 0$  @(# 0$
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M,5IK?'DK:EZ6CG6U;1%JS'C$Q$ONB7'
M
M
M
M
M
M
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MJQ$1K-Z3?'$<;6K,^6-V Y+P
M
M
M
M
M
M
M            !A5S']@W%?@KBIW^_=D0*J_FP'9V+ZRH/%?;/S,D&ZVW^08E
M'?;D-0'I+*F3LIRX54TZ7:[)0HR(Z\F6F*-;SQ]GB_?]B^F7>/J+O/LW;6TM
M?;5M$9-Q?6FWQ?Q\DQIK$3KY*1;),<8I,(67/SWW\I^6Y76 ZA?F\:=&S37%
M<I<.N7_XF9=7]SB%)S'84),&9#@SV3Z.UE0F'&4VI3,EV:C\1];EW5\G"ONU
M_=;\>FOW;NSNR?E]2ZY%>K=PUX^?+6/D8[?T6&=8F8GEDR>:VNEJQCG@T0#C
M-C            &\?@)[WN5W#Q5-@VQYDODCHJ$EB"C#\XNI",XQ*N0:&T_H
M384AFQLF(\)A)$U6V:)\ FT$TP43N-U/)Q;K)CX3QJUZ]2ONY]F=\QDZCTJM
M>E=Q6UGYN*D?)R6_IL,36LS,\\F.:7UGS6\^FB:MPP]BW%+GCC/YOH?8D9_*
M84,YF2ZGRPHN/;4Q-M"V6W7K7%5S)7YA5-N2&D_F=8]859N.$V4GRDMM/8X\
MV/+'NSQ]GBT$[]]+>\_3C=_([CVLQL[6TQ[G'K?;Y.?"N32/+;A/\WDBF32-
M?)Y=)G.06O/
M
M
M
M
M
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M^$R[:&3I
M
M
M
M
M
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MF)XQ+WP5@
M
M
M
M
M
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M:$]\>H_=_J'OOMG<^[OEQUG7'AK[F#%X?S>*)\L3I.DWGS9+1\5Y9ABQ^&
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MS,4K[<^/C;#]-I\V/PC),\&W0<AXD
M
M
M
M
M
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M ]2O7WO;U$^9L//_ ./[;MP^S8+3[]?Z?+POF^FNE,4Z1/RO-'F;@!R'AP
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M+;6<=X][%FK'.V+)'NVCC&L<+UUB+UK,Z,J!F_'
M
M
M
M
M
M
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M<*YJ1IYHY7CWZ<-:UV<"YY&
M
M
M
M
M
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M+Y$=U]M=2[.[BW?;/5Z^7?[/--+:<K1SIDKX^3)2:WIKI/EM&L1.L.[QD_/
M
M
M
M
M
M
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M3]@K;7'ML6M-OCX\-*:SY[1^7DF^33AYM.#/ 6O.
M   8/\S/7=Q4YW8NJEWSKJ+*R:'"5"QG:N+_ !L?VEB"34M;::;*D1)*IE>T
MZXI?Y=9,SZM:U&M48UDE159,./+&EHX^WQ>A=A^J'>7ISO/M';>ZM7:6MKDV
M^36^WR_QL>L:6\//CFF33A%]."%=S^]#7*OA]^=9]J^-+Y*:(AG*FN91A-+)
M3L+#:MEHY2W,^UY%783DP8+"7/):U3D^ EIA3\HH!+0R.NR[7)CXUXU;\^FO
MWCNS>^/E]-ZO->D]QVTCY>6\?)RVGA_,YYTC69TTQY(I?6?+3YFDV:+QQFQ
M   "6W]L)RZ?K\HW!PJRJU=56Y%!=W5J5B4\DV8E]4I@4NR,?@^3N>-VZIEU
MUFRPCM:;*KFN].]U1JY^RR<9QS]<?OM*?O==D5R[/8]_;.D?-Q6C:[F8CC-+
M:WP7GP]RWGQS,\9^9CKRK&DR8=@T2
M
M
M
M
M
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M?AP
M
M
M
M
M
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M[[K<VM?<9;VO>TSK-K6F9M:9\9F9F9GVOJ I
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MT1:/&(:C]:Z%UCMW?6Z9US;9=KOJ<ZWKIK'MK/*U9\+5F:SX3+DP[AU(
M
M
M
M
M
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MK
M
M
M
M
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M8HF8K']-3C;%]<^;'KPB\S.C)D>R/)0
M
M
M
M
M
M                       !3_#H'W#  !DAPW_PO.*W^4AH[^Z=BXSQ_I*_
M7'X7Y7OK_1'6?_5;O_#Y%KB.\?&8                              %5
M_P"PK_#[YQ?Y8')?^[1FHZ3+^EM_&G\+[%^F/^VO;W_H]A_A<3#X5OW   +=
M'7G_ # P;^P_&?ZRPAWT<H^I\2NJ?YGN/U^3^7+F EP0  8S\D^151HO'6F8
MK;%KGE]'?/'*5Q1FQ&:0?A7>W)-J2XW61GCZ-H(TKENI-M!DE+KC?C?K!ZM[
M#TSZ37'ABN?N?=4M]GPS\-8CA.;-I.L8ZSPK7A;+:)K68B+WIZUZ4^EV^]1.
MJ3?--L/;FVM'S\L<[3/&,.+7A.2T<9GC&.LQ:T3,TK?1_EN7Y+G=].R;+;B9
M>WEBYWR9TUPE*[2,S;CQVD$AB'#CD?:TPRE#+2?PH21?0?-GKO7^L]S=4R]9
MZ]N,FYZEFG6U[S^U6L1I6E*\JTK$4K'"L1#Z#]%Z'TGMWIN/I'1,&/;]/Q1I
M6E(_;M:9UFUIYVO:9M:>-IF7&QU#M0   '*\-P;+M@W3&/890V&06T@T](\%
MGJW';,^TY$Z6X;<2OB(/^<\^XVTG^50[SM[MKKW=?4:]*[>VN7=;ZWXM(X5C
M\J]ITICK'C>]JUCQETW7>XNB=L["W4^O;G%MME7\:\\;3^32L:VO;V5I%K3X
M0V?:6X&T%%\2_P!ORV<FM2)MYO$JUUYO'H3GT6E-I.3X)=T\T?0E-H)F+W$I
M*O.@R,;H^G7W8>E],^7U3O[)7>[[A,;7',Q@I//^<O[MLTQXUCR8]=8GYM9U
M:B=_?>.ZEU'S]-['I;:;/C$[G)$3GO'+^;IQKBB?"T^;)II,?+M&C81 KX%5
M"BUM7"B5M="91&AP($9F'"B1VB[6V(L6.AMAAEM)=$I0DDD7["&UNUVNUV.W
MIL]ECQX=ICK%:4I6*4K6.5:UK$5K$>$1$1#63<[G<[S/?=;S)?+NLEIM:][3
M:UK3SFUK3,S,^,S,S+VQ>H8J[HXC:TVV<JWB,%A69ODMP\AI(S7Q;"0KJ???
M4I+8BV2E*49J>;5'E*/IW.J21)'B'J)Z#=G=^3??X*_^.[AMK/S\-8\M[>W/
MAUK7)QYWK-,D\-;S$1#V3L+UL[L[)BFQS6^W]!KI'R,MI\U*^S#ETFU/HK,7
MQQX4B9F6IG;?'W9>F9:BRJF5(HUO$U"RNH\L['I9K4HFD+EDTVY72W.T^C$I
M#+JNAFDE)Z*/13OSTJ[Q]/,\_P#F]O-^F3;2FYQ:WP7UY1-M(G':?R,D4M.D
MS6)CC.Z79/J9VGWYAC_PVXBO48KK?;Y=*9JZ<YBNLQ>L?EXYM6.&LQ/!TF/.
M'H    #^D+6TM#C:U-N-J2MMQ"C0M"T&2DK0I)DI*DJ+J1E]2,36UJ6B])F+
MQ.L3'"8F.4Q/M1:M;UFEXB:S&DQ/&)B?"6TSB7RVEW$NLU;M.Q.3823;@XCE
M\UPS?GOF:6XU#?/J+]]->_FQI:S[WE]&W34XI*U;M>A/KOGW^?#V3WMF\^[O
MI3:[J\^]>W*N#//C>>6/+/&\Z4O,WF+6T\]:O13!L<&;O#L[%Y-K36^YVU8X
M4CG;-ACPI'/)CCA6-;4TI$UC9<-QFIH
M
M
M
M
M
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MSKVM/TM0.X.YNN]U;^>I=P;G+N=W.NDVGW:Q/XM*1I2E?S:5B/H<Q'Z!T0
M #UIL*'91)$"QB1I\&8RN/+A36&I424PZDTN,2(SZ%LOLN)/HI*B-)E^TA3N
M-OM]W@OM=WCIEVV2LUM2]8M6U9X3%JS$Q,3XQ,3$K<&XS[7-7<[6]\>XI:+5
MM69K:LQRFMHF)B8\)B=8:^]T<#\<R'Y5[J26QBENKR/.XO8+><QJ<X?XC37R
M2)Z71NK/KT1VO1C,R2E+*2,QJKZB?=BZ1U;S]3[#R5V._G69VV29G;WGG_-V
MXVPS/A&E\?*(C''%LSV%]XWJO3/)T[O:EM[L8TB-Q2(C/2/SZ\*YHCVZUOSF
M9R3P:O<UP/,-=W3N/9KC]AC]JT7>EB:T7BDL]324F!,:4["L8BE$9$ZPXXV:
MB,NO4C(M+.XNU^O]I=1MTKN/:Y=IOJ\?+>.%H_*I>-:9*^'FI:U==8UUB6WO
M0.X^A]T;"O4^@;G%NME/#6D\:S^3>LZ6I;Q\MZUMII.FDPXD.A=V  #]0M3:
MDK0I2%H42T+09I4A23(TJ2HC(TJ29=2,OJ1B:VM6T6K,Q:)UB8YQ*)B+1-;1
M$UF.,-]'%;;SFWM55T^TD$]E6-NECF3*4LU/RI41AI<*W=)1$HSMX*T.+5_-
M.0ETB_F]"^H'HAW[?O[L?#NM[?S=;V=OL^XX\;6K$33+/ZVDQ:9Y3DB\1R?.
M#UC[(IV1WEEVVSKY>C;N/GX.'"M;3,7Q1^KO$Q$<XI-)GFR3'L#RD
M
M
M
M
M
M                                           %/\.@?<,  &2'#?\
MPO.*W^4AH[^Z=BXSQ_I*_7'X7Y7OK_1'6?\ U6[_ ,/D6N([Q\9@
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MN'URW!#?UHX
M
M
M
M
M
M "G^'0/N&  #)#AO_A><5O\ *0T=_=.Q<9X_TE?KC\+\KWU_HCK/_JMW_A\B
MUQ'>/C,                              "J_]A7^'WSB_P L#DO_ ':,
MU'29?TMOXT_A?8OTQ_VU[>_]'L/\+B8?"M^X  !;HZ\_Y@8-_8?C/]980[Z.
M4?4^)75/\SW'Z_)_+ES 2X( UT^Q4S_1>N2ZGT/*+4S+^0S*I3T/I_LEU/\
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ML59GG%*WF:QK[*^;RQ[*Q$1PAB:/"GM( RRX2?X1.)?\697_ -&[(>Z_=O\
M]V=A^IW/^'R/%OO _P"U^]_7;?\ KZ-Y0^ECYY
M
M
M
M
M
M                             I_AT#[A@  R0X;_ .%YQ6_RD-'?W3L7
M&>/])7ZX_"_*]]?Z(ZS_ .JW?^'R+7$=X^,P
M      *K_P!A7^'WSB_RP.2_]VC-1TF7]+;^-/X7V+],?]M>WO\ T>P_PN)A
M\*W[@  %NCKS_F!@W]A^,_UEA#OHY1]3XE=4_P SW'Z_)_+ES 2X( UT>Q7_
M )EZY_LGM?ZU(&I/WMO].](_ON7^J;2?=<_S[JO]SQ_UDM30T4;I #Z=)_[Y
MJ/\ C.!_OIH<WIO^8[?]=3^5#B=0_L&?]3?^3*32/LH^2@
M-)/.O_K^L?[&,:_WL\/G!]YK_=++_<MO_)E] ?NZ_P"VN+^^9_Y4,.1KZ]U
M&67"3_")Q+_BS*_^C=D/=?NW_P"[.P_4[G_#Y'BWW@?]K][^NV_]?1O*'TL?
M/(
M
M
M
M
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M'R/%OO _[7[W]=M_Z^C>4/I8^>0
M
M
M
M
M
M                 *?X= ^X8  ,D.&_^%YQ6_RD-'?W3L7&>/\ 25^N/POR
MO?7^B.L_^JW?^'R+7$=X^,P                              *K_ -A7
M^'WSB_RP.2_]VC-1TF7]+;^-/X7V+],?]M>WO_1[#_"XF'PK?N   6Z.O/\
MF!@W]A^,_P!980[Z.4?4^)75/\SW'Z_)_+ES 2X( UT>Q7_F7KG^R>U_K4@:
MD_>V_P!.](_ON7^J;2?=<_S[JO\ <\?]9+4T-%&Z0 ^G2?\ OFH_XS@?[Z:'
M-Z;_ )CM_P!=3^5#B=0_L&?]3?\ DRDTC[*/DH              #23SK_Z_
MK'^QC&O][/#YP?>:_P!TLO\ <MO_ "9?0'[NO^VN+^^9_P"5##D:^O=0!EEP
MD_PB<2_XLRO_ *-V0]U^[?\ [L[#]3N?\/D>+?>!_P!K][^NV_\ 7T;RA]+'
MSR
M
M
M
M
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M (?(\6^\#_M?O?UVW_KZ-Y0^ECYY
M
M
M
M
M
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MG$O^+,K_ .C=D/=?NW_[L[#]3N?\/D>+?>!_VOWOZ[;_ -?1O*'TL?/(
M
M
M
M
M
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MW_[L[#]3N?\ #Y'BWW@?]K][^NV_]?1O*'TL?/(
M
M
M
M
M
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MWF^QUT\9ICBV2T_5%JTB?IM#<X/H<T-
M
M
M
M
M
M                     !!G^YIXM2=?<G=><I:.M4G%]_X@QB^736(I^)C9
M^LHD6J;=L9;9$TTYD&OGJMN(VLO([^3RE$:DH,D=9O::7B\<I_##Z'?=*[PI
MU/M'==G[B_\ WG3,\Y,<3//;[B9MI6.?N9HR3:8X1\VD<->,98<-MJ  #L74
M^W-F:*V!CFT]/YOD.N]A8G,^=095C$]ROLX3BVU,R8ZS3W,3JVPBN+8EPY"'
M8DR,XME]MQI:T'-;6K/FK.DNKZUT3I/<73,O1^N;?%NNF9JZ7QY(\U9\8GVQ
M:LZ36U9BU;1%JS$Q$I>W '[E'%,F32ZUY[4+&%7YIBU\3?\ @=1*?P^U>Z$R
MF5L/!H"95EBTMXT$IZ=3IEP''G3/X,!A!J'88MY$^[EX3[6D'J5]U'>[2<G5
MO3?).XVW&T[/-:(RUCGI@S3I7)$>%,OEO$1^DR6G1*=PK.,,V1BU+G&O<KQS
M.,,R2$U98_E>)W-?D&/74!XNK4NLN*J1*@36%=#+N;<41&1D?U(R'-B8F-8X
MPT[W_3]_TK>9.G]3PY=OO\5O+?'DK:EZ6CPM6T1,3]<.4B7#
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M66\70>@=%[8Z7BZ+T#;8MITO#&E<>.-(X\YF9UFUK3QM>TS:T\;3,\75PAW
M  )'OVU7%N5M/F!D_(^YKEKP_C5A\LJB8\T1QI.T-F0+3%Z**V3Q>*5^68;^
M>2W#1W+B2?AK/M-QM1\O9T\V3SSRK^&6J_WK^\*=&['P]JX+Z;[JV>/-$<XV
M^":Y+SPY>;+\JL:\+5^9''283Q!VCYR   X=L+#:_86$91A5GVIB9)3S*TWE
M-D[\22ZWWP9Z&S,B6[73D-OH+J7XVR'Y_NOM[:]V=M[WMS>Z1@WFWOCUTU\E
MIC6EXCQG'>*WCZ:P[WMCKVY[8[@V?7]IK.?:9ZY--=/-6)TO29\(O2;4GZ+2
MCHY/C=QA^0W.+7\54*YH;&366,91]Q(D17#;4II?0B>CO$1+:<+\+C:DJ3U(
MR,?)'K71]_V_U;<=$ZI2<?4-KFMCR5]EJSIK$^-9YUM'"U9BT<)A]2.D=5V/
M7.EX.L=-O&38;G%7)2WMK:->,>%HY6B>-;1,3QA\(=8[$  ',L'V%F>MKIO(
M,(R"?C]F@DI=7$<2J--92KO*-90'TNP;*)W?7Q/MN(Z_7IU(C'Z'MKNON'L_
MJ,=5[;W>7:[R.<TGW;Q''RY*3K3)77CY;UM&O'37BZ+N'MCH/=>PGIO<&UQ;
MG:3RBT>]6>7FI>-+X[?G4M$Z<-=&T;2W.W%\G^+0[8C1L-O%]K3>20R>7BD]
MPS)*3F-K4_,Q]U?<1&:U/1?HI2G6BZ)+=;TZ^\YT3K7DZ9WU2G3^I3PC<4UG
M;7G\^)UO@F?;,WQ\)M-Z1I5I_P!_?=SZQTCS]1[+O??]/CC."VD;BD?FS&E<
MT1[(BF3E$4O.LL_(DN)/BQYL&5'FPI;+<B++B/-R8LEAU)+:?CR&5+:>9<09
M&E23-)D?4C&TN#/@W6&FYVUZ9-ODK%JVK,6K:L\8FMHUB8F.,3$Z2UKS8,VV
MS6V^XI;'GI::VK:)K:LQPF+1.DQ,3SB8UA[ M5     #&/<_*W6>GTR:U4LL
MMS%M*THQ>CD,K.(^DOPIOK0B>BTR.[^<@R=E$1D9,F7U+QGU$]<>S>P*WV<Y
M/M_<$1,1ML-HGRV_I\G&N*/;&ELGC&.8XO7.PO1GNSOB:;N*?8NA3,:[C-68
M\T?T./A;+/LG6N/PG)$\&IC<'(W9FYY#C60VIUN-)>-R'B-*IZ)2-$E1&RN:
MCR*?N)C9)(_+)4LD+ZFTEHE=HT3[_P#5WO'U$S3CZKG^3T>+:TVN&9KACCPF
M\:ZY;Q^5DF=)UFE:1.C=/L;TL[3["Q1?IF'YO5IKI;<Y=+99]L4X:8JS^32(
MUC3SS>8U=##S!Z.    W9<)=4OZ^U7^H[:.<?(-BO1;UYIQ'8]&Q^.TXWC<5
MTC^O<\S)>F?MZDF6E)D2DF/H[]W#L?)VIV1_Y??4\G5>KVKFF)C2:X*Q,;>L
M_3,6OE^B,L1,1,2T ^\!WGC[F[R_\5LK>;IG2ZVPQ,3K%LUIB<]H^B)K7%]>
M.9B9B89E#81X0
M
M
M
M
M
M   #"3V'<-L<YW<4MD<?[AZ'69#91F<FUCD\U"E-8CM#&T2)&*7+JD,27FZV
M6I]ZMLC:;6\JIL)2&NCBDJ*O-CC+CFGCX?6] ],.^]UZ<]Y[7N;!%K[6DSCW
M&./^KM\FD9*\XCS1I&3'K.GS*4F>$2K"=@X#F&J\YRW6NP:"?BV<8+D-KBN5
MX[9MDU.I[VEF.P+&$^234VOQ2&3[7$*4VZCHM"E(42CZ68FL^6></KKTSJ6Q
MZST[!U;IF6N;I^YQ5R8[UY6I>(FLQ^Q/*>,3PF(EP\0YP   #-OAK[#.5/!/
M*D7VA=BS(..RY[,[)]79)\B^U?F7C+L6B]Q5R5'1'F.L_@_,*]V#:-H_"W)2
MGJ1V8\M\4ZUGA[/!Y_WWZ8=F^HNS^S=R;6MMU6LQCW&/2FXQ?Q,FDZQ$\?)>
M+XYGG24T_@%[ZN*W+S\DP':\B'QJWK,1'AIQ_,[J/_#?,;178QVX-L*8F#"8
MF3Y!EX:JV3#F&XZEB,Y/4E3A]CBW5,G"WNV:#>I7W;^\>R/F=2Z+%NK=NUUG
MSXJ3\_%7G_/88UF8K'/)CFU=(FUXQQ,0WKCE-=0                   &C
M[G][V>*/#C\ZP/7LV)R.WQ!5*@.X9@US'_16'6C31I(L_P!@QVI]7'D1)75#
MU96%/LFW6E,R40S,G"XV7=8\?".-FPGIK]W3O/OOY?4>J5MTKMRVDQES5GYN
M6O\ 0X9F+3$QQC)D\F.8F+4F_)"IYH^QOE;SQR0[3>FPI*\2AS%2\:U-B?RL
M?U?BZB-SPNP,9;ER"M+5EMU2"LK-V=9&A1H\Y-]$%UN3-DRS[T\/9X-^^PO2
MSLSTXVGR>W=K'VVU=,FYR:7W&3VZY-(\M9_(QQ2FO'RZ\6"HK>B    .389A
MN4[$R[&<#P>BL<GS',KVKQK%\=J6#DV5U>W4QFOJZV$R1D2Y$N6^A">IDDNO
M51D1&9(B9G2.<N)O]_L^E[+-U+J&2N'8X,=LF2]ITK2E(FUK3/LB(F5G!ZT>
M$U)P)XF8%I%@X,[.91+S?<&0P2[F,@VCD<."60+BOF2%R:C'XT*-45[AI;4[
M!KVG5H0XXLAW6''&+'%?'Q^M\D?5GU W'J1WKN>X+>:O3J_S6VI/.FWI,^36
M/"UYFV6\<=+WF(F8B&?8M>:@   ,%.7W&1[9T,]AX+#0K/*F&35M5M))#F75
M45OHR3/0B)R^K6D]K'7ZR&2)KJ:D,I&LOKYZ,W[SV\]V=LXXGN?!CTRXXX3N
ML58X:>W/CCA37CDI_-ZZUQPV*]$/5NG:.?\ ^K]Q7F.W,]]<>2>,;;):>.OL
MPWGC?3A2_OZ:6O+3G(COQ'WXLIAZ-)C/.1Y,:0VME^.^RM3;S#[+B4N-/-.)
M-*DJ(E)41D9=1\^\N++@RVP9ZVIFI::VK:)BU;1.DQ,3QB8GA,3QB>$MZ<67
M'FQUS8;5OAO6+5M68F)B8UB8F.$Q,<8F.$P\0P9@   .\]1<B-F::DMHQJX.
M;CZG27,Q.Y-V;12"4LE.JCLFXEZKE.?[K&6VI1].\ED7:/2^PO5GO+T\S17H
M^X^9TJ;:WVN76^&W'6?+&L3CM/Y6.:S,_%YHX/.^]_2_M+OS#,]5P?+ZG$:5
MW.+2N:O#AYITTR5C\G)%HC\7RSQ;9],<LM9[>^+5+D_H_,W^C?Z9O)#1(FOG
M_04-OVLQ;;N_H6S2S*,R/HSVEW'O9Z=^NO9O?WDV-K_^/[AMP^SYK1I>WLP9
M>%<OT5TIDY_S>D:M+._?1;NWLCS[VM/MW0:\?M&*L^Y'MS8^-L?TVUOCY>_K
M.C*(>U/( !UALW<6O=15?YEF^01J]QUI;E?3L=)=];&CN22*VJ:5\AU"G"[#
M>7XX[:C+R.(+ZC\9WEZ@=I]A;+[9W)NJ8KVK,TQ5][/ET\,>*/>F->'GGRXZ
MS\=ZQQ?KNTNQ>Y^]]Y]D[?VU\M(F(OEGW<./Z;Y)]V)TX^6-;VCX:VG@U3;I
MYK;!V)\NDPOS8!B3OD95\*1W91:QU%V&5A<-=OY>TZ1=38A]AD2C0MYY(T<]
M1?O&]U=V_,Z;V[YNE="MK$^2VNYRUY>_EC3Y<3^1BTTUFMLF2&Y?87H#VSVO
MY.H=>\O4^M5TF//7_M\=N?N8I^.8_+RZZZ1:M*2PL4I2E&I1FI2C-2E*,S4I
M1GU,S,_J9F8UTF9F=9XS+WR(B(TCA$/P$@   ,X^)O%V=LFU@; S> Y%UY5R
MDR(,&4TI#F9S8RNYMAEM9%UQ]A])?)>,C3(Z&PWUZN+:V5]"_17<]X;[%W5W
M)BFG:>"_FI2T:3N[UY5B)_Z%9_27Y7TG'77W[4UZ]:/5_;]J;/)VUV]DB_=&
M:GEO>LZQM:6YS,Q_UIC]'7G36,EM/<K?<PE*4I)*2)*4D24I21$E*2+H1$1?
M0B(A]"XB*QY:\(AH?,S,ZSQF7Z)0
M
M
M
M
M
M                    CE>[_P!/KO+NEE<G^-]"R?)C%*J+&S##H9PX2-W8
MC41C9CDRIQ#+;FR\;A-MM0''74_F->T4)1J<:ADGB;G;_,CST^/\/_%M-]WS
MUQCLC<5[0[JR3_\ 4LUYG%EG6?LF2TZSKS_F,DZS>(CW+S\R-(G)K!"M:JTH
MK2RI+NMGT]U3SYE5;U%K#D5]I56E?(<B3ZVR@2VV9<&?!ELK:>9=0EQIQ)I4
M1&1D.KY<)YOHSAS8=SAIN-O>N3;Y*Q:MJS%JVK:-:VK:-8F)B8F)B=)CC#T
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MCA$1'"(CA$-9\F2^6]LN6TVR6F9F9G69F>,S,SQF9GC,SS>09L
M
M
M
M
M
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MA6/R:5C2M*^RM(K7Z'+1WKI0
M
M
M
M
M
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M]2^Z^_,\SUG/->GQ;6FWQZUPT]GNZS-[1^7DFUN>DQ'!W4/1GX
M
M
M
M
M
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M!YEZ@^D?97J3MYCKNV\G5(KI3=8=*;BFG*)OI,9*1Q]S+6]8UF:Q6VEHFP\
M_=YQ*YN?D^$W-DC0&^9WQHB=7;#N87Y5DUH]T3\?6V>*:KJG+5N.J2AJ%(9K
M;AU9GXX;B$&Z?98MSCR<.5O8T!]2ON^]Z^GWS.H8*?\ D^VZZS]HP5GS8ZQX
MY\/O6Q^V;5G)BB.>2)G1N8'(>#@#3YS[]U7$C@TBXPYJX1O/?<#NCIT_KNVA
MK103R-PC:V3FR6;&EP;PFV9.0_'.NDFMM7P/"YYD\?+N<>+ASO[/X7N7IKZ!
M=[>H<X]_./\ \=VW;C]ISUGWX_H,6M;YM?"VM,7"8^9YH\LPF^<?M,Y;\][5
M^/M?-OTWK!F8<FCTK@!S*#7=:3;A+B/VT0Y3]CF=PQV$HIEL_+4TX:SC(C-J
M\1=;ESY,OQ3[OL;_ 'IYZ/=D^F^&+=%V_P WJ\UTONLVE\]O;%9TBN*L_DXX
MKK&GGF\QJURBIZF     /-'CR)<AB)$8>E2I3S4>-&CM+>D2)#RTMLL,,MI4
MXZ\ZXHDI2DC4I1D1%U!C:U:5F]YB*1&LS/"(B.<S/A$)#/ /[>?DCR2.CV%R
M:=M>,^FI?Q9[=+8P&CWAF%<XLU*:J<1L6EQ\ 9D--J24R_;*4T:FW&ZR4TON
M+EXMI>_&_NU_=:Q>I7WG>U.U/F=,[2BG5NO5UCSUG_M,5OSLE>.:8_)PSY9X
MQ.:EHT3-^*7"?C/PJPL\*X[ZOI,+:F,QD9'E+B#ML\S-^,1FB7EV9V'FO+GM
M?6XXU&-U$"&IU916&$*[!V./'3'&E(T:&]Y^H'=O?^__ /(=T;S)N)K,^3'\
M.'%$^&+%72E>&D3;2;VTCSVM/%E6,WXT   !K^YJ>SCB!P,K5)WAL9N3GC\1
MF94:>P5$/*-J6T>22CBRSQQ,^%&Q^KDI0HVIMO)KH;W8I+3JUEV'=BV^7-\$
M</;X/Q?=??\ VQV=C_\ Y?/KO)C6N#'I?-:)Y3Y=8BL3X6O-:SX3,\$7'D5]
MT)R5R^985G&G3>NM-XXI2VH619VN;L_/EH3WI;G--)7CN%5#KY&2E1G:^U2T
M9=I/K+ZGV-.GXX_23,S^U#7KKGW@^O;JUL?0-K@VN#PMDURY/K_%QU^J:WT]
MLM7N7>Z3V@YI*D2K3E]L*N.0F0@V,1JL(P:*RW(0EM2(\?#L5HT,J:0@B;<+
M]ZV?51*)9J4?(C:[>.58_"\]W/JKZ@[NTVR=3SUUU^",>../L\E*_L>/[+YN
M+^Y#V=8@_"D57,;:DMR 2$L)R@L8S=A9(=0\GYL7-,=OXUD9K;(C.0ATU(ZI
M/JDS(T[7;S^+##;^J/J!M9BV/JFYF8_+\F3]N,E;1/[.OLY-D7'[[G/F1@4R
M!"W[KS5N_L;0MLK&? @/:IV"\CM0VMR/<XXBPP=/0B-SQGCJ36L^A.(3T[:+
M]/Q6^"9K/[<?_/V7[OHOK_W3L[5IUK!M][@\9B/DY/V+5UQ_3I\K]F$GO@[[
M?^%_.YV%C&O<VDZ_V](9)2M,[517XSFD]YMI3DDL0DLV$_'<[9033KA-UDQZ
M>B,V;TB)'3U(NOS;7+AXVC6OMAL#VCZG=J]X3&WV6:</4YC]!FTI>?;Y)UFN
M3QGW+3;2-;5JVC#CO0@    !TUMG0NM=RPO%EU*E-LTR;4#)ZHVX.10"Z?@2
MB<33B)D=OJ?1B4A]@C,S)!*^H\\[Z]+^S_4+;^3KVVB-_6NE-SBTIGI[-+Z3
M%ZQX4R5O2-9F*Q/%^\[+]2.Z^Q-QY^B;B9V4VUOM\FM\%_;K36)K:?&^.:7G
MA$VF.#5ULW@WMK#7Y$K$&V-B4*34MMVJ\4&_9:^ID4NBER.Y]POH1%#=DJ5U
MZ]J?J1:5]Y?=J[[[>R6S] BO5NF1QB<6E,\1^=AM;C/A_-6R3//2.4;?=I?>
M&[*Z[CKAZY-NE]1GA,9-;X9G\W-6O"/'^=KCB.6L^.)5WBV3XT\J/D>.7U!(
M0KL4Q=U%A5/)674NQ34Z.PLE=2/Z=.OT'A'4NB=9Z/DG%U?:;K:Y8G33-BR8
MIU]FEZUG5[7T_K'2.K4C+TK=;;<XYC77%EIDC3VZTM,/F0X,ZQ?3&KX<J=)5
M]4QX<=Z4^HNY*.J6F$+</\2B+]G[3(</;[7<[O+&':8[Y<T_BTK-K>SE$3/.
M8<O/N=OM<?SMUDICQ1^-:T5CV\YF(9"8#Q0WCG[S)QL-FXU6.+2ERYS)#N.Q
M66U&7[Y,.6U^<S&S2?4CCQ74GT_:/5NU_0SU*[IR5^3T[)L]G,\<N[B<%8CV
MQ2T?.O'TTQVCZ7F7<GK/Z>=M8[?-W^/=[N(X8MK,9[3/L\U9^56?HODK+99I
MCAIK?6)QKG(D-Y_E[1H=1/MX:$T=6\G\1'4T3BY#!O-KZ=)$E3SI*02VR9,S
M2-Q?3O[O7:'9GDZAU>(ZKU^NDQ?+2/DXYY_S6&9M76)Y9,DWMK$6I\OC#4[O
MWUW[J[N\^QZ7,],Z).L33%:?FY(_I,T16=)CG3'%*Z3-;>?A+,(>_O#0
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M]T
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MG]!&DP.VP
M                                    0[?;?[N>9?$GG5M3CQH.[UU7
MX+KFEUNTXUD6!0LCLEWV5:]QS.+)Q=G*?CJ4T3>3LH2VGN2CL,NO=W)396L3
M&LH:UO\ 61?9O_\ A3IW^U)4?_;QEY*A_K(OLW__  IT[_:DJ/\ [>'DJ-]?
MHB]E7,'V"["Y"1>05QA-EANJ<,PB16-XIA$/&'F\FS6\NVX:YDR*N0;[7Y5B
MLPDM&M'4^JNBNWJG"T1')*2@,
M
M    &K7GAZA>(G/.)8W^88K_  TW4]&6FOW?KB)"J\I>E)2CX_ZVJO&BEV'
M2;+;:RL6_P P;C)-J+-B]W<5&7;X\O&>%O:]A].?6_O?TXO3;;'-]KZ!$^]M
M,\S;'$>/RK?'@GC,QY)\DVXWQWY(3'/+U <N^!LFTR+*\7_B?I&-)44'>&N(
M<VRQF+#<>)N&>=TYH<NM=3W"=:0Y\]*JQ4IPF8TZ4KZGUV7;Y,7&>-?:^@'I
MQZX=D>H]*;799OL?<$QQVF>8KDF=./R;?!GCG,>2?F>6/-?'2&J\4/8@
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MD8Q']@
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M=V;M:S)Y4A$[8V=Y/FDEEY7D(UQW,CM+%4?HEY1$2.TDI49$1%]!EH.K
M 'FCR)$.0Q+B/O1945YJ1&DQW5L2(\AA:767V'FE)<9>9<22DJ29*2HB,CZ@
M-BF@O;;[$N-SD1K7O*;95I0Q/"VC$-F63>VL41":42CK8%3L9G)/T_#=Z'W?
ME:X+A=QFE:5&9B)K$B1/Q(^Z.Q2[D5.+\T]*KPM]];<:5MC21S[K&&5N.$@I
MEUK._FS,GJX$=O\ &^[7VMQ(6?\ 2H?]",)I[#5*#T?R#TCR5PB'L;0VT,.V
MIADSQH_.<1N(]C\"2XV3OY;>5W5NUQVY:;,C<A3V(TMK^C;28KTTYI=Q
M
M                    JYO;-FA9[[*.:EX3BG/@[]S?"^Y7=U(];S$Z[-O\
M4:(?:T>+=I?@,NA?1;A='%7U^&$->0D $VG[4W!_@:/Y;[)\/;^K-K:]P?S]
MO],_A[B-O?>'N_E\'\3N[I_)Y/\ ;%>0A*]%:0
M
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M@;89D3L3S2A-UV3C^1UR)"#6RLU-O-+0_'<>C.M/.53$QPE+(\0
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M*V:^_"EO$11I9.O-PD5VIIQCDE(\&
M                                                   *B7=6:%LC
M<FVMB$[YRSW9N>9H3W:A'F+*<IM;PG>QMB*VGR%.Z]$M-D77Z)27T*^.2'68
MD %A/]M7A'Z4]:<"^\7C_B9O7:V;]W^[? 1C6M_+_37/V?P^[/V-_P S^;_1
M*IO\26_\8@
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M91$:6M#5C!1,:<:>;-4>;$=:D,J4TXDQ3,:3HEEH(
M                                      !73?<6YO\ JSVB[2I"<\B=
M:Z\T]A"2_H6_F8)6["6VD_$V1]KN>*,_Q.=%&9=Q&78FZGPH:,AD "55]JG@
MWYAR)Y4;+\'=^DM+8G@WR>SKX?XAYRB_\'E\*NSY'\+^[M\B>[Q=>U7;U1A?
MD0F^"I(  *G7FEI>_P"._+3D3I?)8TF/88#MS-:J*Y+9<8<M,>DW,FUQ+(6F
MW4H7\/)L4L(5C'49%WQY2%?RB^.2&,8D  !,S^U4T;=P,:Y4<C[2$XQ19):8
M1IW#9BS<04Z7C#-GEV>&EHUI0['C?J&A0V[V*+R>9"5$:'$BN\^!"7F*T@
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MU0X9,S'%5YH>KZ[5\8$TQ*DK2E:%)4A224E23)25)475*DJ+J1I,C^ABM+]
M
M                 '1O)[-2UMQJY#;%-[XQ8#HW;6:G(_!^X+%L!O[TWOWB
M5M_NB@=WXB,OI]2,A,<Q4EB]   +.CTOX6>!>KSAS1FV39SM:3LT[4]O0RV1
MFF4[$)S\,J675TLI[C_&1]3^J&SZMHHM\4I;/A
M
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MW_:/>W0N]-C]KZ1D_GJQ'S,5M(R8YG\JNLZQ/A:LS6?;K$Q&<(I?K@
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M+API;7R:[S'(2PA6D
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ME<0^U41@GZ[U\8$LL5I
M                                    &LWW)9L>O_6'S)O2>2P<_5"\
M)[U.);)1;+R7']<&SW*-)&J265^,D_M6:NTNIGT&5?B@5A8N0  "VHXH86>N
M.+7&O7BFO K M Z<PM3/<M7A/%]=XY1FUW./RG%>,X/3JIUPSZ?52C^IT3S2
M[^$
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MA5>3)3%7S7G2'=]![;ZWW-O(V'0]ODSY_'2-*TCVWO.E:1]-IC6>$:SP3*N
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MT2- KX$9B%!@PF&HL.%#BM(8C1(D9A#;$:-&8;2AMM"22A)$1$1$*DO9
M                                                     ?BE)0E2
MUJ2E"4FI2E&24I2DNJE*4?0B21%]3 5#^X,U5LG;6T=BK6IQ>?;%S;-5N*(T
MJ6K*<EL[U2U)-J.:5*.?U,O&CI_Y)?L+D0AUT  +"W[:_!_TGZSZB^\/C_B=
MN_;&<=_;T^1\!ZAUMYNO]%V_P]\?7_S.G\@JO\28;^1@    ,%>3WK1X.<Q+
M!R^W[QZP[*LP<9;87GU,Y<8+GSR&$$W$38YA@UGCMY>,P4ET99L'I<=LNI$W
MVF9',6F.0PTP;[>KU=87=HO)>F<KSM3#S,B)5YSM/.I])'=94XI/?6TMM0-6
M;*S67>S-.4RLD$1H,C5W3Y[#;_KS6NO-1XE58%JS!L2USA-&T;51B>$X_58Q
MCU<E70W#BU-/%APFG7E%W.+)'>XLS4HS49F,1S8      :&?N*^2DC1?KVO<
M"HK'X65\D\QIM2,)96M$U&%-LRLKV#+:,NC9PY=31LT\DE&9FU<]"(^IFG*D
M:R*[\7( &4G"?C;;\O>5NB^.=0N1'3L[/*VKO["*VIV33836(?R#/KYAM*5$
MN11X543Y;:5=J%N,I2I2",U%$SI&HM8\4Q;'L&Q?&\*Q&HAX_BF'T%/BV,4-
M<WX:^DQ['ZZ/4TM1 :,U>*'6UL1IEI/4^U""(4)??       !B;SMY#M\4>'
MO(CD$3K+5GK?65]/Q7Y*4KC/Y[<(:QK7D.4E7T.-/SJZKF'/H9]CA]",_H<Q
M&LZ"J4FS9EE,EV-C+DS["?)?FSITU]V5,FS)3JWY,N7)?6MZ1)D/+4MQQ:C4
MM1F9F9F+T/6 >]65MA=65?3U,.186EM.B5M; B-J>E3K"<^W%APXS*"-3LB3
M(=2A"2^JE*(@%JKP%XJT7"WB1I;CU41XA6F'XE"E9[9Q2099#LR_05SL"]-\
MNYQ^/*R:8^W#[UN*8KVH[!*-#211,ZSJEF&(                 !TKR)Y
MZPXM:8S[?.XK]O'< UY2N6UM*Z)<FSY+CC<.HQ^DB*6V=CD&1V\AB#!CD9&]
M*?0DS2GJHIB-9T%9=["N>^V?87O^WW%L5UVGQFN*50ZHUK&F*E4FML&^8Y)B
MU,=Q+,5NSR"Q4:7[:T6TAZ?*(B)+49F+&8NB-(T0P4$@ ^I24=UDUS58YC=1
M:9!D-]8PZ>CHJ2OEVUS<VUC(;B5]755<!F1-L;&?+=0TRPRA;KKBB2E)F9$
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MG6'>E%HTG1+8@(
M                              &@[[DG-SQ/UEY%0E()DMF[GU+A!MF\
MEHY90+"UV1\=*%/LG(-)Z^)WL)+ID31J[2))K1E3XA7E"Y  ["U)AB]C;6UE
MKUIM3SN=["PO#&V4FXE3J\HR2MI$-I-I2'24M4[H1I,E?7Z&1@+>-*4H2E"$
MI2A*22E*2)*4I271*4I+H1)(B^A#CI?H
M
M                                " !]Q%SFLN1'+27QMQ2V4K4/%J=+
MQJ3%B2#5#R/=#["&L_NIJ6G?&Z[AZC+'H[;J/)$D1+!25=LI1%W.QP^3%YY^
M*WX/#^%I?ZW]WY.N=RST';6__C.G3-9B)X6S_P#4M/\ $_11$\:S%]/B1Z1S
MGB8  .2X?AN7;"R:FPK L6R'-<PR*8FOH,5Q.FL<AR*[GK0MQ,.II:F/+L;"
M2;;:E=C3:U=J3/IT(S$3,5C6TZ0OVNUW.]W%-IL\=\NZR3I6E*S:UI]D5K$S
M,_5"4YP ^VIS;,/R?9//.^DZ\QM?QI\+0^#6L*5G=LR?1Y+&>YC#.;3XA&>0
M22<A5BIM@IMQ25R(#Z#2.NS;^(]W#QGVSR_8;$=E^@N[W7EW_>-YP8.$QM\<
MQ.2?UEXUK2/S:>:VD\;4F$OK2FB-.<<<!K-7Z,USBVL,#J%+=BX]BM:W!8>E
MNI;1(L[24HW;&\NIB6D^>=->D3'S21N.*,AUE[VO;S7F9ELWTGH_2^A;*O3^
MD8,>WV=>5:1IQ\9F>=K3XVM,VGQEVT,79         #A6Q-;Z_VYAMYKS:.%
MXSL'!<EB'"OL3R^F@7]#:1^]+C92JVQ8D1ENQWT)=9<)).,NH2XVI*TI44UM
M:L^:LZ2XF^V&RZGM;['J&+'GV>2-+4O6+5F/IB=8X<XGG$\8XHG?L ^VC@2D
MW>S. &0?E\G^J+"3QUV#=+=@/*4XMPX>M-C6SZI$+L;[4,U^0NO)6KN4JT;(
MDM#LL.__ !<W[<?OQ_!^TUO[T]!*6\^_[+OY;<9G;9+</JQ9;<8^BN29_61P
MA$HVIJ/9^CLWN-;;@P+*=;YW0N^.UQ;+Z>92VT=*E+2S*;8EMME+KI9(-4>4
MR;D:0WT6TM:#(S[*MJWCS5F)AK9U'IG4.D;NVPZIAR8-Y3G2]9K,?3QYQ/A,
M:Q,<8F8==#)P0  ;>/2ISCF<*.:>%O7]P["TMN^75ZIW!$<<Z5T.)<351\-S
MF0E7<AEW LHG-R'GR2MU-2_/:;+N>'%W>'YN*=/CCC'_ ,^EZ9Z4=W6[3[KQ
M3FMITK=S&'/'A$6G2F2?U=YUF>?DF\1S63HZ)O@              #7Y[+>>
M&'^O?B_EFY[<JRWS^R[\2TS@\]Y9?K'8UE%>76HEL1W69BL:QUAM=C;.(6UT
MAQS90ZB0_')4Q&LZ"L5V9LK.=Q[!S':FS,DL<OS_ #[(++*,LR2U<2N;;7-K
M(7)E/J2TAN/%CH-1-L1V4-QXS"$--(0VA""OCAP0X,  ,EN)'$[</-3>6):$
MTG1_FF4Y*\J196\Q,IO&L)QB&MK\ZS3,+*-'DG58[3-.I[U]BG9$AQJ-'0[)
M?9:<B9B.8LD?7OZYM#>NW4S>!ZMK_P ^SB^9A2MH;>NX45&7[ NV&4$LE+;\
MIT.(U\CO_+*9EU;$-"C6XN1*<?E/4S,S*6?X@             &,^V.&'$;>
M^4Q\XW1QGT9M+,HS46.659UJ_#\DR&1$@I;1"@V%O9U,B?:5T1MHDM1Y*W6&
MT=4I01*41SK,<AD#08_0XI25>-8M25&-8Y1P8]924%!6PJ>DIZV(V342OJZJ
MN9C0:^#%:226VF6T-H270B(A ^N
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ME!%C>-8%B4*4@
M                            (J'W5V<*K^/O%/6I/FE&6;DS+.%1O(9)
M=5KW"6Z%+YL_+02SCELXTDKP.=GE,O(WW=KN=.:)0B!: #8!ZJ<)+8/L?X6X
M\IE4A$;D'K[+GF2;4ZEQC7MNWG\@G6TI5W1R8QE1N]Q=GC)7=^'J(MRD6DPH
M2
M
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M]R1-6VTN2;+5-IUGZ$MH Q
M                                      &K_P!T6;?H#U=\Q;WO\?S]
M:U^$]W;W]?XEYMBFN>SI\2;T\OZJ[>O87;UZ^1KIY495^*!6,BY   +;'B[A
M'\,^,W'76_B\/\/M%:CPCP_[E^E, Q^A\7]-?_I?P.G\]?[/YQ_M''GFEWJ
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MM=?O+D[#N<6@RZ^2EJSPK4[#3</8&6-N-+.57V5VU.12U;I);7WRI<F.ZEZ
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M&G7\4V)$9C]REQXC6:4DXXR5=#5%4VO]BB,Z)C2=$LQ!
M                                                           "
M$?\ =89S^8;YXFZT\_=^DM19WG/QO)U\/\0\R@T'G\7F5V?(_AAV]WC3W>+I
MW*[>B+,?BB44D6  W?\ V[V$%EWM*T[;KCJD,ZYPG<&;O)-E3S+1NZZO,(BR
M'R)AYMM+$_-&5-K6;9)?)LTJ[^U*L;_"+&<4I
M
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M#:7H\F-(94MI^.^TLE(6DS2I)D9&9&,1[       XIFV>8/K3&[#,MC9GBF
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MV_G+Z5-^-USQ;"NL%BONI-EI9^>OPAE3:C-?<R:#)7::4IIO\26\$8@
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M,&AQC%J6JQS'**L81%K:6AHX+%945-?%;(FXT&NKXK;+3:?HAM!$7T(4)?:
M                :,/N%.+C/(3U[9EG556E+SOC/;P]RT+[+*%358E%3^2;
M0K3D*_$S5MXA/7<R$E_3':-C_8&5)TD5U N0  ";G]K#OQW(M'<C.-UI--R1
MK'/\>V?BS$AWN<_3^S:J12WD*O;Z=40:>_P5$ETOV$_<=?VJ,5WYZD)68K2
M #IG>G(;2G&;"FMC;ZV-CNK\'?O(&--9+D[TABM<O;./.E0*Q*XT>2Y\F5'K
M7UI+MZ=&E?43$3/(8>_YX7UD?XYFG?\ XC;_ /(XGRV]@Y5AOM2]<V>WL/&L
M:YE:&=N;!Q#$"-<9O Q9F9)=63;$.-/RDJ6O?G2G5$AEA+IO/.*)*$J49$<>
M6?8,^VW&WFVWF7$.M.H2XTZVI*VW&UI)2'&UI,TK0M)D9&1F1D8@?V     P
M;Y&>RK@OQ0D3ZS>/)77&,9/6^1,W!J>PE9SL&*\VLVB8G8+@D/),IJUNOD:$
MJEQ6&NY*C-9)0LTS$3/(:F=A?=!<#\:D2H6":UY&;*?9)[X]FQBN%XEC<Q24
MR$L$W+R#.TY(REUUMLU&Y4)-#3G=T4M)MC+R2:NF/]:NX_\ ^*EN+_\ '3"O
M_P"2)\DHU9/:E^Y=]=6P)T6MSB-O'2+KSGB>MLZU_!R#&F34\:&5E-UED><W
MJFS:-*EJ76-$VHU%]4I):H\EDZMVFEN0&D>1F)MYSHG:N"[7Q5?A2];81D==
M>HKGWTK4W"NHL1]<ZBLNC2NZ+-:8DH-)DI!&1C#28YCM\              =
M,[CY%:$X\U#5[O7<VLM15<E#JX,C86:X_BKEH;/],:IH=O/BS;J2G_<HC;SI
MG]"29B8B9Y#4WM/[B?UB:X?D1*396P=PRXOG2^SJS5^1.,>=GZ>"/:["_A]2
M3O,?\QV/)=CJ_;Y"(3Y+#$.^^ZBXC1_D?I?CIR-N.UY*8OY\>LL;\T<_Y[LC
M\OS;*OC/)_D;3Y4G_P"60GR2C5ZU']U+Q2D=/U)QLY"5/]4H0?Y',UQD/2&?
M9Y7R^?E.,]9*.JNUKZ(5T+JXGJ?1Y)-65FL/N//65L&5$B9#EVV=.+EK)I+N
MS]664B*PZLDDTB7+U?8[,CQD..*[3=4HF6_JIQ:$$:A'DLEMTTKR6X]\CZAR
M\T+NK66W*^.RR_/_ $%F5%D4ZG2_T\3=_4U\UVVQ^2KN+]S-8CNEU+JDNHC2
M8YCN\0            ,,N0'L/X0\6W9L+>O)K56$WM:I:9^'-7WZLV!$-'?W
M>?7>$L9)G+:>Y"DD9U_12R-)=5?03$3/(:GMC?<Y>OC$GGHF%XKR&VJ\E2R8
ML,?P3&\;H'2;6V7<[*SC-L>OV4O(6HV^E6L^J#)9(ZD9Y>235B_:_=;:E9>;
M32<.]BV$<VNKKMKM;&J9Y#W>HO&VQ$Q"]0ZUV$1]YN(/J9EV_3J<^24:OL8Y
M]U?H64MHLNXG;=HVS=>)Y6.9SAF5+;92R:H[C2+.'AQ/.NR.B5H-2";1^(E+
M/\ CR2:LW]2?<8>LK9S[$3(,XV;I.7*>\##.V]9626#69]$*?M=9SMETL%E9
M_P#K)$EIM'[5J20CR62W"ZFWAIK?6-IS#2>U=>[9Q?N:;=O-=Y?0Y?7Q)#R#
M<3"L7Z.=-*LL4$E1.1I'BD-+2I*T)4E1%CI,<QVD          *]'[D_./U9
M[,+BA\WE_ACI'4^#]G=U^/\ F#-[LGP].OX.[^(7DZ?^?U_E%U/A0T#C( $G
M[[6+!TVG+[D#L-UA+S>'<=EXPRMQLG$19V=;&PZ>U(:4J(X3,LX.#R6DK)]I
M?B==22'$J4;>%^1"=0*D@        #KK9VW]4:4QM[,=P[+P/5F*,*4A>1;!
MRRBQ"G-Y*#<^,U/OIT"._+6DOPLMJ4ZL^A)29F1!S&HS;_W"GK%U2_+@U>U\
MNW)9PNY+\'4&N[ZV84ZGKT:B9%F!81B%CWD1&3D>Q=9^O\\CZD67DL,$LI^Z
MKXWQ')!83Q;W=D#24=8B\IR7 \/<?<^2M/;(;J9><IBH^(25]R5O'Y#-'3M(
MG%3Y)1JX=7_=<:O<ELHM>&N>PX"O)YY-?M_'K*6WT:6;7AA2,&J67N]XDI5U
MD-]J3-1=QD23GR2:LCM<?= <$,G>CP\^UQR'UA)=[//8R,6Q#,,;B]4H\G?,
MQW-59&[V.&KIV5!]R$D?T,^TH\DIU;9N//LIX*\J),2LTAR9UIE&23R;^'A=
MM9R<&SR6MPR0;<+!\\AXUE-BIIQ1)6J-$>0E2D_BZ*29XS68YC.(0
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M4\;YUI0X%L+&<COH%?WMM_F4FDKK%ZU:K/*ZE'R39\'D/L[N[Z!I,<QD4(
M          &-^Y>8G%/CQ<0<>WGR+TSJC(K*,4Z#CV=;#QC'K^1 5]$ST4D^
MQ:M"@+471+YM$TI7T)1G]!.DSR'3/^=+]<?^.UQK_MKXI_R@&D^R0_SI?KC_
M ,=KC7_;7Q3_ )0#2?9(R4TMR$T?R-Q^TRS0^U,(VYC%+<+QZVR# ;^#DE/
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M_P!&9PU_[GJW^NUN/S^Z_M%_K?0'TQ_T#TK^ZQ^&S9(*'[L
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M%9NW>05>.4==>W+RDK>M[B%618UG9NJ2VTE3L^:TMU1DE)&:_P!A?L%"7(P
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M_OMFO]'/>?Y26S?^BNMQTN__ $__ "Q^^W/] O\ 0U_[_E_D8DA<<)[:
M      #"_P!B')%'$GA5R+WVS,*%?8;KJTB8.Z?C-7\1LM6QAVO3)I?]/:9S
M*^A.O)21F4=MQ7[$F93$:SH*JQQQQYQQUUQ;KKJU..NN*4MQQQ:C4MQQ:C-2
MUK49F9F?4S%Z'\  "8G]K3Q296G?/,[(ZWN=;>8T+JV2^A1>+HS5Y?M&U8:>
M;)*_(E^@A1I32OITGLF?U60KO/@0F)BM(                          /
MD9!D%#B=';Y/E-W48UC6/UTNXOLAR"RA4U'25->PN3/M+>VL7HT"MKH49M3C
MS[SB&FD)-2E$1&8"'_[,/N0I*)=_ICU[+92RQ\NIR#DQ?53<@WWR4MF0C3V+
MVS*V/C-D71-[;,+\IFOXL)*4L37+*T\90B,9IF^9;'RBYS?8&59%F^8Y%,<L
M;[*<KN;#(,@N9SO3OE65O:2)4Z8\9$1=SBU&22(B^A$0L'%P           6
M=WIFPH\ ]7_#BB-HF3GZN>S7L2E*2,ME9;DNQ2=Z)<=+J^65=YGU(S-74R2?
M5)4V^*4MG Q   537L(S<MC\[.8N:-2?F0KODONIRHD>1#ODH(6P;^MQ[]XU
M)F,+[*.''3U;=6U]/P'V=HOCE"&'PD %MEQ?H7L5XT<=\7DE(*1C>B]24+Y2
MXZX<HGJ? ,?KW2DQ'#-<602XY][:OJA75)_L''GFEZ'*/D]J'A[I/,=][NR$
MJ'"</B),F(Y,R+[)[V7WMTN(8E5NOQCN,GOY2?''8):&T));[[C,9EYYN8B9
MG2!6C^P'V [L]AF[)NU-J33J<:J3FUFK=6UDU]_%=9XJ^^APJ^O)Q#!6>069
M,-.6ULXTB18R$)_"S&9BQ8]M:Z?6A@H,@  &0_$;5?\ ''E/QRT\N,S*B[,W
M?J_"[)J2CR12IK_,Z>ONWYC9$:G(<6H>?=>21&HVD*(B,^A'$\(%L^*$@  Z
MJW;NW5W'35V7[FW-E]7@VNL&JW+7(,@M7%$AM!*2U$@0(C27)EM=6TQQ$:%"
MC(=E3)3J&64+<6E)A7L^U7W+;C]@>2VVO<(DWFJ^*%59$6/:W8E%#O=A%7R%
M.0,JVW*KY#S5G->=2F1'I6WG:FL4AHR^3*:^:NZM8CZT-*@R        'OU5
MK:4-I6WE'93Z:ZII\.UI[BJF2*ZTJK2ND-S*^RK;"&XS+@SX,ME#K+S2TN-.
M))23)1$8#/SG![%=M<]L)XR5>ZF&9N>\?L.S'#[C-XZF&OXBN9%;4TJ+E5E6
M,1([=;D2ZFBBQK#QJ6Q*D,');2SYE,HB(T&O02 #>G]N;A/ZJ]HFM+WL[_X:
M:UW%FW=W=OB^?A,[7/?T^7'[^OZ_[>G8_P#SNOC+IY6\;_"+%,4I  !@Q[-\
MU/7_ *\N:.3(>^-(1QOVQ109!=_='LLOQ*RQ"L?;-"5&3S5A>M*09EVDLB[O
MP]1-><"K %Z   6KWKOP@M<\#.'&'*C?#EU/&C2[EM'\:&O'?VF 45QD7X$1
MH9EW7MA(5U6V3JNO5PU.&I1T3SE+,@0 "M;]]=K;6OM<Y3G;1I$/\ND:EJJR
M*_W=$5,+1VM4PY+!K;;,X]H:US$_M(CD&1&9?474^%#3Z,@          &\W
M[=/!"S#VB:ONU,H>;UEKS;^=K)PT=K9R<)GZ]9>)"WF_(MN3GJ#21)=4E719
M)+M[T8W^$9U_=86EF[O?B92NQ9"*:OU)GEI FJ;9*+(L[?,:^);Q67DJ^0N1
M#BTD);J5$2$)?;-)F:E],<9**.+           &2W## BVER_P"+.N'&/D1\
MXY#Z9Q><V;2'T)K+G8>/0;1]]IR/+:5&C5SSKCO>TZ@FT*-25%U(XGD+9 4)
M          !7P?<A\EG-T<^G=255@N3B'&/"*? V([4@WJ]>>Y8Q%S;/;2.C
MKV,S"9L:JHE$1=?+2=#Z]!;2."$?@9@ R(XDZ!NN4W)G1_'JB.0U*VOL7'<6
MG3HS9NNTV./S$RLNR+QDE9K:QO%8LV>Y]#_=QC$3.D:BV"QG&J+#,;Q[#\7K
M(U)C.*4=3C6.TT)*DPZBBHH$>KJ*R(E:EK3&@5\5MILC,S)""ZF8H2^X
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MKO*<FG*F3Y'87;'B1FTI;AU=3 9Z-1845IB'$92EIEIMM*4E;$:<D.L@
M     !MS]4OM<VGZ[-H0*JSG7.9<7\QO&E[4U6EPI2ZPYOQ(DK8>O694AABL
MSBJBQFS<9\C46XC-?&DFE91I47&U?-]8L>=8[,P3<VO<.VKK#)JW,=?Y]05^
M38GDM0Z;L&UJ+)DGF'4I6EN1%DLF9M2([R&Y$60A;+R$.H6A-*7.@   >M-F
MPZV'+L;&7&@5\",_-G3IK[46'"AQ6EOR9<N2^MMB-&C,-J6XXM1)0DC,S(B
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MAUGH_L;D=L+(&9"D]%.5=+BNO\,C,)/Z$IEBRQR:HOY>]U?U_8157YIA(J&
M     -3/M#]M&E_7#A2*N0W$V/R+RVH>FZ[T[#G&QX8BW'(C.:;"L(R'G<;P
MR/+;632.A3;=YE;$1))1)E1<JU\PKVN5W,'D%S5VA/VSR$SZQS&_=5(8H:=*
MG(6'X-3/NI<1CF"XRAYR!CE*UXT=R6R5(E.)\\IU^0IQY=L1$<D,9!(
M    .R-1;>V7H;8N*[9U!F5U@6PL+M(]OCN34,GX\R))861K8D-+2Y$LJN<U
MU9EPI+;T29'6ME]MQI:D&F-8TD6,OJ4]JV"^Q_5DF!<L5>%<E=;U<%6UM=QI
M!(@V\):VH+>R<!9DONSI6&6DYQ#<EA9N/TLYY$9];B'8<F73:LQ]26WD8@
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M.Z-3FA.T]0[0UHIQ9MMIV!@&5X::W"6;9MH+(JFM-2R<2:>A?7J703J.KP
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M9:ZVT\$) OVU7^C3@_\ ?MM;_P!#&1C?XDM_XP
M          &JKW=?Z++EY_8?AO\ =6P(<C:?VBOU_O/.O5K_ &[ZG^JI_78U
M9^._:$   L\?3_\ Z,SAK_W/5O\ 7:W'Y_=?VB_UOH#Z8_Z!Z5_=8_#9LD%#
M]V                 ,;>9?^"!RL_R;=Y_W,,H&>+]+7^-'X70]T_Z8ZE_<
M-Q_575/@_2/G"  "?]]LU_HY[S_*2V;_ -%=;CI=_P#I_P#EC]]N?Z!?Z&O_
M '_+_(Q)"XX3VT          $53[IW>[F.:$XZ<=*V;XI.T=CW^R\D98<43R
ML>U=3,U%7!G()1).!:Y!GZ9+9*2?<_4D9&7C,CLI'BB4(06   +2WU><=F.+
M? CC+J1<#\OR"-K6HS+.67$$4I.?[')>>9E&EN]5+D+J+S(78#2U'](T1I)$
ME*4I*BTZREGR(                         !U5NW=NKN.FKLOW-N;+ZO!
MM=8-5N6N09!:N*)#:"4EJ) @1&DN3+:ZMICB(T*%&0[*F2G4,LH6XM*3"O4]
MK'N0V_[!\GLL PQZZU?Q2I;3NQK6S4HHMUGZJ^3Y:_+MM/P)+S%G8K=;1(BT
M[;KM75*2WV_(E-G-<NK6(^M#2R,@ >W @3K6="K*R%+LK*REQX%?7P([TR=/
MG3'D1XD*%$CH<D2I<J0XE#;:$J6M:B2DC,R(!O\ .&WVZ/-/D;%JLNW2Y6\4
MM=6*&Y+9Y]5R;S;$Z(X;:D.P]5PYE6_3]R36E2+VQIY;:DD91W$*(QA-XCD)
M(^@/MV/7!IJ-%DYMA>9\ALF9)MQRXVSF%DQ4-RNG1XX6'8&K#\>7!69GVLV3
M=FI!?M<4HNX83>92V>X9PIX=:ZC%%P3BGQSQ)KQ&TXJ@TKKFMDR4**,EPYLR
M-CB)DYUTH;7>MY:UK-I!J,S272-9';U?JK5]3#9KZK6^!5D"/Y/!!K\/QZ%#
M8\KJWW?#&C5S;+?D><4M7:DNJE&9_4S$#2O[M>$?#:UX+<@=[7>B\&QW:.K,
M-3>X1L/ J.!@^4M9+.O*>CIHE]/QNK2G*J*58VJ&WX=FS):2VXM32XKIE);R
MK,ZBN^%R   6V/%W"/X9\9N.NM_%X?X?:*U'A'A_W+]*8!C]#XOZ:_\ TOX'
M3^>O]G\X_P!HX\\TN]0 !\F^NH&-T=SD5J[X:NAJ;&ZLGNK:?% JX;TZ8[W.
MN--)\<=A1]5*2DNGU,B^H"H)R2]G93D5_DUFM3EED=U:7MBXIUYY3DZWG/V$
MM:GI#CLAU2I$A1FI:E+5^U1F?4QR$/B@/>K*Z5;V5?4P$$[.M)T2NAMJ6AI+
MDJ:^W&CH4XX:6VR6\Z1&I1D1?M,!;_,HI\1QUIMZ9'K*#&*5M#L^SEM1XM?3
MTL$DN3+"?)4TPQ'B0HQK=><4E"4I-2C(B,<=*N-]T'LTN.?_ "$E8_@UO+:X
MPZ<M+&EU+4(\L:/F%HWW0;S;-Q&62'7IV2J0INK0\E*H-.3:2;:D/S#=NK72
M/I0TRC(?J4J6I*$)-2U&24I21J4I2CZ)2E)=3,S,_H0#)W$^$G,_/:EF^P;B
M+R>S.CD)2IBYQ/0>ULBJ7TJ-1)4S8T^)S(;B5&@^AI6?7H?^P(U@<<V%Q4Y0
MZC@N6>U^-V^]8UK+)R'K#86GMAX7!:CD2C-]R7DF.UK"&2)"C[C42?H?U^@:
MP-F'V^NK/XF>T+2E@^PB36:IQW9.T[1IQKRI_P""<-L\8H7R,VW$-+AY?EU<
M\E9].BFR[3)1I$7^$6/8I2 ..9AF&+Z^Q3(\YS>^J\6P_$*6RR/)\DNY;4"H
MHZ.HB.SK.TL9CRDMQXD.(RI:U&?["^G4_H KA?;Y[4LQ]B>WSI,5E66.\7=9
M7-@WJ7#'$/5\G)Y9H^#(V?G,/S+*5DMPPE::^.X792USIL-I)]^<])NK73ZT
M-.PR !YXD25/E1H,&-(F39DAF)#AQ&7)$J7*D.)9CQHT=E*W7Y#[JR2A"2-2
ME&1$1F8"1QP;^V_Y.\@ZZFV!R8OO[UW75DRS/B8O8TRKW=MS#<Z+0F1A[\BO
MKL!1):ZEW6[ZK*.OIY*TR,C&$WB.1HD>Z;^WY]8FI8$5NUTS?;FO(S:6UY/N
M#/LGN9<GZI4M3^.8K,P[ C-:T$?4JCN275)*(E*)6'GLEE,]ZI/6X_7G6+X4
M\>4QCCHC>1G7E/'L/&VE*4J*V8::M2D&22[G2>\JCZF:C,SZQYI]HQ*W+]O7
MZQ]KPYOY%J;*M)WLM3KGZBU'L/)H;C+KGD4@FL;S:5F^$L1T.+Z^-FL9_"1)
M(R(BZ3%[0(^_,G[9_DKIRLMLVXLYS7<E\5KVI,Y_!9E8S@^WX4)HG'C:J:]V
MRGXOG;L6*WU5\:77SY3IDW&KW%F21G%XGFC1&NNZ.ZQFYM<<R2HM,?R&AL9E
M/>45W7RZFYIK:ND.1+"KM:N>S'FUUC EM+:>8>0AUIQ)I4DC(R&8^6   "4Q
M]JQA/S^4/)K8W9U_2NA*C"?)W=.S]?[#HKWL[/EH[O)_#3KU\#G3M_IC?7M=
MPOR(3CA4D  &EK[@K-#Q'U7;_A-.^&7G%YJ+"XKA)6I723M;$+^Q:21,/ME\
MFEQV4T9N&VDDK/M5Y.Q*LJ?$*WX7( 'TJ:IG7]Q5458UY[*ZLH-37L_4O-.L
M934.(UU(E&7D?>27T(_V@+??%L?A8GC..XK6DE-=C-%48_ 2EM#*4PJ:OCUT
M4DLM_NVDDQ&3T2GZ)_87T''2^Z  -6_/[U$<2_8;*@Y9L^LR/!MNU-6S2UNW
M=;3H-7DTFHB../0Z;**ZTK[7'LKJXCCJO$<F,4Z.V9ML2F4&:3RBTQ]0T=YW
M]J)%4;\C67--]DB2KXU/G>DVY!J5VNJ2;^28_LB+V)-9(29)JE="-2NOT)!Y
M?,^A&C53SI]#G)C@KI'+^1.8;:T5G.LL.GXQ6SH^-V6>U^>2I.69/"Q>M.'C
MEM@R*!;+,FS8=?,[DEH;\G:E?87?E%XF=!H[&0 /:@095G.AUL%E4B=82X\&
M''2:$J?E2WD,1V4J<4A"5.O.$DC49$77ZF DZ_ZJ_P P?\8;C7_[?:'_ ,@#
M#SP:'^JO\P?\8;C7_P"WVA_\@!YX-#_57^8/^,-QK_\ ;[0_^0 \\&A_JK_,
M'_&&XU_^WVA_\@!YX-&W?TX^F'<'KDWSLS<VV-F:LSK]7:CDZQH(>OU9>N9!
M_-,RQ/*K638*R*@HHR8R_P!(1DI)ORK-7_DD1]V-K:I;;.:'!'C?SWUO#UMR
M(P^1<L44N9987F&/V!T.>8#;V$9N).L<3OT,RFV4SV&6BDPID>963%,,JD1G
M5L,*;QB9CD(\6>?:CZ]F*E.ZPYDYGCJ"4^Y!@YYJ&DS-2TD<Q4:)*M<>S? R
M:4HE1T+D(A+[>QQ9,GWI0WG\Q&C G>?VRO*K4^%9ML/'^0''G+L7P+&,AS&Z
M.^?SW!;==#C-787-F[%CEB>54R9:*^#WDF18,,D9J)3I$DE*F+P:(V S   2
M#.,WVZO*?D[H/5?(#&]R:,Q3'MLXG!S*CH,J5L5K((%39K>.O_,D0,(EP?+*
MB-H?2;+KK2FW$FE:B,C/";Q$Z#O/_57^8/\ C#<:_P#V^T/_ ) #SP:'^JO\
MP?\ &&XU_P#M]H?_ " 'G@T/]5?Y@_XPW&O_ -OM#_Y #SP:,O>!'V[7(7BY
MS T3R#V9N;1^4X9J?+9&6V5#B*L\>R&PF1*"Y9H$UR+K$:JL[H^12(CKIN2$
M=K+:U)[EDE*HF^L:"74*T@        #X&5Y-3X5B^29CD,GX=!B5!<9->2^W
MN^+3T-=)M+.3V]4]W@A15JZ=2Z] %2)NG:%WNW<.T]QY*:_S_:NQ,RV'<(6\
MJ1X+#,<AL,@DQ4/*))J9B.3S:;Z$DB0@B(B(B(N0AUF  ),OVOV@&L]Y@[4W
MY9Q%/UO'[51UM*]V="AYYM^9+Q^LE>8^J326#4&1L*;(B4HY"5=Q$DTKPO/#
M0A/!%20                   %>C]R?CK-)[,+BR;)DEY?I'4^12/$E25F]
M&9O<32<@U&9+>\&+H(C3T+QDDOVD8MI\*):!QF #O_B==*QKE-QIR)"'7%T&
M_P#3=TEMEXX[SBJK8N.3DH:D$E1L.K-CHE?0^T_KT^@B>0MIQ0D  $ 3[G+-
ME9)[#<6QE#BOCZ\XX:]H5L?7L38W65["S"3)Z'_ZU^!D,1"NGT[64_R]>MM.
M2)1U!F "P*^V4QPJ3UQW5F31-_K'DEL[(S43RG3>.+BVM\1\JD&9E',BQ;L[
M"Z$9()?[5&*K\TP^![S_ ' _WH&+R^+O'+(V_P"^>SJE2[EF6U3[3KNA\-M6
MFU1YB5FVZTULC+(#JCK&NOFJX:OS!9-K<KS>5KKQGD(#LV;,LIDNQL9<F?83
MY+\V=.FONRIDV9*=6_)ERY+ZUO2),AY:EN.+4:EJ,S,S,Q:AZP#:YPB],W-S
MG+"K<PPO!HFLM/V"FG&-O[<=G8OC-O#<0AXI6&U#4&=E>;QWF3,FI=?!75J=
M2;;DQI1'TQFT0)'.H/M8^+U!!CN[QY"[JV5=I:(WFM?P</U9C1O.,J0XVN';
MU>RKR2TPXON;6BPC&I2"-2>TS;&$WGP-'=^5?;)>NN\@N,45_P C,*G%!1'C
MSZ;8^-6:2F-&XI,^7$R? +MN0I]2DI>:;4PA3:>C?B49K#SRG1H"]B_V_?(#
MAGA]YN?4&5_WQVDL:AS;C,9%?CCF.[(UW1PD')EW>08JQ8W42_Q>JB$;DNTK
MG^Z,TVX_)AQHS:W4Y1>)YH1^!F   F!_:N\DI2+7DCQ'MYJW(4BOJN0."1%O
M$3<25#D56 ;)2VVOJ;B[%F=C2T)09=A175&1]QFFN\>)"9&*T@    "-Q[RO
M<8CB3C]GQ7XUY$VKDWEM0R>:9I52(LG^!.*7$?RMDTM#CJHVTLBKG4.5[:D$
MNK@O)GGVNN0C7G6NO&>0@4S9LRRF2[&QER9]A/DOS9TZ:^[*F39DIU;\F7+D
MOK6](DR'EJ6XXM1J6HS,S,S%J'K  #(+CAQ5Y"<N<\:UOQUU9D^S\I[6';!N
MECLQZ7'H<EQ;3-GEF3VC\#&\4JW'&E)3(L)<9I:T]B#4OHDXF8CF)1/&/[6%
MV3!K[WF#R)?KI<AI#LS76@*^*\]![S0ZEJ3L_.:N5$=EH;,VWV6,;<90Z1FU
M*=01*5A-_8:-K^'_ &[_ *K\9AMQKK2F9[">1'2RJPS#=&U(4QYPO'UEN(P#
M*<'@%(5V'U)#"&OQGT07X>W'SV2_O+?MX?5;D<1V/3Z0S# 7G(_A1/Q+=.V)
MDMESO4KY;2,ZRS-()R.BB3T6RMKH1?@Z]3-Y[#5+RB^UD;9KIM[PXY!3)<^.
MA]YG77("/$_X0)/[TF*_96#4D)F))[$J;99E8^;3BU)\LME)*6,HO[4:(L'(
M7C/O?BGL*;J[D%K/)=99G$0J0S OHJ#@W5<3SD=%SC-["<E4>3T;SS2D(F0)
M$B.:TJ3W]R5)+.)B>0Z+$CNCCSQ_VERDW'@NB=-8Z]DVP-@7+-34Q$D\B!7Q
MR)3]ID-_-98D'58UCM:T[,L):D*3'BLK7T49$DTSIQD6>/ /AMBG WB_@/'3
M%K^TRMS'BG7>5Y19R)O9D.;Y"ZB;D]I45,J9,CXU1/3B[8E?',FVFD$MPW9+
MC[[M$SK.J69H@  !!@]Y_N=L-\7N5<..*V6*CZ'HI<FAW!LK'Y:DN;FO8$IV
M/8XGCMK&<Z.ZGK)#/8](95X\B?2HTJ76I;5,MI73C/-"+P,P ?J4J6I*$)-2
MU&24I21J4I2CZ)2E)=3,S,_H0#?WP0^WKY9\KJNGV+N&8UQ<U%:IBS:Z3F=%
M+M=IY54R$)D-3L>UQ\JI74UTQG\+<JZF5[AI6AYB-*9,C/";Q'(26])_;M>M
M'5$*(>6:\S;?%\PT@WKS:VP+YMA<HT-D^MC&M>O8+C?Q#<2KQ-2HTQ3:%=%.
M.*(EC";V2S+B^J3UN0X":YKA3QY7'0TXT3DK7E/.GFETUFHU6DUJ19K=(UGV
MK4\:T%T))ET+I'FGVC&[;7H+]7VU8,IJ-H.7JRXD-$TUDNI<[S#&IT(B9)E*
MXM%:VV0X(IU/:2NYZH>-2RZJZ]RNZ8O81N>??VXO(+CK3WVT.+>13.2VL:=E
MZPL\*_*/R_>6.UK2%..O1:"K2_4[)C1&V^YU=442S4:R)NL6A*W2SB\3SYH1
MM5)4A2D+2:5I,TJ2HC2I*DGT4E23Z&1D9?4AF/P  2@/MRO9!8:>V^QP=VI>
MJ7JC==NX]IV;:2U>#!=Q2B4M.,P3=/L8I=JF7@2R1F2;Y$;Q()4V2L\+U\8$
MZ85)    =<;BS0M;ZBVGL13OA3@6N,XS0WNU"O"6+8S:7AN]KC$IM7C*#UZ*
M:<(^GU2HOH85$ Y"   67?HOPC]">K#BC!<:[)=_0YUF\QP_YTC]:[3S?(ZY
MU22==0GQTEA%:+M[>J6R-224:B%-OB2VUC$    :D?;5[2L)]<.GV"J&:G,>
M1^R(<UC4>NYKKRH4)AKOBS=C9JB*IM]G#L?E&2&XZ7&9%Q-Z1F%H0B7)B95K
M,_4*X?:FU=B;OV%E>UML9?>9YL+-K5ZYR;*<AFNSK*QF.DEMM'>X?9%@0(K;
M<>)%92W&AQ6FV&&VV6T(3=$:(=?@ #-'AIZ_N4O/+,GL4X\Z[DW595R8\?+M
MC7[CM#K'!DR>U3:LHRYV-(81,6PHW6ZZ$U-MI#*5K8BNI0LTQ,Q',2S^,GVO
MG&;"8-=;\I-K9UO#*?"RY/Q;"'?X8ZVCOK)MR3!.3'.QSZ]1'6DVVYC=C3^5
M!FI45"C22*YO/@:-KN'^GCUD8/$;A4O#/3TUEJ.F,E>85]QL*6;:?'T4Y89_
M<Y-/>D?NBZNK<4Z?4^JOQ*ZX^:WM2\.8^G'UB9U&=BW?#74L%IYM+2U8<QD&
MNY))03J2-J9K^]QB6PX9/'U6A:5J,DF9F:4])\UO:-/O*_[7?2V45]ID'#O;
MN2ZMRHD/R(6OMLR',UUU.>^GQZV%E=?!:SK$XQ%U[I$I&1N*/H78DNIE,7GQ
M1HB$<D^+V]>(NSK34/(+7MSKW-:U!2F(\]+4JIR"H=<<:BY!BM_!<DTV2T$M
M;2DHE0WG6TNH6TYV/-N-HLB8GC Z!$@ R%XJ\F=F\/\ ?6O.0>I;,X.68#=,
MS7*]YUY%1E5 ^9,9%AF1LL*2N5C^45*W(DE)&3C9+)UE3;[;3B(F-8T%I9QE
MY"8#RLT+J_D)K*4N1AVT<7B9! 8?6VN=33B<>@7^-6OA,VDW.+9!#E5TPD&:
M"DQE]IFGH9TS&DZ)=ZB   &*W-/EMKGA#QQV'R)V6OY-9B$!N-CV,L3(\.US
MK-K91Q,6PRE4_P!YG,N+ R-YQ#;QPX#4B6M"FH[G28C6=!5[<E.1NU>6.ZLZ
MWUN:_7D&=YY;.3YBFR=:JJ2M:+P4V+8W!=>?.LQK&ZU#<2%'[UJ2RV2G%N.J
M<<7=$:1HAT6) !)/]6'V_N><JZ;'-^\KYV0:AT'<-1+C#<(JT(@[3VO4.E'E
M1+A2["+(CX+@=Q'<ZQYCK3UG8LD:X[###L><O"U].$<Q-%X\</N,/$_'V<;X
M\Z1P#5\1$=$>59T-(R[EERA"32ES),VLSGYADT@DGT)R?.DK)/T(R+H0KF9G
MFEDD('H6M55WE=+J+NM@7%38,JC3ZNUAQ["NG1U].]B7"EMO1I+*NGU2M*DG
M_L (]/L9^WSXW<D<;R#/^*N/8YQSW[%B2Y]?28Y%33:9V#.0A+C5-?XC!:57
M8-+EJ:\;-E2,1VFG'5+E1)74E-YUO,<^0@9;&UUG&H\[RS66R\8M<,SW!KR=
MCF5XO=Q_C6=-<5SQLRHKZ$J6TZ@S(EM/-+<8?:4EUI:VUI4=J'"P !VAJS2.
MYMY7,C'M+:EV5MN]AH8=FU&M,'R;.+&"Q*6XW'D3XF-5ED]!C.K:61.NDAO\
M"OK^$^C6(YC9)K#T5>T7:/@?B<8[;":QY#"UVFS\PP7 _C)D_5LGZ&ZR1O+C
M6E!&;B45RU-=O19)4:4JQ\U1L4UA]K%RMO51'=N<A]%:YB/K)4AG#8.;[/N8
M+!MI/]]"L*G6]0[,2[U2;;5@MKM(E$Z9F:2B;QX&B5'Z[_7AIOUR:8EZLU=,
MM,JO\IMVLEV5LO(XT*-D6<9"Q#1!AD<6"E3-+C-'&[T5E8AU]$0GWG%.O2)$
MA]VN9F4L^E)2M*D+2E2%)-*DJ(E)4E1=%)4D^I&DR/ZD(%4?SQT)_>P<R>26
MB&8:X%1KW;.50<3CN?TS]!6LT\BUZ^Y_(2Y>#W%>Z?3J1&OZ&8OB=8U0Q*$@
M F)?:H[P^O*WC;/F?_@7O#%*_O\ _P"-@6P9GC,_]O&4=Q?_ $'_ $(KO'B0
MF*"M(       #6E[:>;$?@IPLV3M*JL&8NTLK9_AEI6,I2#D+V-EL.:U%O6F
M5]Q.LX131IETX2D^-Q4!#"C(WD]9K&LZ"L,D2)$R0_+EOO2I4IYV1)DR'5OR
M)$A]:G7GWWG5*<>>><4:E*49J4HS,SZB]#P@.>ZLUEFFZ-DX)J37-,]D.=[(
MRNCPO$Z9A26SG7N0V#%; ;>D.=&8<-#T@ER)#II9CL)6ZXI*$*406I_#CC)B
M'#KC/J'CGA9,O5VM\4B5UM<-,>!>49?.6Y;9IEDA!_C2]DF43I<LD*-7A;=2
MTD^QM)%1,ZSJEDT(   :=??Q_HD^6/\ ^0G_ /27TV,J?$-2'VGO_-WG-_QU
MQV_WCNH99/!$)?(K2B0_==_]77"[^S7=/]8M="RG-$MRWK9UYAVV_4IQAU=L
M*DBY)@VP>,5;AV6T,SN^/:T&0U<^LM(:EMJ0\PMV+)5V.MJ2ZTOHM"DK21EC
M;XDHH?$K/<O]&WMLRG2FVKR7'T3E-S&UWGN0SVWV*F^U'ED@K356YS0S#=97
M(PZ1,8D6"XK3JHZ"MH#9]YKZ9S[U?I0\7'/$,P]Z/MYR#:FQ(-@O1&+74?/,
MKJ9K;LFLQ[1. 63,#7.I")72#'FY])2S'GMMJ:6\J9;6#:5.(<ZI]VOTB0']
MR9&C0O66]#AQV(D2)N_4D:+%C--L1HT9AC)&F(\=AI*&F6&6D$E"$D24I(B(
MN@QI\27G^VJ_T:<'_OVVM_Z&,A?XAO\ Q@
M      -57NZ_T67+S^P_#?[JV!#D;3^T5^O]YYUZM?[=]3_54_KL:L_'?M"
M  6>/I__ -&9PU_[GJW^NUN/S^Z_M%_K?0'TQ_T#TK^ZQ^&S9(*'[L
M           8V\R_\$#E9_DV[S_N890,\7Z6O\:/PNA[I_TQU+^X;C^JNJ?!
M^D?.$  $_P"^V:_T<]Y_E);-_P"BNMQTN_\ T_\ RQ^^W/\ 0+_0U_[_ )?Y
M&)(7'">V@          KXON5=MNY_P"QR3@#;RO@Z+TWKC"%1"5U;1<93%G;
M6G333VD:9$JKSVO:5]3(T1D?[8MI\*)1]AF #*3A#IQKD%S!XS:8EQU2:G8>
M[==8_DC:4>12<1=R:OD9@^EOZ$X<7%H\QTDF:25V=#,B^I1/(6P0H2
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MB+NXC[T=;$R!KJE<7.AZZHG$/.H,HKCME*:<-$N9(03:&ZIM,_4EM@&(
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M=2W^/VEA27E-9QG85E4W%5+=@6=980WTH?B3H$UA;3K2R);;B#29$9"Y#Y8
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M%MC6B67&VY4%V9$63E=>;5:4HEOR5$]%IG4DW#-3[:I:ZK6UX1R$ET8)
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M<E7NB\B1W$CYR-CUJXN(PNY7T_'LN!1.=/VJ\?:7U,C&-_A%E,*4@
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M)A-/B#[:K_1IP?\ OVVM_P"AC(7^(;_Q@
M     -57NZ_T67+S^P_#?[JV!#D;3^T5^O\ >>=>K7^W?4_U5/Z[&K/QW[0@
M  %GCZ?_ /1F<-?^YZM_KM;C\_NO[1?ZWT!],?\ 0/2O[K'X;-D@H?NP
M            !C;S+_P0.5G^3;O/^YAE SQ?I:_QH_"Z'NG_ $QU+^X;C^JN
MJ?!^D?.$  $_[[9K_1SWG^4ELW_HKK<=+O\ ]/\ \L?OMS_0+_0U_P"_Y?Y&
M)(7'">V@          JS_:3L!>S?8MS/RI3R)+2.0FQL4@R&C)34BJU[>2-?
M4\AE:7GTN,O5>,,J0HE=%),C[4]>TKZ\H0P)$@ WB_;MZ\;SGVAZIN7VDO,:
MMP/;.PW&E^ VS<5A<_ H+JT/+2I:HMEG;+S?C)2TNMI5T)*5*+&_PBQA%*0
M                       !!'^X0]I4G?\ LBTX4:2R!TM(:CR/Q;;O:J4:
M(NU=K4,CM<HC=87UGX3K.S:4TVVKHQ-OFG)/8XB'7R!;2NG&>:$9$9@ S:X"
M\$]N^P3?M)I35[/Y55M(3=[)V-/@R)>.:TPIATD3+ZU2RIDYME,<_J:KKTN-
MN6$YQ"#6RPE^0Q$SI&HLJN('$#2?"'2>.Z-T;CI5./U)%.OKZ<3#^59[E3[#
M+5KF696K3+!V=[9FPDOHE$>)'0W&C-LQF6FD4S.O&4LHA      (L_W4^;?
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M)S_*-083'6E2T.K)6SL9RR=':4AQ'_UFIQ20VX1DHE,J673Z]2RI\0KBQ<@
M<QUWB3^?; P7!8IK3)S3,<9Q*.IOKY$OY'=0J=DV^C3Y]Y.3"Z?@7]?Z$_V
M+>V)%C08L:%#8:C0X<=F+%C,H)MF/&CMI988:;21)0TTT@DI(OH1$..E[
M             (V_W06P/TYP.UM@T9Y")FQ^1V)LRF%&P:GL>Q/"L]OIRVT*
M>3)[V;[\J_$AM2"2HR6I)J02\Z<R4"$6H  !9[^G+7J=9>L;AOCJ8ZHYVNI(
MNPEI4EY*G%;8O+K:/R#^0RPXI,A.8$M)]#1V&78I:.U1T6^*4MEX@
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M7:.PTQV4I(U+==2E)&9D0F.,Z"I=SG-,CV1FV8[$S&Q=N,NSW*<@S3*;9_\
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MMKDR,=_4V8Y;VW=V44K2;^;YSD.37I_**&W^[.5X4=OX$)ZGU3,SQD9 "
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M^^)K_C7B#,F/Y.[P7V3YWL6[FJ[$O+0WYJ,ZP^AH0X?;U/N3V=+:<D2C;C,
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M.85T-$BNP_+*[,+*,X1_M;D0*)Q"NG0^U1]/J(MRD6GPH2
M  B%?=?Y.]'Q?A#AK:NK%O?;\R>6A,A)>-['*_4E57J=B>-2U^9&4RB;<[TD
MGQK+HKNZHLQ^*)0SA8   MIN)N--89Q8XTX>P@FV<4X_Z:QIE"8OP4H:HM=8
MY5MH3"-;APR2B*1$UW*\?\WJ?3J*)YI9 "                    !6\?<"
MY<G*O:IR(BM.K>BX=5:@Q&,XIYQQ'=%U!A-Q8M,M.,M'$1'N;N2TI!&M*G$*
M<)1DYT*ZGPH:8!D #/KU7XD]FOL>X34[#;KBX?(_5^6J2T:B63. Y+#SN0X9
MH9?/Q-1\<4I9=I$:",C4@NJTQ;X9%I8*$@#X>37\#$\;R'*;5?CJ\:H[:_LG
M.YM'9 IH$BQF+[W5(:1VQXRCZJ422_E,B 5 ]S;3K^XM;VS=\]E=64ZVL'OJ
M7FG6,IV9+=Z&:C+R/O*/ZF?[1R$/F@   E"_;K>LN/O'8A\WMTX_\O56GLB*
M'I>AM(R%0<[V[4J:DNY<\Q(2HYF.ZO<6TY'4E)-R+]3?:Z9UTEA>%[>$"="*
MD@      B+_=>R(Z<'X31%/LIE/Y7O60S&4Z@I#T>+4:L:DOM,FKR.,QW)C*
M7%$1I0IU!&9&I/6S'S1*&"+  9O^M"I3=>P_@_#4^<<F>5>B+8G$H)PU*H=D
MX[>(8[34CH4E=<39JZ_A)?=T/IT.+<I%J.*$@  CJ?<?\TY/'[B-6<=L-LU0
M]A<JY=ICEP]%>-N74Z:QPH+^?KZMFHVU9?*L(-'V.)[)-=+L"2?<W],Z1QU)
M0!!:@ ?8QW'KO+L@HL4QFKF7F29/<UF/8_2US*I%A<7=U-8K:FK@1T?C?F6$
M^2VTT@OJI:R(OV@+0CUD<',:X!\3<"TS#C0']AV49G--UY/#Z.JR7:5Y"BJO
M$M3/H<BCQ=IIJHK#)+:5P82'E-D\\\I5%IUE+8,(             !"?^Y_Y
MF/9/LS6?"'$;5?Y'K.'"VQM^/%?3XI>>916N-Z_Q^P;0LG4/8QA4UZS-"B\;
MJ<@87]5-),K*1XHE$Y%@ ,W?75Q N^<O+O4O'ZO1,9QNZN2R'9UU#)25XYJW
M&%-66:6A2"2I$29*@)37P%K+L59SHR#_ )XBTZ1J+2K%<6QW!L8QW"\0IH&.
MXIB5'58UC-!5,)BUE)0T<%BMJ*JOC(_ Q#KX$9MIM!?S4((A0E]\
M! #^YLU-'P?V"8]L2!$4W&W7HG",DM9O@-M$K*\/M,BUY.9)WJI$AV)BF-TA
MJ/J2DI<2DTD1)4JVG)$HZHS !NZ^WDV5(U_[1=/4R7_CU^U\.VOK6W69+-*X
MZ\$ML\JV%$V?7^J,FP. @C,E))2B,^A%W)QO\(L;!2D  $7O[J#-SK>)''?7
M:'TM.9?R&<RMQI+R4/28F!ZZRRM=0;1/H=?B-R\]86LO&M"74M&I25=A*SIS
M1*"Z+0 9J>N#"SV%S^X98H;/R8TWDOIN=9Q_Q_OJ6@SJER&];ZMJ2M'?353Y
M=Q'^']O\@B>4BU2%"0  8 ^SWEXQPBX4;GWC$E-,YPU2IPG4\=?B4Y+VCFQK
MI<5D-,2&W(\MK&3=>NY+*^A.PJMY)?B,B.:QK(JX)LV993)=C8RY,^PGR7YL
MZ=-?=E3)LR4ZM^3+ER7UK>D29#RU+<<6HU+49F9F9B]#U@ !8]>B?@HQPVX8
M8UD^5TOP-W<C(U1M+9"Y;'CLZ2AF1'7M;8(]WH;D1OT]C-@4N9'<2EV/;V4Q
MI74FT=*;3K/T);K!B        --_OPU/&VIZO>0+IQ42;C6#^"[8Q]:TLG\.
M3BV94\*_E(4]T-"_T+=V[9&A25GY.TNXC-*LJ3[PK:1<@  %KGP,V6]N+A/Q
M/V9,F?/M<OX]ZEL[^7YDOF[E"<)IHF4DIU+CO>MK(HTI"NX_)U29+)*NJ2HG
MA*668@:3?N$=GRM<>KW<M? EKA6&TLHUEK"/(:,B=.+99E791>Q$F:B+LLL9
MQ*;%=+HKJR\OH1'T4G*GQ"N+%R !L\],VH8N[/9IQ)Q2P80_5T.Q'MI6)/)-
M<8DZ>QV[VA7MR4$APG&9MWB<6-V*2:%J>)*^B3,RQM\(LZA2D      &L/W.
MW$*C]7W,>;/6I##^L8M.V:>SJ<W(<QQB@K4?O%MI[7+&S:2?U[NA_0C/H1Y5
M^*!6*BY  SW]6>-JRKV.<):Q,=4HXO)+562&TETV32G#<I@9>N1WDI'5,-%&
M;QHZ_O"1V]#Z]#BW*1:7BA(   #H_DSIJNY$<>-W:+M2CE%VSJW-\#;D2N[Q
M5]AD>/SZZHMNJ$K6AVGM7F93:B)1I<9(^A].@F)TG45+%K5V%':65+;Q'J^V
MIY\RKLX$E/9(A6%?(<B38CZ.I]CT:2RI"B_D4DQ>AZ   LA/0%O#^-7K)TS#
MES/FWVE;G,M'WSGD[O%^D[8KW$8?89J4S\+6^64C7:9GU[.XNB5$DJ;1I9+=
M$,0     5XOW!_.#^^EYES=18?;_ #=1<6/S?751\5_R5]YLZ1)C_P 5,D3V
M'V._#M:YBC95^)'94*>:/MDJZVTC2-4-"8S !,4^V)X,*(L\Y[9_1&1+*UU3
MQ_781#(E))1Q]HY]5*>1^(NY*<=BRF3_ &E;QU?RD*[SX$)B0K2
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M_P ?S]:U^$]W;W]?XEYMBFN>SI\2;T\OZJ[>O87;UZ^1KIY495^*!6,BY
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M]"6IU7CE'73&TK0ZEN7"K(L:0A+C9J;<2AYHR)23,C_:0XZ7(P
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M*8Y",TKDN1H#7]4V=E(0AOYMU=SW'ILZ29$N3,D.NJ_$LQ1/'BEVP
M"%1]UOER9NV.'6!D_P!R\;UWMC+E1N]D_"G-LEP^F0_XTI^0GY)Z_4GJHS0K
MQ?A(C)?6S'XHE$P%@ -I/I3P\\X]I'#RE)MEWX6P;S,.U]IAY!%KW7N99\;B
M42%);)YHL:[VUD?>VXE*D$:R21XV^$6;HI2  "M%]W?*)WE+[$MUVL"P3.PK
M3LXM!8#XE$N,FHUI/LH>1S(SJ22W*CW.PYMS-9>3U)R-(:(E*0E)G=6-(0U)
MC( $B#[;WB"QOKF?8[YRFM^;@O%2CB99#2^V2X<S;.6G8U&NV'4K;-+GY%$@
MVMRVI"R6Q.KHBC(TJ,CPO.D:"P&%20            !Q?.,RQ[76%Y?L'+IZ
M*K%,$Q>_S+)[1PNK=;CV,5,N[NI[A%TZHAUL%UP_]I("ILY(;OR7DIOS;^^\
MO-97^V=@9-FTJ(IXWT5,:YLGWZJ@BNJ(C.!CM1X($8C_ )L>.@OY!R(C2-$.
ME  !.&^U[XI,X9H?;'+S(*XDY#N?(W-:X!+>:0;C&M]?2R5D<V ^226F/DVP
M%N1I*#,R->.M']/Y:KSQT(2H!@D         0TONP<?BQ\BX.94VVGYMM2\A
M<?ENE';)7Q<>G:9L:]MR4E/E<3Y<GE&AM1]J/Q&DNJEBS'XHE$&%@ -@7JFO
MEXY[(N%%@B1&C*D<B-<T)N2W";:4C*;MG&'(Z%&XT1R9;=N;3*>IFIY:4D2N
MO:<6^&1:2"A(  (7GW7.<*EY_P --:MOJ2F@P_<.<2XR'#)+RLNNL$H:Y^0R
MF6HG%1BPB4EE2F$=GE=)+B^Y:6[,?BB41P6  W)>@?"3S/VI\;W7(_R(&'1M
MJYM8EVK5XBJ-29M$J)'<EMQ"/#DMG!/JOM(_V$?<:>N-_A%DH*4@  A&?='\
MHG\HW1I/B/16'=1:LQ=S;6=QF%F;3^>9Y\FIQ:!8-FX?29C&%UKLIDR0DO#D
M2NJE_0D64CQ1**8+  ;%_5!Q49YC<\=#ZBN8"+#!(61'L7:#+[:G(3^O==ME
MDMW43R0E2TQLNDQ(U&2B+\+EF@^J2ZJ*+3I M#DI2A*4(2E*$I)*4I(DI2E)
M=$I2DNA$DB+Z$*$OT        !B+[ ,<9R[@IS+QQ\FO^%>+6^V([CWD\4>>
MC5V4/ULM9,J2XI,.P::=[2/HKLZ&1D9D<QS%4F+T   LN_17?R,D]4G$6QDD
M\3D>@V90)\\I<Q?Q\4W?LS%XAI=<0A2&3BTZ/&UT[6&^UM)F2",Z;?$EMK&(
MC;_='2)#'K[U0TR^\RW,Y?Z]CRVVG5MHE1TZ<WY+2Q(0A1)?93*BM.DE75).
M-I5TZI(RSIS)0(1:@ ;_ /[:JF9L_99"FNO--+QW1.UKF,AQE#JY+S[F,X^I
MEAQ3B#C.ICWKCAK22S-#:D=.BS4G"_PD+"<5)      !'=^YBW3%U_Z^ZW5;
M4Y*+K?FX<,QTZQ+BT/2\5P)<C8]W8&A*T)=B5N1X_1M+)1*Z.RVC)/4NY.=(
MXDJ_L6H &^W[<+2DS9WLCQC/50S>H] ZWV%L:QD.M]T-%G>TKFL,?B+6?X/G
M+E9TY,CI_G?U M9?TLS+"\\!8<BI(     K*_=5H7^]\]E/)?'HD+X>/9]EC
M.Z<74ACXT617[:A,YA<E!9(B;1#K,SGVL!!(Z(+X9DDDD7:5U?A0U6C( $N_
M[5/>2HN6\J>-=A.4INYQ[#]W8I7J=,FX[V.V"\%SR4TT9FE;L]K)<=2HRZ&2
M8I=>I=.VN\>)"9N*T@   -:7MIYL1^"G"S9.TJJP9B[2RMG^&6E8RE(.0O8V
M6PYK46]:97W$ZSA%-&F73A*3XW%0$,*,C>3UFL:SH*PR1(D3)#\N6^]*E2GG
M9$F3(=6_(D2'UJ=>??>=4IQYYYQ1J4I1FI2C,S/J+T/" [XXQ<>L[Y7;]U7Q
MYULRA>7;2RN%CL.6^T\]!HZ[M=G9#E-JB.1OG38ICT.593.PC<^-%7VD:NA'
M$SI&HM6-%Z:PCCQIS6FCM;U_Y;A&K,.I,,QYA9-_)?B4T-N.Y9V3K2&TRKFY
MEDY,FOF1*D2WW'5?B69BF9UG5+M80
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M88@YG#.<;!C/M>6%)P/6\61G&1U4\NI=D;)HM&522OVD[/0(M.D:BT>%"0
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M67I+(D&[X6Y,?;%>_BN.I>=/JE#,/.Y51+5W%VF4;H9IZ]Q8VC6!9D"E(
M"O%^X/YP?WTO,N;J+#[?YNHN+'YOKJH^*_Y*^\V=(DQ_XJ9(GL/L=^':US%&
MRK\2.RH4\T?;)5UMI&D:H:$QF ":G]LAP5;QK!\SYY9[4K3>Y]^;ZPT8W,93
MVQ,'JK%IG8&;1"<;7U>R/**TJ:*\@VW66:J<G\34LC%=Y\"$M,5I
M                                            <(V9@5)M76^P=7Y,
MWY<<V1A&5X%D#78ESR4F84,_'K5OQK,D.=\"Q<+M/Z'UZ&)K::VBT<XG5Q-_
ML\/4=AGZ?N..#/AOCM_%O6:S^Y,JF/;.L\JTOM'8FHLXA'7YAK'-<FP3)HAD
M?8U=8K<3*6P-A9_1Z([(AJ6RXDS0ZTI*TF:5$9_I*VB]8M7E,/FWU+I^XZ5U
M#/TS=QY=UM\M\=X_.I::S^QK'"?&.+KT9.$ ,F^)/+K=_"?<M'N[0^3?D>3U
M:%P+BHGH?FXIFV-R7&G+'$LSI6I,4KB@L#90HTDXU(C/MMR(SK,EIIU%>7%3
M+7R7Y._[:[FZOVGU2G5NCY/)N*\+5GC3)6>=+UUCS5GZXF)B+5F+1$Q.;X >
M_+BGR\.BU_MF1$XT[VGE'@HQ_,KAE6M<QM5)2UTPC8DIN#!BR[!_IX:NX3"E
MFZZB/&<GK(W#ZC-L\F+WJ^]3]W]IMYV7ZR]N=S>39=2F-AUBVD>6]OYJ\_T>
M6=(B9\*7\MM9BM9O/%O?'#>P@              T]\_O=9Q&X*HM\.*Y3O+?
M<)+D=O3NN;:"[^06!-FM"-EYF2)]/@;2>B>^+XYUT1.-K* ;*C=3RL.TRYN/
M*GMG]YYAWIZK]L]GQ;:^;[9UF/\ H8ICW9_I;\:X_JTM?C$^32=4%+GA[!>0
M7L)VE'V)NVXAQJ;'$6,#6^M,;;=AX3KFELGH[LV+31GG'I=A<6RH3"[&SF..
MS)JV6T=S<9B-'8[?#@I@KY:<_&?:U [Q[UZWWMU&-]U:T1BQZQBQ5X8\59TU
MBL<YM;2/->TS:VD1PK%:Q@V+GY$ >W @S;2=#K*V+(G6-C+CP8$*(TM^5,FR
MWD1XL6,PV2G'I$A]Q*$(21J4HR(OJ(Y<65*7R7C'CB9O:8B(CG,SPB(^F5K/
MPET'_>N\2>/.@G4M%::RU7BM%DZV'&G8\C-GH"+7.YD5;*EM'$G9E83GFB)2
M^C:TEWKZ=Q_G<M_F9;7\)E]&>T^C?_7NVMCT:=/F;?;4K?3E.337),?1-YM,
M?1XRRC%;]"         /FW-5'O*>VI):WFXMQ6SJJ2Y'4A$AN/8178CRV%NM
MO-I>2V\9I-2%))73J1E] %/E+BR8,J3"F,.QI<.0]%E1GD&V]'DQW%,OL.MJ
M(E(=:=0:5$?U(R'(0\   D]?:Q9:S7\Q.0&$NN--KR?CA(R".3A(2MY[$-E8
M+"4PRXIY)FZ<?+G'#;2A9J0VI75)-GW87Y$)U@J2
M  ""#]T!R%5GO+S5W'NMF*=I>/\ K!%Q=1DNF26,_P!NOQ+VP9>82DDJ-G!J
M3'W6UJ4HR^4X1$DNIKMI'#5$HRXS !(;^VKXZ-;;YZS]O7%<J5CG&K6]WE\2
M0MORPT;!S?NP3$(DE!F3?E_(K*]GQU*)1MR*U"TEW))2<+SP%@6*D@
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M9-KV3G^XLV=Z="4XJ)L"WU\VXX7[2-4?!$=.O[4$DR^AD*;_ !);R1B
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M'L-C2DM>%=O-JX+:;K(93?51)GY+=KDV$GI]#D25F70OH*)G6=4N[Q
M   K/?>5FAYS[3^6=BEQ:XU+DN$X7%:4M:D1BPC5N#XM-;92LS\:';:JD/*(
MOIY'5&7[1=7X4-38R !*Y^U/PDY^]>6FQ_!W)Q74N X2<KM6?A/8&865ZECO
M)LVT_)+6AJZ&M)GXOH2B(S37DY$)MHK2 (^?W+&V58!ZY3P6-(<1+WANK76#
M2([*C2IVDQLKG:,Z0]^))*B,VN"0&U%]3-Q]'X3+N-.=(XBOE%J !]W%\<M,
MPR;'<2I&B?NLIO:C'*AA7?VO6EW81ZR TKQ-NN]')<I!'VI4KZ_0C/Z +=#6
M& TNJ=::\U=CB";Q[6V#8E@-"A+1,)12X=05^.U:$LI6XEDDP:YLB22E$G]G
M4QQTN<@             "'9]UKM5S_\ T_TA#E]&C_BCM7(H/XOQ.)_2^(X;
M+_FDDNQ*KY'\XS_%^POIULI[42AV"P &<'K3U0SNWGYQ%UO+91)K+?>N!VU]
M$<)1HF8UAMLUFV3PC["-2?F8_CLEKN_8DU]3^A"+3I M1A0D          $,
M'[KW)&Y6<<)L/);)NT6*;UR1:$LR$R$MY7;ZMJVUNR%'\1UE:L,43:$%Y$*2
MLU_1;8LQ^*)1%Q8 #8YZA\<?RKV8<,*R.3IN1=W8[D:O%X^_P8<Q.RZ29^52
M$^(HU&OOZ'W=G7M(U=".+?#(M"A0D  %9[[R<X_7OM.Y8V+;WEB462X7@\1L
ME=R(WZ%UCA6*V#*/J9EW7-5*<677Z..*_87T*ZOPH:FQD "8C]J'@Z35S5V3
M(82:TITA@]/)\1=Q)6>S+[(V#>7$ZDE1HJE$EI_Z]#-UOZ,J%>3P(3%16D 8
MM<X-JNZ/X<<HMM1928=I@6AMI7] \J1\7KE$?#K9O%6$2?VLNR\C=BM(4DC6
M2EEVDI70CF.8J?A>@  %DQZ$=3HU5ZO./BWHA1+G9CN=;8O#3XS*4O+,TNH^
M-2^J$I,S=P.HJ"/N-2B-/3KT(B*FWQ);CAB         #"_V-Y.G#^ '-6_\
M[L9^-Q:WI$KY#)1S<8MKC6V14U,Z29*T,J)NUL&3,C[C-)'VI6KHDYCG JJ1
M>@  %FGZ1\:+$_5CP_JR90Q\K",JR7L;=?>2H\SV?G.8&\:Y'[PER3O?(I)?
M@0I9I1^ DBFWQ2EM3&(UY^U[1<OD9Z[N5NL*N%^8W[NKYV;XQ"0A2I<[)=5V
M-=L^DK*\T=%HGW4_$40FOJE"SD]CADVI8FLZ2*N47H ':>CMMY+H3<NJ]VX<
M:/U1J;8.);"HVGEFB-+L,2O(5TS7S3)*^Z!9?#./(0:5)6PXI)D9&9&F-8T%
MKOH3=N \D=,ZVWKJ^U1<8)M#%*S*Z"42VE2([<YLTSJ>S;:6XF)>8_:-/P+"
M.9FN--C.M*Z*09"B8TG1+MP0    -,_N3]H6,>OW1%AC6%7-=8<IML4LZKU3
MC33L:5+PNNFID5T[;V205&X46HQU:7"JFWVU)M+AM#1-N1V)JV,JUUGZ!6]3
M9LRRF2[&QER9]A/DOS9TZ:^[*F39DIU;\F7+DOK6](DR'EJ6XXM1J6HS,S,S
M%R'K ,S_ %_<.LMYU\JM9<>L9.7!J[ZQ_.]BY/%8\Q87K"@=8DYEDRR41L%+
M;A.)B5Z'32U(M9D5A2D^7N*)G2-1:8X5AN,ZZP[%-?X741,?P_!\<I,1Q6B@
M(-$*FQW'*V-44M7%09J44>!70VVD=3,^U/U,S%"7)@     !J)]Y^@SW[ZT.
M0<2%"3,R+4M=5[XQQ1M)=5#7K"6=IETIM)F2TN*UI(O&2-)DHO+_ $1=4JRK
M.DBM/%R !]O&<BM\/R3'\MQ^6NOO\7NZG(J2>W_3(5O23X]G6RV_J7XXTV,A
M9?[:0%M]I79U1NO3NJ=Q8_V?DFU=<83L6I2A?D2U S3&ZW(HK!J_;WQVK$D*
M(_Q$I)D?0R,43&DZ)=FB  :TO;3S8C\%.%FR=I55@S%VEE;/\,M*QE*0<A>Q
MLMAS6HMZTRON)UG"*:-,NG"4GQN*@(849&\GK-8UG05ADB1(F2'Y<M]Z5*E/
M.R),F0ZM^1(D/K4Z\^^\ZI3CSSSBC4I2C-2E&9F?47H>$!DWPWXQ9CS'Y+ZC
MXZ84B0U8;%RJ) N+EF.<AO%<.@DNSS/+I:.GC./C>,PY,HD*-)/NMH92?>XD
MCB9TC46J.L-;89IS76$:IUW2QL=P;7>+TN'XK2Q$)2U I*& S7P6UJ2E)OR5
MM,$MYY75Q]Y2G%F:U*,Z$N=
M                 "$S]REZ_P"PPK9=3SQUO1K<P?9GY/A^]&:Z+U:QG9%?
M$;J\5S2:A@^V-59W10V8#[OC0TW;0$J==4_9MI/MMAFUK\FW..7U?\/_ )R:
MG>O/9=]IOZ]X["G_ &FX\M-QI'P98C2F2?9&2L169TTB]>,^;)"*@.Q:Z
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M;T=A]BXVVEYB!C->SG&>M1UJ3YU1+.;D= 2C(R;-V!T_$I!]M=Y\"$N<5I
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MW%,&L=6V3#AH-Z$]JS*+W!*]AWQ_@)+U#10Y#1=3/P/H[NBNI%3;XDMJ(Q
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M:[SX"4B*T@
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MC6M:QY:QI#7#>[[>]2W5][U#+DS[O).MKWM-K3/TS,S/#E'LCA'!PL9.*
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MF*$N3
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M;$B#D^@\OL?%T2P["D2=AZYA&^1F:U2T3\J<))].WPF9=>Y72RD^")0^A8
M L$OMQ.7L??/";^!&06:)&Q>*]S^CS8>=0J=8:KR=^?=ZYM31^ S9J7$V-$E
M*$&34>ICFM1K>^M5XTG5*0H,                    !A%[+;ARC]>7-Z<T
MUY7'.*V]:M)>53)M_GNM\AI#D)6E*C[XB;$W4E].XT$74NO4ICG JMA>@  %
MI+ZJ(,2N];O"B/"9)AESCMKB<M"5+42I=I1L6<][JM2E=9$Z6XX9=>A&KH1$
M70BHMSE+8"(       8R\Q^3>(<.N,^WN1F:&R]7:WQ278U-.Z_X%Y1E\Y;=
M3A>)QUE^-+V291.B1#6DE>%MU3JB[&U&4Q&LZ"JGV1L'*]L["SG:.=6:[G-=
MC9=D6<9;;.))M5CD>56\N[N9A-)_ RA^PFN*2A/X4),DET(B%_)#A8  [ U-
MA;FR-J:SUVRE:WL]V!AF%M(;-1.+<RG(ZVC0ELT_B):E3B(NGUZ@+>-MMMEM
MMEEM#332$MM--I2AMMM"22AMM"2)*$(21$1$1$1$..E_8  Z"Y6YH6M^+G)/
M8AN*:+ M!;BS0W4]W<V6+:[R*\-Q/9&FK[D?!ZET9>/Z?1"OYIS',5*PO0
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MI*HP
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M..=:5B)7]8[X[MZ_AG;]6ZAN<VVGG3S>6D_QJ4BM9_9B6%XN?E0    !NNX
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M0US:6F64MP:B"Q7Q$)9CMM1VDICQTD24)2A/[$D1="''2^T
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M/J;0Q'9V.Z]KMQ^0Z\AQIB.TG*NYQQ7:3:"-7<CIW%%OAD6C@H2
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M6JD>.KQJCJ:"M;[6T=D"F@1ZZ&CL:2AI';'C)+HE))+^0B(<=+[@
M  PG]CN@O[Y[@SR>THQ#_,+G*M4W]CB,,D=ZI&>X43.=8 RG\231YLSQJ"@U
M%U,DJ/Z*_FG,3I(JL1>@ >_56EA1VE;=5$MZOMJ>?#M*R?&5V2(5A7R&Y<*6
MPOH?8]&DLI6D_P"122 63'//V/0N/OJYI^7../M5^P>0&I]<L:.AD:'%,[!W
M9@;.35-HV7XVG&L(Q]Z;=&2NK;WY:EDSZNIZTQ76=$JUZ1(D3)#\N6^]*E2G
MG9$F3(=6_(D2'UJ=>??>=4IQYYYQ1J4I1FI2C,S/J+D/" ST]:?#*[YW<O\
M5NBHT:=^BEV*<QW!=0C<;/'M38O)B2<LD_+;_%!G7A/,4U>[T42+.SC&HNSN
M,HF=(U%H]1TE/C-+3XWCU9!I*#'ZNOI*.FK(S4*MJ:>JB,P*RLKX;"4,1(,"
M%'0TTT@B0VV@DD1$0H2^H
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MR^27'O7"&U/+V!O#4^$I:21FIU65Y[0426TD7U-2SG]"_P#I">0MMAQT@
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M%Y'2V5SB&6UL>1*_)LHH)+GCDQS6M!D:'F5NQW67G*9B8G24L@1
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M#EUTR77SXST.=!DOPYL20VIJ1%EQ75L2(S[2R);3S#R#2I)D1I41D8O0]8
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M.O32_P#)5"S.MKVZ/.Z=]_\ G.R:3,ZN?$<4?0U+9,^A=11,:3HEE2(
M      56/L>T&?&/G1R?TLS"374^+[8R&RQ*$AI++<? \V4SG> LH0@_'T9P
MW)8*#-/1)J2?1*?YI7UG6-4,)Q( -B_,3FU/Y#<<.!7'BNES/TSQ;T=-H,@C
MNH<CM3=DVN46M6MTDF2?GPZ;7.-T+,5Q?])>DS$MD2%FIR(C29D:Z!( +!+[
M=K@JYQHXF.<@<YJ41=L<JF:;+8B)+)E/QS3,)EU[752?E;[HSV5E.?OWS:5V
MOQ9L!#I$[&Z)JO.LZ)2%!@
M                           #T+6JJ[VLL*6[K8%S36T.376M3:PX]A66
M5?,:6Q+@V$"6V]%F0Y3#BD.-.(4A:#,E$9&$3,<8YL,F/'FQVQ9:UMBM$Q,3
M$3$Q/"8F)X3$^,2C3>P'[<+1^ZSNMD<,[&HX];,?*5/DZQL&YCNC\JGN.J>\
M=6S#;F6^JY#IN*(BKV9M.A*&VF:Z*7>\?/P[Z]/=R^]7V^/_ !>"]Z>A?2.K
M>??]K6KLM_.LSBG7[/>?HTUMAG^+%J<HBE>,H;')'BER#XC9[)UOR%U?DNN,
MD;7(.O<M8J7Z#)8<=PFU6N(Y/!7*Q_**HU*+]_!D/(0H^Q?8LC27:8\E,M?-
M2=8:M]>[<ZWVSO)V'6]ODP9^.FL>[:(\:7C6MX^FLS[)TECR+'2    .V-+:
M*W%R+SVKUAHW7&5[/SRWZKB8[B=6]8268B'&FG[2TDEV0*.DAK?1\B?->CPH
MR5$IUU"?J,+WKCKYKS$0[+I71^J=<WE>G](P9-QO+<JTC6=/;,\JUCQM:8K'
MC,)>_ #[:C#<2*DV7SSOX^>9$A,2QBZ$P>TDQ\)J9*5-R$1<^S2$N-9Y=(9_
MF/0JLXE>3B3(Y4YE70^MS;^9]W#PCV_P-FNR_07:[;R;_O&\9L_"8V^.9C'6
M>>F3)&DWGVUIY:Z_C7A*AP_#<0U[C%-A6!8MCV$X=CD--=C^*XG35V/8[20$
M+6XF'4TM3'B5U?&)QQ2NQIM">Y1GTZF9CKIF;3K:=9;$[7:[;9;>FTV>.F+:
MXXTK2E8K6L>R*UB(B/JAR40O                     &JKW >OR'[ ^)M]
MB&/1(R=XZP7.V#HRS>6U'^1DT6%V7&"RY3JFFVJG8=2Q\(S6XVRQ8HA2G3-$
M8TJRK.DBL_MZBUQ^VM*&]K9U/=TEC-J+FHLXKT&RJK6MDNP["ML(4E#<B'.@
MRV5M.M.)2MMQ)I41&1D+D/G    EF^I/[@QS6M7C'&[GC<VEOA%9'BT> <BE
MLS;N_P 6@QVVHU;C^UHD1J5:Y%1164$VQ>,(?L8Y$E,QN0V:I4>NU/&!,WQ+
M+\4S[&J7,\&R:@S+$,D@,6N/93BUO7W^/7E9)+NCV%1<U4B57V,-XB_"XRXM
M!]/VBM+D0       /Q2DH2I:U)2A*34I2C)*4I2752E*/H1)(B^I@-!OL7]^
M?&;B)77. Z(L\=Y)<A4(D1&JC&[3\QU5@<]/D9^1GV:4T@HUK,AR4&2Z2GD.
M3N]I3<I^O,VUJRBLS]0@F\E^4>].7NTKC</(#/K;/,SM>L>,J6HHU)C5,AYU
MZ)C6(T,;LK,;QV IY1MQ8S:$J<4MUTW'W'75VQ$1PA#'X2.U-(;JV1QUVO@N
MZ]1Y)+Q38>N[V-?XW<Q%*-*'V26S+K[".2DMV-+<U[SL.?$<ZLRX;[K+A&A:
MB-S%F_ZY.=^!>POC5CF[\2A_I_)X4D\0VQ@RU.NJPG9%9 @R[BKARW2+\RH+
M"-/9G5DHC-3L&2VEXFY*'V6Z)C2=$L\Q ]:;#BV,.77S64284Z,_#EQW.IMO
MQ932V)#+A$9&:'6EFD_]HP%1WOK5UCI#>.XM-6R7BL=4;0SS74M3Z>UQYW#<
MHM,?^2?0S2I$I->3B%),T+0LE),TF1CD1R0ZF  $D/[:KF#5Z/Y:97QTS.X:
MJ\0Y1T5;6XP],>;:A,[BPER?.Q""IY]:&8AY906MK7M]I^279G CI2I2T=,+
MQK&HGQBI(   #"[G9SLTCZ_](V>XMQ6?R)LCY59KO7=9*CHRW9N6HCDZQ04#
M#I.?'A1_(ARQL7$*C5L97>OO<6RR],1,R*TOF)RYV[S<WSF&_=RVJ9=_D<@X
ME%00U+3C^"8=#D25X_@^+QE_6/2T4>0I)+7UD2WUNR9"W)#SKB[HB(X0AT;K
M_ <QVIG&):VU]C]CE><9UD%5BV*8Y4L'(L+F]NIC4&N@QFRZ$2GI#Q=RU&E#
M:>JEFE*3,IY#??[G>(N*< >*_KDXM4"HEEEZFN0>U-UY;'BMI+,MH7\?2=7+
ML(LOM9?744C41ZKKVUMH4FLA15.=SQNJ/"LZS,B/",P 2@OM8,(.RY=<AMAK
MC>5G$./!8JA]3:UMQ9N=[&Q"R84A?QELM27H>!R4)5YFW#;-PDI6DUFC"_(A
M.D%20  12ONK\W.!H7B=K?Y!)++-O9SFYQ?,E*GCU]AD.A*03!OI6Z48MFFD
MUDTLD>4B-2.\B7G3FB4(X6@ V5>G?"#V#[..&E"F-\HX&X(.;^+QK=[2UG2W
M.R%2>U$:6HOAIQ0WN[L(D=G<:VR(W$XV^$6?@I2        _AQMMYMQEYM#K
M3J%-NM.)2MMQM:32MMQ"B-*T+29D9&1D9& J1^2>IYFB.0N\=+3XZXTC56V=
M@8 3:U.K)<;%<IM*:#):=?4MV1&F0HC;S+IFKRM+2OJ?=U%\3K&J'2@D $CK
M[;;FA7:$Y89#QQS:V:KL&Y4P::FQV3-D-,PJ_<N)JL7L(C>1_HF.K-*ZWGU"
M$MF2Y=FY7-=%&2.W"\:QJ)]@J2    ^'DN38YA>/766Y??4V+8MC=;,N<@R3
M(;.'345'45[*Y,ZTMK6P>CP:Z!#CMJ6Z\ZM#:$D9F9$ K_O=;[BI_.7)W= :
M#L;2EXH81=*>EV)_)K;#?.3UDEM4'*;R"ZAF5"P:CE1_+15CR4NNN**?-04C
MXL>!;6NG&>:$?89B6U]NAZWF)4N5[&=[T9Q\1PUN[C\=:RTBN/-V5O5HFP<P
MV\J EIQR3!Q9,>16TQDEPW+'Y<A*$N1(KBZ[V\!$\R"YE9'?7>0SB24V]M[*
MYF$E3BTE*M)CTZ025O+<=6GROGT-2E*/^4S/ZBP?(  %L9PKP;^&7#SBKKQ3
M'QW\+XZ:7QN:V;?B6JRJ==8[#LWGT>&.929-@TZXZ9MH,W%J,TD9]!1/-+)H
M0   KG/N)<V/+/:3MVG*1YVM<X+I["6>BEK0R4C7E+G;\=LU.+1^[F9N[WD@
MDDEPU$9=Y*,[J?"AH\&0 )67VJ.#JL-_\KME$P:D8GI["L'5)\9FEI6PLU?O
MDL&]\19(.06L342?.WW^(S\;G;W-5Y/ A-T%:0    !7A?<AYN65^SC+:$I/
MG/6>H-1X0;7D0OX9SZ67LCXW:F2^IGN+8)/=JD,F?E[NPR43CEM/A0T+#, $
MK+[5'!U6&_\ E=LHF#4C$]/85@ZI/C,TM*V%FK]\E@WOB+)!R"UB:B3YV^_Q
M&?C<[>YJO)X$)N@K2        A]_=>YH;=7PIUTP]U*7/WCFEK'_ !EV'71]
M84= ]_-\:_*5I9)_;U3V?LZ*%F/Q1*&Z+  ;>O0_A19M[4^+4=YGRP<;L-CY
MK-5^ _CGBVI<ZLZA[M6I)J_^\3<)'TZFGO[NGT,8V^$65@I2
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MQ3,<UDNDTAMV4>=[/S?+X;TA:6&%/K;J[EAE"E$HR9:0DE*2DC.FWQ);7QB
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MTAB-$B1F$-L1HT9AM*&VT))*$D1$1$0I2]D
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MAR;U]CT-3DF0W$9[E;MHJJ*R:WG&HS?;E*&OQ&A"+,VS/\RD"REO"4(;@L
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M1C'&C1]3/+M[#<M8VML;*WD*;*1+2TN59F\XI"75H0:S))FDB%$\TLK!
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MI;U1@
M                                                 /$\RS)9=CR&
MFI$>0TXR^P\VAUEYEU!H=:=:62D.-.(49*29&1D?0P$+3W%^@^SPZ5E'*/@G
MB,NVPR0JQR+:/'BACG)M,.>6X4F;D6G*>''^19XDLEN.R<?;\DJK4DU0"=AJ
M3%@V5MX2A$J4E2%*0M)I6DS2I*B-*DJ2?125)/H9&1E]2%@_
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MXB;A:VG".8G.I2E"4H0E*4)224I21)2E*2Z)2E)="))$7T(5)5Z?W*&4(O\
MV7VU2EQ*SPC1^J,76DE/*-E<MN_S0FU$Z1(0HT9>2^C?5'11&?XS416T^%$M
M PS !8$_;+8+^EO71<9,Y&['ME\A]D92U*6SVNR*^GH,%P-AEM]4..MV'&GX
MA*-"2<?0AYQWHM*E+;15?XDPD.C   !7G_<G9L65^S&ZHB>4[_#/26I\)-!N
M*648Y\>\V/X4I4HR92HM@>3M+H1FX:NG51F=M/A0T$C, $J'[57"BG\E>4.Q
M?#W'BVC<>PHI'X/W19]GU?>FS]5$Y^_/6Q*^A&7[OZF1].N%^1"<**D@
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MI)UE+I#"ZYW\1I>*]G;,O+ILNV2E"513QV 9][*C5YB[%IZ+2NO)X$)EHK2
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MB<>Q_,<;D//MTV9X?:J;;;N,:NVV%&TZDDN,NH<CR$,R67F6[HF)Y(8Y"0
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M^WU^.H8VG2!9B)2E"4H0E*4)224I21)2E*2Z)2E)="))$7T(4I?H
M
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M9T_56RM783Y.[KW_ * Q?*+WL[/EK[?'_$OKU\#?7N_ICG3M:KOS(2R16D
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MLBKNE1?1XRR;>L,5R:"N9C>65:'%$DY5;+E1R5^$U]Q&161,3R'08D
M    !MGX?>E/GOS"<K;FCU7)U!K.:MEQ>T-W-6.#4DB"LV5JEXWCTB _FN7(
M>C.*5'?@URZYUQ!MKEM'U,L9M$"8#P*]#?#SAD]39SF-?_?)[QK%L36,^V33
M0T8GC-FTG\,G M9&_9T=0\P\E+K$RR>M[.,^@G(\F/\ S"KFTSRY);OAB
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MQ96"2,T&@BIM.L_0EN5&(
M
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M&V+ET9_8.Q&9A(\;LVNR_-'[NTQYV07\]NK5!C_7HEM)?083:92S[$
M      "/C[M/59R@]E&6<?9ND\XTABV+:>QW8,6PB;6R;8%)82+_ #JRQ5V3
M)J8^):XSJ"[#_+L1BI6MQR.[WIZ=JDDDRSK:*\QHU_U6SV _]L'#K^V!NO\
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M;G?AYYF<&:R9JCS<?B.5U?AN(3(JEJ\<FHJH4SM5T<><Z$983:92VH#$
M     $$G+_MD/8=F.69/E]CM_AT5AE617623R_B%NE72;>64FSE%W(X\,I5^
M_E*^I(21_P"P7[!;YX^E&CCO^JV>P'_M@X=?VP-U_P#A\#SQ])H?ZK9[ ?\
MM@X=?VP-U_\ A\#SQ])HE3^I;A-G/ /AW1:#V;<81?Y^G.\ZS3)K;7<^ZM,5
ME/Y'9,M57P9^18QB%S(>8QVLAMO^:$CM=0I*%+;2DQA:=9U2V8C$
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MR5454]OJ1FD8VG2!9%BE(
M
M
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MN7
M
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M-]"D*ZTVG64MJXQ
M
M
M                                            !%M^ZES?\OXL<:]<
MDYVJRS?UCF9ME]#<;P#7F0TJC,_$9FAMS8Z.I>1)&9D?:KH1HSIS1*#6+0 2
ME?M8M-%DG)GD3O27&\\356H*7 ZY;K:#;C9!MK*$V+<Z,M71SYD>AUG/CGV]
M4I9FJ)7U4@87Y:$)R(J2        U2^[[.$X#ZM.6]J3Z6I%SB&*X/&;)PD/
M2E9_LG#,,EL,(^7#6^I%;=ONN)2I71AMQ1MN(2I"LJ_$*S,7( &UCTDZ>_C1
M[.N+%1(B^>JP;,IVX;5XT]R(/\):&TSC'Y3B24E7[S,ZBL809=>UQY)F70C&
M-ITJ+,X4I
M
M                                             1!/NPK.8UC_  8I
MD,]U?/N.1=G)D='?W4RIA:3BP6>XE>$O.S=2%=%$:C\?X3(B5ULQ^*)0U!8
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M<N9C:TN-.1*E4=U)%*08QO.D:>(L2!2D
M
M
M
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MHEMLSNT_PO'UKO/#0A-P%:0
M
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MG9V45U>=K3MRV2[)-;AD"+&IHJTGV.MP3?Z$MY?6FTZRELA&(
M
M
M
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M%2I9_7"J#"J*)(=0EPFT_3/WTMFI!FK\?:9$2R.S&B4+(6#E>#8+F>S<OQ[
M-=XK?YOF^663%/C6*8O5S+J_O+.29^&%6UD!I^7*>-*349)29)0E2E=$I,R"
MRS]0? Z5Z_\ A[C>M,L*"]M_.[>3L[<<B \S,BPLNO(%?!AXG"L&D$4N#AN/
MUD6$I:%N,.STRGV5&V\0IM.LI;2!B
M
M
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MLFQO%8:K')\AH\<KT(?<5.OK:!3PTMQFC?DN*DV$B.P2(["36LS5T0@NI]"
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M$W5Z]K$$\@FI)X>F,]D#JFU*7%EPZ\G$]DDNN%YTC06!8J2
M
M
M
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M54L2_>KY%NRPG&,AHVWTS7JJ.I1O$X:?&7:9=3ZS$S'(8N_YD#U7?XH&'?\
MXY[7_P#GX3YK>T9>Z X7\4>+!2G./>@-8ZJL)\1,"QR#&<9A(RVS@(4E:8%G
MF,Y,S*K*"EQ)+)E^8XV2^JNWN,S.)F9YC)P0
M
M
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M!IU-L4]>\:4+75UD;N(E=11:=9U2SO$
M
M
M
M
M
M
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MHVQLQQV:A,[%ZO$F'U+J84QIFQD6IMRU(CLPV?FUWMX0)E0K2
M
M
M
M
M
M
M                         ZCWM_U4YA_U1_\ NQ7_ %[?]5/\]/\ SP__
M *9_L_[?03 A7<K?X/?G>0?Q+_U;?M_,K'N_@M_?U?J7L[IO3\Y_O2?WWY]X
M>[Y?;^\^9^W][V"R/V4--.T/X">6?^E/[QSL\,CX_P#"_P#SE/B[_F.^/X'\
M:/W_ )O#T\?ROW?A[>_][W#*-?I_<&/W_P!RO_\ #O\ _P! !Q^D<TPO^%WS
M'OSS^]I\'?#[/UI_?B?#[?*OS>'^'?\ PAV=G3S>3\79T\7XNH<?I&S'0O\
M>S?*A?I__,<?GWF;\O\ 'K_.Y?%[_DS_ (OS?XG?_P!MO#XNO=X?W?C\7R/W
MG01Q^G]P2]/6!V?I6;XO\U!X_!.\?^;1^1^3=GRV>S\\^7_5?F[?_KGE_>?)
MZ=WUZBNW[*6VL8@
(        _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_02.jpg
<TEXT>
begin 644 image_02.jpg
M_]C_X0G*17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  "OR    G$  *_(   "<0061O8F4@4&AO
M=&]S:&]P($-3-2!-86-I;G1O<V@ ,C Q,3HP-3HQ,B Q-CHP,3HT,    Z !
M  ,    !  $  * "  0    !   !PJ #  0    !    /          & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
M 04! 0$! 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!
M  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ [+ZX_6Q_U>KQZ\>@7Y.7
MO+#8=M;&LV;W/CW/_G6>SV?\8JW2_K#];K,VBO.Z73D8606@Y>#8'L8'$-]1
MSC9:VST_\(S]SZ'J)_KQ5U.QN.*ND4]8P!K:TAYOK=.OHFE[+6>K7[?4I]3_
M (5<ST_H6?=]8,/)Z)TG,Z+34]C\E^0]P :' V[?6VV6,=5NK]#]+ZW_  :M
MXX8SBU$0:E<B?L_2XH_XK6G.8RZ$U8 B/Q_O/1=-_P 8.(_)SV=7]' IPW^G
M4\/<]UAWVU>RD,]1WMK:[]&U;V-]8>B96!9U&G,J.'28MN<=@8?W;6V;'UN]
MWM:]<M]3_J_8.M=7NZITXMIL<[[,<A@<TM?;<;!7OW-]]?I+!P/JE]8;^AY]
M P[*;VY&/?75;##:UC<JI[*W/=LW5>LRSWN1EBPDFI<'#P=?3Z]T#+E %QXK
MX_/T?*]WC_7CZJ9-XQZNHU^HXP-X?6)_XRUC*_\ I(^9]:OJ]@Y=N'F9M=&1
M0-UM;PX0"T6CW;=KG.K>W:QJX0]-ZCGX&)TN[I75KG8XVFJQV/C8["!LW8^2
M_$=8YEGY[;G_ /L18H9=3\+Z\FMN$>JG$KJ!Q7.#WV"O$J:ZS=8QK;KJOY[^
M9_2O_P 'O2^[8R2+.D92KBC^CMJHYY@ T-91C=2_2W>^Q_K5]7\G"OSJ,UC\
M?% .0Z'!S ?HN?2YHNVN_,=Z: ?KQ]5 6 ]1KFSC1^FNW])[/T/_ %W8N&;T
MOJ(HZ_UJ[IQZ7AVXME=>,\;"'664/:RNIP:_8STO4>_TZZ_4_F4'&JS<CZLM
MP,;H+LBW)M+ZNJU-W'VV>[<[;^B>W8[%_26U5^BB.6Q_O'YA'YH>FQ_W*#S&
M3307PF6TM:/_ '3Z3U+ZR]"Z6RI^=FUU"]N^H EY<P_X1C*18]U?_"?00L#Z
MW?5SJ)>W$SF6.K8ZQS2',=L8-UCFMM8QS]C?I;%Q>9TCZQ],=T>IV)==CX^.
MP6WX---V4QX?;:^BO)MKN?5]E]9C,?\ [3?N>_Z$,3I'7G_6<9F1@Y@KLINV
MVY!9:_W8MU-/KWXX92VU[MK/3_P7\TFCE\?"3Q]"01*.O#_57'/DL#AZ@$5J
M.(/<X7UK^KV?;53B9U=MM[G-K8 X.)8SU[#M<UNQC:O\(_\ 1K.ZG]?NAT8>
M2[IN35F9M !902YC;/>VM_I7%FRW:UV_]#ZBP_JQ]4+[?JYU$96&<7J]@LIQ
M+KP0YK'4L9M;]+TZ['67U6O:LVOIO6F] R>BGZN/.6VSU#U"&[@ ]KOT;_\
M#6-;^@9]FNV>A_US>1AP\1J1/#("C*(\Y?W42RY>$: &0)T$CY1_O/1GZ]9@
MZ;T_,&'7NSF7/>TV. ;Z5OH#:?3]V[Z2T[OK36SZN5]8;6TW6D5C'+M/5G9;
M7OV_1KV6V?0_FUR]/1NL-Z;T&LX-Q?C^KZ["T>S=DBT"W7\^KW_U%?Q?J[U
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M:&]P(#,N,  X0DE-!"4      !                      .$))300Z
M  ";    $     $       MP<FEN=$]U='!U=     0     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    3 $( <@!O '0 : !E '(
M( !$ $, 4  M #D ,  T #  0P!.    .$))300[      &R    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    2     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D        X0DE- ^T      !  2     $  0!(
M 0 !.$))300F       .             #^    X0DE-! T       0   !X
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M      H  0         !.$))30/U      !( "]F9@ ! &QF9@ &       !
M "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M   &       !.$))30/X      !P  #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@  #A"
M24T$         @  .$))300"       ,                .$))300P
M   & 0$! 0$!.$))300M       &  $    ..$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      O8    (
M$     $       !N=6QL     P    AB87-E3F%M951%6%0    % %4 <P!E
M '(       9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<    \     %)G
M:'1L;VYG   !P@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG    /     !29VAT;&]N9P   <(    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG     #A"24T$*       #
M  (_\        #A"24T$%       !     XX0DE-! P     "+     !
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
M A$#$0 _ .R^N/UL?]7J\>O'H%^3E[RPV';6QK-F]SX]S_YUGL]G_&*MTOZP
M_6ZS-HKSNETY&%D%H.7@V![&!Q#?4<XV6ML]/_",_<^AZB?Z\5=3L;CBKI%/
M6, :VM(>;ZW3KZ)I>RUGJU^WU*?4_P"%7,]/Z%GW?6##R>B=)S.BTU/8_)?D
M/< &AP-NWUMMEC'5;J_0_2^M_P &K>.&,XM1$&I7(G[/TN*/^*UISF,NA-6
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M %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
M<P!H &\ <  @ $, 4P U     0 X0DE-#Z      !;9M;W!T     P    $
M        !P    ,!              #__________P    '_____
M                  #_____      3_____     /____\     _____P
M  #_____          #_    _P   /\   #_    _P   /\   #_    _P
M /\   #_    _P   /\   #_    _P   /\   #_    _P   /\   #_
M_P   /\   #_    _P   /\   #_    _P   /\   #_    _P   /\   #_
M    _P   /\   #_    _P   /\   #_    _P   /\   #_    _P   /\
M  #_    _P   /\   #_    _P   /\   #_    _P   /\   #_    _P
M /\   #_    _P   /\   #_    _P   /\   #_    _P   /\   #_
M_P   /\   #_    _P   /\   #_    _P   /\   #_    _P   /\   #_
M    _P   /\   #_    _P   /\   #_    _P   /\   #_    _P   /\
M  #_    _P   /\   #_    _P   /\   #_    _P   /\   #_    _P
M /\   #_    _P   /\   #_    _P   /\   #_    _P   /\   #_
M_P   /\   #_    _P   /\   #_    _P   /\   #_    _P   /\   #_
M    _P   /\   #_    _P   /\   #_    _P   /\   #_    _P   /\
M  #_    _P   /\   #_    _P   /\   #_    _P   /\   #_    _P
M /\   #_    _P   /\   #_    _P   /\   #_    _P   /\   #_
M_P   /\   #_    _P   /\   #_    _P   /\   #_    _P   /\   #_
M    _P   /\   #_    _P   /\   #_    _P   /\   #_    _P   /\
M  #_    _P   /\   #_    _P   /\   #_    _P   /\   #_    _P
M /\   #_    _P   /\   #_    _P   /\   #_    _P   /\   #_
M_P   /\   #_    _P   /\   #_    _P   /\   #_    _P   /\   #_
M    _P   /\   #_    _P   /\   #_    _P   /\   #_    _P   /\
M  #_    _P   /\   #_    _P   /\   #_    _P   /\   #_    _P
M /\   #_    _P   /\   #_    _P   /\   #_    _P   /\   #_
M_P   /\   #_    _P   /\   #_    _P   /\   #_    _P   /\   #_
M                   !-    !     !       .5&%R9V5T4V5T=&EN9W,
M   '     $UT=$-/8FIC     0      "DYA=&EV95%U860    #     $)L
M("!L;VYG    _P    !'<FX@;&]N9P   /\     4F0@(&QO;F<   #_
M %1R;G-B;V]L 0    IF:6QE1F]R;6%T96YU;0    I&:6QE1F]R;6%T
M!5!.1S(T    "FEN=&5R;&%C961B;V]L      QN;TUA='1E0V]L;W)B;V]L
M     !MT<F%N<W!A<F5N8WE$:71H97)!;&=O<FET:&UE;G5M    #T1I=&AE
M<D%L9V]R:71H;0    !.;VYE    &'1R86YS<&%R96YC>41I=&AE<D%M;W5N
M=&QO;F?_____.$))30^A      :);7-E=    !     !       $;G5L;
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M:6YG;&]N9P         21FEL95-A=FEN9U-E='1I;F=S3V)J8P    $
M  1N=6QL    "@    Y#;W!Y0F%C:V=R;W5N9&)O;VP!    &41U<&QI8V%T
M949I;&5.86UE0F5H879I;W)L;VYG     0   !9(=&UL1FEL94YA;65#;VUP
M;VYE;G1S5FQ,<P    9L;VYG     FQO;F<    8;&]N9P   !AL;VYG
M&&QO;F<    8;&]N9P   !8    226UA9V53=6)F;VQD97).86UE5$585
M  < :0!M &$ 9P!E ',      !%.86UE0V]M<&%T:6)I;&ET>4]B:F,    !
M       $;G5L;     ,    -3F%M94-O;7!A=$UA8V)O;VP     #DYA;65#
M;VUP87153DE88F]O; $    13F%M94-O;7!A=%=I;F1O=W-B;V]L     !-/
M=71P=71-=6QT:7!L949I;&5S8F]O;      84V%V:6YG1FEL94YA;65#;VUP
M;VYE;G1S5FQ,<P    EL;VYG     6QO;F<    4;&]N9P    )L;VYG
M$VQO;F<    &;&]N9P   !AL;VYG    &&QO;F<    8;&]N9P   !8    7
M4VQI8V5&:6QE3F%M94-O;7!O;F5N='-6;$QS    !FQO;F<     ;&]N9P
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M=6QL    "     M!9&1#=7-T;VU)4F)O;VP!    !T%D9$58249B;V]L 0
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M   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M    245#('-21T(               $  /;6  $     TRU(4" @
M                                                       18W!R
M=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4
M<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0
M  !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0
M _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U12
M0P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y
M.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@
M245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M
M %A96B        #S40 !     1;,6%E:(                     !865H@
M        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M             !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                            9&5S8P         N
M245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="                             &1E<V,
M+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M             "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#
M-C$Y-C8M,BXQ                                  !V:65W       3
MI/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?
MYVUE87,          0                        */     G-I9R
M0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $
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MDW.ZCN:6*H4$$B0"4J!@@C9@?0[=E:D?_+0+^*#_ -OHPC_U#<K?^</,M?\
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MT^>M[IJ.F'J!R8,Q8512MB>6,PX9*:/&<$K73RS44%6@+1LP #HP:-P '1@
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MUO5G!I,M]6.NV#5'4?,.5Z]2E7@^%QBDH\-HJI"3LG""2>139D,WEL R$<Q
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MFXI3ULH\^*8V7>[1FQ";XY[ ^T:VO,O1E[J@E]H0D'^-/".M(P(Z #TQ)'U
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MMLQT%K:W'5]V";J-MEQ:%(2D23K($=)))B@'8?4!O8XX&T+2XM1@#NP23T
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M'_<L1A].^_+&77KEH^K2A^-).P+& !Z-0,3T@#C0,^HW<1_,K%N\MTZEL3J
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M;&3;1@S25"?&'E'#A6Q4?\:/_J]_'?\ P7,O?^4\G/-;*\:#C\)3_LX-Z?\
M_P 2O_V"<8YMS97A3C^*_P!#LS](_6)U'S%7X5+#D_J_4?YP\F8[M8T]4:J*
M,UT0?51+#5;PR7N%*,0 Z\\V<*\:++Z7O59U<](W4";J#TEQ"E6JQ*F_DN8\
MO9BIS589BE'YJS"*HC1XG!5T#*\;HZZ@-M9@=J2#6J-#ZF_Q-/4YZQ,EU/2>
MKP'#,JY*J$?'LT9=Z:T5?)48C!A2G$W>KEJ9ZE_EZ<0>>P0*H";G)"Z:2@"M
MS59G+UJMA/U3?]F4_2S_ -['+O\ T@Q?C*?NK=:]G'JU6PE^/Q_S%_IG_P"]
M;F?_ ,JL-XTU6S58/X<__5[_ *;/_!C@_P#*>;EU[*T*&O\ &'_ZORZG?]ZW
M+/\ Y8*7FF]E;-#5^!+_ -7<]1?_  G&+_\ L38!S3NRO"JO_4G_ -7%=?/_
M  =<U?\ E]JN7&RM5?C^ /\ \PAZF/\ O998_P#*7$N-.UL58Y^*#_U8;ZB?
M^];AO_E_H.41MK9K2)XIJM;[_H[_ .K1O2Q_X3C(_P#[#-%Q*K;5J,=RM>K_
MU-_CGJ]2*ZA=-^G_ %:REBN0^J&2L*ZA9+QQ/(Q?*V<J&FQ&@J%\"\-4CI=>
MZM:X.H(/%N7YE<6CP=864+&PI)!]HI#F.66]XR6GT)6@[0H CV&J@>H__"?3
M\-+/U?-B.%=-\>Z735#>=/#TXS-B*4Y8FYVPXT<2CC!_PQJH'@!R7\M^H+>6
MW3"G$N?XR1\4Z??4.YE]/.[%PJ4M*;_Q5'X*U>Z@\P__ (3=?AU454E14U'4
M#%HE#!J'$,ST:Q-<6!)I<-A?3N+,/CPQ<^I#>)0@=T/\T_-1HN;^FK=M)D]Z
M?-0^215@_IQ_#+]"_I1Q:CS+T4].^"X'G+#SYM#GK,35F8,;II"NQI*:MQZ:
MLEIF87!\@H+$BUCR/=X^TW/<V047-PHH/\(A*3YA( /K-2)NWV89#E*PNVMD
MA8_B,J4/(J)(](HV/5'I?D/K3T^S7TKZGY=CS;D#.]*V"YJRW62U$,592LRN
M8V>EDBD4$J#=6!X$\KS1^RN$/L*TN(,@]!]:%N:Y7;WMNMA].IM8@CI'IC5>
MO_#*WX7W_<).$?\ CXS3_P"?3DA?[-.]'_,VKV(_P:CO_82W6_YDT^U?^%5B
MO3KI[DWI-D3*73+IY@<>6<BY$H*;*^4\O4LDTL=%04<8AAA5ZEY)&"J  68G
MVGD=YCF#UV^MYY6IQ9))Z2=IPJ1\MRYFTMT,,ITMH  '0!L&- )ZDO0[Z5/5
M[6Y3Q'U']'Z/JC6Y&BJZ+*D^*UN+4AHXJ]XI)U48;54P;>8$)W7[:6X?;M[\
M9KE"5BS>+87$P 9C9M!Z:#^\NXN4YPI"KQD.%$Q)(B=NPCHH(NEWX4OX?71;
MJ#E3JITP]->&92S_ )(JEQO*N9*/$\PS2T=4BL@D5*K$)8V(#'1E(X;YIVK;
MP7MNMA^Y*FUB"(3B/04495V3;O65PA]BU"7$&095@?5458%64='B-'58?B%+
M'74%=&]'74-8BRPS0RJ4='1P5964D$$6(Y'Z%E)!!@BI"6@*!!$@U5IUB_!2
M_#5ZT8C68WC'IMH,DX]6EGEQ/I+78GEB(%E()6APJ>*A!N0U_E[W'Q-Y2R?M
MJWELDA*;DK2."P%>\C5[ZBK.>Q'=F]45*M@A1XH)3[@=/NH$\&_X3R_AFX97
M1U=;T\S+F*G2V["\9S=C"0/[P.IP]Z67PMHXT/ML>';WU"[S*3 <0GK"!\Y'
MNHC9^G7=A*I+:U=16KY0??5CGI\]$WI.]*J2-Z?N@F7>FN(SQ_)U.9,*H_F,
M:FA-SY<N)U[3UDB:_9:8CX<CG>#?;-LU_P"*[A3@Z"83_I1 ]U23N[N/E&4_
M\26Z6ST@2K_3&5>^B6?CP?\ 9J7U4_\ B#_^S(R_P:=A'_3UVO\ G_\ *:Z!
M/;Y_TZ5W_N?_ "JBOG-\Z+US=KZ$.7?PB?07ZM_37Z9<\]3.C$>"=0\1Z=9*
MEQ7/W3.KJ,OXC72/EJB+25BT)%/52FP_2SPO)86W6TYSYN.UW/LHS*Z:9>EL
M.KA*AJ \1V3B!U @5T0M^Q_(,XRRU=?8APM(E224D^$;8P)ZR">NLG3+_A/G
M^&QTZQNDQW$L@9@ZIS4,HK*7#NIN8JF>BWKM*B2GPE,/25 5OLE#*;D,"+ :
MS/Z@MY;E!2EQ+<\4I$^TS'I6\K^GC=FV6%*;4Y'!2C'L&F?6:N7RME7+&1LN
M8+D_)>7:'*64\N4\>$Y?RSEJE@H:"AI85VI#!3TRI'&BCLJ@ <AJZNW7W%..
M**EJ,DDR2>DD[:FFTM&F&TMMI"4)$  0 .@ ;*^7]^()_P!7Z^MS_P *]U*_
M]C/$>=/NS[_E@V/^T-?[XFN6W:'_ ,M^^_V]W_?U5>[_ ,)[_2GZ=_5GT3]8
MN1O4/THPOJ?@%)C.3YL*.-1R15V'R38?B\;R45=1O#54SL+ M#*I-A?MR"/J
M#WKS'*;VS=M'2VHI7,;#BG:#(/J*GOZ=]TLMS>QO6KQE+B0I$3M&"MA$$>A%
M6PR?\)R_PWWQU<77"\[0X>K%SE:/-3&@8&_NEWI6JK"_A/?3OWO% ^HS>3N]
M,MSTZ,?C'NJ6C]-V[7>:H<CHUX?"??5I7II]'/IF]'^6JK*WISZ087TUHL2V
MG&\4H%FJ\6Q'82R_.8EB,D]74!"Q*+)*52YV@ \BW>7?',\X="[QXN$;!L \
MDB /08\:E7=C<S*\F:+=FREL':=I/FHR3ZG#A0K=4NDW3/K=DC&>F_5W(N%]
M1LB8^HCQ;*V;J2&MI)2AW(X28';(A]Y)%LR-8J01?A3E>;7-B^EZW<*'$["#
M!_=TC8:-LURBUOF%,W#8<;5M!$C]_0=HJH7'_P#A/3^&;C6+5>)473K,>6*>
MJ8RK@N 9LQ<TD-R3:/Y]ZJ4#7L9#R7K?ZA-YD("2XE4<2@3[H'NJ'KCZ=MV%
MK*@TM,\ LQ[Y/OHT'03\)/\ #T].-=1XWT^]-."XEFBA=:JFS9U(:KS5713H
MVY)H#F"6KCIY%TLT"1D=^]SP+Y]VM;PYDDI=N5!)X)A \CI@GU)H4[O]D.[N
M6J"F;5)6.*I6?,:B0/0"F#JA^#7^&UUFZAYQZK=2/3<N8,^Y_KZC,^;<<AS;
MGJ@6KKJI_,EE^7PW&J>"/<VI6.-1\.*,K[9-Y+*W0PS<Z6T" -#9@#K*2?::
M3YKV+[LWMRM]ZVU.+,DZW!)/4%@#T%"UT%_#@]&GICP#JCE7HATDGR7E?K3A
MCY0ZGY;DS5G+%:#%J"2&6F*R4^,XM5QI)Y<\B"6-5D"L0& )X4Y]VCYSF;C3
MER\%J:,I.A (.W:E(.T# X=5&^0=FN2Y6VZW:LE"'1I6-:R",1L4HC83B,>N
M@8_X96_"^_[A)PC_ ,?&:?\ SZ<.?]FG>C_F;5[$?X-$O^PENM_S)I]J_P#"
MH^W1;HKTO]._3/+71WHQE*'(O37)_P Y_5O*M!-55$5+_,,0GQ2HVR5LLTIW
MU%3(YW.;%K"PL. +.LZNLQN57%RO6ZJ).&,  ;(&P 4/\DR2URZU3;VR-#29
M@8X223MD[230I<*Z-:K(Z^_@[_AW>H[,N(YUSWZ>:+!<Z8N[U.*9FZ;5V)Y:
MDJII0=\LU/@\\%++*S'>TLD+.S"Y8W-Y-R#MAWBRUH-M7!*!L"@%1Y$@D#J!
MBHOW@[&MW,R=+KML L[2DE,]9"2 3UD34?H;^#7^'+Z?\>H<V9/].5!F+->&
M/'44&/=3J[$\S&&6)1LDCI<8J)Z1)%8;PZP!@QN"++:V>=LF\>8-EMRY*4'@
MD!/O2 ?2:KD78ONWE[@<;M@I8XK)5[E$CUBG3-/X/?X;6=,S9BSCF?TLX3BN
M9<V5]7F;,.*28KF6-JFNKZAZJ>4K#B2(I>1V:RJ +Z #C5KVP;R,-);1=*"4
M@ "$X 8#^&G;KL<W9?=4XNT25*)),JQ),G^*C-^G#TB^G+TC8)F3+GISZ84O
M3#!<WU46-9CH,+JL2JEJJJ"'R(Y&.)5-2P*H;64@<#.\>]V8YNM*[QTN*2($
M@"!Z 4*-VMS\MR="D6;0;2HR8),GU)H&/^&OO0;_ -P[8;_X\L?_ /._@>UF
MA+%&2Z*^GWHYZ=L!Q7+'1?(\&1,!QRL_GV*X=03UM0LU684I_,)K9IF!V1J+
M @:=N5))KU!3U-]!GI&ZQYVQKJ-U)Z)X?F?.N8C V-X]-58K3R5+4]/'21LZ
M4=5"EQ'$JW"W-M;GFPLUZA*Z)>FSH=Z<:''\-Z*=/*3(-)FB6"NS N'2U<[U
M4E,C1Q%WK9IGL@=MJ@V%R;7)YHDFO4ANK?HB]+'7?.,V?^K72&CSGG"HIX,+
MFQNMK,5@D:GIE*Q)MI*J)+*#_AOS8417J;^F'H.])/1C/.!]2NF/1BBRGGC+
M?S/\DS!25N+S24_SE'+0362JJY8SOAG=#=3WTUUYXJ)KU#QU-Z3=-.L^5ZC)
MG57(^&Y]RQ4,)SA.9*:.H2.505$L3,-T4@!($D9#"^AYH&*]1 JW\'CT'5>(
M_/1=,L2P^G.^^$T69<=^7NUK:S5,DHVVTL_TWY;O#6HHT?3[T9>EWI5D[-F1
M,@=&,(R[E[/>&5F3,XM"*F?$<2PJOA>GGI9\1JI9:QXW1R+&;3N+'7FBHUN@
MD_X:^]!O_<.V&_\ CRQ__P [^;UFO10Z9D]*OI^S?TBRWT&S)TVIL4Z290DI
MZK+>2Y:G$$@I9*595B*R15"S':)W^TY[\KJ->H"_^&OO0;_W#MAO_CRQ_P#\
M[^6UFO10Y];O2IZ?O4?59>K>MG3:ES[594CJ:7+TV(5.(4YIHZMHWF"_(U$
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7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_2.jpg
<TEXT>
begin 644 image_2.jpg
MB5!.1PT*&@H    -24A$4@   ,P    %" 8    )Q0..    "7!(67,  $SE
M  !,Y0%USO"5    ,4E$051XG.W3L0T ( P#0>^_=! L *DBI'OI>C=.D@+N
E=ID> ;]P&&AP&&@XARE)SRWUD&7OY"ROO     !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_210.jpg
<TEXT>
begin 644 image_210.jpg
MB5!.1PT*&@H    -24A$4@  ##4    -" 8    #U;1W    "7!(67,  $SE
M  !,Y0%USO"5    V4E$051XG.W;,0$ ( S L,V_:'!!#W+DKX'.[AX
M         (#7I@X               #^9&H                2I@8
M         "!A:@               !*F!@              (&%J
M        $J8&               @86H                2I@8
M     "!A:@               !*F!@              (&%J
9    $A>#"/>T#N'P)@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_29.jpg
<TEXT>
begin 644 image_29.jpg
MB5!.1PT*&@H    -24A$4@  #+(    -" 8    '#*8/    "7!(67,  $SE
M  !,Y0%USO"5    X$E$051XG.W;,0$ ( S ,.9?-*B@'.3(7P-=,[,!
M          #@MO4Z                @#\860               $@860
M             $@860               $@860               $@860
M             $@860               $@860               $@860
M             $@860               $@860               $@860
@             $@</JU=SU'+T%T     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
